THE CATECHOLAMINE HYPOTHESIS OF AFFECTIVE D EVIDENCE

American Journal of Psychiatry

122, 509-522

DOI: 10.1176/ajp.122.5.509

Citation Report

#	Article	IF	Citations
2	Catecholamine metabolism in affective disorders: I.. Journal of Psychiatric Research, 1965, 3, 213-228.	1.5	124
3	Norepinephrine in Depressive Reactions. Archives of General Psychiatry, 1965, 13, 483.	13.8	1,042
4	The effects of lithium ion on H3 -norepinephrine metabolism in brain. Life Sciences, 1966, 5, 1479-1483.	2.0	118
5	Monoamine Oxidase Activity in Various Parts of the Rat Brain during the Estrous Cycle. Science, 1966, 154, 649-649.	6.0	52
6	The clinical laboratory and electroencephalographic effects of lithium. Journal of Psychiatric Research, 1966, 4, 207-219.	1.5	114
7	Chapter 2. Antidepressants, Stimulants, Hallucinogens. Annual Reports in Medicinal Chemistry, 1966, 1, 12-29.	0.5	0
8	Normetanephrine Excretion and Affective State in Depressed Patients Treated with Imipramine. American Journal of Psychiatry, 1966, 123, 690-700.	4.0	46
9	Chapter 2. Antidepressants, Stimulants, Hallucinogens. Annual Reports in Medicinal Chemistry, 1967, , 11-23.	0.5	0
10	The Endogenous Depressive Pattern. Archives of General Psychiatry, 1967, 16, 241.	13.8	91
11	Biochemical Changes in Psychotic Depression. Archives of General Psychiatry, 1967, 16, 448.	13.8	52
12	Depression with the Use of Alpha-Methyldopa. American Journal of Psychiatry, 1967, 124, 80-81.	4.0	28
13	Norepinephrine Metabolism and Drugs Used in the Affective Disorders: A Possible Mechanism of Action. American Journal of Psychiatry, 1967, 124, 600-608.	4.0	127
14	The Biochemistry of Affective Disorders. British Journal of Psychiatry, 1967, 113, 1237-1264.	1.7	1,089
15	The effects of psychoactive drugs on norepinephrine-3H metabolism in brain. Biochemical Pharmacology, 1967, 16, 393-399.	2.0	152
16	Binding of biologically active amines to plasma protein fractions. Biochemical Pharmacology, 1967, 16, 849-861.	2.0	7
17	The systolic blood pressure response of depressed patients to infused norepinephrine. Journal of Psychiatric Research, 1967, 5, 1-13.	1.5	44
18	Influence of age on monoamine oxidase and catechol-o-methyltransferase in rat tissues. Life Sciences, 1967, 6, 581-586.	2.0	37
19	Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sciences, 1967, 6, 1895-1903.	2.0	252

#	Article	IF	Citations
20	Biogenic Amines and Emotion. Science, 1967, 156, 21-30.	6.0	884
21	The catecholamine hypothesis of depressions: Further arguments. Comprehensive Psychiatry, 1967, 8, 1-6.	1.5	5
22	5-HYDROXYTRYPTOPHAN FOR DEPRESSION. Lancet, The, 1967, 290, 987-988.	6.3	46
23	A Dualistic Approach to Some Biochemical Problems in Endogenous Depressions. Psychosomatics, 1967, 8, 82-94.	2.5	23
24	Psychiatry. Archives of General Psychiatry, 1967, 17, 347.	13.8	10
25	New developments in brain chemistry: Catecholamine metabolism and the action of psychotropic drugs.. American Journal of Orthopsychiatry, 1967, 37, 864-879.	1.0	12
26	The action of reserpine in imipramine-resistant depressive patients. Psychopharmacology, 1967, 11, 18-30.	1.5	39
27	The effect of lithium on cerebral monoamine neurons. Psychopharmacology, 1967, 11, 345-353.	1.5	127
28	A clinical trial of a-Methyl-para-tyrosine in mentally ill patients. Psychopharmacology, 1967, 11, 422-429.	1.5	24
29	Effect of Lithium on the Uptake of Noradrenaline by Synaptosomes. Nature, 1967, 215, 1395-1397.	13.7	180
30	The influence of antidepressant drugs on akinesia produced in mice by intracisternally administered noradrenaline, dopamine and noradnamine. Experientia, 1967, 23, 807-808.	1.2	3
31	Clinical and Pharmacological Effects of Monoamine Precursors or Haloperidol in Chronic Schizophrenia. Nature, 1968, 217, 854-854.	13.7	26
32	Recent Contributions to Psychoendocrinology Part II. Psychosomatics, 1968, 9, 217-224.	2.5	0
33	Depression as Viewed Through Neurologic Spectacles. Psychosomatics, 1968, 9, 252-254.	2.5	5
34	Schizophrenic Physiopathology. Psychosomatics, 1968, 9, 19-29.	2.5	2
35	New Theory of Cerebral Amine Function and its Clinical Application. Nature, 1968, 218, 1130-1133.	13.7	136
36	Tyrosine metabolism in manic depressive illness. Life Sciences, 1968, 7, 1219-1231.	2.0	46
37	Lithium in psychiatric therapy and prophylaxis. Journal of Psychiatric Research, 1968, 6, 67-95.	1.5	475

#	Article	IF	Citations
38	Catecholamine metabolism of manic-depressive illness. Journal of Psychiatric Research, 1968, 6, 185-199.	1.5	35
39	Effects of electroconvulsive shock and prior stress on brain amine levels. Experimental Neurology, 1968, 20, 21-30.	2.0	19
40	Controlled evaluation of lithium and chlorpromazine in the treatment of manic states: An interim report. Comprehensive Psychiatry, 1968, 9, 563-573.	1.5	150
41	Monoamines and Affective Disorders. Australian and New Zealand Journal of Psychiatry, 1968, 2, 240-242.	1.3	0
42	On Manic-Depressive Psychosis: A Study of the Transition of States. Journal of the American Psychoanalytic Association, 1968, 16, 809-832.	0.2	7
43	REM Deprivation. Archives of General Psychiatry, 1968, 18, 312.	13.8	43
44	Psychochemical Research Studies in Man. Science, 1968, 162, 1442-1453.	6.0	96
45	EEG, Physique, and Androgens. Perceptual and Motor Skills, 1968, 26, 419-429.	0.6	3
46	The Involutional Depressive Syndrome. American Journal of Psychiatry, 1968, 124, 21-35.	4.0	33
47	A Behavioral-Biochemical Study of Lithium Treatment. American Journal of Psychiatry, 1968, 125, 499-512.	4.0	86
48	Lithium Effects on Electrolyte Excretion. American Journal of Psychiatry, 1968, 125, 536-543.	4.0	50
49	Toward an Ego Psychological Appraisal of Drug Effects. American Journal of Psychiatry, 1968, 125, 593-604.	4.0	5
50	REM Deprivation. Archives of General Psychiatry, 1968, 18, 301.	13.8	64
51	Suppression Studies in Affective Disorders. Canadian Psychiatric Association Journal, 1968, 13, 477-488.	0.3	10
52	3-Methoxy-4-Hydroxy Phenylglycol (MHPG) Excretion in Depressive States. Archives of General Psychiatry, 1968, 19, 129.	13.8	197
53	RECENT STUDIES OF SEVERE DEPRESSIVE ILLNESSES: PART 2. Medical Journal of Australia, 1969, 1, 557-565.	0.8	3
55	A Longitudinal Drug Study and Central Amines. Archives of General Psychiatry, 1969, 20, 290.	13.8	9
56	Enhancement of Imipramine Antidepressant Activity by Thyroid Hormone. American Journal of Psychiatry, 1969, 126, 457-469.	4.0	363

#	Article	IF	Citations
57	Neuropsychopharmacology and the Affective Disorders. New England Journal of Medicine, 1969, 281, 197-201.	13.9	55
58	History of Biological Psychiatry in America. American Journal of Psychiatry, 1969, 126, 29-42.	4.0	11
59	Brain and liver tryptophan pathways and adrenocortical activation during restraint stress. Pharmacological Research Communications, 1969, 1, 363-368.	0.2	14
60	Imipramine antagonism of the CNS effects of norepinephrine behavioral and biochemical correlates. International Journal of Neuropharmacology, 1969, 8, 235-244.	1.2	10
61	The effect of lithium chloride administration on brain and heart norepinephrine turnover rates. Psychopharmacology, 1969, 14, 315-322.	1.5	68
62	The effect of reserpine and monoamine oxidase inhibitors on paradoxical sleep in the monkey. Psychopharmacology, 1969, 14, 12-17.	1.5	39
63	Chronic administration of electroconvulsive shock and norepinephrine metabolism in the rat brain. Psychopharmacology, 1969, 15, 296-304.	1.5	31
64	Chronic administration of electroconvulsive shock and norepinephrine metabolism in the rat brain. Psychopharmacology, 1969, 15, 305-309.	1.5	6
65	Supersensitivity to the central stimulant actions of adrenergic drugs following discontinuation of a chronic diet of ?-Methyltyrosine. Psychopharmacology, 1969, 15, 96-101.	1.5	71
66	INTENSIFICATION OF THE CENTRAL SEROTONINERGIC PROCESSES AS A POSSIBLE DETERMINANT OF THE THYMOLEPTIC EFFECT. Lancet, The, 1969, 293, 132-136.	6.3	628
67	METHYSERGIDE IN MANIA. Lancet, The, 1969, 294, 338-340.	6.3	31
68	General Principles of Chemotherapy of Mental Illness. Psychosomatics, 1969, 10, 82-87.	2.5	6
69	METHYSERGIDE IN MANIA. Lancet, The, 1969, 293, 624-625.	6.3	8
70	TEACHING OF RADIOLOGY. Lancet, The, 1969, 293, 884-885.	6.3	1
71	EFFECT OF L-DOPA ON DEPRESSION. Lancet, The, 1969, 293, 885-886.	6.3	61
72	PHARMACOLOGICAL STUDIES ON THE BRAIN MECHANISMS UNDERLYING TWO FORMS OF BEHAVIORAL EXCITATION: STEREOTYPED HYPERACTIVITY AND "RAGE". Annals of the New York Academy of Sciences, 1969, 159, 928-938.	1.8	47
73	Animal Model of Depression. Archives of General Psychiatry, 1969, 21, 240.	13.8	436
74	The investigation of adrenergic metabolism with 7H3-Norepinephrine in psychiatric disordersâ€"I Temporal changes in the distribution of urinary tritiated metabolites and the effects of drugs. Journal of Psychiatric Research, 1969, 6, 307-319.	1.5	6

#	Article	IF	Citations
75	The investigation of adrenergic metabolism with 7H3-norepinephrine in psychiatric disordersâ€"II Temporal changes in the distribution of urinary tritiated metabolites in affective disorders. Journal of Psychiatric Research, 1969, 6, 321-333.	1.5	16
76	Indoleamines and Affective Disorders. Psychosomatic Medicine, 1969, 31, 107-114.	1.3	55
77	A Psychoendocrine Study of Pregnancy and Puerperium. American Journal of Psychiatry, 1969, 125, 1380-1386.	4.0	39
78	Lithium Carbonate. Canadian Psychiatric Association Journal, 1970, 15, 189-200.	0.3	3
79	Swim-Stress-Induced Inactivity: Relation to Body Temperature and Brain Norepinephrine, and Effects of d-Amphetamine. Psychosomatic Medicine, 1970, 32, 51-60.	1.3	50
80	Catecholamines, a Dream Sleep Model, and Depression. American Journal of Psychiatry, 1970, 127, 43-50.	4.0	12
81	The effect of Î²â€adrenergic blockade on the determination of the total amount of haemoglobin in affective psychoses. Acta Psychiatrica Scandinavica, 1970, 46, 137-144.	2.2	0
82	Methysergide as a Treatment for Mania. American Journal of Psychiatry, 1970, 127, 354-356.	4.0	11
83	A CONTROLLED STUDY OF THE ANTIDEPRESSANT EFFECT OF Pâ€CHLOROâ€Nâ€METHYLAMPHETAMINE, A COMPOUND WITH A SELECTIVE EFFECT ON THE CENTRAL 5â€HYDROXYTRYPTAMINE METABOLISM. Acta Psychiatrica Scandinavica, 1970, 46, 365-373.	2.2	9
84	Serotonin Now: Clinical Implications of Inhibiting Its Synthesis with Para-Chlorophenylalanine. Annals of Internal Medicine, 1970, 73, 607.	2.0	106
85	PARKINSONISM, Lâ€DOPA AND MENTAL DEPRESSION. Journal of the American Geriatrics Society, 1970, 18, 513-516.	1.3	19
86	Theories of Biological Etiology of Affective Disorders. International Review of Neurobiology, 1970, 12, 145-175.	0.9	58
87	Dopamine Excretion in Affective States and following Li2CO3 Therapy. Nature, 1970, 225, 868-869.	13.7	45
88	Influence of Hydrocortisone and Glucagon on Liver Tyrosine Transaminase and on Brain Tyrosine, Norepinephrine and Serotonin. Nature, 1970, 228, 73-75.	13.7	15
89	Effects of Lithium and of pH on Synaptosomal Metabolism of Noradrenaline. Nature, 1970, 228, 1301-1303.	13.7	56
90	Inhibitory effect of two newer antidepressants, Lu 5-003 and Lu 3-010, on serotonin uptake in human blood platelets in vitro. Psychopharmacology, 1970, 17, 94-99.	1.5	13
91	Investigation into the possible influence of chlorinated amphetamine derivatives on 5-hydroxytryptamine synthesis in man. Psychopharmacology, 1970, 18, 412-420.	1.5	10
92	Vanilmandelicaciduria in the Different Clinical Phases of Manic Depressive Psychosis. British Journal of Psychiatry, 1970, 116, 435-436.	1.7	4

#	Article	IF	Citations
93	Folate Deficiency in Depressive Illness. British Journal of Psychiatry, 1970, 117, 287-292.	1.7	154
94	Norepinephrine Turnover and Metabolism in Rat Brain after Long-Term Administration of Imipramine. Science, 1970, 168, 867-869.	6.0	128
95	Thyroid-Hormone Enhancement of Imipramine in Nonretarded Depressions. New England Journal of Medicine, 1970, 282, 1063-1067.	13.9	141
96	Tryptophan metabolism in depression. Journal of Neurology, Neurosurgery and Psychiatry, 1970, 33, 698-704.	0.9	67
97	Psychosis and Other Psychiatric Manifestations of Levodopa Therapy. Archives of Neurology, 1970, 23, 193-200.	4.9	181
98	Brain Norepinephrine: Enhanced Turnover after Rubidium Treatment. Science, 1970, 168, 501-503.	6.0	74
99	ADMINISTRATION OF A PERIPHERAL DECARBOXYLASE INHIBITOR WITH L-DOPA TO DEPRESSED PATIENTS. Lancet, The, 1970, 295, 908-911.	6.3	69
100	L-DOPA IN DEPRESSED PATIENTS. Lancet, The, 1970, 295, 352.	6.3	28
101	Catecholamine metabolism in affective disordersâ€”III. Journal of Psychiatric Research, 1970, 7, 171-183.	1.5	201
102	THE SWITCH PROCESS FROM DEPRESSION TO MANIA: RELATIONSHIP TO DRUGS WHICH ALTER BRAIN AMINES. Lancet, The, 1970, 295, 1022-1027.	6.3	117
103	Rapid elevation of biogenic amine metabolites in human CSF following probenecid. Life Sciences, 1970, 9, 1397-1408.	2.0	114
104	The influence of imipramine on the central effects of dihydroxyphenylalanine. Neuropharmacology, 1970, 9, 467-468.	2.0	3
105	Levodopa. Drugs, 1971, 2, 262-400.	4.9	46
106	Desipramine (DMI): Effect on the levels of acetylcholine (ACh) in whole brain and in striatum of rats. European Journal of Pharmacology, 1971, 15, 141-144.	1.7	19
107	BIOCHEMICAL CHANGES IN DEPRESSION. Lancet, The, 1971, 297, 448-449.	6.3	6
108	AMPHETAMINE WITHDRAWAL: DEPRESSION AND M.H.P.G. EXCRETION. Lancet, The, 1971, 298, 485-486.	6.3	52
109	Biochemistry of Affective Disorders. Psychosomatics, 1971, 12, 260-272.	2.5	16
110	DRUGS AND THE FETAL EYE. Lancet, The, 1971, 297, 448.	6.3	5

#	Article	IF	Citations
111	Depression of behavior and the brain content of Î±-methylnorepinephrine and Î±-methyldopamine following the administration of Î±-methyldopa. Neuropharmacology, 1971, 10, 33-44.	2.0	25
112	Effect of L-DOPA treatment on brain serotonin metabolism in depressed patients. Life Sciences, 1971, 10, 751-759.	2.0	48
113	A comparison of the inhibitory activities of iprindole and imipramine on the uptake of 5-hydroxytryptamine and noradrenaline in brain slices. Life Sciences, 1971, 10, 1267-1277.	2.0	86
114	Effect of tranquilizers and antidepressants on glycogen phosphorylase of rat brain. Biochemical Pharmacology, 1971, 20, 1889-1900.	2.0	13
115	Trace metals may decrease hypercholesterolemia in crowded cholesterol-fed roosters. Environmental Research, 1971, 4, 520-529.	3.7	1
116	Mechanisms of renal lithium handling and their relationship to mineralocoticoids: A dissociation between sodium and lithium ions. Journal of Psychiatric Research, 1971, 8, 91-105.	1.5	52
117	Effect of lithium salts on electrolyte metabolism. Journal of Psychiatric Research, 1971, 8, 139-159.	1.5	54
118	A fluorimetric method for the determination of 4-hydroxy-3-methoxyphenylglycol in urine. Clinica Chimica Acta, 1971, 34, 387-392.	0.5	11
119	3-Methoxy-4-hydroxyphenylethylene glycol in human cerebrospinal fluid. Clinica Chimica Acta, 1971, 35, 145-150.	0.5	125
120	Lithium's site of action: Clues from side effects. Comprehensive Psychiatry, 1971, 12, 224-229.	1.5	16
121	Combined Antidepressant Therapy. British Journal of Psychiatry, 1971, 118, 301-304.	1.7	47
122	Dextroamphetamine Response as a Possible Predictor of Improvement With Tricyclic Therapy in Depression. Archives of General Psychiatry, 1971, 25, 247.	13.8	69
123	Biochemistry of Depression. Canadian Psychiatric Association Journal, 1971, 16, 247-252.	0.3	10
124	Resting Plasma Catecholamine Concentrations in Patients With Depression and Anxiety. Archives of General Psychiatry, 1971, 24, 65.	13.8	236
125	Clinical Hypothyroidism Occurring During Lithium Treatment: Two Case Histories and a Review of Thyroid Function in 19 Patients. American Journal of Psychiatry, 1971, 128, 158-163.	4.0	50
126	Monoamine precursors in the treatment of depression. Clinical Pharmacology and Therapeutics, 1971, 12, 743-761.	2.3	68
127	A Possible Genetic Factor Related to Psychosis. American Journal of Psychiatry, 1971, 128, 311-317.	4.0	20
128	Differential Catechol-O-Methyltransferase Activity in Unipolar and Bipolar Affective Illness. Archives of General Psychiatry, 1971, 25, 348.	13.8	87

#	Article	IF	Citations
129	Retarded depression and the dopamine metabolism. Psychopharmacology, 1971, 19, 199-203.	1.5	140
130	A comparative study of the therapeutic effects of some 4-chlorinated amphetamine derivatives in depressive patients. Psychopharmacology, 1971, 20, 66-76.	1.5	11
131	Regular Induction of Hypomania by L-Dopa in â€œBipolarâ€•Manic-depressive Patients. Nature, 1971, 229, 135-136.	13.7	249
132	Catecholamine Metabolism, Depression and Stress. Nature, 1971, 230, 330-331.	13.7	67
133	Determination of 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) in cerebrospinal fluid. Analytical Biochemistry, 1971, 39, 498-504.	1.1	62
134	Objective therapy predictors in depression: A multivariate approach. Journal of Clinical Psychology, 1971, 27, 3-29.	1.0	23
135	Hydrocortisone-Mediated Increase of Norepinephrine Uptake by Brain Slices. Science, 1971, 171, 178-179.	6.0	39
136	Rubidium and Lithium: Opposite Effects on Amine-Mediated Excitement. Science, 1971, 172, 1355-1357.	6.0	97
137	Effects of Long-Term Reserpine Treatment on Brain Tyrosine Hydroxylase and Behavioral Activity. Science, 1971, 173, 847-849.	6.0	75
138	Social Behavior of Monkeys Selectively Depleted of Monoamines. Science, 1971, 174, 428-431.	6.0	68
139	Relation of Sex and Aging to Monoamine Oxidase Activity of Human Brain, Plasma, and Platelets. Archives of General Psychiatry, 1971, 24, 536.	13.8	280
140	Mental Effects of High-Dosage Levodopa. Archives of General Psychiatry, 1971, 24, 61.	13.8	85
141	Facilitation of Noradrenaline Uptake by Lithium. Australian and New Zealand Journal of Psychiatry, 1971, 5, 280-285.	1.3	9
142	Adenosine 3',5'-Monophosphate and Mania. JAMA - Journal of the American Medical Association, 1971, 216, 1856.	3.8	0
143	Basic psychosomatic concepts. Postgraduate Medical Journal, 1975, 47, 525-532.	0.9	5
144	Altered Tyrosine Daytime Plasma Levels in Endogenous Depressive Patients. Archives of General Psychiatry, 1971, 25, 359.	13.8	22
145	Thyroid State: Effects on Pre-and Postsynaptic Central Noradrenergic Mechanisms. Science, 1972, 175, 79-82.	6.0	93
146	Biogenic Amine Metabolites in Cerebrospinal Fluid of Depressed and Manic Patients. Science, 1972, 175, 1380-1382.	6.0	176

#	Article	IF	Citations
147	The Brief MAST: A Shortened Version of the Michigan Alcoholism Screening Test. American Journal of Psychiatry, 1972, 129, 342-345.	4.0	809
148	The "Switch Process" in Manic-Depressive Illness. Archives of General Psychiatry, 1972, 27, 304.	13.8	122
149	The "Switch Process" in Manic-Depressive Illness. Archives of General Psychiatry, 1972, 27, 312.	13.8	69
150	The Continuum Model as a Resolution of Paradoxes in Manic-Depressive Psychosis. British Journal of Psychiatry, 1972, 120, 133-141.	1.7	27
151	Amphetamine Withdrawal: Affective State, Sleep Patterns, and MHPG Excretion. American Journal of Psychiatry, 1972, 129, 263-269.	4.0	125
152	Plasma Dopamine-Î²-Hydroxylase Activity in Hypertension and Various Neuropsychiatric Disorders. Scandinavian Journal of Clinical and Laboratory Investigation, 1972, 30, 283-289.	0.6	82
153	Suicidal Depression and Physical Illness. JAMA - Journal of the American Medical Association, 1972, 219, 1303.	3.8	26
154	Synergistic Action Between Iodine and Lithium. JAMA - Journal of the American Medical Association, 1972, 221, 506.	3.8	5
155	Chapter 5. Recent Developments Relating Serotonin and Behavior. Annual Reports in Medicinal Chemistry, 1972, 7, 47-58.	0.5	16
156	Catecholamine Metabolism in Affective Disorders: Excretion of 3-Methoxy-4-Hydroxymandelic Acid in Depressive States. Canadian Psychiatric Association Journal, 1972, 17, 221-227.	0.3	0
157	Catecholamine Metabolism, Depressive Illness, and Drug Response. Archives of General Psychiatry, 1972, 26, 252.	13.8	336
158	Biochemical and Pharmacological Variations in Manic-Depressive Illness. American Journal of Psychiatry, 1972, 129, 337-342.	4.0	11
159	The Comparative Antidepressant Value of L-Tryptophan and Imipramine With and Without Attempted Potentiation by Liothyronine. Archives of General Psychiatry, 1972, 26, 234.	13.8	229
160	Changes in Fluid Intake suggesting Depressed Appetites in Rats with Central Catecholaminergic Lesions. Nature: New Biology, 1972, 237, 279-281.	4.5	21
161	Specific Noradrenergic Neurones destroyed by 6-Hydroxydopamine Injection into Newborn Rats. Nature: New Biology, 1972, 239, 247-248.	4.5	67
162	Skin melanin concentrations in the affective disorders: possible relationships to the catecholamine hypothesis. Psychological Medicine, 1972, 2, 391-396.	2.7	1
163	Daily variations of the urine content of 3-methoxy-4-hydroxyphenylglycol in two manic-depressive patients. Psychological Medicine, 1972, 2, 81-85.	2.7	127
164	Catecholamine metabolism in affective disorders â€"IV. Preliminary studies of norepinephrine metabolism in depressed patients treated with amitriptyline. Journal of Psychiatric Research, 1972, 9, 173-185.	1.5	38

#	Article	IF	Citations
165	Thyroid-imipramine clinical and chemical interaction: Evidence for a receptor deficit in depression. Journal of Psychiatric Research, 1972, 9, 187-205.	1.5	64
166	Psychobiological and pharmacological studies of manic-depressive illness. Journal of Psychiatric Research, 1972, 9, 207-226.	1.5	17
167	Adrenocortical steroid hormones, electrolytes, and the disposition of the catecholamines with particular reference to depressive states. Journal of Psychiatric Research, 1972, 9, 227-241.	1.5	24
168	The effects of drugs on the behavioural and biochemical actions of intraventricular 6-hydroxydopamine. European Journal of Pharmacology, 1972, 17, 16-24.	1.7	32
169	Abnormalities of Indoleamines in Affective Disorders. Archives of General Psychiatry, 1972, 26, 474.	13.8	285
170	EFFECT OF PHYSICAL ACTIVITY ON URINARY M.H.P.G. EXCRETION IN DEPRESSED PATIENTS. Lancet, The, 1972, 300, 766.	6.3	59
171	Cyclic Adenosine Monophosphate Phosphodiesterase in Brain: Effect on Anxiety. Science, 1972, 176, 428-430.	6.0	200
172	EFFECTS OF THYROTROPIN-RELEASING HORMONE IN DEPRESSION*1. Lancet, The, 1972, 300, 999-1002.	6.3	506
173	CHOLINERGIC REVERSAL OF MANIC SYMPTOMS. Lancet, The, 1972, 299, 1236-1237.	6.3	103
174	Weight Gain and Other Symptoms of the Ascending Depressive Curve. Psychosomatics, 1972, 13, 23-33.	2.5	13
175	AGEING, MONOAMINES, AND MONOAMINE-OXIDASE LEVELS. Lancet, The, 1972, 299, 634.	6.3	1
176	RADIATION-RELATED LEUKÃ†MIA AND LYMPHOMA. Lancet, The, 1972, 299, 1236.	6.3	6
177	PRESYSTOLIC MURMUR IN MITRAL STENOSIS. Lancet, The, 1972, 300, 765-766.	6.3	1
178	A CHOLINERGIC-ADRENERGIC HYPOTHESIS OF MANIA AND DEPRESSION. Lancet, The, 1972, 300, 632-635.	6.3	984
179	BLOOD-BARBITURATE LEVELS. Lancet, The, 1972, 299, 634.	6.3	0
180	Effect of intraventricular infusion of dopamine and norepinephrine on motor activity. Physiology and Behavior, 1972, 8, 653-658.	1.0	92
181	THE BLACK CLOUD THE RECOGNITION AND TREATMENT OF ENDOGENOUS DEPRESSION IN GENERAL PRACTICE. Medical Journal of Australia, 1972, 1, 637-643.	0.8	11
182	Serum dopamine-?-hydroxylase (D?H) activity and affective states. Psychopharmacology, 1972, 27, 11-16.	1.5	63

#	Article	IF	Citations
185	Cerebrospinal Fluid Levels of MHPG in Affective Disorders. Nature, 1972, 235, 440-441.	13.7	121
186	Specificities of Antibodies to Normetanephrine. FEBS Journal, 1972, 26, 191-195.	0.2	21
187	Depression: Loss of reinforcers of loss of reinforcer effectiveness?. Behavior Therapy, 1972, 3, 240-247.	1.3	139
188	RELATIONSHIP OF SLEEP TO NEUROANATOMICAL CIRCUITS, BIOCHEMISTRY, AND BEHAVIOR. Annals of the New York Academy of Sciences, 1972, 193, 95-111.	1.8	50
190	The balance of biogenic amines as condition for normal behaviour. Journal of Neural Transmission, 1972, 33, 163-178.	1.4	43
191	Identification of free and conjugated 3-methoxy-4-hydroxyphenylglycol (MOPEG) in rat brain by gas chromatography and mass fragmentography. Analytical Biochemistry, 1973, 55, 420-431.	1.1	37
192	5-Hydroxyindole acetic acid and homovanillic acid in cerebrospinal fluid in manic-depressive psychosis and the effect of probenecid treatment. European Journal of Clinical Pharmacology, 1973, 6, 75-80.	0.8	42
193	Effects of lithium and amitriptyline therapy on somatosensory evoked response â€œexcitabilityâ€• measurements. Psychopharmacology, 1973, 29, 185-196.	1.5	15
194	The uptake of dopamine and serotonin in rat brain during progesterone decline. Psychopharmacology, 1973, 32, 183-191.	1.5	34
195	Nonlinear changes in activity and emotional reactivity scores following central noradrenergic lesions in rats. Psychopharmacology, 1973, 32, 313-325.	1.5	38
196	Central mechanism of the hyperthermic effect and its potentiation by antidepressants following injection of large doses of noradrenalin into the cerebral ventricles of mice. Bulletin of Experimental Biology and Medicine, 1973, 76, 1333-1336.	0.3	0
197	Accumulation of 3-methoxy-4-hydroxyphenylglycol-sulfate in rabbit cerebrospinal fluid following probenecid. Brain Research, 1973, 54, 403-407.	1.1	23
198	Monoamine fluorescence histochemistry of human post mortem brain. Brain Research, 1973, 63, 231-247.	1.1	72
199	Desynchronized sleep and MHPG excretion: an inverse correlation. Brain Research, 1973, 61, 412-416.	1.1	19
200	Changes in human serum dopamine-Î²-hydroxylase activity in various physiological and pathological states. Life Sciences, 1973, 13, xxxvii-xxxix.	2.0	1
201	The identification of depressed patients who have a disorder of NE metabolism and/or disposition. Life Sciences, 1973, 13, cvi-cxi.	2.0	9
202	Hypothalamic releasing hormones and catecholamines: A new interface. Life Sciences, 1973, 13, cxxxiv-cxxxvi.	2.0	1
203	On the mechanism of central action of amphetamine: The role of catecholamines. Neuropharmacology, 1973, 12, 917-931.	2.0	23

#	Article	IF	Citations
204	Effect of desmethylimipramine on acetylcholine uptake by slices of rat brain cortex. Biochemical Pharmacology, 1973, 22, 2062-2066.	2.0	3
205	An in vitro model for the study of psychotropic drugs and as a criterion of antidepressant activity. Biochemical Pharmacology, 1973, 22, 73-84.	2.0	59
206	Simultaneous separation of acid metabolites of catecholamines: Application to urine and tissue. Clinica Chimica Acta, 1973, 45, 159-164.	0.5	15
207	Intracellular lithium concentration and clinical response: Towards a membrane theory of depression. Journal of Psychiatric Research, 1973, 10, 9-18.	1.5	223
208	Skeletal muscle abnormalities in patients with affective disorders. Journal of Psychiatric Research, 1973, 10, 43-57.	1.5	21
209	Effects of Isocarboxazid on Sleep. Psychiatry and Clinical Neurosciences, 1973, 27, 117-142.	1.0	1
210	Blood platelets as a model for monoamine-containing neurones. Progress in Neurobiology, 1973, 1, 151-198.	2.8	381
211	CLINICAL SIGNIFICANCE OF PLASMA LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS IN THE TREATMENT OF DEPRESSION. Lancet, The, 1973, 301, 556-558.	6.3	9
212	GOLDEN LIQUOR AMNII. Lancet, The, 1973, 301, 556.	6.3	5
213	Cerebral Monoamines and Depression. Archives of General Psychiatry, 1973, 28, 827.	13.8	165
214	Urinary Catecholamine Metabolites during Behavioral Changes in a Patient with Manic-Depressive Cycles. Science, 1973, 179, 300-302.	6.0	113
215	Central Norepinephrine Metabolism in Affective Illness: MHPG in the Cerebrospinal Fluid. Science, 1973, 179, 1002-1003.	6.0	162
216	MHPG Excretion in Depressive Disorders: Relation to Clinical Subtypes and Desynchronized Sleep. Science, 1973, 181, 762-764.	6.0	77
217	Behavior of Free-Ranging Macaques after Intraventricular 6-Hydroxydopamine. Science, 1973, 181, 1256-1258.	6.0	37
218	Hyperactivity and Brain Catecholamines in Lead-Exposed Developing Rats. Science, 1973, 182, 1022-1024.	6.0	175
219	Hidden Conceptual Models in Clinical Psychiatry. New England Journal of Medicine, 1973, 288, 345-351.	13.9	126
220	Melancholia, a Model in Madness: A Discussion of Recent Psychobiologic Research into Depressive Illness. Psychiatry in Medicine, 1973, 4, 351-378.	0.4	21
221	Imipramine Withdrawal: An Akathisia-Like Syndrome. American Journal of Psychiatry, 1973, 130, 1286-1287.	4.0	34

#	Article	IF	Citations
222	Depressive Disorders: Toward a Unified Hypothesis: Clinical, experimental, genetic, biochemical, and neurophysiological data are integrated. Science, 1973, 182, 20-29.	6.0	394
223	Catecholamine-containing neurones and electrical self-stimulation: 2. A theoretical interpretation and some psychiatric implications. Psychological Medicine, 1973, 3, 66-73.	2.7	219
224	3-Methoxy-4-hydroxyphenylglycol in depression. Psychological Medicine, 1973, 3, 333-336.	2.7	72
225	Parasympathetic Suppression of Manic Symptoms by Physostigmine. Archives of General Psychiatry, 1973, 28, 542.	13.8	212
226	Cerebrospinal Fluid Amine Metabolites in Affective Illness: The Probenecid Technique. American Journal of Psychiatry, 1973, 130, 73-79.	4.0	230
227	Yesterday, Today and Tomorrow a Point of View. Canadian Psychiatric Association Journal, 1973, 18, 371-376.	0.3	2
228	An Animal Model for Psychopharmacological Research with Relevance to Psychiatry. Canadian Psychiatric Association Journal, 1973, 18, 139-146.	0.3	0
229	Psychomotor Activity and Cerebrospinal Fluid Amine Metabolites in Affective Illness. American Journal of Psychiatry, 1973, 130, 67-72.	4.0	262
230	The Effect of Clomipramine (Anafranil) on Brain Metabolism. Journal of International Medical Research, 1973, 1, 299-307.	0.4	1
231	Cerebrospinal Fluid MHPG. Archives of General Psychiatry, 1973, 28, 230.	13.8	80
232	L-Tryptophan in Mania. Archives of General Psychiatry, 1974, 30, 56.	13.8	257
233	L-dopa and arousal. Journal of Neurology, Neurosurgery and Psychiatry, 1974, 37, 416-421.	0.9	33
234	Alterations in Brain Norepinephrine and Serotonin Metabolism Following Experimental Hypothyroidism Induced by Methimazole. Endocrine Research Communications, 1974, 1, 261-270.	0.5	10
235	Brain Biogenic Amine Depletion and Mood. Archives of General Psychiatry, 1974, 30, 447.	13.8	116
236	Differential effect of chlorimipramine and nortriptyline on cerebrospinal fluid metabolites of serotonin and noradrenaline in depression. European Journal of Clinical Pharmacology, 1974, 7, 365-368.	0.8	97
237	Platelet adenylate cyclase responses in depression: Implications for a receptor defect. Psychopharmacology, 1974, 36, 291-300.	1.5	53
238	Serum dopamine-beta-hydroxylase in depressed patients and the effect of electroconvulsive shock treatment. Psychopharmacology, 1974, 40, 241-248.	1.5	14
239	Effect of ECT on dopaminergic and noradrenergic mechanisms. Psychopharmacology, 1974, 35, 149-158.	1.5	17

#	Article	IF	Citations
240	Effect of lithium on the eeg and serotonin concentration in the brain. Bulletin of Experimental Biology and Medicine, 1974, 78, 901-903.	0.3	0
241	EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON UPTAKE AND RELEASE OF 3H-NORADRENALINE IN ISOLATED GUINEA-PIG ATRIA. Clinical and Experimental Pharmacology and Physiology, 1974, 1, 429-439.	0.9	10
242	A STUDY OF SELECTED CATECHOLAMINE METABOLIZING ENZYMES: A COMPARISON OF DEPRESSIVE SUICIDES AND ALCOHOLIC SUICIDES WITH CONTROLS. Journal of Neurochemistry, 1974, 23, 791-802.	2.1	116
243	Measurement of the two conjugates of 3-methoxy-4-hydroxyphenylglycol in urine. Biochemical Medicine, 1974, 10, 219-228.	0.5	38
244	The identification of depressed patients who have a disorder of ne metabolism and/or disposition. Biochemical Pharmacology, 1974, 23, 907-912.	2.0	7
245	Changes in human serum dopamine-Î²-hydroxylase activity in various physiological and pathological states. Biochemical Pharmacology, 1974, 23, 924-929.	2.0	0
246	Hypothalamic releasing hormones and catecholamines: A new interface. Biochemical Pharmacology, 1974, 23, 962-968.	2.0	1
247	Affective disorders: The catecholamine hypothesis revisited. Biochemical Pharmacology, 1974, 23, 969-976.	2.0	4
248	Catecholamine metabolism and affective disorders: Studies of MHPG excretion. Biochemical Pharmacology, 1974, 23, 977-983.	2.0	2
249	Effect of lithium on prostaglandin E1â^' stimulated adenylate cyclase activity of human platelets. Biochemical Pharmacology, 1974, 23, 845-855.	2.0	49
250	Behavioral effects of a new dopamine-Î²-hydroxylase inhibitor (fusaric acid) in man. Journal of Psychiatric Research, 1974, 11, 211-217.	1.5	17
251	A method for determination of catechol-O-methyltransferase activity in red blood cells. Clinica Chimica Acta, 1974, 54, 391-394.	0.5	17
252	Mania and marriage: The relationship between biological and behavioral variables. Comprehensive Psychiatry, 1974, 15, 411-421.	1.5	5
253	The effect of tri-iodothyronine in combination with imipramine on [3H]-cyclic AMP production in slices of rat cerebral cortex. Neuropharmacology, 1974, 13, 1131-1140.	2.0	93
254	Estimation of the contribution of peripheral and central noradrenergic neurones to urinary 3-methoxy-4-hydroxyphenylglycol in the rat. Neuropharmacology, 1974, 13, 165-176.	2.0	42
255	Evidence of altered regulation of ventilation during exposure to hypoxia. Respiration Physiology, 1974, 20, 379-392.	2.8	46
256	Subtype of Affective Psychoses Classified by Response on Amineprecursors and Monoamine Metabolism. Psychiatry and Clinical Neurosciences, 1974, 28, 93-100.	1.0	8
257	EFFECTS OF IMIPRAMINE AND DESIPRAMINE ON RESPONSES OF SINGLE CORTICAL NEURONES TO NORADRENALINE AND 5â€HYDROXYTRYPTAMINE. British Journal of Pharmacology, 1974, 52, 349-358.	2.7	57

#	Article	IF	Citations
258	AMINES AND THEORIES IN PSYCHIATRY. Lancet, The, 1974, 304, 52-53.	6.3	51
259	A possible mechanism for the anti-depressant activity of thyrotropin releasing hormone. Life Sciences, 1974, 15, 1073-1082.	2.0	109
260	SERUM-LITHIUM CONTROL. Lancet, The, 1974, 304, 52.	6.3	3
261	On the roles of dopamine and noradrenaline in animal behaviour. Progress in Neurobiology, 1974, 3, 31-70.	2.8	21
262	Inhibition of Dopamine-B-Hydroxylase in Manic Patients. Archives of General Psychiatry, 1974, 31, 649.	13.8	52
263	The Effects of Cocaine on Depressed Patients. American Journal of Psychiatry, 1974, 131, 511-517.	4.0	180
264	Antihypertensive drugs and depression. Psychological Medicine, 1974, 4, 393-398.	2.7	30
265	More on "Assumption and Inference on Human Origins". Current Anthropology, 1974, 15, 457-461.	0.8	1
266	Effects of Amitriptyline and Imipramine on Amine Metabolites in the Cerebrospinal Fluid of Depressed Patients. Archives of General Psychiatry, 1974, 30, 234.	13.8	49
267	Urinary excretion of the sulphate and glucuronide of 3-methoxy-4-hydroxyphenylethyleneglycol in a manic-depressive patient. Psychological Medicine, 1975, 5, 279-285.	2.7	17
268	Amine Precursors and Depression. Archives of General Psychiatry, 1975, 32, 22.	13.8	102
269	Neurochemical and Neuropharmacological Aspects of Depression. International Review of Neurobiology, 1975, 18, 357-387.	0.9	15
270	Erythrocyte Soluble Catechol-O-Methyl Transferase Activity in Primary Affective Disorder. Archives of General Psychiatry, 1975, 32, 1351.	13.8	71
271	Time-dependent variations in aversively motivated behaviors: Nonassociative effects of cholinergic and catecholaminergic activity.. Psychological Review, 1975, 82, 359-385.	2.7	145
272	Lithium Carbonate Response in Depression. Archives of General Psychiatry, 1975, 32, 1107.	13.8	143
273	Consequences of commitment to and disengagement from incentives.. Psychological Review, 1975, 82, 1-25.	2.7	882
274	Biochemical post-mortem findings in depressed patients. Journal of Neural Transmission, 1975, 37, 95-109.	1.4	112
275	Metabolism of tyrosine and phenylalanine in Trtpanosoma brucei gambiense. International Journal of Biochemistry & Cell Biology, 1975, 6, 197-203.	0.8	27

#	Article	IF	Citations
276	The effect of lithium treatment on manic symptoms and levels of monoamine metabolites in cerebrospinal fluid of manic depressive patients. Psychopharmacology, 1975, 44, 99-103.	1.5	37
277	Modifications by lithium of behavioral responses to methamphetamine and tetrabenazine. Psychopharmacology, 1975, 42, 243-248.	1.5	50
278	The effect of lithium on urinary MHPG in unipolar and bipolar depressed patients. Psychopharmacology, 1975, 42, 277-282.	1.5	31
279	Neurochemical and pharmacological studies on a new 5HT-uptake inhibitor, FG4963, with potential antidepressant properties. Psychopharmacology, 1975, 42, 21-26.	1.5	86
280	Plasma renin activity in depressed patients treated with increasing doses of lithium carbonate. Psychopharmacology, 1975, 45, 171-175.	1.5	22
281	Effect of experimental cerebral infarction in rat brain on catecholamines and behaviour. Nature, 1975, 255, 332-334.	13.7	233
282	BEHAVIORAL EFFECTS OF A NEW DOPAMINE-Î²-HYDROXYLASE INHIBITOR (FUSARIC ACID) IN MAN. , 1975, , 211-220.		0
283	Overview of Recent Research in Depression. Archives of General Psychiatry, 1975, 32, 285.	13.8	507
284	Antidepressant Response to Tricyclics and Urinary MHPG in Unipolar Patients. Archives of General Psychiatry, 1975, 32, 17.	13.8	259
285	Menstrual Cycle and Ovarian Hormone Effects on Plasma and Platelet Monoamine Oxidase (MAO) and Plasma Dopamine-Beta-Hydroxylase (DBH) Activities in the Rhesus Monkey. Psychosomatic Medicine, 1975, 37, 417-428.	1.3	47
286	Biogenic Amines and Depression. Archives of General Psychiatry, 1975, 32, 1357.	13.8	331
287	Behavioral Effects of Hypothalamic Releasing Hormones in Animals and Men. Progress in Brain Research, 1975, 42, 1-9.	0.9	15
288	Pharmacotherapy of Depression - A Critical Review. Psychosomatics, 1975, 16, 17-20.	2.5	4
289	IS THERE AN INCREASE IN MONOAMINE-OXIDASE ACTIVITY IN DEPRESSIVE ILLNESS?. Lancet, The, 1975, 305, 1045-1049.	6.3	63
290	Effect of Drugs on Energy Metabolism of the Brain and on Cerebral Transport. , 1975, , 1-46.		0
291	Doxepin and imipramine: Effect on catecholamine inhibition of ganglionic transmission. Life Sciences, 1975, 17, 257-262.	2.0	4
292	The effect of drugs with antidepressant activity upon the hypothermia and behavioural depression induced in mice by pimozide or centrally administered noradrenaline. Neuropharmacology, 1975, 14, 85-90.	2.0	12
293	The effects of thyrotropin-releasing hormone on the behaviour of rats pretreated with Î±-methyltyrosine. Neuropharmacology, 1975, 14, 489-492.	2.0	31

#	Article	IF	Citations
294	Influence of desmethylimipramine on some neurochemical alterations during experimental hypothyroidism. Neuropharmacology, 1975, 14, 747-753.	2.0	4
295	The pharmacologic meaning of successful antipsychotic-antidepressant combinations. Comprehensive Psychiatry, 1975, 16, 427-434.	1.5	10
296	Monoamine oxidase activity in blood platelets from patients with cyclophrenic depressive syndromes. Biochemical Medicine, 1975, 14, 347-354.	0.5	53
297	The nature of [3H]imipramine binding to synaptosomes. Biochemical Pharmacology, 1975, 24, 681-685.	2.0	17
298	Antidepressant drugs affect dopamine uptake. Biochemical Pharmacology, 1975, 24, 1896-1898.	2.0	126
299	The effect of lithium treatment on the acetylcholine content of rat brain. Biochemical Pharmacology, 1975, 24, 1819-1820.	2.0	9
300	Comparative studies of a new 5HT-uptake inhibitor and some tricyclic thymoleptics. European Journal of Pharmacology, 1975, 32, 108-115.	1.7	44
302	EFFECT OF FLUPHENAZINE ON TISSUE NORADRENALINE CONCENTRATIONS AND ITS INTERACTION WITH PARGYLINE. British Journal of Pharmacology, 1975, 53, 593-595.	2.7	0
303	EFFECTS OF IPRINDOLE ON RESPONSES OF SINGLE CORTICAL AND CAUDATE NEURONES TO MONOAMINES AND ACETYLCHOLINE. British Journal of Pharmacology, 1975, 55, 17-25.	2.7	32
304	Neurochemical and pharmacological properties of a new serotonin-potentiating phenylpiperidine derivative FG 4963. Nordic Journal of Psychiatry, 1975, 29, 475-481.	0.2	2
305	Thyreoidea och depression En Ã¶versikt Ã¶ver hormonbehandling vid depressioner med tonvikt lagd pÃ¥ TRH:s roll som ett eventuellt antidepressivum och diagnosinstrument. Nordic Journal of Psychiatry, 1975, 29, 487-496.	0.2	2
306	Precursors of Ego in Neonates. Journal of the American Academy of Child Psychiatry, 1976, 15, 257-268.	0.7	10
308	The determination of a brain arteriovenous difference for 3-methoxy-4-hydroxyphenethyleneglycol (MHPG). Brain Research, 1976, 118, 167-173.	1.1	140
309	Neonatal Cerebral Intraventricular HÃ¦morrhage. Lancet, The, 1976, 308, 1341-1342.	6.3	2
310	The possible role of beta-adrenergic and alpha-adrenergic antagonist sensitive systems in the brain in the mechanism of psychosis. Medical Hypotheses, 1976, 2, 104-106.	0.8	1
311	Elevated serum and hepatic tyrosine aminotransferase in voles chronically infected with Trypanosoma brucei gambiense. Experimental Parasitology, 1976, 39, 1-6.	0.5	24
312	Biochemical Basis of An Animal Model of Depressive Illness â€" A Preliminary Report â€". Psychiatry and Clinical Neurosciences, 1976, 30, 207-218.	1.0	0
313	Measurement of 5â€"Hydroxyindole Compounds During L-5â€"HTP Treatment in Depressed Patients. Psychiatry and Clinical Neurosciences, 1976, 30, 463-473.	1.0	5

#	Article	IF	Citations
314	Reduction of Blood Platelet Serotonin Levels in Manic and Depressed Patients. Psychiatry and Clinical Neurosciences, 1976, 30, 475-486.	1.0	27
315	The biochemical evaluation of psychotropic drugs.. British Journal of Clinical Pharmacology, 1976, 3, 42-44.	1.1	0
316	A Twin Study of Human Red Blood Cell Catechol-O-Methyl Transferase. British Journal of Psychiatry, 1976, 128, 494-498.	1.7	22
317	Exploration of Affective Illness. Neuropsychobiology, 1976, 2, 145-160.	0.9	2
318	Late Effects on Rabbit Brain Morphology and Monoamine Metabolites Produced by60Co-Irradiation. Acta Radiologica: Therapy, Physics, Biology, 1976, 15, 433-446.	0.4	2
319	Serum creatine phosphokinase in schizophrenia. American Journal of Psychiatry, 1976, 133, 192-197.	4.0	40
320	Parachlorophenylalanine Reversal of Tranylcypromine Effects in Depressed Patients. Archives of General Psychiatry, 1976, 33, 811.	13.8	253
321	EFFECTS OF RUBIDIUM ON BEHAVIORAL RESPONSES TO METHAMPHETAMINE AND TETRABENAZINE. The Japanese Journal of Pharmacology, 1976, 26, 395-402.	1.2	1
322	Thymoleptic and Neuroleptic Drug Plasma Levels in Psychiatry: Current Status. International Review of Neurobiology, 1976, 19, 269-309.	0.9	37
323	EFFECT OF LITHIUM ON DOPAMINE UPTAKE BY BRAIN SYNAPTOSOMES. Journal of Neurochemistry, 1976, 27, 1237-1239.	2.1	14
324	Lithium inhibition of adrenaline-stimulated adenylate cyclase in humans. Nature, 1976, 259, 411-413.	13.7	125
325	A possible common mechanism of action of antidepressant treatments. Naunyn-Schmiedeberg's Archives of Pharmacology, 1976, 293, 109-114.	1.4	399
326	Psychopharmacological studies on echitovenidine. Pharmacological Research Communications, 1976, 8, 159-166.	0.2	2
328	The relationship between acetylator status and inhibition of monoamine oxidase, excretion of free drug and antidepressant response in depressed patients on phenelzine. Psychopharmacology, 1976, 46, 289-294.	1.5	40
329	Effect of lithium and other alkali metals on brain chemistry and behavior. Psychopharmacology, 1976, 45, 233-237.	1.5	14
330	Effect of lithium and other alkali metals on brain chemistry and behavior. Psychopharmacology, 1976, 45, 239-242.	1.5	26
331	Acute and chronic effects of 4-chloroamphetamine on monoamine metabolism in the rat brain. Psychopharmacology, 1976, 46, 11-18.	1.5	22
332	The effect of haloperidol on epinephrine-stimulated adenylate cyclase in humans. Psychopharmacology, 1976, 49, 215-217.	1.5	8

#	Article	IF	Citations
333	Drug-related test patterns of depressed patients. Psychopharmacology, 1976, 50, 205-210.	1.5	25
334	Rapid Procedure for Assessment of Compounds that Modify Uptake and Release of Tritiated Norepinephrine. Journal of Pharmaceutical Sciences, 1976, 65, 1556-1558.	1.6	1
335	Pharmacotherapy in Older Depressed Patients. Journal of Gerontology, 1976, 31, 304-310.	2.0	20
336	Mania in Childhood. American Journal of Diseases of Children, 1976, 130, 380.	0.5	129
337	Cholinergic changes during conditioned suppression in rats. Science, 1976, 193, 332-334.	6.0	87
338	Human Sleep and Its Disorders. , 1977, , .		93
339	Alteration of Free Serum Amino Acids in Voles Infected with Trypanosoma brucei gambiense. Journal of Parasitology, 1977, 63, 15.	0.3	31
340	The Influence of Oestrogens on the Wellbeing and Mental Performance in Climacteric and Postmenopausal Women. Acta Obstetricia Et Gynecologica Scandinavica, 1977, 56, 2-91.	1.3	55
341	Solubilization and partial purification of particulate catechol-O-methyltransferase from rat liver. Canadian Journal of Biochemistry, 1977, 55, 1108-1113.	1.4	42
342	The Switch Process in Manic-Depressive Psychosis. Annals of Internal Medicine, 1977, 87, 319.	2.0	46
343	Time Experience During Depression. Archives of General Psychiatry, 1977, 34, 1441.	13.8	81
344	Biochemistry of Mental Depression. Canadian Psychiatric Association Journal, 1977, 22, 467-481.	0.3	9
345	CNS Monoamine Metabolism in Bipolar Affective Disorder. Archives of General Psychiatry, 1977, 34, 735.	13.8	39
346	Sleep and behavioral changes possibly reflecting central receptor hypersensitivity following catecholamine synthesis inhibition in man. Acta Psychiatrica Scandinavica, 1977, 56, 189-203.	2.2	14
347	Evaluation of the combination of tryptophan and ECT in the treatment of depression. Acta Psychiatrica Scandinavica, 1977, 56, 319-334.	2.2	23
348	Studies of endocrine activity, plasma tryptophan and catecholamine excretion on psychosurgical patients. Acta Psychiatrica Scandinavica, 1977, 56, 1-14.	2.2	12
349	Estrogen Treatment in the Past and the Future in Cases of Estrogen Deficiency. Acta Obstetricia Et Gynecologica Scandinavica, 1977, 56, 5-10.	1.3	3
350	Electroencephalographic responses to photic stimulation in habitual smokers and nonsmokers.. Journal of Comparative and Physiological Psychology, 1977, 91, 418-422.	1.8	17

#	Article	IF	Citations
351	Antidepressant evaluation and the pharmacological actions of FG4963 in depressive patients. European Journal of Pharmacology, 1977, 42, 31-37.	1.7	72
352	Selective inhibition of noradrenaline and serotonin uptake by C 49802-B-Ba and CGP 6085 A. European Journal of Pharmacology, 1977, 46, 387-391.	1.7	37
353	A profile of nomifensine.. British Journal of Clinical Pharmacology, 1977, 4, 243S-248S.	1.1	13
354	Review of the pharmacology of existing antidepressants.. British Journal of Clinical Pharmacology, 1977, 4, 57S-68S.	1.1	28
355	NEONATAL CEREBRAL INTRAVENTRICULAR HÃ†MORRHAGE. Lancet, The, 1977, 309, 305.	6.3	4
356	Some aspects of monoamine oxidase activity in brain. Progress in Neurobiology, 1977, 8, 325-348.	2.8	52
357	On â€œlearned helplessnessâ€• The therapeutic effects of electroconvulsive shocks. Physiological Psychology, 1977, 5, 355-358.	0.8	23
358	Effects of org 6582, chlorimipramine and desmethylimipramine on the depletion of biogenic amines from the rat brain in vivo. Biochemical Pharmacology, 1977, 26, 1083-1084.	2.0	9
359	Non-random relation between drugs of abuse and psychiatric diagnosis. Journal of Psychiatric Research, 1977, 13, 179-184.	1.5	96
360	Electrophoretic pattern of plasma MAO in schizophrenia and affective illness. Journal of Psychiatric Research, 1977, 13, 119-123.	1.5	3
361	A gas chromatographic-mass spectrometric (GC-MS) assay for 3-methoxy-4-hydroxyphenethyleneglycol and vanilmandelic acid in human serum. Clinica Chimica Acta, 1977, 81, 183-192.	0.5	66
362	Catecholamines in neocortex of rhesus monkeys: regional distribution and ontogenetic development. Brain Research, 1977, 124, 576-580.	1.1	110
363	Plasma Cholinesterase Polymorphism in Down’s Syndrome. Human Heredity, 1977, 27, 52-58.	0.4	5
365	Metaraminol uptake by human thrombocytes: A poor model for neuronal noradrenaline uptake. Experientia, 1977, 33, 1354-1355.	1.2	2
366	Blockade of presynaptic ?-receptors and of amine uptake in the rat brain by the antidepressant mianserine. Naunyn-Schmiedeberg's Archives of Pharmacology, 1977, 300, 31-37.	1.4	206
367	Depression: a new animal model sensitive to antidepressant treatments. Nature, 1977, 266, 730-732.	13.7	3,843
368	Development of Î²-adrenergic receptor subsensitivity by antidepressants. Nature, 1977, 268, 455-456.	13.7	746
369	EFFECT OF CHRONIC EXERCISE ON THE PERSONALITY OF ADULTS. Annals of the New York Academy of Sciences, 1977, 301, 958-969.	1.8	17

#	Article	IF	Citations
370	Noradrenaline, depressive illness, and the action of amitriptyline. Psychopharmacology, 1977, 54, 57-60.	1.5	37
371	Comparative effects of d-amphetamine, l-amphetamine and methylphenidate on mood in man. Psychopharmacology, 1977, 53, 1-12.	1.5	83
372	Neurochemical characterization of a new potent and selective serotonin uptake inhibitor: Lu 10-171. Psychopharmacology, 1977, 51, 225-233.	1.5	170
373	Plasma renin activity in primary and secondary depression. Archiv Fur Psychiatrie Und Nervenkrankheiten, 1977, 224, 313-318.	0.6	4
374	The differential effect of lithium on noradrenaline- and dopamine-sensitive accumulation of cyclic AMP in guinea pig brain. Psychopharmacology, 1978, 58, 213-216.	1.5	40
375	Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ?cheese effect?. Psychopharmacology, 1978, 57, 33-38.	1.5	247
376	Haloperidol and lithium blocking of the mood response to intravenous methylphenidate. Psychopharmacology, 1978, 57, 83-87.	1.5	32
377	Opiates, catecholamines, behavior, and mood. Psychopharmacology, 1978, 56, 327-333.	1.5	8
378	Brain histamine receptors as targets for antidepressant drugs. Nature, 1978, 272, 329-333.	13.7	260
379	Inhibition by lithium of dopamine-sensitive adenylate-cyclase in the rat brain. Journal of Neurochemistry, 1978, 30, 257-258.	2.1	15
380	REGIONAL DISTRIBUTION OF ENZYMES ASSOCIATED WITH NEUROTRANSMISSION BY MONOAMINES, ACETYLCHOLINE AND GABA IN THE HUMAN BRAIN. Journal of Neurochemistry, 1978, 30, 827-839.	2.1	128
381	REGIONAL DISTRIBUTION OF MONOAMINES AND THEIR METABOLITES IN THE HUMAN BRAIN. Journal of Neurochemistry, 1978, 30, 841-848.	2.1	99
382	The effect of acute and chronic desipramine and amitriptyline treatment on rat brain total 3-methoxy-4-hydroxyphenylglycol. Naunyn-Schmiedeberg's Archives of Pharmacology, 1978, 305, 207-211.	1.4	86
383	Effects of thyroid state on brain stem responses to iontophoretic noradrenaline. Experientia, 1978, 34, 1527-1528.	1.2	7
384	Effect of desipramine on the contents of some free amino acids of mouse brain. Experientia, 1978, 34, 227-228.	1.2	0
385	d-Amphetamine and ethanol: A drug-drug interaction study. Brain Research Bulletin, 1978, 3, 595-599.	1.4	3
386	Roles of the gonadal steroid hormones in psychiatric depression in men and women. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 1978, 2, 487-503.	0.6	79
387	EVIDENCE FOR THE ROLE OF ADRENOCORTICAL HORMONES IN THE REGULATION OF NORADRENALINE AND DOPAMINE METABOLISM IN CERTAIN BRAIN AREAS. British Journal of Pharmacology, 1978, 62, 131-136.	2.7	57

#	Article	IF	Citations
388	THE INFLUENCE OF Lâ€TRYPTOPHAN AND MONOAMINE OXIDASE INHIBITORS ON CATECHOLAMINE METABOLISM IN RAT BRAIN. British Journal of Pharmacology, 1978, 64, 341-345.	2.7	20
389	Stress-Induced Depression Model in Female Ratsâ€"Biochemical and Histochemical Investigation of Brain Monoamines. Psychiatry and Clinical Neurosciences, 1978, 32, 159-169.	1.0	0
390	The in vivo binding of [3H]-desipramine and [3H]-chlorpromazine to1areas in the rat brain. European Journal of Pharmacology, 1978, 51, 121-127.	1.7	20
391	Anomalies of cyclic AMP excretion in some abnormal offenders. Biological Psychology, 1978, 7, 103-108.	1.1	2
392	CNS 3-methoxy-4-hydroxyphenylglycol: Its peripheral assessment by isotopic dilution and theoretical significance. Brain Research Bulletin, 1978, 3, 669-674.	1.4	5
393	Phantom Tooth Pain. Journal of Endodontics, 1978, 4, 362-372.	1.4	83
394	Effects of Schistosoma mansoni and Schistosoma japonicum infections on induction of hepatic tyrosine aminotransferase in mice. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1978, 59, 51-53.	0.2	0
395	A review of studies of the psychological symptoms found at the menopause. Maturitas, 1978, 1, 55-64.	1.0	55
396	Electrophysiological studies with a new anti-depressant drug: Comparison of the effects of viloxazine (ICI 58,834) with three tricyclic anti-depressants in the EncÃ©phale isolÃ©. Neuropharmacology, 1978, 17, 835-849.	2.0	9
397	Magnitude of stress-induced brain norepinephrine depletion varies with age. Brain Research, 1978, 152, 170-175.	1.1	96
398	Ability of biochemical and personality variables in discriminating between high and low physical fitness levels. Journal of Psychosomatic Research, 1978, 22, 193-199.	1.2	14
399	The acute and chronic effects of D-amphetamine, chlorpromazine, amitriptyline and lithium chloride on adenosine 5-triphosphatases in different regions of the rat brain. Biochemical Pharmacology, 1978, 27, 1049-1053.	2.0	14
400	Mode of action of antidepressant drugs. Biochemical Pharmacology, 1978, 27, 257-261.	2.0	472
401	Desmethylimipramine-induced decrease in Î²-adrenergic receptor binding in rat cerebral cortex. Biochemical Pharmacology, 1978, 27, 2179-2181.	2.0	137
402	Medical treatment of mental illness. Science, 1978, 200, 974-981.	6.0	58
403	Presynaptic alpha-receptor subsensitivity after long-term antidepressant treatment. Science, 1978, 202, 322-324.	6.0	326
404	Use of Antidepressant Drugs in Schizophrenia. Archives of General Psychiatry, 1978, 35, 1368.	13.8	101
405	Effects of a Dopamine Agonist Piribedil in Depressed Patients. Archives of General Psychiatry, 1978, 35, 609.	13.8	165

#	Article	IF	Citations
406	Reversal of Learned Helplessness by Peripheral Arousal. Psychological Reports, 1978, 43, 1211-1217.	0.9	3
407	Toward a Biochemical Classification of Depressive Disorders. Archives of General Psychiatry, 1978, 35, 1436.	13.8	73
408	Cerebrospinal fluid norepinephrine in affective illness. American Journal of Psychiatry, 1978, 135, 907-912.	4.0	111
409	6 Non-Tricyclic Antidepressants. Progress in Medicinal Chemistry, 1978, 15, 261-320.	4.1	3
410	Toward a Biochemical Classification of Depressive Disorders. Archives of General Psychiatry, 1978, 35, 1427.	13.8	207
411	Combined Tricyclicâ€"MAOI Therapy for Refractory Depression: A Review, with Guidelines for Appropriate Usage. Journal of Clinical Pharmacology, 1978, 18, 143-147.	1.0	58
412	State Anxiety, Physical Activity, and Urinary 3-Methoxy-4-Hydroxyphenethylene Glycol Excretion. Archives of General Psychiatry, 1978, 35, 1418.	13.8	111
413	Disturbed circadian variation of serum thyrotropin in patients with endogenous depression. Acta Psychiatrica Scandinavica, 1978, 57, 281-289.	2.2	55
414	Prediction of imipramine antidepressant response by a one-day dextro- amphetamine trial. American Journal of Psychiatry, 1978, 135, 1179-1184.	4.0	48
415	Biogenic amine metabolites in cerebrospinal fluid of patients with affective disorders. Acta Psychiatrica Scandinavica, 1978, 58, 88-96.	2.2	100
416	Central neurotransmitter function and its behavioral correlates in man.. Environmental Health Perspectives, 1978, 26, 135-141.	2.8	8
417	Probenecid-Induced Norepinephrine Elevations in Plasma and CSF. Archives of General Psychiatry, 1978, 35, 237.	13.8	12
418	Decreased Urinary Output of Tyramine and its Metabolites in Depression. British Journal of Psychiatry, 1978, 132, 125-132.	1.7	59
419	Primary Affective Disorder, Clinical State Change, and MHPG Excretion. Archives of General Psychiatry, 1978, 35, 1378.	13.8	42
420	Urinary MHPG Levels and Tricyclic Antidepressant Drug Selection. Archives of General Psychiatry, 1979, 36, 1111.	13.8	63
421	Animal Model of Depression, I. Review of Evidence: Implications for Research. , 1979, , 79-90.		2
422	Cognitive Therapy of Depression. , 1979, , 153-203.		50
423	Cerebral norepinephrine: influence on cortical oxidative metabolism in situ. Science, 1979, 206, 69-71.	6.0	57

#	Article	IF	Citations
424	Interaction of antidepressants with clonidine on rat brain total 3-methoxy-4-hydroxyphenylglycol. Canadian Journal of Physiology and Pharmacology, 1979, 57, 435-437.	0.7	53
425	Clomipramine-Induced Mania in Unipolar Depression. Archives of General Psychiatry, 1979, 36, 560.	13.8	67
426	The effect of clonidine withdrawal on total 3-methoxy-4-hydroxyphenylglycol in the rat brain. Psychopharmacology, 1979, 61, 11-12.	1.5	17
427	Mood alterations during deanol therapy. Psychopharmacology, 1979, 62, 187-191.	1.5	36
428	Urinary 4-hydroxy-3-methoxyphenylglycol is not a predictor for clinical response to amitriptyline in depressive illness. Psychopharmacology, 1979, 64, 95-97.	1.5	77
429	Chronic effects of miaserin on noradrenaline metabolism in the rat brain: Evidence for a pre-synaptic ?-adrenolytic action in vivo. Psychopharmacology, 1979, 64, 329-332.	1.5	43
430	Studies on human blood platelets in affective disorder. Psychopharmacology, 1979, 60, 131-135.	1.5	90
431	Action of d-propranolol in manic psychoses. Archiv Fur Psychiatrie Und Nervenkrankheiten, 1979, 227, 301-317.	0.6	16
432	Antidepressant and antipsychotic agents. Die Naturwissenschaften, 1979, 66, 403-409.	0.6	8
433	Deficient production of tyramine and octopamine in cases of depression. Nature, 1979, 278, 357-358.	13.7	96
434	Hypothalamic mechanisms of ageing and of specific age pathologyâ€”II. On the sensitivity threshold of hypothalamo-pituitary complex to homeostatic stimuli in adaptive homeostasis. Experimental Gerontology, 1979, 14, 175-181.	1.2	22
435	Atypical odontalgia. British Journal of Oral & Maxillofacial Surgery, 1979, 16, 212-218.	0.3	68
436	Effects of chronic lithium administration on concanavalin A binding to plasma membranes from the corpus striatum of rat brain. Experientia, 1979, 35, 655-656.	1.2	2
437	Reevaluation of the indoleamine hypothesis of depression. Evidence for a reduction of functional activity of central 5-HT systems by antidepressant drugs. Journal of Neural Transmission, 1979, 46, 85-103.	1.4	182
439	Prenatal programming of hepatic monoamine oxidase by 5,5-diphenylhydantoin. Biochemical Pharmacology, 1979, 28, 2585-2590.	2.0	10
440	Studies of monoamine oxidases. Biochemical Pharmacology, 1979, 28, 1197-1203.	2.0	8
441	Equal inhibitory effect of dimethyl- and monomethyl-Î²-aminopropionylic derivatives of dibenzazepine on the uptake of [3H]noradrenaline by rat brain synaptosomes. Biochemical Pharmacology, 1979, 28, 938-939.	2.0	0
442	Origin and distribution of 3-methoxy-4-hydroxyphenylglycol in body fluids. Biochemical Pharmacology, 1979, 28, 3043-3050.	2.0	112

#	Article	IF	Citations
443	The effects of amitriptyline, mianserin, phenoxybenzamine and propranolol on the release of noradrenaline in the rat brain in vivo. Biochemical Pharmacology, 1979, 28, 2333-2336.	2.0	24
444	Oral contraceptives and depressive symptomatology: Biologic mechanisms. Comprehensive Psychiatry, 1979, 20, 347-358.	1.5	35
445	Biological and behavioral effects of one night's sleep deprivation in depressed patients and normals. Journal of Psychiatric Research, 1979, 15, 21-40.	1.5	185
446	A biochemical measure of monoamine oxidase type A and B inhibitor effects in man. Journal of Psychiatric Research, 1979, 15, 77-84.	1.5	9
447	Effect of lithium on the physostigmine-induced behavioral syndrome and plasma cyclic GMP. Journal of Psychiatric Research, 1979, 15, 133-138.	1.5	46
448	REVERSAL OF DOPA-INDUCED AROUSAL IN RESERPINE-TREATED RABBITS AND MICE BY HISTIDINE. British Journal of Pharmacology, 1979, 65, 303-309.	2.7	2
449	POTENTIATION OF RESPONSES TO MONOAMINES BY ANTIDEPRESSANTS AFTER DESTRUCTION OF MONOAMINE AFFERENTS. British Journal of Pharmacology, 1979, 65, 501-510.	2.7	16
451	PRESYNAPTIC Î±â€ADRENOCEPTOR BLOCKING PROPERTIES AMONG TRIâ€•AND TETRAâ€CYCLIC ANTIDEPRESSANT DRUGS. British Journal of Pharmacology, 1979, 67, 511-517.	2.7	24
452	Depression as seen by the psychiatrist. Disease-a-Month, 1979, 25, 1-64.	0.4	1
453	GENETIC SUBTYPES OF UNIPOLAR PRIMARY DEPRESSIVE ILLNESS DISTINGUISHED BY HYPOTHALAMIC-PITUITARY-ADRENAL AXIS ACTIVITY. Lancet, The, 1979, 313, 739-741.	6.3	140
454	Olfactory projection systems, drugs and behaviour: A review. Psychoneuroendocrinology, 1979, 4, 253-272.	1.3	117
455	TRYPTOPHAN AND TYROSINE AVAILABILITY AND ORAL CONTRACEPTIVES. Lancet, The, 1979, 314, 472.	6.3	19
456	CAUSE OF DEPRESSION IN CHRONIC SCURVY. Lancet, The, 1979, 314, 1077-1078.	6.3	9
457	The central noradrenergic system and affective response to MAO inhibitors. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 1979, 3, 535-542.	0.6	10
458	RELAPSE OF PSEUDOMEMBRANOUS COLITIS AFTER VANCOMYCIN THERAPY. Lancet, The, 1979, 314, 1076-1077.	6.3	10
460	NATURAL Å'STROGENS FOR ORAL CONTRACEPTION. Lancet, The, 1979, 314, 471-472.	6.3	29
461	DUAL RECOMBINATION AS ORIGIN OF PANDEMIC INFLUENZA VIRUSES. Lancet, The, 1979, 314, 1077.	6.3	4
462	Antidepressant drugs potentiate suppression by adenosine of neuronal firing in rat cerebral cortex. Neuroscience Letters, 1979, 11, 93-97.	1.0	23

#	Article	IF	Citations
463	DEATHS OF INFANTS AFTER TRIPLE VACCINE. Lancet, The, 1979, 314, 472-473.	6.3	10
464	Changes in lymphocyte beta-adrenergic receptors in depression and mania. Psychiatry Research, 1979, 1, 191-197.	1.7	120
465	Opposite effects of acute and repeated administration of desmethylimipramine on adrenergic responsiveness in rat pineal gland. Life Sciences, 1979, 24, 2237-2244.	2.0	38
466	The contribution of CNS MHPG to plasma MHPG in the rat. Life Sciences, 1979, 25, 601-605.	2.0	14
467	The locus coeruleus in behavior regulation: evidence for behavior-specific versus general involvement. Behavioral and Neural Biology, 1979, 25, 271-300.	2.3	46
468	NIMH Clinical Research Branch Collaborative Program on the Psychobiology of Depression. Archives of General Psychiatry, 1979, 36, 765.	13.8	209
469	Novel Antidepressants and the Biogenic Amine Hypothesis of Depression. Archives of General Psychiatry, 1979, 36, 1097.	13.8	84
470	Electrooculographic (EOG) findings in manicâ€depressive illness. Acta Psychiatrica Scandinavica, 1979, 60, 155-162.	2.2	20
471	Altered platelet monoamine oxidase activity in affective disorders. Psychological Medicine, 1979, 9, 729-736.	2.7	79
472	Estrogen Therapy for Severe Persistent Depressions in Women. Archives of General Psychiatry, 1979, 36, 550.	13.8	339
473	Biological component of the NIMH Clinical Research Branch Collaborative Program on the psychobiology of depression: II. Methodology and data analysis. Psychological Medicine, 1980, 10, 777-793.	2.7	50
474	Thyroid Status and the Depressed Elderly. Journal of the American Geriatrics Society, 1980, 28, 433-438.	1.3	3
475	TRACE AMINE DEFICIT IN DEPRESSIVE ILLNESS: THE PHENYLALANINE CONNEXION. Acta Psychiatrica Scandinavica, 1980, 61, 29-39.	2.2	19
476	Hypothalamic-Pituitary-Adrenal Axis Activity in Depressive Illness. Archives of General Psychiatry, 1980, 37, 737.	13.8	349
477	Resistance to inhibiting effect of dexamethasone in patients with endogenous depression. Acta Psychiatrica Scandinavica, 1980, 61, 169-177.	2.2	111
478	Reuptake of biogenic amines by brain slices: Effect of hydrocortisone. Psychopharmacology, 1980, 70, 59-61.	1.5	4
479	Behavioural responses to stereotactically controlled injections of monoamine neurotransmitters into the accumbens and caudate-putamen nuclei. Psychopharmacology, 1980, 71, 227-235.	1.5	45
480	Presynaptic Î±-adrenoceptors and the action of tricyclic antidepressant drugs in behavioural despair in rats. Psychopharmacology, 1980, 71, 169-172.	1.5	33

#	Article	IF	Citations
481	Effect of citalopram (Lu 10-171) on tranylcypromine and tryptophan-induced wet-dog shakes in rats. Psychopharmacology, 1980, 70, 209-212.	1.5	3
482	Assessment of peripheral adrenergic activity and its interactions with drugs in man. European Journal of Clinical Pharmacology, 1980, 17, 233-238.	0.8	33
483	Ratio scales of the reward values and punisher aversions of depressed undergraduates. Journal of Clinical Psychology, 1980, 36, 640-646.	1.0	17
484	Motivational deficit in depression: People's expectations Ã— outcomes' impacts. Journal of Clinical Psychology, 1980, 36, 647-652.	1.0	27
485	THE PSYCHOLOGY OF RUNNING: implications for nursing and health. Nursing Forum, 1980, 19, 108-121.	1.0	9
486	The Origins of Affectâ€“Normal and Pathological. Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry, 1980, 8, 497-520.	0.1	3
487	Patterns of Peptides and Protein-Associated-Peptide Complexes in Psychiatric Disorders. British Journal of Psychiatry, 1980, 136, 59-72.	1.7	45
488	Depression and Hormones. An Outline and Some Perspectives. International Journal of Mental Health, 1980, 9, 67-90.	0.5	2
489	Noradrenergic Function and Depression, Too Much or Too Little?. Canadian Journal of Neurological Sciences, 1980, 7, 267-268.	0.3	36
491	Integration: Putting It All Together. , 1980, , 209-253.		1
492	Platelet monoamine oxidase activity in megaloblastic anaemia.. Journal of Clinical Pathology, 1980, 33, 963-965.	1.0	21
493	CSF monoamine metabolites in depression and schizophrenia. American Journal of Psychiatry, 1980, 137, 174-180.	4.0	157
494	Run for your mind: Aerobic exercise as a means of alleviating anxiety and depression.. Canadian Journal of Behavioural Science, 1980, 12, 126-140.	0.5	34
495	The differential effect of right versus left hemispheric cerebral infarction on catecholamines and behavior in the rat. Brain Research, 1980, 188, 63-78.	1.1	183
496	Effects of oral clonidine on plasma 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) in man: Preliminary report. Life Sciences, 1980, 26, 2179-2185.	2.0	77
497	Thyrotropin nyctohemeral pattern in primary depression : Differences between unipolar and bipolar women. Life Sciences, 1980, 27, 1695-1703.	2.0	54
498	Effect of single and repeated electroconvulsive shock on serotonergic system in rat brainâ€”I metabolic studies. Neuropharmacology, 1980, 19, 1049-1053.	2.0	17
499	A comparison of the inhibitory effects of new non-tricyclic amine uptake inhibitors on the uptake of norepinephrine and 5-hydroxytryptamine into synaptosomes of the rat brain. Neuropharmacology, 1980, 19, 349-354.	2.0	14

#	Article	IF	Citations
500	MHPG excretion in depression. Psychiatry Research, 1980, 2, 295-305.	1.7	29
501	Depression vulnerability and 5-hydroxytryptophan prophylaxis. Psychiatry Research, 1980, 3, 75-83.	1.7	96
502	Presnyaptic noradrenergic regulation during depression and antidepressant drug treatment. Psychiatry Research, 1980, 3, 93-105.	1.7	91
503	Effects of Î±-adrenoceptor agonists and antagonists and of antidepressant drugs on pre-and postsynaptic Î±-adrenoceptors. European Journal of Pharmacology, 1980, 67, 33-40.	1.7	63
504	Inhibition of neuronal uptake reduces the presynaptic effects of clonidine but not of Î±-methylnoradrenaline on the stimulation-evoked release of 3H-noradrenaline from rat occipital cortex slices. European Journal of Pharmacology, 1980, 64, 143-155.	1.7	112
505	Inhibition of (3H)-dopamine uptake into rat brain synaptosomes by the new non-tricyclic antidepressants, FS32 and FS97. European Journal of Pharmacology, 1980, 62, 147-155.	1.7	10
507	Neuroendocrine markers of CNS drug effects.. British Journal of Clinical Pharmacology, 1980, 10, 5-21.	1.1	25
508	Biochemical assessment of antidepressive drugs.. British Journal of Clinical Pharmacology, 1980, 10, 539-550.	1.1	11
509	The therapeutic potential of Glucose Tolerance Factor. Medical Hypotheses, 1980, 6, 1177-1189.	0.8	21
510	A neurochemical theory of appetite and weight changes in depressive states. Acta Psychiatrica Scandinavica, 1981, 64, 217-225.	2.2	34
511	The classification of affective disorders: A synthesis of old and new concepts. Comprehensive Psychiatry, 1981, 22, 54-77.	1.5	31
512	Effects of antidepressant drugs on different receptors in the brain. European Journal of Pharmacology, 1981, 70, 393-407.	1.7	309
513	Î±1-adrenoceptor-mediated responses in the lateral geniculate nucleus are enhanced by chronic antidepressant treatment. European Journal of Pharmacology, 1981, 74, 27-35.	1.7	127
514	Inhibition by lithium of dopamine receptors in rat prolactin release. Brain Research, 1981, 223, 335-342.	1.1	15
515	Suction lesions of the frontal cerebral cortex in the rat induce asymmetrical behavioral and catecholaminergic responses. Brain Research, 1981, 218, 233-242.	1.1	105
516	Influence of a chronic new potential antidepressant, 1-[3-(dimethylamino)propyl]-5-methyl-3-phenyl-1H-indazole(FS32) and its N-Desmethylated compound(FS97): Treatment on monoaminergic receptor sensitivity in the rat brain. Neuropharmacology, 1981, 20, 285-292.	2.0	17
517	Biologically stable analogues of trh with increased neuropharmacological potency. Neuropharmacology, 1981, 20, 497-503.	2.0	51
518	High-affinity binding of 3H-imipramine in brain and platelets and its relevance to the biochemistry of affective disorders. Life Sciences, 1981, 29, 211-220.	2.0	136

#	Article	IF	Citations
519	Î±2-adrenergic receptors in platelet membranes of depressed patients: No change in number of 3H-yohimbine affinity. Life Sciences, 1981, 29, 2059-2064.	2.0	76
520	An inverse correlation between serum levels of desmethylimipramine and melatonin-like immunoreactivity in DMI-responsive depressives. Psychiatry Research, 1981, 4, 109-113.	1.7	15
521	Catechol-O-methyltransferase of erythrocytes in patients with endogenous psychoses. Psychiatry Research, 1981, 4, 139-146.	1.7	29
522	Plasma MHPG in depression: Effects of acute and chronic desipramine treatment. Psychiatry Research, 1981, 5, 217-229.	1.7	54
523	Anatomical, Physiological, and Behavioral Aspects of Olfactory Bulbectomy in The Rat. International Review of Neurobiology, 1981, 22, 251-286.	0.9	199
524	Current concepts on the mechanisms of action of antidepressant drugs. , 1981, 13, 219-247.		110
525	Relevance of tryptophan and tyrosine availability in endogenous and â€˜non-endogenousâ€™ depressives treated with imipramine or clomipramine. Journal of Affective Disorders, 1981, 3, 231-244.	2.0	25
526	Receptor Sensitivity and the Mechanism of Action of Antidepressant Treatment. Archives of General Psychiatry, 1981, 38, 1160.	13.8	637
528	The neuro- and cardiovascular pharmacology of RS-51324, a potential antidepressant. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 1981, 4, 569-584.	0.6	4
529	Plasma and erythrocyte membrane long chain polyunsaturated fatty acids in endogenous depression. Neurochemistry International, 1981, 3, 37-42.	1.9	48
530	A framework for refining the diagnostic categorization of substance abusers. Addictive Behaviors, 1981, 6, 23-27.	1.7	1
531	5-HYDROXYTRYPTAMINE AND PSYCHIATRIC ILLNESS. Lancet, The, 1981, 318, 788-789.	6.3	2
532	Adaptive changes in catecholamine receptors in the central nervous system. Neuroscience, 1981, 6, 1471-1502.	1.1	120
533	DRUG LICENSING OR INNOVATION. Lancet, The, 1981, 318, 788.	6.3	1
534	The Effects of Tranylcypromine on the Levels of Some Cerebral Amines in Rat Diencephalon. , 1981, , 7-13.		2
535	Chemoprophylaxis of depressions An attempt to compare lithium with 5â€hydroxytryptophan. Acta Psychiatrica Scandinavica, 1981, 63, 191-201.	2.2	51
536	Depressed Mood and Other Psychiatric Manifestations of CushingÊ¼s Syndrome: Relationship to Hormone Levels. Psychosomatic Medicine, 1981, 43, 3-18.	1.3	257
537	Catecholamine neurotransmitters, psychoactive drugs, and biological clocks. Journal of Neurosurgery, 1981, 55, 669-677.	0.9	17

#	Article	IF	Citations
538	Doubleâ€blind comparative clinical trial of pimozide and chlorpromazine in mania. Acta Psychiatrica Scandinavica, 1981, 64, 381-397.	2.2	60
539	Platelet Î±2-Adrenergic Receptors in Major Depressive Disorder. Archives of General Psychiatry, 1981, 38, 1327.	13.8	212
540	The pharmacology of zimelidine: A 5â€HT selective reuptake inhibitor. Acta Psychiatrica Scandinavica, 1981, 63, 127-151.	2.2	102
541	Physostigmine for Treatment of Delirium Tremens. Journal of Clinical Pharmacology, 1981, 21, 57-60.	1.0	6
542	Monoamine oxidase inhibitor efficacy in depression and the â€˜cheese effectâ€™. Psychological Medicine, 1981, 11, 455-458.	2.7	29
543	Serotonin and noradrenaline uptake inhibitors in the treatment of depression â€“ relationship to 5â€HIAA in spinal fluid. Acta Psychiatrica Scandinavica, 1981, 63, 209-218.	2.2	8
544	A Controlled Trial with Diclofensine, a New Psychoactive Drug, in the Treatment of Depression. Journal of International Medical Research, 1981, 9, 324-329.	0.4	17
545	Bromocriptine treatment of depressive disorders. Acta Psychiatrica Scandinavica, 1981, 64, 25-33.	2.2	64
546	Mood change following left hemispheric brain injury. Annals of Neurology, 1981, 9, 447-453.	2.8	436
547	Determination of the primary metabolite of central nervous system norepinephrine, 3-methoxy-4-hydroxy-phenethyleneglycol, in mouse brain and brain perfusate by high-performance liquid chromatography with electrochemical detection. Biomedical Applications, 1981, 223, 295-303.	1.7	12
548	Studies on possible mechanisms of action of electroconvulsive therapy; effects of repeated electrically induced seizures on rat brain receptors for monoamines and other neurotransmitters. Psychopharmacology, 1981, 73, 345-349.	1.5	121
549	Effect of lithium on prolactin responses to thyrotropin releasing hormone in patients with manic state. Psychopharmacology, 1981, 72, 129-133.	1.5	31
550	Subsensitivity of human ?-adrenergic adenylate cyclase after salbutamol treatment of depression. Psychopharmacology, 1981, 75, 169-172.	1.5	43
551	Behavioural changes during withdrawal from desmethylimipramine (DMI). Psychopharmacology, 1981, 75, 60-64.	1.5	14
552	High-affinity 3H-imipramine binding in platelets from untreated and treated depressed patients compared to healthy volunteers. Psychopharmacology, 1981, 75, 368-371.	1.5	128
553	Quantitative determination of 3-methoxy-4-hydroxyphenylethyleneglycol and its sulfate conjugate in human lumbar cerebrospinal fluid using liquid chromatography with amperometric detection. Biomedical Applications, 1981, 223, 305-314.	1.7	24
554	DIFFERING NORADRENALINE KINETICS IN ESSENTIAL HYPERTENSION AND DEPRESSIVE ILLNESS, TWO DISEASES IN WHICH THE PLASMA CONCENTRATION OF NORADRENALINE IS SOMETIMES ELEVATED. Clinical and Experimental Pharmacology and Physiology, 1981, 8, 525-530.	0.9	7
555	Animal models and human depressive disorders. Neuroscience and Biobehavioral Reviews, 1981, 5, 231-246.	2.9	220

#	Article	IF	Citations
556	Central and peripheral effects of lithium on amphetamine-induced hyperactivity in rats. Pharmacology Biochemistry and Behavior, 1981, 14, 439-442.	1.3	15
557	Postsynaptic action by four antidepressive drugs in an animal model of depression. Pharmacology Biochemistry and Behavior, 1981, 15, 125-130.	1.3	97
558	A Hypothesis of Thyroid-Catecholamine-Receptor Interaction. Archives of General Psychiatry, 1981, 38, 106.	13.8	312
560	Effect of antidepressants, lithium and electroconvulsive treatment on rat serum prolactin levels. Acta Psychiatrica Scandinavica, 1981, 63, 100-121.	2.2	46
561	Increased intracranial self-stimulation in rats after long-term administration of desipramine. Science, 1981, 214, 683-685.	6.0	155
562	Imipramine: effect of ovarian steroids on modifications in serotonin receptor binding. Science, 1981, 211, 1183-1185.	6.0	105
563	Serotonin Uptake in Blood Platelets of Psychiatric Patients. Archives of General Psychiatry, 1981, 38, 1322.	13.8	225
564	Adverse Psychiatric Reactions to Modern Medication. Australian and New Zealand Journal of Psychiatry, 1981, 15, 87-103.	1.3	15
565	Depression: The predisposing influence of stress. Behavioral and Brain Sciences, 1982, 5, 89-99.	0.4	411
566	On mapping anxiety. Behavioral and Brain Sciences, 1982, 5, 506-534.	0.4	26
567	The Peripheral Kinetics of Norepinephrine in Depressive Illness. Archives of General Psychiatry, 1982, 39, 295.	13.8	172
568	Beta-adrenerg receptorfunktion ved depression og under antidepressiv behandling. Nordic Journal of Psychiatry, 1982, 36, 301-304.	0.2	0
569	Selective and Nonselective Monoamine Oxidase Inhibitors. Archives of General Psychiatry, 1982, 39, 535.	13.8	34
570	A Second Generation Catecholamine Hypothesis. Pharmacopsychiatry, 1982, 15, 111-115.	1.7	20
571	Trends in Research and Treatment of Affective Disorders. Psychological Reports, 1982, 51, 1287-1306.	0.9	0
572	Alteration of Norepinephrine Metabolism With Desipramine and Zimelidine in Depressed Patients. Archives of General Psychiatry, 1982, 39, 1025.	13.8	130
573	Depression, neurotransmitters, and stress: some neuropsychological implications. Behavioral and Brain Sciences, 1982, 5, 100-101.	0.4	0
574	Stress, neurochemical substrates, and depression: Concomitants are not necessarily causes. Behavioral and Brain Sciences, 1982, 5, 101-102.	0.4	13

#	Article	IF	Citations
575	The psychological homeostatic response to stress and its relation to depression. Behavioral and Brain Sciences, 1982, 5, 102-103.	0.4	0
576	Does a commonality of neurochemical sequelae imply a relationship between stress and depression?. Behavioral and Brain Sciences, 1982, 5, 103-103.	0.4	0
577	Biological fitness and affective variation. Behavioral and Brain Sciences, 1982, 5, 103-104.	0.4	0
578	Appraising psychobiological approaches to the influence of stress on depression. Behavioral and Brain Sciences, 1982, 5, 104-105.	0.4	1
579	A cognitive/information-processing approach to the relationship between stress and depression. Behavioral and Brain Sciences, 1982, 5, 105-106.	0.4	1
580	A tripartite physiology of depression. Behavioral and Brain Sciences, 1982, 5, 106-107.	0.4	0
581	Monoamine receptor sensitivity and antidepressants. Behavioral and Brain Sciences, 1982, 5, 107-108.	0.4	0
582	Hypersensitive serotonergic receptors and depression. Behavioral and Brain Sciences, 1982, 5, 108-109.	0.4	9
583	Triggering stimuli and the problem of persistence. Behavioral and Brain Sciences, 1982, 5, 109-109.	0.4	0
584	Neurochemical correlates of stress and depression: Depletion or disorganization?. Behavioral and Brain Sciences, 1982, 5, 110-110.	0.4	22
585	Depression and the action inhibitory system (AIS). Behavioral and Brain Sciences, 1982, 5, 111-111.	0.4	0
586	An alternative hypothesis of depression. Behavioral and Brain Sciences, 1982, 5, 111-112.	0.4	3
587	On the utility of stress as an explanatory concept. Behavioral and Brain Sciences, 1982, 5, 112-113.	0.4	0
588	Schizophrenia, not depression, as a result of depleted brain norepinephrine. Behavioral and Brain Sciences, 1982, 5, 113-114.	0.4	1
589	Coping, depression, and neurotransmitters. Behavioral and Brain Sciences, 1982, 5, 114-115.	0.4	0
590	Stress as activation. Behavioral and Brain Sciences, 1982, 5, 115-116.	0.4	2
591	Documenting the association of stress (or stressors) with depressive illness. Behavioral and Brain Sciences, 1982, 5, 116-117.	0.4	0
592	Stress, learning, and neurochemistry in affective disorder. Behavioral and Brain Sciences, 1982, 5, 117-119.	0.4	0

#	Article	IF	Citations
593	Stress: Chicken or egg?. Behavioral and Brain Sciences, 1982, 5, 119-119.	0.4	0
594	Is chronic stress better than acute stress?. Behavioral and Brain Sciences, 1982, 5, 119-120.	0.4	0
595	Problems with a stressâ€“depression model. Behavioral and Brain Sciences, 1982, 5, 120-121.	0.4	1
596	Stress, depression, and helplessness. Behavioral and Brain Sciences, 1982, 5, 121-122.	0.4	0
597	Noradrenergic function during stress and depression: An alternative view. Behavioral and Brain Sciences, 1982, 5, 122-122.	0.4	23
598	Stress (whatever that is) and depression. Behavioral and Brain Sciences, 1982, 5, 122-123.	0.4	0
599	Stressing our points. Behavioral and Brain Sciences, 1982, 5, 123-137.	0.4	0
600	Anxiety: Dysfunction of transmission or modulation?. Behavioral and Brain Sciences, 1982, 5, 484-484.	0.4	0
601	Homunculus in the subiculum. Behavioral and Brain Sciences, 1982, 5, 485-486.	0.4	0
602	Integrating the literature on anxiety, memory, and the hippocampus. Behavioral and Brain Sciences, 1982, 5, 487-488.	0.4	0
603	The evolution of hesitation, doubt, and map-making. Behavioral and Brain Sciences, 1982, 5, 488-489.	0.4	0
604	Putting anxiety in its place?. Behavioral and Brain Sciences, 1982, 5, 489-489.	0.4	0
605	Conditioned suppression and behavioural inhibition. Behavioral and Brain Sciences, 1982, 5, 489-490.	0.4	1
606	Some questions of strategy in neuropsychological research on anxiety. Behavioral and Brain Sciences, 1982, 5, 490-491.	0.4	1
607	Noradrenaline: Attention or anxiety?. Behavioral and Brain Sciences, 1982, 5, 491-492.	0.4	1
608	Gray'sNeuropsychology of anxiety: An enquiry into the functions of septohippocampal theories. Behavioral and Brain Sciences, 1982, 5, 492-493.	0.4	31
609	On novelty, places, and the septo-hippocampal system. Behavioral and Brain Sciences, 1982, 5, 493-494.	0.4	1
610	Functions of the septo-hippocampal system. Behavioral and Brain Sciences, 1982, 5, 494-495.	0.4	1

#	Article	IF	Citations
611	Anxiety viewed from the upper brain stem: Though panic and fear yield trepidation, should both be called anxiety?. Behavioral and Brain Sciences, 1982, 5, 495-496.	0.4	3
612	The anatomy of anxiety?. Behavioral and Brain Sciences, 1982, 5, 496-498.	0.4	3
613	The relationship between memory and anxiety. Behavioral and Brain Sciences, 1982, 5, 498-499.	0.4	0
614	The dynamics of action and the neuropsychology of anxiety. Behavioral and Brain Sciences, 1982, 5, 499-499.	0.4	2
615	Does hippocampal theta tell us anything about the neuropsychology of anxiety?. Behavioral and Brain Sciences, 1982, 5, 500-502.	0.4	5
616	Inferring anxiety and antianxiety effects in animals. Behavioral and Brain Sciences, 1982, 5, 502-503.	0.4	1
617	Substrates of anxiety: But if the starting point is wrong?. Behavioral and Brain Sciences, 1982, 5, 503-504.	0.4	0
618	The septo-hippocampal system and behavior: Difficulties in finding the exit. Behavioral and Brain Sciences, 1982, 5, 504-504.	0.4	1
619	Leaping up the phylogenetic scale in explaining anxiety: Perils and possibilities. Behavioral and Brain Sciences, 1982, 5, 505-506.	0.4	40
620	Is stress a predisposing or precipitating factor in clinical depression?. Behavioral and Brain Sciences, 1982, 5, 99-100.	0.4	0
621	Inhibition, attention, and the hippocampus. Behavioral and Brain Sciences, 1982, 5, 484-485.	0.4	1
622	â€œAntianxiety and opiatesâ€. Behavioral and Brain Sciences, 1982, 5, 486-487.	0.4	1
623	A doubleâ€“blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression. Acta Psychiatrica Scandinavica, 1982, 66, 50-65.	2.2	65
624	High plasma norepinephrine levels in patients with major affective disorder. American Journal of Psychiatry, 1982, 139, 1315-1318.	4.0	227
625	Diurnal variation of urinary MHPG in unipolar and bipolar depressives. Acta Psychiatrica Scandinavica, 1982, 66, 243-253.	2.2	23
626	Neuroendocrine risk factors of suicidal behavior. American Journal of Psychiatry, 1982, 139, 1323-1325.	4.0	58
627	Onset of depressive psychiatric crises and the menstrual cycle. American Journal of Psychiatry, 1982, 139, 475-478.	4.0	71
628	Plasma Prolactin and Growth Hormone Levels in Manic Patients Treated with Pimozide. British Journal of Psychiatry, 1982, 140, 274-279.	1.7	20

#	Article	IF	Citations
629	High Correlation of Norepinephrine and Its Major Metabolite Excretion Rates. Archives of General Psychiatry, 1982, 39, 521.	13.8	40
630	Manic psychosis associated with procarbazine.. BMJ: British Medical Journal, 1982, 284, 82-83.	2.4	9
631	DEPRESSION. Lancet, The, 1982, 320, 1259-1264.	6.3	154
632	Evaluation of role of the biogenic amines in affective illness: A clinical strategy. Medical Hypotheses, 1982, 9, 51-53.	0.8	0
633	Analysis of urinary excretion patterns of bioactive amines and their metabolites in normal control subjects. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1982, 6, 495-498.	2.5	3
634	CLONOGENIC ASSAYS FOR THE CHEMOTHERAPEUTIC SENSITIVITY OF HUMAN TUMOURS. Lancet, The, 1982, 319, 780-781.	6.3	5
636	Growth hormone response to clonidine as a probe of noradrenergic receptor responsiveness in affective disorder patients and controls. Psychiatry Research, 1982, 6, 171-183.	1.7	198
637	High reverse T3 levels in manic and unipolar depressed women. Psychiatry Research, 1982, 6, 271-276.	1.7	36
638	Reduced presynaptic dopamine receptor density after chronic antidepressant treatment in rats. Psychiatry Research, 1982, 7, 111-119.	1.7	22
639	Post-stroke depressive disorders: a follow-up study of 103 patients.. Stroke, 1982, 13, 635-641.	1.0	512
640	Oxaprotiline, a noradrenaline uptake inhibitor with an active and an inactive enantiomer. Biochemical Pharmacology, 1982, 31, 2169-2176.	2.0	97
641	Depression by chronic electroconvulsive treatment of clonidine hypotherma and [3H]clonidine binding to rat cortical membranes. European Journal of Pharmacology, 1982, 80, 109-113.	1.7	86
642	Postdecapitation convulsions in the rat measured with an animex motility meter: Relation to central Î±-adrenoceptors. European Journal of Pharmacology, 1982, 85, 269-275.	1.7	34
643	Loss of rat cerebral cortical opiate receptors following chronic desimipramine treatment. European Journal of Pharmacology, 1982, 77, 39-44.	1.7	60
644	Mood, performance, and pain sensitivity: Changes induced by food constituents. Journal of Psychiatric Research, 1982, 17, 135-145.	1.5	110
645	Psychopathology of Parkinson's disease. Comprehensive Psychiatry, 1982, 23, 421-429.	1.5	17
646	HLA-linkage in affective disorder. Trends in Neurosciences, 1982, 5, 104-105.	4.2	0
647	Pharmacological comparison of the potential antidepressant UP 614-04 with viloxazine and imipramine; Behavioral studies. General Pharmacology, 1982, 13, 381-391.	0.7	10

#	Article	IF	Citations
648	Behavioral, biochemical and neuroendocrine responses to amphetamine in normal twins and â€˜well-stateâ€™ bipolar patients. Psychoneuroendocrinology, 1982, 7, 163-176.	1.3	81
649	PrÃ©cis ofThe neuropsychology of anxiety: An enquiry into the functions of the septo-hippocampal system. Behavioral and Brain Sciences, 1982, 5, 469-484.	0.4	1,550
650	Tetrahydrobiopterin: Efficacy in endogenous depression and Parkinson's disease. Journal of Neural Transmission, 1982, 55, 301-308.	1.4	47
651	Serotonergic inhibitory control of experimental aggression. Pharmacological Research Communications, 1982, 14, 1-13.	0.2	39
652	Increased permeability of blood brain barrier after electroconvulsive shocks (ECS). Pharmacological Research Communications, 1982, 14, 983-992.	0.2	10
653	The relation between the status of adaptive system and the number of postoperative complications in patients with gastrointestinal cancer: The effect of phenazepam. Journal of Surgical Oncology, 1982, 20, 192-196.	0.8	3
654	Simultaneous determination of 4-hydroxy-3-methoxy-phenylacetic (homovanillic) acid and other monoamine metabolites in human lumbar cerebrospinal fluid. Biomedical Applications, 1982, 227, 379-389.	1.7	25
655	Genetic regulation of neurotransmitter enzymes and receptors: Relationship to the inheritance of psychiatric disorders. Behavior Genetics, 1982, 12, 11-35.	1.4	22
656	Do urinary MHPG and plasma drug levels correlate with response to amitriptyline therapy?. Psychopharmacology, 1982, 76, 236-239.	1.5	13
657	Changes in noradrenergic neuroendocrine responses following repeated seizures and the mechanism of action of ECT. Psychopharmacology, 1982, 77, 53-57.	1.5	36
658	Urinary 3-methoxy-4-hydroxyphenylglycol determination using reversed-phase chromatography with amperometric detection. Biomedical Applications, 1982, 233, 89-95.	1.7	16
659	Effects of adrenergic blockers on the inhibition of muricide by desipramine and noradrenaline injected into the amygdala in olfactory bulbectomized rats. Pharmacology Biochemistry and Behavior, 1983, 18, 203-207.	1.3	34
660	Some effects of chronic antidepressant treatments on rat brain monoaminergic systems. Journal of Neural Transmission, 1983, 57, 281-295.	1.4	39
661	?-adrenergic receptor regulation and antidepressants: The influence of adrenocorticotropin. Journal of Neural Transmission, 1983, 57, 297-307.	1.4	7
662	Effect of lithium hydroxybutyrate on brain serotonin level in intact rabbits and during hyperactivity of central serotoninergic systems. Bulletin of Experimental Biology and Medicine, 1983, 96, 951-953.	0.3	0
663	3H-Rauwolscine binding in platelets from depressed patients and healthy volunteers. Psychopharmacology, 1983, 79, 308-312.	1.5	66
664	The behavioral effect of salbutamol (a beta-adrenergic receptor stimulant) on reserpine- and propranolol-treated rats. Journal of Neurology, 1983, 230, 43-55.	1.8	4
665	Behavioural evidence that chronic treatment with the antidepressant desipramine causes reduced functioning of brain noradrenaline systems. Psychopharmacology, 1983, 81, 73-77.	1.5	15

#	Article	IF	Citations
666	Clinical investigations into antidepressive mechanisms. Archiv Fur Psychiatrie Und Nervenkrankheiten, 1983, 233, 59-70.	0.6	13
667	Second generation antidepressants: The pharmacological and clinical significance of selected examples. Drug Development Research, 1983, 3, 203-211.	1.4	10
668	Treatment with antidepressants and down regulation of beta-adrenergic receptors. Drug Development Research, 1983, 3, 393-406.	1.4	31
669	The biochemistry of depression. Acta Psychiatrica Scandinavica, 1983, 67, 36-51.	2.2	27
670	Platelet monoamine oxidase and erythrocyte Catechol-o-Methyltransferase activity in alcoholism and controlled abstinence. Drug and Alcohol Dependence, 1983, 12, 85-91.	1.6	8
671	Concluding remarks: Mechanisms of antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1983, 7, 365.	2.5	0
672	Mental and emotional aspects of long-distance running. Psychosomatics, 1983, 24, 133-151.	2.5	37
673	Clinical implications of research on the mechanism of action of lithium. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1983, 7, 287-296.	2.5	11
674	Hypothalamic-pituitary-adrenal regulation, neurotransmitters and affective disorders. Peptides, 1983, 4, 775-784.	1.2	25
675	Dissimilar responses of cortical neurons to chronic trazodone or desipramine treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1983, 7, 175-181.	2.5	3
676	Platelet alpha2 adrenoreceptors are decreased in number after antidepressant therapy. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1983, 7, 241-247.	2.5	67
677	Involvement of Î±- and Î²1-adrenergic mechanisms in the immobility-reducing action of desipramine in the forced swimming test. Neuropharmacology, 1983, 22, 1055-1060.	2.0	84
678	On the mode of action of imipramine: Relationship between serotonergic axon terminal function and down-regulation of $beta;-adrenergic receptors. Neuropharmacology, 1983, 22, 373-383.	2.0	78
679	Interaction between mianserin, an antidepressant drug, and central H1- and H2-histamine-receptors: In vitro and in vivo studies and radioreceptor assay. Neuropharmacology, 1983, 22, 259-266.	2.0	20
680	Potential antidepressant activity of rolipram and other selective cyclic adenosine 3â€²,5â€²-monophosphate phosphodiesterase inhibitors. Neuropharmacology, 1983, 22, 267-272.	2.0	232
681	Serotonin receptor changes after chronic antidepressant treatments: Ligand binding, electrophysiological, and behavioral studies. Life Sciences, 1983, 32, 1791-1801.	2.0	53
682	Urinary MHPG and ward behavior in unmedicated psychiatric patients. Psychiatry Research, 1983, 10, 275-283.	1.7	4
683	CSF and Urinary Biogenic Amines and Metabolites in Depression and Mania. Archives of General Psychiatry, 1983, 40, 999.	13.8	298

#	Article	IF	Citations
684	A calcium hypothesis of antidepressant action. Medical Hypotheses, 1983, 10, 207-221.	0.8	9
685	Effects of long-term treatment of rats with antidepressants on adrenergic-receptor sensitivity in cerebral cortex: Structure activity study. Neurochemistry International, 1983, 5, 649-659.	1.9	38
686	The Na,K-ATPase hypothesis for manic-depression. I. General considerations. Medical Hypotheses, 1983, 12, 253-268.	0.8	32
687	Do antidepressants possess a common mechanism of action?. Biochemical Pharmacology, 1983, 32, 1811-1817.	2.0	84
688	Chronic antidepressant treatment enhances agonist affinity of brain Î±1-adrenoceptors. European Journal of Pharmacology, 1983, 87, 35-41.	1.7	100
689	Solubilization and assay of [3H]imipramine binding sites from human platelets. European Journal of Pharmacology, 1983, 86, 353-359.	1.7	21
690	Inhibition of in vitro amine uptake into rat brain synaptosomes after in vivo administration of antidepressants. European Journal of Pharmacology, 1983, 95, 305-309.	1.7	23
691	Mood changes in stroke patients: Relationship to lesion location. Comprehensive Psychiatry, 1983, 24, 555-566.	1.5	218
692	Depression in diabetics: A critical appraisal. Comprehensive Psychiatry, 1983, 24, 65-74.	1.5	51
693	5â€hydroxytryptamine and depression: a model for the interaction of normal variance with pathology.. British Journal of Clinical Pharmacology, 1983, 15, 393S-405S.	1.1	57
694	Biological classification of depressive illness.. British Journal of Clinical Pharmacology, 1983, 15, 161S-164S.	1.1	3
695	Biochemistry of tryptophan in health and disease. Molecular Aspects of Medicine, 1983, 6, 101-197.	2.7	290
696	Chronic antidepressant therapy and associated changes in central monoaminergic receptor functioning. , 1983, 21, 1-33.		156
697	Dopamine and depression: A review of recent evidence. I. Empirical studies. Brain Research Reviews, 1983, 6, 211-224.	9.1	261
698	Distal colon motility and clinical parameters in depression. Journal of Affective Disorders, 1983, 5, 19-26.	2.0	25
699	Tryptophan and tyrosine ratios to neutral amino acids in endogenous depression. Journal of Affective Disorders, 1983, 5, 67-79.	2.0	21
700	Depressive Illness in Patients with Epilepsy: A Review. Epilepsia, 1983, 24, S109-16.	2.6	98
701	Propranolol-Induced Depression: Mechanism and Management. Australian and New Zealand Journal of Psychiatry, 1983, 17, 400-402.	1.3	10

#	Article	IF	Citations
702	Cognitive Strategy Research. Springer Series in Cognitive Development, 1983, , .	2.8	8
703	Circadian rhythms of hormones in primary affective disorders. Cephalalgia, 1983, 3, 105-110.	1.8	3
704	Neuroendocrine regulation in depressed postmenopausal women and healthy subjects. Acta Psychiatrica Scandinavica, 1983, 67, 43-49.	2.2	35
705	CSF monoamine metabolites in mania. American Journal of Psychiatry, 1983, 140, 396-400.	4.0	73
706	AFFECTIVE DISORDERS IN THE ELDERLY: DIAGNOSTIC AND RESEARCH CONSIDERATIONS. Age and Ageing, 1983, 12, 1-10.	0.7	30
707	The research and development of a 5â€HT selective reuptake blocker. Preclinical aspects. Acta Psychiatrica Scandinavica, 1983, 68, 18-24.	2.2	1
708	Problems with current catecholamine hypotheses of antidepressant agents: Speculations leading to a new hypothesis. Behavioral and Brain Sciences, 1983, 6, 535.	0.4	160
709	The need for primate models in the psychopharmacotherapy of depression. Behavioral and Brain Sciences, 1983, 6, 548.	0.4	0
710	Cascading transmitter function in depression. Behavioral and Brain Sciences, 1983, 6, 548.	0.4	1
711	Postsynaptic serotonergic action of antidepressive drugs. Behavioral and Brain Sciences, 1983, 6, 549.	0.4	7
712	Output hypothesis: Peering into the black box. Behavioral and Brain Sciences, 1983, 6, 551.	0.4	0
713	The dynamics of neurotransmitter regulation and antidepressant efficacy. Behavioral and Brain Sciences, 1983, 6, 551.	0.4	0
714	Conceptual frameworks and biological psychopathology research. Behavioral and Brain Sciences, 1983, 6, 552.	0.4	0
715	Î²-Adrenergic receptors and antidepressant action. Behavioral and Brain Sciences, 1983, 6, 553.	0.4	1
716	Is theâ€œnewâ€•more useful than theâ€œoldâ€?. Behavioral and Brain Sciences, 1983, 6, 554.	0.4	0
717	An evaluation of the central concept in the output hypothesis for the mechanisms of action of antidepressant treatments. Behavioral and Brain Sciences, 1983, 6, 555.	0.4	0
718	Stone's revised aminergic hypothesis and the functional significance of receptor binding sensitivity. Behavioral and Brain Sciences, 1983, 6, 555.	0.4	4
719	Stress: Cause and cure of depression?. Behavioral and Brain Sciences, 1983, 6, 557.	0.4	0

#	Article	IF	Citations
720	Epinephrine, the neglected catecholamine. Behavioral and Brain Sciences, 1983, 6, 557.	0.4	0
721	Can a unitary hypothesis for depression be valid?. Behavioral and Brain Sciences, 1983, 6, 559.	0.4	1
722	Alpha-1-up, beta-down hypothesis: A counterproposal to Stone. Behavioral and Brain Sciences, 1983, 6, 560.	0.4	10
723	Input on output. Behavioral and Brain Sciences, 1983, 6, 561.	0.4	1
724	Form, content, and affect in the theory of stories. Behavioral and Brain Sciences, 1983, 6, 595.	0.4	8
725	The output hypothesis: New peripheral indicators of brain function?. Behavioral and Brain Sciences, 1983, 6, 556.	0.4	0
726	Mode of action of antidepressant agents: Increased output or increased efficiency?. Behavioral and Brain Sciences, 1983, 6, 558.	0.4	0
727	Alpha-2 adrenergic receptors and the mechanism of action of antidepressants. Behavioral and Brain Sciences, 1983, 6, 559.	0.4	2
728	Running as Treatment for Depression: Is It Worth It?. Journal of Sport and Exercise Psychology, 1983, 5, 288-301.	1.0	19
729	Dexamethasone Suppression Test and Serum Prolactin in Dementia Disorders. British Journal of Psychiatry, 1983, 143, 277-281.	1.7	148
730	Electroconvulsive Treatment and Lithium Carbonate. Archives of General Psychiatry, 1983, 40, 677.	13.8	42
731	Phaeochromocytoma with Schizophreniform Psychosis. British Journal of Psychiatry, 1983, 142, 422-423.	1.7	9
732	CSF monoamine metabolites and cyclic nucleotides in depression. Okayama Igakkai Zasshi, 1983, 95, 347-367.	0.0	0
733	Pharmacologic Mechanisms of Action of Antidepressants. Psychiatric Clinics of North America, 1984, 7, 575-586.	0.7	25
734	Dopamine Receptors and Monoamine Oxidase as Virion Receptors. Perspectives in Biology and Medicine, 1984, 27, 239-250.	0.3	14
735	Neurotransmitter Hypotheses of Depression: Research Update. Psychiatric Clinics of North America, 1984, 7, 563-573.	0.7	9
736	Biological Studies of Schizoaffective Disorders. Schizophrenia Bulletin, 1984, 10, 49-70.	2.3	25
737	Hypotheses concerning the mechanism of action of antidepressant drugs. Reviews of Physiology, Biochemistry and Pharmacology, 1984, 100, 1-74.	0.9	42

#	Article	IF	Citations
738	The Emerging Neurobiology of Mood Disorder. , 1984, , 119-150.		0
739	The comparative approach in personality study. Behavioral and Brain Sciences, 1984, 7, 440-441.	0.4	11
740	3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, and homovanillic acid in human cerebrospinal fluid. Biomedical Applications, 1984, 336, 259-269.	1.7	22
741	The state of the art of the science of drug discovery?an opinion. Drug Development Research, 1984, 4, 375-389.	1.4	19
742	Effect of cyclo(Leu-Gly) on reserpine-induced hypomotility and increases in cortical ?-adrenergic receptors. Psychopharmacology, 1984, 83, 76-78.	1.5	0
743	Chronic antidepressants and GABA â€œBâ€•receptors: A GABA hypothesis of antidepressant drug action. Life Sciences, 1984, 35, 2149-2154.	2.0	109
744	Antidepressant withdrawal-induced activation (hypomania and mania): Mechanism and theoretical significance. Brain Research Reviews, 1984, 7, 29-48.	9.1	69
745	An increase in sensitivity of rat cingulate cortical neurones to substance P occurs following withdrawal of chronic administration of antidepressant drugs. British Journal of Pharmacology, 1984, 81, 659-664.	2.7	25
746	Pharmacology of the GABAergic system: Effects of progabide, a GABA receptor agonistâ˜†. Psychoneuroendocrinology, 1984, 9, 135-140.	1.3	8
747	Common mechanism of action of biochemically â€œspecificâ€•antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1984, 8, 153-161.	2.5	14
748	Stereopsychopharmacology: Past, present and future. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1984, 8, 327-350.	2.5	7
749	Reflections on experimental and human pathology of aggression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1984, 8, 311-325.	2.5	79
750	Psychotherapeutic Drugs and Biogenic Amines Current Concepts and Therapeutic Implications. Drugs, 1984, 28, 127-143.	4.9	20
751	The pharmacological management of depression. International Rehabilitation Medicine, 1984, 6, vi-viii.	0.6	1
752	MOOD DISORDERS IN STROKE PATIENTS: IMPORTANCE OF LOCATION OF LESION. Brain, 1984, 107, 81-93.	3.7	1,053
753	Drugs: Guide and caveats to explanatory and descriptive approachesâ€”II. Drugs in psychiatric research. Journal of Psychiatric Research, 1984, 18, 391-400.	1.5	3
754	Biological markers in obsessive-compulsive and affective disorders. Journal of Psychiatric Research, 1984, 18, 407-423.	1.5	46
755	Effects of mianserin on noradrenergic mechanisms. Journal of Psychiatric Research, 1984, 18, 79-88.	1.5	6

#	Article	IF	Citations
756	Depression viewed as a state of disturbed psychic contact. Comprehensive Psychiatry, 1984, 25, 594-605.	1.5	3
757	Changes in amphetamine-induced anorexia and stereotypy during chronic treatment with antidepressant drugs. European Journal of Pharmacology, 1984, 98, 397-406.	1.7	13
758	Corticosterone prevents the increase in noradrenaline-stimulated adenyl cyclase activity in rat hippocampus following adrenalectomy or metopirone. European Journal of Pharmacology, 1984, 103, 235-240.	1.7	37
759	Tetrabenazine-induced depletion of brain monoamines: Characterization and interaction with selected antidepressants. European Journal of Pharmacology, 1984, 102, 425-430.	1.7	94
760	Urinary excretion of bioterin and neopterin in psychiatric disorders. Psychiatry Research, 1984, 11, 83-89.	1.7	83
761	The effects of desmethylimipramine on cognitive function in healthy subjects. Psychiatry Research, 1984, 12, 89-97.	1.7	13
762	Searchingâ€"waiting strategy: A candidate for an evolutionary model of depression?. Behavioral and Neural Biology, 1984, 41, 180-189.	2.3	100
763	Platelet receptor binding studies in affective disorders. Journal of Affective Disorders, 1984, 6, 219-239.	2.0	45
764	Panuramine, a selective inhibitor of uptake of 5-hydroxytryptamine in the brain of the rat. Neuropharmacology, 1984, 23, 1049-1052.	2.0	10
765	Five Antidepressant Treatments in Depressed Patients. Archives of General Psychiatry, 1984, 41, 688.	13.8	19
766	Clinical and Biological Correlates of Sleep Deprivation in Depression*. Canadian Journal of Psychiatry, 1984, 29, 530-536.	0.9	7
767	Tricyclic Antidepressants in Treatment of Depression and Chronic Pain. Anesthesia and Analgesia, 1984, 63, 1025???1032.	1.1	39
768	Platelet MAO activity in anorexia nervosa patients with and without a major depressive disorder. American Journal of Psychiatry, 1984, 141, 1244-1247.	4.0	25
769	Sensation seeking: A comparative approach to a human trait. Behavioral and Brain Sciences, 1984, 7, 413-434.	0.4	590
770	A balanced emphasis on environmental influences. Behavioral and Brain Sciences, 1984, 7, 434-435.	0.4	2
771	Personality traits: Causation, correlation, or neo-Bayesian. Behavioral and Brain Sciences, 1984, 7, 435-436.	0.4	1
772	Biological correlates of personality: Suppose it's not so simple. Behavioral and Brain Sciences, 1984, 7, 436-436.	0.4	3
773	Going over the top with optimal arousal theory. Behavioral and Brain Sciences, 1984, 7, 436-437.	0.4	0

#	Article	IF	Citations
774	The logic of the comparative approach. Behavioral and Brain Sciences, 1984, 7, 437-438.	0.4	1
775	Monoamines and human traits: A nice idea, butâ€¦. Behavioral and Brain Sciences, 1984, 7, 438-439.	0.4	1
776	Are sensation-seeking behavior, sleep patterns, and brain plasticity related?. Behavioral and Brain Sciences, 1984, 7, 439-440.	0.4	0
777	Is there a relationship between sensation seeking and strength of the nervous system?. Behavioral and Brain Sciences, 1984, 7, 441-441.	0.4	2
778	Sensation seeking and augmentingâ€“reducing: Does a nerve have nerve?. Behavioral and Brain Sciences, 1984, 7, 441-442.	0.4	10
779	Emotion variables as personality traits. Behavioral and Brain Sciences, 1984, 7, 442-443.	0.4	2
780	Sensation seeking: A clarification, a caveat, and a conjecture. Behavioral and Brain Sciences, 1984, 7, 443-443.	0.4	1
781	The biochemical basis of sensation-seeking behavior. Behavioral and Brain Sciences, 1984, 7, 443-445.	0.4	6
782	The noradrenergic locus coeruleusâ€“the center of attention?. Behavioral and Brain Sciences, 1984, 7, 445-445.	0.4	0
783	Spanning the transspecies gulf. Behavioral and Brain Sciences, 1984, 7, 446-447.	0.4	0
784	Biochemical substrates for a human â€œsensation-seekingâ€•trait. Behavioral and Brain Sciences, 1984, 7, 447-448.	0.4	1
785	The concept of sensation seeking and the structure of personality. Behavioral and Brain Sciences, 1984, 7, 448-449.	0.4	0
786	Sensation seeking: Exploration of empty spaces or novel stimuli?. Behavioral and Brain Sciences, 1984, 7, 449-450.	0.4	0
787	Sensation seeking and the orienting reflex. Behavioral and Brain Sciences, 1984, 7, 450-450.	0.4	2
788	Sensation seeking, orientation, and defense: Empirical and theoretical reservations. Behavioral and Brain Sciences, 1984, 7, 450-451.	0.4	2
789	Zuckerman's sensation-seeking theory: A view from Eastern Europe. Behavioral and Brain Sciences, 1984, 7, 451-452.	0.4	2
790	Sensation seeking: Where is the meat in the stew?. Behavioral and Brain Sciences, 1984, 7, 452-453.	0.4	0
791	What are sensation seekers seeking?. Behavioral and Brain Sciences, 1984, 7, 453-453.	0.4	12

#	Article	IF	Citations
792	Home from a perilous journey. Behavioral and Brain Sciences, 1984, 7, 453-471.	0.4	8
793	The septo-hippocampal system and ego. Behavioral and Brain Sciences, 1984, 7, 744-745.	0.4	0
794	Information processing in the hippocampal formation. Behavioral and Brain Sciences, 1984, 7, 745-746.	0.4	0
795	From angst to information processing. Behavioral and Brain Sciences, 1984, 7, 747-749.	0.4	1
796	The neuropsychology of depression. Behavioral and Brain Sciences, 1984, 7, 746-747.	0.4	11
798	Physiological substrates of a psychological dimension. Behavioral and Brain Sciences, 1984, 7, 445-446.	0.4	0
799	Physical Fitness and Mental Health: A Review of the Literature. Adapted Physical Activity Quarterly, 1984, 1, 207-220.	0.6	13
800	Role of olfactory bulbectomy and DSP4 treatment in avoidance learning in the rat.. Behavioral Neuroscience, 1984, 98, 496-505.	0.6	23
801	Urinary 3-Methoxy-4-Hydroxyphenylglycol and Major Affective Disorders. Archives of General Psychiatry, 1984, 41, 337.	13.8	88
802	Differences in nocturnal melatonin secretion between melancholic depressed patients and control subjects. American Journal of Psychiatry, 1985, 142, 811-816.	4.0	195
803	Plasma Cortisol Levels in Mania: Associated Clinical Ratings and Changes during Treatment with Haloperidol. British Journal of Psychiatry, 1985, 146, 498-502.	1.7	25
804	Influence of Physical Fitness in Determining the Impact of Stressful Life Events on Physical and Psychologic Health. Psychosomatic Medicine, 1985, 47, 164-173.	1.3	88
805	Neurochemical Aspects of Depression: The Past and the Future?. International Journal of Neuroscience, 1985, 27, 19-47.	0.8	20
806	Neuropeptides and psychiatry - basic and clinical aspects. Nordic Journal of Psychiatry, 1985, 39, 9-19.	0.2	3
807	Toward a Biochemical Classification of Depressive Disorders IX. British Journal of Psychiatry, 1985, 146, 633-637.	1.7	15
808	Adrenergic Receptors in Depression. British Journal of Psychiatry, 1985, 147, 23-29.	1.7	54
809	The effect of clorgyline on noradrenergic function. Psychopharmacology, 1985, 85, 227-230.	1.5	17
810	Ro 11-2465 (cyan-imipramine), citalopram and their N-desmethyl metabolites: Effects on the uptake of 5-hydroxytryptamine and noradrenaline in vivo and related pharmacological activities. Psychopharmacology, 1985, 86, 156-163.	1.5	27

#	Article	IF	Citations
811	Effects of carbamazepine on noradrenergic mechanisms in affectively ill patients. Psychopharmacology, 1985, 87, 59-63.	1.5	13
812	Urinary peptides in schizophrenia and depression. Stress and Health, 1985, 1, 169-181.	0.7	12
813	Mechanisms of the central action of lithium. Neuroscience and Behavioral Physiology, 1985, 15, 81-88.	0.2	0
814	Cholinesterases in primary affective disorders. Clinical Biochemistry, 1985, 18, 308-310.	0.8	7
815	Evolution of the concepts of the molecular mechanism of the action of antidepressants (survey). Pharmaceutical Chemistry Journal, 1985, 19, 733-741.	0.3	0
816	Tricyclic antidepressants antagonize prostaglandin (PG) E20induced contractions of the guinea pig ileum and hypomotility in the mouse. Experientia, 1985, 41, 474-476.	1.2	0
817	AHR-9377, a new antidepressant agent. Drug Development Research, 1985, 5, 233-242.	1.4	5
818	Effect of treatment with some atypical antidepressants on3H-DHA binding in rat brain. Drug Development Research, 1985, 5, 251-259.	1.4	7
819	Early experience with CGP 4718 A (Sercloremine), a new selective and reversible MAO-A and 5-HT-uptake inhibitor, in the treatment of depressive patients. Drug Development Research, 1985, 6, 371-384.	1.4	5
820	GABA receptor agonists: Pharmacological spectrum and therapeutic actions. Medicinal Research Reviews, 1985, 5, 55-75.	5.0	64
821	The relationship between anorexia nervosa and depression: A reevaluation. International Journal of Eating Disorders, 1985, 4, 389-405.	2.1	15
822	Endorphin Patterns within the Headache Spectrum Disorders. Cephalalgia, 1985, 5, 201-210.	1.8	27
823	Diurnal Hypersecretion of Growth Hormone in Depression*. Journal of Clinical Endocrinology and Metabolism, 1985, 60, 505-512.	1.8	163
824	Reduced Sensitivity of Lymphocyte Beta-Adrenergic Receptors in Patients with Endogenous Depression and Psychomotor Agitation. New England Journal of Medicine, 1985, 313, 715-720.	13.9	159
825	Stereochemical Considerations of the Actions of Some Psychotropic Drugs. Pharmacopsychiatry, 1985, 18, 225-230.	1.7	0
826	Drug Abuse and Psychiatric Disorders. Applied Clinical Psychology, 1985, , 137-172.	0.3	7
827	Second Generation Antidepressants: A Comparative Review. Journal of Clinical Pharmacology, 1985, 25, 241-260.	1.0	78
828	A strong influence of serotonin axons on beta-adrenergic receptors in rat brain. Science, 1985, 230, 323-325.	6.0	82

#	Article	IF	Citations
829	Plasma melatonin during desmethylimipramine treatment: evidence for changes in noradrenergic transmission.. British Journal of Clinical Pharmacology, 1985, 19, 799-805.	1.1	51
830	Correlations between aminergic metabolites simultaneously obtained from human CSF and brain. Life Sciences, 1985, 37, 1279-1286.	2.0	231
831	Diurnal rhythm of 3-methoxy-4-hydroxyphenylglycol (MHPG); relationship between plasma and urinary levels. Life Sciences, 1985, 37, 1731-1741.	2.0	20
832	Role of female gonadal hormones in the CNS: Clinical and experimental aspects. Life Sciences, 1985, 37, 893-906.	2.0	160
833	Free triiodothyronine (T3) and thyroxine (T4) in a group of unipolar depressed patients and normal subjects. Biological Psychiatry, 1985, 20, 1047-1054.	0.7	42
834	Daily patterns of serotonin uptake in platelets from psychiatric patients and control volunteers. Biological Psychiatry, 1985, 20, 1073-1081.	0.7	24
835	Peptide-containing fractions in depression. Biological Psychiatry, 1985, 20, 245-256.	0.7	17
836	Cerebrospinal fluid and plasma monoamines and their metabolites in euthymic bipolar patients. Biological Psychiatry, 1985, 20, 257-269.	0.7	61
837	Opposite effects of chronic imipramine treatment on brain and urine MHPG levels in the rat. Biological Psychiatry, 1985, 20, 858-865.	0.7	14
838	Decreased triiodothyronines in depression: A preliminary report. Biological Psychiatry, 1985, 20, 922-925.	0.7	34
839	New antidepressant drugs: Is there anything new they tell us about depression?. Trends in Neurosciences, 1985, 8, 427-431.	4.2	7
840	On factors determining orderly recruitment of motor units: a role for intrinsic membrane properties. Trends in Neurosciences, 1985, 8, 431-433.	4.2	50
841	The TRH-induced TSH response in psychiatric patients: a possible neuroendocrine marker. Psychoneuroendocrinology, 1985, 10, 237-260.	1.3	148
842	Cardiovascular peripheric effects of a new tricyclic antidepressant, cianopramine (RO 11-2464) in dogs. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1985, 9, 381-386.	2.5	2
843	Sex steroids and affect in the surgical menopause: a double-blind, cross-over study. Psychoneuroendocrinology, 1985, 10, 325-335.	1.3	277
844	Are vascular mechanisms involved in antidepressant action?. General Pharmacology, 1985, 16, 553-556.	0.7	2
845	Neurochemical and cognitive aspects of depression. Progress in Neurobiology, 1985, 24, 187-197.	2.8	3
846	Diagnosis and clinical management of post-stroke depression. Psychosomatics, 1985, 26, 769-778.	2.5	52

#	Article	IF	Citations
847	Changes in mouse brain serotonin turnover following chronic imipramine administration. General Pharmacology, 1985, 16, 55-59.	0.7	1
848	Effects of antidepressant drugs on a quickly-learned conditioned-suppression response in mice. Neuropharmacology, 1985, 24, 285-290.	2.0	29
849	Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia. Psychiatry Research, 1985, 15, 281-292.	1.7	112
850	Neuroimmunomodulatory interactions of norepinephrine and serotonin. Journal of Neuroimmunology, 1985, 10, 41-58.	1.1	44
851	Effects of iminodibenzyl antipsychotic drugs on cerebral dopamine and Î±-adrenergic receptors. European Journal of Pharmacology, 1985, 112, 313-322.	1.7	18
852	A corticosteroid/dopamine hypothesis for psychotic depression and related states. Journal of Psychiatric Research, 1985, 19, 57-64.	1.5	232
853	Is there a metabolic basis for the fibrositis syndrome?. American Journal of Medicine, 1986, 81, 50-54.	0.6	42
854	Occurrence and functional significance of serotonin and catecholamine uptake by astrocytes. Biochemical Pharmacology, 1986, 35, 2273-2281.	2.0	76
855	Hippocampal membrane alteration in Alzheimer's disease. Brain Research, 1986, 385, 115-121.	1.1	62
856	Characterization of serotonin receptors and lack of effect of antidepressant therapy on monoamine functions in various regions of the rabbit brain. European Journal of Pharmacology, 1986, 126, 259-271.	1.7	14
857	Cholinergic mechanisms in depression. Brain Research Reviews, 1986, 11, 285-316.	9.1	164
858	Reply from P.J. Tyrer and C.A. Marsden. Trends in Neurosciences, 1986, 9, 314.	4.2	0
859	Longterm amitriptyline treatment alters the affinity state of alpha2 adrenoceptors in rabbit hindbrain. Life Sciences, 1986, 38, 2429-2436.	2.0	5
860	Supersensitive endocrine response to physostigmine in dopamine-depleted rats: A model of depression?. Biological Psychiatry, 1986, 21, 775-786.	0.7	34
861	Lack of correlation between plasma DOPEG and urinary MOPEG levels in depressed patients. Biological Psychiatry, 1986, 21, 900-906.	0.7	5
862	The effects of Mianserin therapy on plasma renin activity in depressed patients. Biological Psychiatry, 1986, 21, 1331-1334.	0.7	3
863	Activation and desensitization of presynaptic Î±₂â€adrenoceptors after inhibition of neuronal uptake by antidepressant drugs in the rat vas deferens. British Journal of Pharmacology, 1986, 89, 673-683.	2.7	37
864	POSTER COMMUNICATIONS. British Journal of Pharmacology, 1986, 88, 323P.	2.7	4

#	Article	IF	Citations
865	Studies on 3â€Methoxyâ€4â€Hydroxyphenylglycol (MHPG) and 3,4â€Dihydroxyphenylglycol (DHPG) Levels in Human Urine, Plasma and Cerebrospinal Fluids, and Their Significance in Studies of Depression. Psychiatry and Clinical Neurosciences, 1986, 40, 47-56.	1.0	3
866	Effects of Electroconvulsive Shock and Serotonin Axon Lesions on Beta-Adrenergic and Serotonin-2 Receptors in Rat Brain. Annals of the New York Academy of Sciences, 1986, 462, 76-90.	1.8	18
867	The Role of the Central Adrenergic System in the Regulation of the Cerebromicrocirculation.. Annals of the New York Academy of Sciences, 1986, 462, 224-231.	1.8	6
868	Neurochemical Mechanisms of Mood Stabilization.. Annals of the New York Academy of Sciences, 1986, 462, 366-375.	1.8	12
869	Effects of antidepressants on receptor-activated and Ca2+-activated contractions of rabbit isolated aorta. General Pharmacology, 1986, 17, 607-610.	0.7	13
870	Basal hypersecretion of cortisol in relation to abnormal dexamethasone suppression test response in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1986, 10, 729-737.	2.5	2
871	Treatment of acute psychosis with non-neuroleptic agents. Psychosomatics, 1986, 27, 7-16.	2.5	23
872	Effects of receptor blockers (methysergide, propranolol, phentolamine, yohimbine and prazosin) on desimipramine-induced pituitary hormone stimulation in humansâ€”III. Hypothalamo-pituitary-adrenocortical axis. Psychoneuroendocrinology, 1986, 11, 475-489.	1.3	37
873	Alcohol withdrawal and carbamazepine. Alcohol, 1986, 3, 113-129.	0.8	45
874	The pharmacology of depression: studies of neurotransmitter receptors lead the search for biochemical lesions and new drug therapies. Trends in Pharmacological Sciences, 1986, 7, 349-354.	4.0	31
875	Imipramine binding sites on platelets of patients with major depressive disorder. Psychiatry Research, 1986, 18, 333-342.	1.7	34
876	Clinical studies on norepinephrine metabolism: How to interpret the numbers. Psychiatry Research, 1986, 17, 229-239.	1.7	36
877	Path analysis of psychopharmacological data: Catecholamine breakdown in man. Psychiatry Research, 1986, 18, 89-105.	1.7	3
878	Abnormal dexamethasone suppression test in daily chronic headache sufferers. Psychiatry Research, 1986, 19, 51-57.	1.7	10
879	Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors. Neuropharmacology, 1986, 25, 1119-1126.	2.0	95
880	Cellular localization of adrenergic receptors in rat and human brain. Brain Research, 1986, 370, 127-135.	1.1	39
881	Cerebrospinal Fluid Amine Metabolites. Archives of General Psychiatry, 1986, 43, 938.	13.8	78
882	Prostaglandin Receptor Sensitivity in Psychiatric Disorders. Archives of General Psychiatry, 1986, 43, 987.	13.8	39

#	Article	IF	Citations
883	Neurochemical and Neuroendocrine Dysregulation in Affective Disorders. Psychiatric Clinics of North America, 1986, 9, 313-327.	0.7	14
884	Cerebrospinal Fluid Monoamine and Monoamine Metabolite Levels and the Dexamethasone Suppression Test in Depression. Archives of General Psychiatry, 1986, 43, 356.	13.8	39
885	Biological Aspects of Depression: A Review of The Etiology and Mechanisms of Action and Clinical Assessment of Antidepressants. International Review of Neurobiology, 1986, 28, 183-239.	0.9	6
886	Headache as a Symptom of Craniomandibular Disorders I: Pathophysiology. Cranio - Journal of Craniomandibular Practice, 1986, 4, 134-142.	0.6	10
887	Antidepressants and biochemical theories of depression.. Psychological Bulletin, 1986, 99, 361-374.	5.5	35
888	Increased Serotonin2 and Î²-Adrenergic Receptor Binding in the Frontal Cortices of Suicide Victims. Archives of General Psychiatry, 1986, 43, 954.	13.8	514
889	Biochemical and Functional Evidence of Supersensitive Platelet Î±2-Adrenoceptors in Major Affective Disorder. Archives of General Psychiatry, 1986, 43, 51.	13.8	141
890	Plasma MHPG in depressive disorders and relationship to the dexamethasone suppression test. American Journal of Psychiatry, 1986, 143, 846-851.	4.0	63
891	Relative activity of metabolic pathways for norepinephrine in endogenous depression. Acta Psychiatrica Scandinavica, 1986, 73, 624-628.	2.2	19
892	Dexamethasone suppression and energy balance in eating disorders. Acta Psychiatrica Scandinavica, 1986, 73, 242-251.	2.2	6
893	Binding of yohimbine and imipramine to platelets in depressive illness. Psychological Medicine, 1986, 16, 765-773.	2.7	43
894	Urinary monoamines and monoamine metabolites in subtypes of unipolar depressive disorder and normal controls. Psychological Medicine, 1986, 16, 541-546.	2.7	50
895	Compounds acting on alpha1- and alpha2- adrenoceptors: Agonists and antagonists. Medicinal Research Reviews, 1986, 6, 431-449.	5.0	65
896	Lack of circadian rhythm in plasma levels of 3,4-dihydroxyphenylethyleneglycol in healthy human subjects. Psychopharmacology, 1986, 90, 471-4.	1.5	8
897	Neuroendocrine effects of l-tryptophan and dexamethasone. Psychopharmacology, 1986, 89, 85-8.	1.5	14
898	Hormonal and behavioral effects associated with intravenousl-tryptophan administration. Psychopharmacology, 1986, 88, 213-219.	1.5	39
899	Decrease in plasma levels of 3,4-dihydroxyphenylethyleneglycol in major depression. Psychopharmacology, 1986, 88, 220-225.	1.5	16
900	Effect of diclofensine, a novel antidepressant, on peripheral adrenergic function. Clinical Pharmacology and Therapeutics, 1986, 39, 582-585.	2.3	5

#	Article	IF	Citations
901	The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome. BJOG: an International Journal of Obstetrics and Gynaecology, 1986, 93, 1290-1296.	1.1	193
902	Action of chronically administered antidepressants on the serotonergic postsynapse in a model of depression. Pharmacology Biochemistry and Behavior, 1986, 25, 805-811.	1.3	14
903	Changes in brain catecholamine levels following olfactory bulbectomy and the effect of acute and chronic administration of desipramine in rats. Pharmacology Biochemistry and Behavior, 1986, 24, 1715-1719.	1.3	37
904	Chronic clorgyline treatment enhances release of norepinephrine following sympathetic stimulation in the rat. Naunyn-Schmiedeberg's Archives of Pharmacology, 1986, 332, 236-242.	1.4	17
905	Urinary 3-methoxy, 4-hydroxyphenylethylene glycol and therapeutic response to maprotiline and indalpine in major depression. Journal of Neural Transmission, 1986, 66, 47-58.	1.4	1
906	Plasma Melatonin Concentrations in Depression. Australian and New Zealand Journal of Psychiatry, 1986, 20, 381-383.	1.3	42
907	Electroacupuncture: An alternative to antidepressants for treating affective diseases?. International Journal of Neuroscience, 1986, 29, 79-92.	0.8	86
908	Comparison of clonidine and lithium in the treatment of mania. American Journal of Psychiatry, 1986, 143, 1608-1609.	4.0	24
909	The Depressive Syndromes. Journal of Psychotherapy and the Family, 1986, 2, 41-78.	0.1	0
910	Nutritional Biochemistry and Behavioral Disabilities. Journal of Learning Disabilities, 1987, 20, 505-512.	1.5	4
911	Running and Depression. Perceptual and Motor Skills, 1987, 64, 1303-1310.	0.6	10
912	Dopamine, schizophrenia, mania, and depression: Toward a unified hypothesis of cortico-striatopallido-thalamic function. Behavioral and Brain Sciences, 1987, 10, 197-208.	0.4	666
913	The â€œextended amygdalaâ€•as a receptor area for psychotherapeutic drugs. Behavioral and Brain Sciences, 1987, 10, 208-208.	0.4	1
914	Roles for glutamate and norepinephrine in limbic circuitry and psychopathology. Behavioral and Brain Sciences, 1987, 10, 208-209.	0.4	2
915	The relevance of feedforward loops. Behavioral and Brain Sciences, 1987, 10, 210-210.	0.4	32
916	The ghost in the machine: What if the midbrain output is excitatory?. Behavioral and Brain Sciences, 1987, 10, 210-212.	0.4	1
917	Neural circuit models of psychopathology: Dancing on the precipice of neuromythology?. Behavioral and Brain Sciences, 1987, 10, 212-213.	0.4	0
918	The neuropathology of schizophrenia, mania, and depression: Diseases of cognitive initiation and switching?. Behavioral and Brain Sciences, 1987, 10, 213-214.	0.4	0

#	Article	IF	Citations
919	An electrophysiologist's eye view of the basal ganglia. Behavioral and Brain Sciences, 1987, 10, 214-215.	0.4	1
920	Don't leave the â€œpsychâ€•out of neuropsychology. Behavioral and Brain Sciences, 1987, 10, 215-217.	0.4	54
921	The prefrontal cortex â€" accumbens circuit: Who's in charge?. Behavioral and Brain Sciences, 1987, 10, 217-218.	0.4	6
922	Where have all the peptides gone?. Behavioral and Brain Sciences, 1987, 10, 218-219.	0.4	0
923	Dopamine and mental illness: Phenomenological and anatomical considerations. Behavioral and Brain Sciences, 1987, 10, 219-220.	0.4	1
924	Searching for a technology of behavior. Behavioral and Brain Sciences, 1987, 10, 220-221.	0.4	32
925	Toward a neurological psychiatry. Behavioral and Brain Sciences, 1987, 10, 221-222.	0.4	0
926	Unified theories of psychoses and affective disorders: Are they feasible without accurate neural models of cognition and emotion?. Behavioral and Brain Sciences, 1987, 10, 222-222.	0.4	0
927	Psychopharmacology of psychosis: Still looking for missing links. Behavioral and Brain Sciences, 1987, 10, 223-224.	0.4	0
928	Dopamine and mental illness: And what about the mesocortical dopamine system?. Behavioral and Brain Sciences, 1987, 10, 224-225.	0.4	7
929	Madness and clarity. Behavioral and Brain Sciences, 1987, 10, 225-226.	0.4	0
930	Toward a unified neuropsychiatric hypothesis. Behavioral and Brain Sciences, 1987, 10, 226-245.	0.4	1
931	Intracellular considerations in models of psychopathology. Behavioral and Brain Sciences, 1987, 10, 209-210.	0.4	0
932	Neuropsychiatry: Pitfalls of inferring functional mechanisms from observed drug effects. Behavioral and Brain Sciences, 1987, 10, 222-223.	0.4	0
933	Is the dexamethasone suppression test predictive of response to specific antidepressant treatment in major depression?. Acta Psychiatrica Scandinavica, 1987, 76, 129-133.	2.2	7
934	Effects of RS-2232, a potential antidepressant, on the levels of monoamines, precursor amino acids and their related metabolites in mouse brain.. The Japanese Journal of Pharmacology, 1987, 44, 413-420.	1.2	5
935	RS-2232, a compound with a reversible and specific type-A monoamine oxidase inhibiting property in mouse brain.. The Japanese Journal of Pharmacology, 1987, 44, 421-427.	1.2	3
936	Neurochemical changes in experimental African trypanosomiasis in voles and mice. Annals of Tropical Medicine and Parasitology, 1987, 81, 673-679.	1.6	12

#	Article	IF	Citations
937	Monoamine Neurotransmitter Interactions and the Prediction of Antidepressant Response. Archives of General Psychiatry, 1987, 44, 1078.	13.8	54
938	Effects of subchronic treatment with imipramine, zimelidine and alaproclate on regional tissue levels of substance P-and neurokinin a/neurokinin B-like immunoreactivity in the brain and spinal cord of the rat. Neuropharmacology, 1987, 26, 581-590.	2.0	38
939	Alpha2-adrenergic receptors in platelet membranes of depressed patients: Increased affinity for 3H-yohimbine. Psychiatry Research, 1987, 20, 107-116.	1.7	24
940	Beta-adrenoceptors on lymphocytes of patients with major depressive disorder. Psychiatry Research, 1987, 20, 239-248.	1.7	38
941	Decreased beta-adrenergic receptors in the leukocytes of depressed patients. Psychiatry Research, 1987, 22, 265-273.	1.7	45
942	Molecular genetics of catecholamines as an approach to the biochemistry of manic-depression. Journal of Psychiatric Research, 1987, 21, 559-568.	1.5	7
943	Search for a gene that predisposes individuals to BPI disorder. Journal of Psychiatric Research, 1987, 21, 569-575.	1.5	3
944	Right hemisphere involvement in depression: Toward a neuropsychological theory of negative affective experiences. Biological Psychiatry, 1987, 22, 1201-1215.	0.7	74
945	Dexamethasone suppression test and urinary MHPG Â· SO4 determination in depressive disorders. Biological Psychiatry, 1987, 22, 883-891.	0.7	25
946	Skin fibroblast beta-adrenergic receptor function in manie-depressive illness. Biological Psychiatry, 1987, 22, 1439-1443.	0.7	19
947	Adrenoreceptors and the pharmacology of affective illness: A unifying theory. Life Sciences, 1987, 40, 1947-1963.	2.0	37
948	The pineal hormone melatonin in panic disorder. Journal of Affective Disorders, 1987, 12, 203-206.	2.0	18
949	Enhanced histamine- and Î²-adrenoceptor-mediated cyclic AMP formation in leukocytes from patients with endogenous depression. Journal of Affective Disorders, 1987, 13, 227-232.	2.0	17
950	5-HT and 5-HIAA in cerebrospinal fluid in depression. Journal of Affective Disorders, 1987, 12, 13-22.	2.0	54
951	The effects of thyroid state on beta-adrenergic and serotonergic receptors in rat brain. Psychoneuroendocrinology, 1987, 12, 261-270.	1.3	81
952	Biochemical Profile of Depressed Adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 1987, 26, 873-878.	0.3	22
953	Treatment of rats with thyrotropin (TSH) reduces the adrenoceptor sensitivity of adenylate cyclase from cerebral cortex. Neurochemistry International, 1987, 10, 173-178.	1.9	6
954	Catecholamine Metabolism and Disposition in Healthy and Depressed Subjects. Archives of General Psychiatry, 1987, 44, 337.	13.8	83

#	Article	IF	Citations
955	Effects of RS-2232, a Potential Antidepressant, on the Levels of Monoamines, Precursor Amino Acids and Their Related Metabolites in Mouse Brain. The Japanese Journal of Pharmacology, 1987, 44, 413-420.	1.2	4
956	RS-2232, a Compound with a Reversible and Specific Type-A Monoamine Oxidase Inhibiting Property in Mouse Brain. The Japanese Journal of Pharmacology, 1987, 44, 421-427.	1.2	1
957	Gas chromatographicâ€"mass spectrometric analysis and preliminary human pharmacokinetics of sertraline, a new antidepressant drug. Biomedical Applications, 1987, 417, 197-202.	1.7	33
958	Increased? 2;-adrenoceptor density in the frontal cortex of depressed suicide victims. Journal of Neural Transmission, 1987, 70, 377-381.	1.4	94
959	In vitro and in vivo effect of chloropromazine, imipramine and lithium chloride on monoamine oxidase activity in rat brain mitochondria. Bioscience Reports, 1987, 7, 701-704.	1.1	6
960	Chronic exposure to elf fields may induce depression. Bioelectromagnetics, 1988, 9, 195-205.	0.9	62
961	SL 81.0385: A novel selective and potent serotonin uptake inhibitor. Drug Development Research, 1988, 12, 29-40.	1.4	40
962	Catecholaminergic neurons in the ventrolateral medulla and nucleus of the solitary tract in the human. Journal of Comparative Neurology, 1988, 273, 224-240.	0.9	83
963	Regional distribution of monoamines in the nucleus accumbens of the rat. Neurochemical Research, 1988, 13, 937-942.	1.6	30
964	The pigmented subpeduncular nucleus: a neuromelanin-containing nucleus in the human pontine tegmentum. Acta Neuropathologica, 1988, 77, 26-32.	3.9	15
965	The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology, 1988, 95, 298-302.	1.5	360
966	Personality factors predisposing to depression correlate significantly negatively with M1-muscarinic and ?-adrenergic receptor densities on blood cells. European Archives of Psychiatry and Neurological Sciences, 1988, 237, 209-217.	0.9	9
967	Is Phosphodiesterase inhibition a new mechanism of antidepressant action?. European Archives of Psychiatry and Neurological Sciences, 1988, 238, 2-6.	0.9	89
968	Post-stroke depression in the elderly. Journal of General Internal Medicine, 1988, 3, 508-517.	1.3	10
969	Baseline studies on transmitter substances in cerebrospinal fluid in depression. Acta Psychiatrica Scandinavica, 1988, 78, 1-35.	2.2	16
970	Impact of Î²-blockade on complex cognitive functioning. American Heart Journal, 1988, 116, 311-315.	1.2	33
971	Amino acid levels in depression: A preliminary investigation. Journal of Psychiatric Research, 1988, 22, 159-164.	1.5	89
972	Significance of mixed features in acute mania. Comprehensive Psychiatry, 1988, 29, 421-426.	1.5	24

#	Article	IF	Citations
973	Chronic treatment with cholinesterase inhibitors increases Î±2-adrenoceptors in rat brain. European Journal of Pharmacology, 1988, 153, 167-173.	1.7	9
974	Regionally selective increases in Î²-adrenergic receptor density in the brains of suicide victims. Brain Research, 1988, 442, 199-203.	1.1	109
975	Influence of freezer storage time on cerebral biogenic amine and metabolite concentrations and receptor ligand binding characteristics. Brain Research, 1988, 450, 225-230.	1.1	11
976	The pharmacological profile of Org 6906, a potential non-sedative antidepressant that combines monoamine uptake inhibition with alpha2-adrenolytic activity. Neuropharmacology, 1988, 27, 251-260.	2.0	11
977	Norepinephrine and (Na+, K+)-ATPase: Evidence for stabilization by lithium or imipramine. Neuropharmacology, 1988, 27, 261-267.	2.0	4
978	Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, org 3770 and its enantiomers. Neuropharmacology, 1988, 27, 399-408.	2.0	177
979	Anti-serotonin action in combination with noradrenaline-stimulating action is important for inhibiting muricide in midbrain raphe-lesioned rats. Neuropharmacology, 1988, 27, 123-127.	2.0	1
980	Neurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers. Psychiatry Research, 1988, 25, 187-194.	1.7	65
981	TRH: Behavioral and endocrine effects in man. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1988, 12, S87-S117.	2.5	15
982	The neurobiology of aging: Does it predispose to depression?. Neurobiology of Aging, 1988, 9, 101-117.	1.5	63
983	Possible relationship between neuropeptide Y (NPY) and major depression â€“ evidence from human and animal studies. Nordic Journal of Psychiatry, 1988, 42, 131-137.	0.2	34
984	Bright artificial light produces subsensitivity to clonidine. Life Sciences, 1988, 42, 597-601.	2.0	5
985	Bright artificial light produces subsensitivity to nicotine. Life Sciences, 1988, 42, 225-230.	2.0	13
986	Rapid antidepressant response to alprazolam in depressed patients with high catecholamine output and heterologous desensitization of platelet adenylate cyclase. Biological Psychiatry, 1988, 23, 543-559.	0.7	33
987	Urinary MHPG, platelet 3H-imipramine binding and symptomatology in depression: An exploratory study of clinical heterogeneity. Biological Psychiatry, 1988, 23, 560-574.	0.7	15
988	Platelet MAO deamination of serotonin in depressed patients. Biological Psychiatry, 1988, 23, 44-52.	0.7	12
989	Platelet monoamine oxidase in alcoholism. Biological Psychiatry, 1988, 24, 15-24.	0.7	79
990	Melatonin and psychiatry. Biological Psychiatry, 1988, 23, 405-425.	0.7	125

#	Article	IF	Citations
991	Affective changes with estrogen and androgen replacement theraphy in surgically menopausal women. Journal of Affective Disorders, 1988, 14, 177-187.	2.0	264
992	Noradrenergic effects in tardive dyskinesia, akathisia and pseudoparkinsonism via the limbic system and basal ganglia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1988, 12, 849-864.	2.5	20
993	Neuronal Unit Activity Patterns in Behaving Animals: Brainstem and Limbic System. Annual Review of Psychology, 1988, 39, 135-168.	9.9	52
994	Reduced Corticotropin Releasing Factor Binding Sites in the Frontal Cortex of Suicide Victims. Archives of General Psychiatry, 1988, 45, 577.	13.8	520
995	Clinical and Biochemical Manifestations of Depression. New England Journal of Medicine, 1988, 319, 348-353.	13.9	588
996	Î±2-Adrenergic Receptor Sensitivity in Depression. Archives of General Psychiatry, 1988, 45, 718.	13.8	38
997	The Psychobiology of Emotions. , 1988, , .		23
998	Pathophysiology of Depressive Illness: Review of the Literature and Case Example. Issues in Mental Health Nursing, 1988, 9, 271-284.	0.6	1
999	Postpsychotic depression and negative symptoms: an investigation of syndromal overlap. American Journal of Psychiatry, 1988, 145, 1532-1537.	4.0	114
1000	Unusual Stereospecificity of the Potential Antidepressant Rolipram on the Cyclic AMP Generating System from Rat Brain Cortex. Pharmacopsychiatry, 1988, 21, 83-86.	1.7	16
1001	Monoamines, Depression and Antidepressant Drugs. Pharmacopsychiatry, 1988, 21, 6-8.	1.7	13
1002	Major Depression in Primary Dementia. Archives of Neurology, 1988, 45, 1182.	4.9	238
1003	Imipramine binding in depressive patients diagnosed according to different criteria. Acta Psychiatrica Scandinavica, 1988, 78, 156-161.	2.2	17
1004	Past and present strategies of research on the HPAâ€axis in psychiatry.. Acta Psychiatrica Scandinavica, 1988, 77, 112-125.	2.2	19
1005	The 24â€hour pattern of urinary MHPG excretion in depressives and normals. Acta Psychiatrica Scandinavica, 1988, 78, 298-303.	2.2	4
1006	CSF monoamine metabolites in patients and controls: support for a bimodal distribution in major affective disorders. Acta Psychiatrica Scandinavica, 1988, 78, 541-549.	2.2	34
1007	Plasma levels of ÃŸâ€endorphin, cortisol, prolactin and growth hormone in depressed patients. Acta Psychiatrica Scandinavica, 1988, 78, 230-233.	2.2	12
1008	Thyroid hormones in the treatment of affective disorders. Acta Psychiatrica Scandinavica, 1988, 77, 623-636.	2.2	60

#	Article	IF	Citations
1009	Antidepressants Reduce Whole-Body Norepinephrine Turnover While Enhancing 6-Hydroxymelatonin Output. Archives of General Psychiatry, 1988, 45, 150.	13.8	77
1010	Dysrhythmia, dysphoria, and depression: The interaction of learned helplessness and circadian dysrhythmia in the pathogenesis of depression.. Psychological Bulletin, 1988, 103, 163-178.	5.5	99
1011	The Experience of Shame and the Restoration of Self-Respect in Group Therapy. International Journal of Group Psychotherapy, 1988, 38, 3-14.	0.4	60
1012	Cerebrospinal Fluid and Urinary Biogenic Amines in Depressed Patients and Healthy Controls. Archives of General Psychiatry, 1988, 45, 705.	13.8	37
1013	Blunted Î²-Adrenergic Responsivity of Peripheral Blood Mononuclear Cells in Endogenous Depression. Archives of General Psychiatry, 1988, 45, 241.	13.8	67
1014	Biology of Depression. Medical Clinics of North America, 1988, 72, 765-790.	1.1	20
1015	CSF biochemical correlates of mixed affective states. Acta Psychiatrica Scandinavica, 1988, 78, 289-297.	2.2	17
1016	Comparison of spontaneously recovered versus nonrecovered patients with poststroke depression.. Stroke, 1988, 19, 1491-1496.	1.0	28
1017	High Intercorrelations Among Urinary Outputs of Norepinephrine and Its Major Metabolites. Archives of General Psychiatry, 1988, 45, 158.	13.8	12
1018	Thyroid Function in Affective Disorders and Alcoholism. Neurologic Clinics, 1988, 6, 55-82.	0.8	7
1019	High Correlations of Norepinephrine, Dopamine, and Epinephrine and Their Major Metabolite Excretion Rates. Archives of General Psychiatry, 1988, 45, 701.	13.8	17
1020	Fluoxetine Efficacy vs Comparative Drugs: An Overview. British Journal of Psychiatry, 1988, 153, 51-58.	1.7	26
1021	The Involvement of Serotonin in Psychiatric Disorders and Behaviour. British Journal of Psychiatry, 1988, 153, 26-39.	1.7	78
1022	Biochemical Classifications of Diagnostic Subgroups and D-Type Scores. Archives of General Psychiatry, 1989, 46, 269.	13.8	8
1023	The Antidepressant Effects of 5-HT Uptake Inhibitors. British Journal of Psychiatry, 1989, 155, 32-40.	1.7	37
1024	Which Depressed Patients will Respond to Electroconvulsive Therapy?. British Journal of Psychiatry, 1989, 154, 8-17.	1.7	28
1025	A Neurotransmitter Basis for Eysenck's Theory of Personality. Psychological Reports, 1989, 64, 189-190.	0.9	19
1026	An Application of the Item-Response Model to Psychiatric Epidemiology. Sociological Methods and Research, 1989, 18, 66-103.	4.3	16

#	Article	IF	Citations
1027	Folk, functional and neurochemical aspects of mood. Philosophical Psychology, 1989, 2, 17-30.	0.5	13
1028	The American Concept of Schizophrenia. Schizophrenia Bulletin, 1989, 15, 519-531.	2.3	40
1029	Noradrenergic Output and Clinical Response in Depressed Women During Amitriptyline Therapy. Pharmacopsychiatry, 1989, 22, 144-151.	1.7	12
1030	Neurobiology of brain?gut interactions. Digestive Diseases and Sciences, 1989, 34, 1809-1816.	1.1	23
1031	In vivo changes in brain catecholamine release from rat hypothalamus following olfactory bulbectomy. Pharmacology Biochemistry and Behavior, 1989, 34, 879-885.	1.3	13
1032	Inhibition of mouse-killing behavior by S-adenosyl-L-methionine in midbrain raphe-lesioned and olfactory-bulbectomized rats. Pharmacology Biochemistry and Behavior, 1989, 34, 395-398.	1.3	8
1033	GABA-mediated modification of despair behavior in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 1989, 339, 306-11.	1.4	11
1034	Effect of imipramine or ECS on central Î²1 and Î²2 receptor sensitivity in the cardiovascular response of ratreceptor sensitivity in the cardiovascular response of rat. Archives of Pharmacal Research, 1989, 12, 282-288.	2.7	2
1035	Dysbalance of neuronal second messenger function in the aetiology of affective disorders: A pathophysiological concept hypothesising defects beyond first messenger receptors. Journal of Neural Transmission, 1989, 75, 21-29.	1.4	53
1036	monoamine oxidase inhibitors revisited. Canadian Journal of Anaesthesia, 1989, 36, 64-74.	0.7	59
1037	Depression and dementia of the alzheimer type: Implications for psychopharmacological research. Human Psychopharmacology, 1989, 4, 237-245.	0.7	3
1038	Acute effects of lithium on catecholamines, serotonin, and their major metabolites in discrete brain regions. Journal of Neuroscience Research, 1989, 22, 338-345.	1.3	29
1039	Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system. Cellular and Molecular Neurobiology, 1989, 9, 1-44.	1.7	104
1040	Pharmacoendocrinology of major depression. European Archives of Psychiatry and Neurological Sciences, 1989, 238, 259-267.	0.9	54
1041	Acute effects of alprazolam and adinazolam on the concentrations of corticotropin-releasing factor in the rat brain. Synapse, 1989, 4, 196-202.	0.6	86
1042	Serotonin and depression: Old problems and new data. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1989, 13, 623-633.	2.5	23
1043	Chronic treatment with amttriptyline produces subsensitivity to the hypothermic effects of yohimbine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1989, 13, 211-215.	2.5	8
1044	Psychoactive drugs, pineal gland and affective disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1989, 13, 653-664.	2.5	8

#	Article	IF	Citations
1045	Chronic treatment with amitriptyline produces subsensitivity to the hypothermic effects of clonidine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1989, 13, 297-302.	2.5	6
1046	Biological and psychological processes in the treatment and maintenance of depression. Clinical Psychology Review, 1989, 9, 653-688.	6.0	38
1047	The organic contribution to depressive illness in patients with epilepsy. Journal of Epilepsy, 1989, 2, 189-230.	0.4	29
1048	Increased 3H-Clonidine binding in the platelets of patients with depressive and Schizophrenic disorders. Psychiatry Research, 1989, 28, 73-88.	1.7	45
1049	Clinical pharmacology of anxiolytics and antidepressants: A psychopharmacological perspective. , 1989, 44, 309-334.		66
1050	Neurobiologic effects of bright artificial light. Brain Research Reviews, 1989, 14, 311-333.	9.1	23
1051	Platelet serotonin uptake dynamic changes in depression: effects of long-term imipramine treatment and clinical recovery. Journal of Affective Disorders, 1989, 16, 233-242.	2.0	8
1052	Cation transport in lymphoblastoid cell lines established from bipolar manic-depressive patients. Journal of Affective Disorders, 1989, 16, 259-267.	2.0	11
1053	Plasma levels of tetrahydrobiopterin and folate in major depression. Biological Psychiatry, 1989, 26, 156-162.	0.7	21
1054	Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects. Biological Psychiatry, 1989, 25, 141-152.	0.7	109
1055	Long-term lithium treatment selectively reduces receptor-coupled inositol phospholipid hydrolysis in rat brain. Biological Psychiatry, 1989, 25, 329-340.	0.7	74
1056	Population frequencies of tyrosine hydroxylase restriction fragment length polymorphisms in bipolar affective disorder. Biological Psychiatry, 1989, 25, 626-630.	0.7	55
1057	Are disturbances in lipid-protein interactions by phospholipase-A2 a predisposing factor in affective illness?. Biological Psychiatry, 1989, 25, 945-961.	0.7	66
1058	Doubleblind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1989, 13, 127-136.	2.5	41
1059	Introduction to the development of paroxetine, a novel antidepressant. Acta Psychiatrica Scandinavica, 1989, 80, 13-13.	2.2	42
1060	Effects of Desipramine and Fluvoxamine Treatment on the Prolactin Response to Tryptophan. Archives of General Psychiatry, 1989, 46, 625.	13.8	70
1061	The effect of antidepressant treatment on alpha₂ adrenoceptor function in DSM 111 major depression. Irish Journal of Psychological Medicine, 1989, 6, 109-111.	0.7	4
1062	The heterogeneity of 3-methoxy-4-hydroxy-phenylglycol levels among depressed patients. Acta Psychiatrica Scandinavica, 1989, 80, 499-504.	2.2	4

#	Article	IF	Citations
1063	Apparent phase advance in diurnal MHPG rhythm in depression. American Journal of Psychiatry, 1989, 146, 1427-1433.	4.0	28
1064	Toward a Biochemical Classification of Depressive Disorders. Archives of General Psychiatry, 1989, 46, 260.	13.8	70
1066	Bipolar Affective Disorder: Causes and Prevention of Relapse. British Journal of Psychiatry, 1989, 154, 321-335.	1.7	63
1067	Pharmacological Management of Refractory Depression. Canadian Journal of Psychiatry, 1989, 34, 451-456.	0.9	6
1068	The New Generation of Serotonergic Anxiolytics: Possible Clinical Roles. Psychopathology, 1989, 22, 13-20.	1.1	48
1069	Altered Waveform of Plasma Nocturnal Melatonin Secretion in Premenstrual Depression. Archives of General Psychiatry, 1990, 47, 1139.	13.8	118
1070	Neuropeptide Y: an overview of central distribution, functional aspects, and possible involvement in neuropsychiatric illnesses. Acta Psychiatrica Scandinavica, 1990, 82, 95-114.	2.2	171
1072	Regional Cerebral Blood Flow in Mood Disorders. Archives of General Psychiatry, 1990, 47, 60.	13.8	241
1073	Alpha-2 adrenergic receptor function in post-stroke depression. Psychological Medicine, 1990, 20, 305-309.	2.7	23
1074	Autoradiographic Analysis of Î±1-Noradrenergic Receptors in the Human Brain Postmortem. Archives of General Psychiatry, 1990, 47, 1049.	13.8	58
1075	Differential modulation of mouse brain biogenic amines by haloperidol and pimozide: implications in tourette's syndrome. Comparative Biochemistry and Physiology Part C: Comparative Pharmacology, 1990, 97, 43-47.	0.2	0
1076	Paraganglionic cell response to chronic imipramine and handling stress: an ultrastructural study. Journal of Neural Transmission, 1990, 79, 169-181.	1.4	1
1077	Synthesis and structure-activity of 4(5)-(2,2-diphenylethyl)imidazoles as new Î±2-adrenoreceptor antagonists. European Journal of Medicinal Chemistry, 1990, 25, 557-568.	2.6	11
1078	Response to Total Sleep Deprivation Before and During Treatment with Fluvoxamine or Maprotiline in Patients with Major Depression - Results of a Double-Blind Study. Pharmacopsychiatry, 1990, 23, 135-142.	1.7	45
1079	The Second-Messenger Dysbalance Hypothesis of Affective Disorders. Pharmacopsychiatry, 1990, 23, 27-32.	1.7	46
1080	Neurochemical Correlates of Major Depression in Primary Dementia. Archives of Neurology, 1990, 47, 209-214.	4.9	221
1081	Cognitive Therapy for Depression. Personality and Social Psychology Bulletin, 1990, 16, 58-73.	1.9	35
1082	The Characterization of Î² Adrenoceptor Subtypes in the Rat Amygdala and Hippocampus. International Journal of Neuroscience, 1990, 54, 231-244.	0.8	6

#	Article	IF	Citations
1083	Premenstrual Syndrome in Three Generations Responds to Antidepressants. Australian and New Zealand Journal of Psychiatry, 1990, 24, 276-279.	1.3	5
1084	Antihypertensive Medications and Depression. Drugs, 1990, 40, 792-799.	4.9	43
1085	Clomipramine: A Tricyclic Antidepressant Effective in Obsessive Compulsive Disorder. DICP: the Annals of Pharmacotherapy, 1990, 24, 739-744.	0.2	22
1086	Doxepin and ethanol interaction. Pharmacological Research, 1990, 22, 683-689.	3.1	0
1087	Adrenal Medullary Transplantation Into the Brain for Treatment of Parkinson's Disease: Clinical Outcome and Neurochemical Studies. Mayo Clinic Proceedings, 1990, 65, 305-328.	1.4	73
1088	Stress as a Factor in Lowered Estrogen Levels in the Early Postmenopause. Annals of the New York Academy of Sciences, 1990, 592, 95-113.	1.8	37
1089	Physical Activity and Cognitive Changes with Aging. , 1990, , 153-180.		5
1090	Disorders of decision in affective disease: An effect of Î²-adrenergic dysfunction?. Biological Psychiatry, 1990, 27, 813-833.	0.7	65
1091	Tonic and dynamic gonadotropin secretion in depressive and normothymic phases of affective disorders. Psychiatry Research, 1990, 32, 229-239.	1.7	28
1092	RFLP alleles at the tyrosine hydroxylase locus: No association found to affective disorders. Psychiatry Research, 1990, 32, 275-280.	1.7	47
1093	Effects of amitriptyline and nortriptyline on cerebral activity of the CDF-1 mouse strain. General Pharmacology, 1990, 21, 955-959.	0.7	2
1094	Antidepressants induce regeneration of catecholaminergic axon terminals in the rat cerebral cortex. Neuroscience Letters, 1990, 111, 64-68.	1.0	52
1096	The effect of oral salbutamol on cation transport measured in vivo in healthy volunteers.. British Journal of Clinical Pharmacology, 1990, 30, 383-390.	1.1	3
1097	Animal models of depression: An overview. , 1990, 45, 425-455.		373
1098	The pharmacology of human anxiety. , 1990, 47, 233-266.		96
1099	Tyrosine for depression: a double-blind trial. Journal of Affective Disorders, 1990, 19, 125-132.	2.0	58
1100	Neuroendocrine challenge tests in depression: a study of growth hormone, TRH and cortisol release. Journal of Affective Disorders, 1990, 18, 229-234.	2.0	17
1101	Plasma ratio trytophan/neutral amino acids in relation to clinical response to paroxetine and clomipramine in patients with major depression. Journal of Affective Disorders, 1990, 18, 59-66.	2.0	27

#	Article	IF	Citations
1102	Fluoxetine vs. clomipramine in depressed patients: a controlled multicentre trial. Journal of Affective Disorders, 1991, 22, 119-124.	2.0	28
1103	The pharmacology of fluparoxan: a selective Î±₂â€adrenoceptor antagonist. British Journal of Pharmacology, 1991, 102, 887-895.	2.7	26
1104	Lithium sensitive G protein hyperfunction: A dynamic model for the pathogenesis of bipolar affective disorder. Medical Hypotheses, 1991, 35, 237-243.	0.8	41
1105	91140949 The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. Maturitas, 1991, 14, 78.	1.0	0
1106	Effects of a secondary and a tertiary amine tricyclic antidepressant on cerebral biogenic amines as a function of mouse strain: A comparative neurotoxicological evaluation. Toxicology Letters, 1991, 58, 77-84.	0.4	2
1107	Antidepressants and synaptic plasticity: A hypothesis. Medical Hypotheses, 1991, 35, 17-22.	0.8	4
1108	Beta-Adrenergic Receptors in Pathophysiologic States and in Clinical Medicine. , 1991, , 295-343.		6
1109	Effect of fluoxetine on noradrenergic mediated growth hormone release: A double blind, placebo-controlled study. Biological Psychiatry, 1991, 30, 377-382.	0.7	18
1110	Correlatos bioquÃmicos da depressÃ£o em crianÃ§as. Arquivos De Neuro-Psiquiatria, 1991, 49, 418-425.	0.3	21
1111	MANIA. , 1991, , 271-303.		0
1112	EVOLUTION OF THE MONOAMINE HYPOTHESES OF DEPRESSION. , 1991, , 77-94.		12
1113	Examining suicide from a life span perspective. Death Studies, 1991, 15, 327-354.	1.8	13
1114	Poststroke Depression. Journal of Speech, Language, and Hearing Research, 1991, 34, 325-333.	0.7	11
1115	Change in barbiturate anaesthesic sensitivity as a prognostic indicator of electroconvulsive therapy outcome. Acta Psychiatrica Scandinavica, 1991, 83, 251-255.	2.2	2
1116	Popliteal lymph node enlargement and antibody production in the mouse induced by drugs affecting monoamine levels in the brain. International Journal of Immunopharmacology, 1991, 13, 621-629.	1.1	6
1117	Determination of peripheral catecholO-methyltransferase (COMT) activityin vivo using [2-14C]-3â€²,4â€²-dihydroxyacetophenone. Archives of Pharmacal Research, 1991, 14, 290-294.	2.7	1
1118	Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter. Nature, 1991, 350, 350-354.	13.7	897
1119	Biological and psychological aspects of depression. Behavior Therapy, 1991, 22, 201-228.	1.3	22

#	Article	IF	Citations
1120	Development of antidepressant drugs for the 1990s: Progress or procrastination?. International Journal of Geriatric Psychiatry, 1991, 6, 431-443.	1.3	2
1121	Plasma MHPG and AMDP depression relations, evolution and drug effect in a follow-up study of depressed patients. Human Psychopharmacology, 1991, 6, 11-17.	0.7	11
1122	Modulation of mouse brain dopamine, serotonin and metabolites by methionine: Implications for schizophrenia and genetics. Human Psychopharmacology, 1991, 6, 165-170.	0.7	1
1123	Effect of chronic administration of antidepressant drugs on 5-HT2-mediated behavior in the rat following noradrenergic or serotonergic denervation. Journal of Neural Transmission, 1991, 84, 19-32.	1.4	49
1124	Acute and chronic effects of the atypical antidepressant, mianserin on brain noradrenergic neurons. Psychopharmacology, 1991, 103, 330-338.	1.5	26
1125	Clinical and biochemical aspects of depressive disorders: II. Transmitter/receptor theories. Synapse, 1991, 9, 251-301.	0.6	117
1126	Central and peripheral benzodiazepine receptors: Involvement in an organism's response to physical and psychological stress. Neuroscience and Biobehavioral Reviews, 1991, 15, 277-298.	2.9	86
1127	Stressor-induced anhedonia in the mesocorticolimbic system. Neuroscience and Biobehavioral Reviews, 1991, 15, 391-405.	2.9	159
1128	The Impact of Different Doses of Estrogen and Progestin on Mood and Sexual Behavior in Postmenopausal Women*. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 336-343.	1.8	296
1129	Steroid-induced psychiatric disorders. Nordic Journal of Psychiatry, 1991, 45, 437-441.	0.2	5
1130	Axonal sprouting of noradrenergic locus coeruleus neurons following repeated stress and antidepressant treatment. Progress in Brain Research, 1991, 88, 587-598.	0.9	45
1131	Pharmacology of locus coeruleus spontaneous and sensory-evoked activity. Progress in Brain Research, 1991, 88, 249-256.	0.9	12
1132	Plasma neurotransmitter profile during different phases of the ovulatory cycle.. Journal of Clinical Endocrinology and Metabolism, 1992, 75, 924-929.	1.8	33
1133	Pterin metabolism in depression: an extension of the amine hypothesis and possible marker of response to ECT. Psychological Medicine, 1992, 22, 863-869.	2.7	34
1134	The Mosaic of Contemporary Psychiatry in Perspective. , 1992, , .		3
1135	Urinary Excretion of Catecholamines and Their Metabolites in Relation to Circulating Catecholamines. Archives of General Psychiatry, 1992, 49, 568.	13.8	36
1136	Evolving Mania in an Adolescent Treated with Low-Dose Fluoxetine. Journal of Child and Adolescent Psychopharmacology, 1992, 2, 299-306.	0.7	17
1137	Learned helplessness and urinary MHPG levels in unipolar depression. American Journal of Psychiatry, 1992, 149, 806-809.	4.0	18

#	Article	IF	Citations
1138	Clinical and neuropathological correlates of depression in Alzheimer's disease. Psychological Medicine, 1992, 22, 877-884.	2.7	191
1139	Psychopharmacological Management of Migraine in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology, 1992, 2, 199-211.	0.7	11
1140	Pharmacology of Second Messengers: A Critical Appraisal. Drug Metabolism Reviews, 1992, 24, 125-194.	1.5	3
1141	Effects of acute and chronic electroconvulsive shock on noradrenaline release in the rat hippocampus and frontal cortex. British Journal of Pharmacology, 1992, 106, 430-434.	2.7	37
1142	Plasma Ratios of Tryptophan and Tyrosine to Other Large Neutral Amino Acids in Manicâ€Depressive Patients. Psychiatry and Clinical Neurosciences, 1992, 46, 711-720.	1.0	0
1143	Relationship between serotonergic measures in periphery and the brain of mouse. Life Sciences, 1992, 51, 75-82.	2.0	39
1144	Quantitative determination of pertussis toxin-sensitive G proteins using [32P]ADP-ribosylation in human platelet membranes: Negative correlation with ages. Life Sciences, 1992, 50, 1851-1857.	2.0	6
1145	Temporal lobe asymmetry with iofetamine (IMP) SPECT imaging in patients with major depression. Journal of Affective Disorders, 1992, 24, 43-53.	2.0	39
1146	Stress, anxiety, and depression: Review of biological, diagnostic, and nosologic issues. Journal of Anxiety Disorders, 1992, 6, 337-363.	1.5	15
1147	Right hemisphere sensitivity to arousal and depression. Brain and Cognition, 1992, 18, 138-151.	0.8	57
1148	In vitro neurotransmitter release in an animal model of depression. Neurochemistry International, 1992, 21, 29-35.	1.9	22
1149	Role of the dopaminergic system in depression. Biological Psychiatry, 1992, 32, 1-17.	0.7	318
1150	Abnormal flash visual evoked response in melancholia: A replication study. Biological Psychiatry, 1992, 31, 325-336.	0.7	14
1151	The involvement of guanine nucleotide binding proteins in the pathogenesis and treatment of affective disorders. Biological Psychiatry, 1992, 31, 435-459.	0.7	107
1152	Î±2-Adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression. Biological Psychiatry, 1992, 31, 471-490.	0.7	160
1153	Cortisol response to intramuscular desipramine in patients with major depression and normal control subjects: A replication study. Psychiatry Research, 1992, 44, 237-250.	1.7	24
1154	Peripheral markers in anxiety and depression. Molecular Aspects of Medicine, 1992, 13, 173-190.	2.7	10
1155	The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Research, 1992, 572, 117-125.	1.1	238

#	Article	IF	Citations
1156	Reduced Clonidine Rapid Eye Movement Sleep Suppression in Patients With Primary Major Affective Illness. Archives of General Psychiatry, 1992, 49, 637.	13.8	19
1157	Platelet Alpha-2 Adrenergic Receptor Binding and Plasma Free 3-Methoxy-4-hydroxyphenyl-ethylene Glycol in Depressed Patients before and after Treatment with Mianserin. Neuropsychobiology, 1992, 25, 14-19.	0.9	9
1158	Decrease in Epinephrine-Induced Attenuation of Platelet Adenylate Cyclase Activity in Depressed Patients: Relation with Plasma Electrolytes. Neuropsychobiology, 1992, 26, 129-135.	0.9	6
1159	Is depression a disorder of a receptor superfamily? A critical review of the receptor theory of depression and the appraisal of a new heuristic model. European Psychiatry, 1992, 7, 259-270.	0.1	5
1160	Reduced tyrosine hydroxylase immunoreactivity in locus coeruleus of suicide victims. Synapse, 1992, 10, 79-82.	0.6	69
1161	Reduced Neuropeptide Y Concentrations in Suicide Brain. Journal of Neurochemistry, 1992, 59, 73-80.	2.1	155
1162	Involvement of Dopamine D1and D2Receptors in the Regulation of Proenkephalin mRNA Abundance in the Striatum and Accumbens of the Rat Brain. Journal of Neurochemistry, 1992, 58, 1104-1109.	2.1	84
1163	Hypothesis: Cytokines may be activated to cause depressive illness and chronic fatigue syndrome. European Archives of Psychiatry and Clinical Neuroscience, 1992, 241, 317-322.	1.8	63
1164	Desmethylimipramine attenuates cocaine withdrawal in rats. Psychopharmacology, 1992, 109, 305-314.	1.5	92
1165	Plasma noradrenaline, adrenaline and DHPG responses to clonidine in control and depressed subjects. Human Psychopharmacology, 1992, 7, 167-173.	0.7	4
1166	Lack of association between bipolar affective disorder and tyrosine hydroxylase DNA marker. American Journal of Medical Genetics Part A, 1993, 48, 87-89.	2.4	36
1167	Clinical data and animal studies on adaptive receptor changes occurring in depression and after antidepressive treatment: A hypothesis of antidepressive action. Human Psychopharmacology, 1993, 8, 1-7.	0.7	1
1168	Effects of Two Substituted Hydrazine Monoamine Oxidase (MAO) Inhibitors on Neurotransmitter Amines, Î³-Aminobutyric Acid, and Alanine in Rat Brain. Journal of Pharmaceutical Sciences, 1993, 82, 934-937.	1.6	14
1169	Dexamethasone target sites in the central nervous system and their potential relevance to mental illness. Cellular and Molecular Neurobiology, 1993, 13, 373-386.	1.7	22
1170	Fluoxetine: A spectrum of clinical applications and postulates of underlying mechanisms. Neuroscience and Biobehavioral Reviews, 1993, 17, 385-396.	2.9	26
1171	The flinders sensitive line rats: A genetic animal model of depression. Neuroscience and Biobehavioral Reviews, 1993, 17, 51-68.	2.9	389
1172	Actions of Lithium on the Cyclic AMP Signalling System in Various Regions of the Brain â€•Possible Relations to its Psychotropic Actions â€‰A Study on the Adenylate Cyclase in Rat Cerebral Cortex, Corpus Striatum and Hippocampus. Basic and Clinical Pharmacology and Toxicology, 1993, 73, 1-47.	0.0	25
1173	Pharmacological aspects of gonadal alcohol and aldehyde-dehydrogenase. General Pharmacology, 1993, 24, 1055-1062.	0.7	1

#	Article	IF	Citations
1174	Tryptamine: A metabolite of tryptophan implicated in various neuropsychiatric disorders. Metabolic Brain Disease, 1993, 8, 1-44.	1.4	58
1175	Cerebrospinal fluid norepinephrine concentrations and dynamics in depressed patients and normal volunteers. Depression, 1993, 1, 149-155.	0.7	11
1176	Cocaine and depression. Depression, 1993, 1, 235-249.	0.7	0
1177	Effects of acute and chronic lithium treatment on amphetamine-induced dopamine increase in the nucleus accumbens and prefrontal cortex in rats as studied by microdialysis. Journal of Neural Transmission, 1993, 94, 75-89.	1.4	22
1178	Dopamine and depression. Journal of Neural Transmission, 1993, 91, 75-109.	1.4	293
1179	Clinical aspects of the melatonin action: impact of development, aging, and puberty, involvement of melatonin in psychiatric disease and importance of neuroimmunoendocrine interactions. Experientia, 1993, 49, 671-681.	1.2	92
1180	Antiâ€immobility activity of different antidepressant drugs using the tail suspension test in normal or reserpinized mice. Fundamental and Clinical Pharmacology, 1993, 7, 219-226.	1.0	37
1181	A Comparison of Psychopathology in Cocaine and Alcohol Dependence. American Journal on Addictions, 1993, 2, 279-286.	1.3	15
1182	Correlation between serotonergic measures in cerebrospinal fluid and blood of subhuman primate. Life Sciences, 1993, 52, 745-749.	2.0	30
1183	The lymphoblast Î²-adrenergic receptor in bipolar depressed patients: characterization and down-regulation. Journal of Affective Disorders, 1993, 27, 163-172.	2.0	18
1184	The multiple interactional biological processes that might lead to depression and gender differences in its appearance. Journal of Affective Disorders, 1993, 29, 159-173.	2.0	97
1185	Noradrenergic and serotoninergic depression?. Journal of Affective Disorders, 1993, 27, 123-129.	2.0	9
1186	Lack of effect of anxiety on total plasma MHPG in depressed patients. Journal of Affective Disorders, 1993, 28, 211-217.	2.0	5
1187	Fluoxetine: Adverse Effects and Drug-Drug Interactions. Journal of Toxicology: Clinical Toxicology, 1993, 31, 603-630.	1.5	36
1188	Nocturnal Melatonin Secretion in Multiple Sclerosis Patients with Affective Disorders. International Journal of Neuroscience, 1993, 68, 227-240.	0.8	34
1189	Increased soluble interleukinâ€2 receptor concentrations in suicide attempters. Acta Psychiatrica Scandinavica, 1993, 88, 48-52.	2.2	124
1190	Platelet Î±-2 adrenoceptor-mediated primary aggregation and adenylate cyclase inhibition in depressed patients. Lancet, The, 1993, 341, 1029-1030.	6.3	6
1191	Visual pattern integration as a function of antidepressant medication in depressed patients. Psychiatry Research, 1993, 46, 295-309.	1.7	2

#	Article	IF	Citations
1192	Increased imidazoline and Î±2 adrenergic binding in platelets of women with dysphoric premenstrual syndromes. Biological Psychiatry, 1993, 34, 676-686.	0.7	44
1193	The cortisol response to clonidine in acute and remitted depressed men. Biological Psychiatry, 1993, 34, 373-379.	0.7	17
1194	Treatment with carbamazepine may enhance Î±2-noradrenergic autoreceptor sensitivity. Biological Psychiatry, 1993, 34, 551-557.	0.7	6
1195	Interaction between antidepressants and phosphoinositide signal transduction system in human platelets. Biological Psychiatry, 1993, 33, 40-44.	0.7	15
1196	A clinical test of noradrenergic involvement in the therapeutic mode of action of an experimental antidepressant. Biological Psychiatry, 1993, 33, 261-266.	0.7	9
1197	Depressive changes in stroke patients. Disability and Rehabilitation, 1993, 15, 55-66.	0.9	70
1198	The Adrenergic-Cholinergic Imbalance Hypothesis of Depression: A Review and a Perspective. Reviews in the Neurosciences, 1993, 4, 63-93.	1.4	38
1199	Effects of Catecholamine Depletion on Alertness and Mood in Rested and Sleep Deprived Normal Volunteers. Neuropsychopharmacology, 1993, 8, 345-356.	2.8	42
1200	Delayed Desensitization of Î±2-Adrenoceptor-Mediated Platelet Aggregation in Depressed Patients. Neuropsychopharmacology, 1993, 9, 55-66.	2.8	17
1201	Nocturnal Melatonin Secretion in Suicidal Patients with Multiple Sclerosis. International Journal of Neuroscience, 1993, 71, 173-182.	0.8	24
1202	5-HT and physical illness. Journal of Psychopharmacology, 1993, 7, 107-111.	2.0	0
1203	The Neuropsychology of Attention. Critical Issues in Neuropsychology, 1993, , .	0.4	156
1205	Exercise and Mood. World Review of Nutrition and Dietetics, 1993, 71, 115-143.	0.1	16
1206	Allergy and depression: A neurochemical threshold model of the relation between the illnesses.. Psychological Bulletin, 1993, 113, 23-43.	5.5	68
1207	Psychotherapeutic approaches to chronic pain.. Psychotherapy, 1993, 30, 115-124.	0.7	24
1208	The role of monoamines in suicidal behavior. Acta Psychiatrica Scandinavica, 1993, 87, 45-47.	2.2	45
1209	The paradox of tianeptine. European Psychiatry, 1993, 8, 89s-93s.	0.1	12
1210	Psychotropic screening procedures. Handbook of Behavioral Neuroscience, 1993, , 23-51.	0.0	23

#	Article	IF	Citations
1211	Adrenaline-Induced Platelet Aggregation in Depressed Patients and Control Subjects. Neuropsychobiology, 1993, 27, 21-25.	0.9	12
1212	Catecholamines in depression: an update. Clinical Chemistry, 1994, 40, 279-287.	1.5	71
1213	The decade of the brain: recent developments in the neurochemistry of depression, mania, and other mood disorders. Clinical Chemistry, 1994, 40, 271-272.	1.5	1
1214	Sympathetic Nervous System Activity in Major Depression. Archives of General Psychiatry, 1994, 51, 411.	13.8	402
1215	Psychedelic and Entactogenic Drugs in the Treatment of Depression. Journal of Psychoactive Drugs, 1994, 26, 41-55.	1.0	33
1216	Psychometric Evidence That Mercury from Silver Dental Fillings May Be an Etiological Factor in Depression, Excessive Anger, and Anxiety. Psychological Reports, 1994, 74, 67-80.	0.9	44
1217	Biochemical predictors of response to somatic antidepressant treatment. Nordic Journal of Psychiatry, 1994, 48, 81-86.	0.7	0
1218	The revised monoamine hypothesis: Mechanism of antidepressant treatment in the context of behavior. Integrative Psychological and Behavioral Science, 1994, 29, 182-188.	0.3	11
1219	Effects of phospholipase A2 inhibitors on the antidepressant-induced axonal regeneration of noradrenergic locus coeruleus neurons. Microscopy Research and Technique, 1994, 29, 204-210.	1.2	14
1220	From serendipity to selectivity. Human Psychopharmacology, 1994, 9, S3-S6.	0.7	1
1221	Antidepressant drugs. Depression, 1994, 2, 1-19.	0.7	18
1222	Current understanding of the mechanism of action of classic and newer antidepressant drugs. Depression, 1994, 2, 119-126.	0.7	17
1223	Pyridostigmine induced growth hormone release in mania: focus on the cholinergic/somatostatin system. Clinical Endocrinology, 1994, 40, 93-96.	1.2	15
1224	Plasma Monoamines in Tension-Type Headache. Headache, 1994, 34, 531-535.	1.8	24
1225	A study of P300 in melancholic depressionâ€"Correlation with psychotic features. Biological Psychiatry, 1994, 35, 474-479.	0.7	51
1226	Modification of reserpine-induced emetic response in pigeons by Î±2-adrenoceptors. Pharmacological Research, 1994, 29, 383-387.	3.1	4
1227	Catecholamine metabolism and psychiatric or behavioral disorders. Current Opinion in Genetics and Development, 1994, 4, 419-426.	1.5	16
1228	Regionally specific changes in extracellular noradrenaline following chronic idazoxan as revealed by in vivo microdialysis. European Journal of Pharmacology, 1994, 261, 53-57.	1.7	9

#	Article	IF	Citations
1229	Sleep patterns in depression and anxiety: Theory and pharmacological effects. Journal of Psychosomatic Research, 1994, 38, 125-139.	1.2	40
1230	The behavioural and reproductive consequences in offspring (first generation) of mice continuously exposed to a strong magnetic field. Behavioural Processes, 1994, 32, 229-234.	0.5	0
1231	Platelet pertussis toxin-sensitive G proteins in affective disorders. Journal of Affective Disorders, 1994, 31, 173-177.	2.0	7
1232	Enhancing central and peripheral insulin activity as a strategy for the treatment of endogenous depression â€" An adjuvant role for chromium picolinate?. Medical Hypotheses, 1994, 43, 247-252.	0.8	32
1233	Echogenicity of the brainstem raphe in patients with major depression. Psychiatry Research - Neuroimaging, 1994, 55, 75-84.	0.9	69
1234	Effects of chronic lithium treatments on central dopaminergic receptor systems: G proteins as possible targets. Neurochemistry International, 1994, 24, 13-22.	1.9	32
1235	Degeneration of locus coeruleus axons in stress-induced depression model. Brain Research Bulletin, 1994, 35, 573-580.	1.4	57
1236	Corticotropin-releasing factor neurotransmission in locus coeruleus: A possible site of antidepressant action. Brain Research Bulletin, 1994, 35, 581-587.	1.4	59
1237	Effects of chronic mianserin administration on serotonin metabolism and receptors in the 5-hydroxytryptophan depression model. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1994, 18, 165-179.	2.5	4
1238	Shifting depression. Psychological Medicine, 1994, 24, 271-273.	2.7	2
1239	Development and self-regulatory structures of the mind. Development and Psychopathology, 1994, 6, 533-549.	1.4	399
1240	Diagnosis and Classification in Psychiatry: Gerald Klerman's Contribution. Harvard Review of Psychiatry, 1994, 1, 306-309.	0.9	2
1241	A theory of cooperativity modulation in neural networks as an important parameter of CNS catecholamine function and induction of psychopathology. Neurological Research, 1994, 16, 330-341.	0.6	4
1242	Frontal lobe dysfunction in secondary depression. Journal of Neuropsychiatry and Clinical Neurosciences, 1994, 6, 428-442.	0.9	225
1243	Controversies and Perspectives. Journal of Clinical Rheumatology, 1995, 1, 185.	0.5	1
1244	The effect of olfactory bulbectomy in the rat, alone or in combination with antidepressants and endogenous factors, on immune function. Human Psychopharmacology, 1995, 10, 7-18.	0.7	48
1245	Locus coeruleus cell loss in the aging human brain: A non-random process. Journal of Comparative Neurology, 1995, 358, 79-87.	0.9	192
1246	Chronic administration of the antidepressants phenelzine, despiramine, clomipramine, or maprotiline decreases binding to 5-hydroxytryptamine2A receptors without affecting benzodiazepine binding sites in rat brain. Cellular and Molecular Neurobiology, 1995, 15, 361-370.	1.7	44

#	Article	IF	Citations
1247	Chromaffin cell xenografts in the rat neocortex can produce antidepressive activity in the forced swimming test. Experimental Brain Research, 1995, 103, 59-69.	0.7	7
1248	Personality and depression: A multilevel perspective. European Journal of Personality, 1995, 9, 401-412.	1.9	1
1249	The effects of running, environment, and attentional focus on athletes? catecholamine and cortisol levels and mood. Psychophysiology, 1995, 32, 49-54.	1.2	91
1250	Behavioral characteristics of SART-Stressed mice in the forced swim test and drug action. Pharmacology Biochemistry and Behavior, 1995, 51, 849-853.	1.3	37
1251	Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacology Biochemistry and Behavior, 1995, 52, 145-152.	1.3	110
1252	MAOIs in the Contemporary Treatment of Depression. Neuropsychopharmacology, 1995, 12, 185-219.	2.8	190
1253	Hypothesis linking the noradrenergic and dopaminergic systems in depression. Depression, 1995, 3, 225-245.	0.7	38
1254	Tianeptine treatment induces regionally specific changes in monoamines. Brain Research, 1995, 696, 1-6.	1.1	22
1255	Genes and Recent Developments in the Epidemiology of Alzheimer's Disease and Related Dementia. Epidemiologic Reviews, 1995, 17, 39-47.	1.3	19
1256	Nefazodone and the serotonin receptor modulators: a new member of a unique class of antidepressant agents. International Review of Psychiatry, 1995, 7, 29-39.	1.4	5
1257	Regional origins of 3-methoxy-4-hydroxyphenylglycol in plasma: effects of chronic sympathetic nervous activation and denervation, and acute reflex sympathetic stimulation. Journal of the Autonomic Nervous System, 1995, 55, 169-178.	1.9	29
1258	Inhibitory effects of antidepressants on NMDA-induced currents in Xenopus oocytes injected with rat brain RNA. Neurochemistry International, 1995, 26, 53-58.	1.9	22
1259	A molecular model for bipolar affective disorder. Medical Hypotheses, 1995, 45, 255-264.	0.8	5
1260	Influence of antidepressant drugs administration on the morphine inhibitory effect in mice vasa deferentia. Life Sciences, 1995, 57, PL339-PL345.	2.0	0
1261	Diurnal neuroendocrine and autonomic function in acute and remitted depressed male patients. Biological Psychiatry, 1995, 37, 448-456.	0.7	15
1262	Involvement of I1-Imidazoline Receptors in Mood Disorders. Annals of the New York Academy of Sciences, 1995, 763, 510-519.	1.8	12
1263	Antidepressant effect of 5-methoxypsoralen: the melatonin synchronizer hypothesis. European Psychiatry, 1995, 10, 142-154.	0.1	6
1264	Chapter 24 Monoamines, cytoskeletal elements and psychiatric disorders: a neurochemical fugue. Progress in Brain Research, 1995, 106, 241-248.	0.9	2

#	Article	IF	Citations
1265	Biological markers of serotonin receptors in depression and animal models of depression. International Review of Psychiatry, 1995, 7, 69-83.	1.4	1
1266	Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients. Acta Psychiatrica Scandinavica, 1995, 91, 28-35.	2.2	25
1267	Psychoneuroimmunology. CNS Drugs, 1995, 4, 125-140.	2.7	22
1268	The New Polypharmacy in Psychiatry. CNS Drugs, 1995, 4, 404-409.	2.7	6
1269	Tyrosine metabolism in users of oral contraceptives. Life Sciences, 1995, 56, 687-695.	2.0	11
1270	Urinary catecholamines and plasma hormones predict mood state in rapid cycling bipolar affective disorder. Journal of Affective Disorders, 1995, 33, 233-243.	2.0	42
1271	Discovery and preclinical development of the serotonin reuptake inhibitor sertraline. Advances in Medicinal Chemistry, 1995, , 113-148.	0.8	16
1272	GÃ©nÃ©tique et psychiatrie. Annales De L'Institut Pasteur / ActualitÃ©s, 1996, 7, 31-35.	0.1	1
1273	Depression as a spreading neuronal adjustment disorder. European Neuropsychopharmacology, 1996, 6, 207-223.	0.3	24
1274	Premorbid History of Major Depression and the Depressive Syndrome of Alzheimer's Disease. American Journal of Geriatric Psychiatry, 1996, 4, 85-90.	0.6	4
1275	Binding and competitive inhibition of amine uptake at postsynaptic neurones (transportâ€Þ) by tricyclic antidepressants. British Journal of Pharmacology, 1996, 117, 811-816.	2.7	12
1276	Fatty acid composition in major depression: decreased Ï‰3 fractions in cholesteryl esters and increased C20:4Ï‰6C20:5Ï‰3 ratio in cholesteryl esters and phospholipids. Journal of Affective Disorders, 1996, 38, 35-46.	2.0	374
1277	Day-to-day intraindividual reliability and interindividual differences in monoamines excretion. Journal of Affective Disorders, 1996, 38, 173-178.	2.0	18
1278	The TiPS/TINS lecture. Catecholamines: from gene regulation to neuropsychiatric disorders. Trends in Pharmacological Sciences, 1996, 17, 129-135.	4.0	19
1279	Rewarding electrical brain stimulation: Similar thresholds for flinders sensitve line hypercholinergic and flinders resistant line hypocholinergic rats. Physiology and Behavior, 1996, 59, 1155-1162.	1.0	25
1280	The TiPS/TINS Lecture Catecholamines: from gene regulation to neuropsychiatric disorders11At the 1995 Annual Meeting of the European Neuroscience Association, held in Amsterdam, the plenary lecture given by Jacques Mallet was sponsored jointly by TiPS and TINS. The following article is adapted from this lecture.. Trends in Neurosciences, 1996, 19, 191-196.	4.2	24
1281	The Neuroendocrinology of Chronic Fatigue Syndrome. The Journal of Chronic Fatigue Syndrome: Multidisciplinary Innovations in Researchory and Clinical Practice, 1996, 2, 49-59.	0.4	2
1282	Effects of Î±-Methyl-Para-Tyrosine (AMPT) in Drug-Free Depressed Patients. Neuropsychopharmacology, 1996, 14, 151-157.	2.8	61

#	Article	IF	Citations
1283	Adaptive changes in the rat dopaminergic transmission following repeated lithium administration. Journal of Neural Transmission, 1996, 103, 765-776.	1.4	25
1284	Distribution ofÎ±2-adrenoceptors in the human locus coeruleus. Brain Research, 1996, 741, 263-274.	1.1	15
1285	Circadian rhythms and the pharmacology of affective illness. , 1996, 71, 253-312.		142
1286	Individual differences in changes in mood and platelet monoamine oxidase (MAO) activity during hormonal replacement therapy in menopausal women. Psychoneuroendocrinology, 1996, 21, 575-592.	1.3	69
1287	Association study of bipolar disorder with candidate genes involved in catecholamine neurotransmission: DRD2, DRD3, DAT1, and TH genes. , 1996, 67, 551-555.		67
1288	Affective Disorders and Nitric Oxide: A Role in Pathways to Relapse and Refractoriness?. , 1996, 11, 309-319.		62
1289	Brain Neuropeptidergic Function in Suicide Victims. Human Psychopharmacology, 1996, 11, 451-461.	0.7	0
1290	Recent advances in the pharmacotherapy of major depression. Archives of Psychiatric Nursing, 1996, 10, 355-364.	0.7	2
1291	Is there a relationship between baseline and treatment-associated changes in [H]-IMI platelet binding and clinical response in major depression?. Neuropsychopharmacology, 1996, 14, 47-53.	2.8	9
1292	From Memories to Mental Illness. , 1996, , .		11
1293	Clinical and Biochemical Effects of Catecholamine Depletion on Antidepressant-Induced Remission of Depression. Archives of General Psychiatry, 1996, 53, 117.	13.8	174
1294	Isolation and Characterization of an Endogenous Peptide from Rat Brain Interacting Specifically with the Serotonergic 1B Receptor Subtypes. Journal of Biological Chemistry, 1996, 271, 726-735.	1.6	60
1295	In Pursuit of Drugs for American Trypanosomiasis: Evaluation of Some "Standards" in a Mouse Model. Experimental Biology and Medicine, 1997, 216, 424-428.	1.1	5
1296	G Proteins and Mood Disorders. , 1997, , 353-378.		0
1297	Selective enhancement of emotional, but not motor, learning in monoamine oxidase A-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 5929-5933.	3.3	146
1298	Selective serotonin reuptake inhibitors and atypical antidepressants: A review and update for psychologists.. Professional Psychology: Research and Practice, 1997, 28, 526-536.	0.6	6
1299	Plasma noradrenaline response to electroconvulsive therapy in depressive illness. British Journal of Psychiatry, 1997, 171, 182-186.	1.7	36
1300	Current Concepts of Mechanisms of Action of Antidepressant Treatments Based on Preclinical Studies. , 1997, 167, 162-167.		1

#	Article	IF	Citations
1301	Molecular Cloning and Characterization of NESP55, a Novel Chromogranin-like Precursor of a Peptide with 5-HT1B Receptor Antagonist Activity. Journal of Biological Chemistry, 1997, 272, 11657-11662.	1.6	189
1302	Increased Nocturnal Activity and Impaired Sleep Maintenance in Abused Children. Journal of the American Academy of Child and Adolescent Psychiatry, 1997, 36, 1236-1243.	0.3	169
1303	Effects of a chronic lithium treatment on central dopamine neurotransporters. Biochemical Pharmacology, 1997, 54, 391-397.	2.0	41
1304	Postsynaptic 5-HT1A receptors mediate 5-hydroxytryptamine release in the amygdala through a feedback to the caudal linear raphe. European Journal of Pharmacology, 1997, 333, 147-157.	1.7	41
1305	Neuroimaging and Neurobiological Models of Depression. Harvard Review of Psychiatry, 1997, 5, 138-159.	0.9	65
1306	A Molecular and Cellular Theory of Depression. Archives of General Psychiatry, 1997, 54, 597.	13.8	1,898
1307	Knockout of the Vesicular Monoamine Transporter 2 Gene Results in Neonatal Death and Supersensitivity to Cocaine and Amphetamine. Neuron, 1997, 19, 1285-1296.	3.8	345
1308	Advantages and limitations of the concept of antidepressant therapy. European Neuropsychopharmacology, 1997, 7, S315-S321.	0.3	2
1309	Serotonergic, noradrenergic, and dopaminergic measures in suicide brains. Biological Psychiatry, 1997, 41, 1000-1009.	0.7	42
1310	Forskolin-stimulated platelet adenylyl cyclase activity is lower in persons with major depression. Biological Psychiatry, 1997, 42, 30-38.	0.7	48
1311	Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biological Psychiatry, 1997, 42, 349-358.	0.7	216
1312	No evidence for an association of affective disorders with high- or low-activity allele of catechol-o-methyltransferase gene. Biological Psychiatry, 1997, 42, 282-285.	0.7	101
1313	Long-Term Stress Degenerates, But Imipramine Regenerates, Noradrenergic Axons in the Rat Cerebral Cortex. Biological Psychiatry, 1997, 42, 687-696.	0.7	73
1314	The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Brain Research Reviews, 1997, 23, 145-195.	9.1	345
1315	Tyrosine hydroxylase allelic distribution in suicide attempters. Psychiatry Research, 1997, 72, 73-80.	1.7	43
1316	Alprazolam, diazepam, yohimbine, clonidine: In vivo CA1, hippocampal norepinephrine and serotonin release profiles under chloral hydrate anesthesia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1997, 21, 1117-1140.	2.5	30
1317	Reduced Levels of Norepinephrine Transporters in the Locus Coeruleus in Major Depression. Journal of Neuroscience, 1997, 17, 8451-8458.	1.7	381
1318	Pathophysiology of the Locus Coeruleus in Suicide. Annals of the New York Academy of Sciences, 1997, 836, 233-252.	1.8	51

#	Article	IF	Citations
1319	Designing a new generation of antidepressant drugs. Acta Psychiatrica Scandinavica, 1997, 96, 7-13.	2.2	25
1320	Premenstrual dysphoric disorders: a diversified cluster of vulnerability traits to depression. Acta Psychiatrica Scandinavica, 1997, 95, 169-176.	2.2	39
1321	Lower serum highâ€density lipoprotein cholesterol (HDLâ€C) in major depression and in depressed men with serious suicidal attempts: relationship with immuneâ€inflammatory markers. Acta Psychiatrica Scandinavica, 1997, 95, 212-221.	2.2	270
1322	Beyond the efficacy ceiling? Cognitive behavior therapy in search of theory. Behavior Therapy, 1997, 28, 601-611.	1.3	37
1323	The olfactory bulbectomized rat as a model of depression: An update. , 1997, 74, 299-316.		594
1324	Antidepressant-Like Effect of Brain-derived Neurotrophic Factor (BDNF). Pharmacology Biochemistry and Behavior, 1997, 56, 131-137.	1.3	774
1325	Effects of a chronic lithium treatment on cortical serotonin uptake sites and 5-HT1A receptors. Neurochemical Research, 1997, 22, 427-435.	1.6	29
1326	Imipramine-induced changes in 5-HT2 receptor sites and inositoltrisphosphate levels in rat brain. Neurochemical Research, 1997, 22, 1095-1099.	1.6	16
1327	Effect of sleep deprivation on the growth hormone response to the alpha-2 adrenergic receptor agonist, clonidine, in normal subjects. Journal of Neural Transmission, 1997, 104, 291-298.	1.4	1
1328	Effects of subchronic administration of antidepressants and anxiolytics on levels of the ? subunits of G proteins in the rat brain. Journal of Neural Transmission, 1997, 104, 747-760.	1.4	22
1329	Psychobiology and psychopharmacotherapy of unipolar major depression: A review. Archives of Psychiatric Nursing, 1997, 11, 304-313.	0.7	8
1330	An evaluation of the role of the noradrenergic system in the neurobiology of depression: a review. Human Psychopharmacology, 1997, 12, 407-430.	0.7	24
1331	Cladistic analysis of disease association with tyrosine hydroxylase: Application to manic-depressive disease and alcoholism. , 1997, 74, 289-295.		11
1332	Regulation of central serotonin transporters by chronic lithium: An autoradiographic study. , 1997, 27, 83-89.		32
1333	Effect of reserpine on 3-methoxy-4-hydroxyphenylethyleneglycol and 3,4-dihydroxyphenylacetic acid in the hippocampus of depression-model rats: An in vivo microdialysis study. Brain Research, 1998, 785, 10-17.	1.1	2
1334	The clinical pharmacologic profile of reboxetine: does it involve the putative neurobiological substrates of wellbeing?. Journal of Affective Disorders, 1998, 51, 313-322.	2.0	20
1335	Neurobiological Similarities in Depression and Drug Dependence: A Self-Medication Hypothesis. Neuropsychopharmacology, 1998, 18, 135-174.	2.8	663
1336	Affective disorder subtyped by psychomotor symptoms, monoamine oxidase, melatonin and cortisol: identification of patients with latent bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience, 1998, 248, 215-224.	1.8	15

#	Article	IF	Citations
1337	The effect of venlafaxine treatment on the behavioural and neurochemical changes in the olfactory bulbectomised rat. Psychopharmacology, 1998, 136, 394-401.	1.5	30
1338	Psychoneuroimmunology and the cytokine action in the CNS: Implications for psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1998, 22, 1-33.	2.5	261
1339	REM sleep deprivation increases the levels of tyrosine hydroxylase and norepinephrine transporter mRNA in the locus coeruleus. Molecular Brain Research, 1998, 57, 235-240.	2.5	68
1340	Decreased monoamine metabolites in frontotemporal dementia and Alzheimerâ€™s disease. Neurobiology of Aging, 1998, 19, 379-384.	1.5	80
1341	Dual diagnosis. Addictive Behaviors, 1998, 23, 717-734.	1.7	520
1342	Tyrosine hydroxylase gene expression in the locus coeruleus of depression-model rats and rats exposed to short- and long-term forced walking stress. Life Sciences, 1998, 62, 2083-2092.	2.0	31
1343	Assessment and treatment of depression in the cancer patient. Journal of Psychosomatic Research, 1998, 45, 215-237.	1.2	160
1344	Effect of antidepressants on intracellular Ca++ mobilization in human frontal cortex. Biological Psychiatry, 1998, 44, 617-621.	0.7	11
1345	Editorial. Biological Psychiatry, 1998, 44, 517-525.	0.7	101
1346	Adrenergic receptors in premenstrual dysphoric disorder: I. Platelet Î±2 receptors: Gi protein coupling, phase of menstrual cycle, and prediction of luteal phase symptom severity. Biological Psychiatry, 1998, 44, 600-609.	0.7	23
1347	Neuroendocrine Markers. CNS Drugs, 1998, 10, 145-157.	2.7	7
1348	Reboxetine in the treatment of depression: Early clinical experience in the UK. International Journal of Psychiatry in Clinical Practice, 1998, 2, 195-201.	1.2	9
1349	Antidepressant treatment influences group I of glutamate metabotropic receptors in slices from hippocampal CA1 region. European Journal of Pharmacology, 1998, 349, 83-87.	1.7	33
1350	Differences and variability in plasma noradrenaline between depressive and anxiety disorders. Journal of Psychopharmacology, 1998, 12, 161-167.	2.0	34
1351	Depressive Symptomatology and Incident Cognitive Decline in an Elderly Community Sample. Archives of General Psychiatry, 1998, 55, 1073.	13.8	228
1352	The role of thyroid hormones in depression. European Journal of Endocrinology, 1998, 138, 1-9.	1.9	162
1353	A Viro-Psycho-Immunological Disease-Model of a Subtype Affective Disorder. Pharmacopsychiatry, 1998, 31, 77-82.	1.7	27
1354	Sertraline, a selective serotonin reuptake inhibitor modulates extracellular noradrenaline in the rat frontal cortex. Journal of Psychopharmacology, 1998, 12, 366-370.	2.0	39

#	Article	IF	Citations
1355	A Review of the Effects of Moderate Alcohol Intake on Psychiatric and Sleep Disorders. , 1998, 14, 197-226.		26
1356	Julius Axelrod. History of Neuroscience in Autobiography, 1998, , 50-78.	0.0	0
1357	The Pathophysiology of Depression: A Synthesis of the Role of Serotonin and Corticosteroids. , 1998, 19, 170-198.		7
1358	Mood and neuropsychological function in depression: the role of corticosteroids and serotonin. Psychological Medicine, 1998, 28, 573-584.	2.7	162
1359	Fundamental Psychopharmacology. , 1998, , 173-206.		3
1360	Adenylyl Cyclase Activity and Mood Disorders: Preliminary Data in Human Brain Postmortem. CNS Spectrums, 1998, 3, 70-75.	0.7	0
1361	Affective Disorders. , 1998, , 339-366.		0
1363	DepressÃ£o: uma breve revisÃ£o dos fundamentos biolÃ³gicos e cognitivos. Interacao Em Psicologia, 1999, 3, .	0.1	7
1364	GenÃ©tica e fisiopatologia dos transtornos depressivos. Revista Brasileira De Psiquiatria, 1999, 21, 12-17.	0.9	17
1365	Transient Depressive Relapse Induced by Catecholamine Depletion. Archives of General Psychiatry, 1999, 56, 395.	13.8	113
1366	A Previously Undescribed Intron and Extensive 5â€² Upstream Sequence, but Not Phox2a-mediated Transactivation, Are Necessary for High Level Cell Type-specific Expression of the Human Norepinephrine Transporter Gene. Journal of Biological Chemistry, 1999, 274, 6507-6518.	1.6	93
1367	The impact of the discovery of lithium on psychiatric thought and practice in the USA and Europe. Australian and New Zealand Journal of Psychiatry, 1999, 33, S54-S64.	1.3	24
1368	Alterations of tubulin function caused by chronic antidepressant treatment in rat brain. Cellular and Molecular Neurobiology, 1999, 19, 109-117.	1.7	12
1369	A neuropsychological theory of positive affect and its influence on cognition.. Psychological Review, 1999, 106, 529-550.	2.7	1,839
1370	Tyrosine hydroxylase immunoreactivity in the locus coeruleus is reduced in depressed non-suicidal patients but normal in depressed suicide patients. European Archives of Psychiatry and Clinical Neuroscience, 1999, 249, 212-219.	1.8	54
1371	Dysthymia: clinical picture, extent of overlap with chronic fatigue syndrome, neuropharmacological considerations, and new therapeutic vistas. Journal of Affective Disorders, 1999, 52, 275-290.	2.0	42
1372	Unipolarâ€“bipolar dichotomy of mood disorders is supported by noradrenergic brainstem system morphology. Journal of Affective Disorders, 1999, 54, 217-224.	2.0	47
1373	Quantitative distribution of monoamine oxidase A in brainstem monoamine nuclei is normal in major depression. Brain Research, 1999, 847, 71-79.	1.1	34

#	Article	IF	Citations
1374	Feeding and Reward Interactions From Chronic Paroxetine Treatment. Pharmacology Biochemistry and Behavior, 1999, 63, 435-440.	1.3	16
1375	Brain Noradrenergic Receptors in Major Depression and Schizophrenia. Neuropsychopharmacology, 1999, 21, 69-81.	2.8	64
1376	4-fluorotranylcypromine, a novel monoamine oxidase inhibitor: Neurochemical effects in rat brain after short- and long-term administration. Drug Development Research, 1999, 48, 61-69.	1.4	3
1377	Serum trace elements in animal models and human depression. Part II. Copper. , 1999, 14, 447-451.		13
1378	Reciprocal changes in prefrontal and limbic dopamine responsiveness to aversive and rewarding stimuli after chronic mild stress: implications for the psychobiology of depression. Biological Psychiatry, 1999, 46, 1624-1633.	0.7	231
1379	Implications of research for the treatment of depressive disorders during childhood. Applied and Preventive Psychology, 1999, 8, 79-102.	0.8	8
1380	Decreased expression of the mRNA for somatostatin in the periventricular nucleus of depression-model rats. Life Sciences, 1999, 65, PL87-PL94.	2.0	10
1381	Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat. Life Sciences, 1999, 65, 1773-1786.	2.0	112
1382	Decreased platelet alpha-2 adrenoceptor density in major depression: effects of tricyclic antidepressants and fluoxetine. Biological Psychiatry, 1999, 45, 278-284.	0.7	36
1383	Serotonin-induced platelet intracellular Ca2+ responses in untreated depressed patients and imipramine responders in remission. Biological Psychiatry, 1999, 45, 1042-1048.	0.7	26
1384	Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biological Psychiatry, 1999, 46, 212-220.	0.7	274
1385	Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biological Psychiatry, 1999, 46, 1219-1233.	0.7	254
1386	Symptom provocation studies in psychiatric disorders: scientific value, risks, and future. Biological Psychiatry, 1999, 46, 1060-1080.	0.7	27
1387	Alpha-1-noradrenergic neurotransmission, corticosterone, and behavioral depression. Biological Psychiatry, 1999, 46, 1287-1300.	0.7	63
1388	Noradrenaline (Norepinephrine) and Depression. CNS Drugs, 1999, 12, 293-305.	2.7	18
1389	Current Issues in Depression in Parkinson's Disease. American Journal of Geriatric Psychiatry, 1999, 7, 110-118.	0.6	5
1390	Inorganic Pharmacology of Lithium. Chemical Reviews, 1999, 99, 2659-2682.	23.0	91
1391	Enhancement of the Serotonin-Mediated Acetylcholine Release by Repeated Desmethylimipramine Treatment in the Hippocampus of Freely Moving Rats. The Japanese Journal of Pharmacology, 1999, 80, 303-310.	1.2	3

#	Article	IF	Citations
1393	Chapter 23 Antidepressant and anxiolytic drugs. Principles of Medical Biology, 2000, , 511-567.	0.1	2
1394	5-HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response. Human Psychopharmacology, 2000, 15, 113-135.	0.7	135
1395	Toward a better understanding of depression: New mechanistic considerations of antidepressant action provide a basis for development of delay-free drugs. Drug Development Research, 2000, 51, 1-6.	1.4	6
1396	A review of the role of serotonin receptors in psychiatric disorders. Human Psychopharmacology, 2000, 15, 397-415.	0.7	211
1397	Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depression and Anxiety, 2000, 12, 2-19.	2.0	746
1398	The mitochondrial hypothesis of bipolar disorder. Bipolar Disorders, 2000, 2, 145-147.	1.1	9
1399	Antidepressant drugs: does it matter if they inhibit the reuptake of noradrenaline or serotonin?. Acta Psychiatrica Scandinavica, 2000, 101, 12-17.	2.2	31
1400	Noradrenaline and serotonin reuptake inhibition as clinical principles:a review of antidepressant efficacy. Acta Psychiatrica Scandinavica, 2000, 101, 28-36.	2.2	36
1401	Neurotransmitter transporters: fruitful targets for CNS drug discovery. Molecular Psychiatry, 2000, 5, 357-362.	4.1	140
1402	Changes in Tyrosine Hydroxylase mRNA Expression in the Rat Locus Coeruleus Following Acute or Chronic Treatment with Valproic Acid. Neuropsychopharmacology, 2000, 22, 27-35.	2.8	41
1403	Effects on Mood of Acute Phenylalanine/Tyrosine Depletion in Healthy Women. Neuropsychopharmacology, 2000, 22, 52-63.	2.8	104
1404	Age of onset in affective disorder: its correlation with hereditary and psychosocial factors. Journal of Affective Disorders, 2000, 59, 139-148.	2.0	81
1405	Antidepressant drug administration modifies the interactive relationship between Î±2-adrenergic sensitivity and levels of TNF in the rat brain. Journal of Neuroimmunology, 2000, 107, 50-58.	1.1	18
1406	Depletion of brain norepinephrine does not reduce spontaneous ambulatory activity of rats in the home cage. Brain Research, 2000, 883, 125-130.	1.1	8
1407	Antidepressants: past, present and future. European Journal of Pharmacology, 2000, 405, 351-363.	1.7	106
1408	Neurosensitization: A model for persistent disability in chronic pain, depression, and posttraumatic stress disorder following injury. NeuroRehabilitation, 2000, 14, 25-32.	0.5	37
1409	Reduced Brain Norepinephrine and Dopamine Release in Treatment-Refractory Depressive Illness. Archives of General Psychiatry, 2000, 57, 787.	13.8	261
1410	Molecular Abnormalities in Brains of Depressed Patients. Neuroscientist, 2000, 6, 401-410.	2.6	0

#	Article	IF	Citations
1411	Neurobiology of Major Depression in Alzheimer's Disease. International Psychogeriatrics, 2000, 12, 217-230.	0.6	23
1412	Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biological Psychiatry, 2000, 47, 305-313.	0.7	535
1413	Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biological Psychiatry, 2000, 47, 818-829.	0.7	319
1414	Dopamine deficiency in mice. Brain and Development, 2000, 22, 54-60.	0.6	16
1415	Elucidation of the neurobiology of depression: insights from a novel genetic animal model. Progress in Neurobiology, 2000, 62, 353-378.	2.8	156
1416	Serum concentrations of estradiol and dehydroepiandrosterone sulfate and soy product intake in relation to psychologic well-being in peri-and postmenopausal Japanese women. Metabolism: Clinical and Experimental, 2000, 49, 1561-1564.	1.5	19
1417	MAO-A and MAO-B activities in rat striatum, frontal cortex and liver are unaltered after long-term treatment with fluvoxamine and desipramine. European Neuropsychopharmacology, 2000, 10, 125-128.	0.3	11
1418	Brain Mapping: The Applications. , 2000, , 491-522.		7
1419	Depression in Patients with Parkinson??s Disease. CNS Drugs, 2000, 13, 253-264.	2.7	5
1420	Histopathology of the prefrontal cortex in major depression: what does it tell us about dysfunctional monoaminergic circuits?. Progress in Brain Research, 2000, 126, 397-412.	0.9	80
1421	RECOGNIZING AND TREATING ANXIETY AND DEPRESSION IN ADOLESCENTS. Medical Clinics of North America, 2000, 84, 891-905.	1.1	3
1422	CELLULAR MECHANISMS IN THE VULNERABILITY TO DEPRESSION AND RESPONSE TO ANTIDEPRESSANTS. Psychiatric Clinics of North America, 2000, 23, 713-729.	0.7	45
1423	Unaltered Î±2-noradrenergic/imidazoline receptors in suicide victims: a postmortem brain autoradiographic analysis. European Neuropsychopharmacology, 2000, 10, 265-271.	0.3	16
1424	Neuropathology of bipolar disorder. Biological Psychiatry, 2000, 48, 486-504.	0.7	127
1425	Noradrenergic dysfunction and antidepressant treatment response. European Neuropsychopharmacology, 2001, 11, 163-168.	0.3	17
1426	Effects of chronic antidepressant drug administration and electroconvulsive shock on locus coeruleus electrophysiologic activity. Biological Psychiatry, 2001, 49, 117-129.	0.7	106
1427	Potential Antidepressants Displayed Combined Î±2-Adrenoceptor Antagonist and Monoamine Uptake Inhibitor Properties. Journal of Medicinal Chemistry, 2001, 44, 787-805.	2.9	39
1428	T-helper-1 and T-helper-2 Responses in Psychiatric Disorders. Brain, Behavior, and Immunity, 2001, 15, 340-370.	2.0	208

#	Article	IF	Citations
1429	Effects of chronic antidepressant treatments on 5-HT and NA transporters in rat brain: an autoradiographic study. Neurochemistry International, 2001, 38, 63-74.	1.9	65
1430	Abnormalities in the cAMP signaling pathway in post-mortem brain tissue from the Stanley Neuropathology Consortium. Brain Research Bulletin, 2001, 55, 625-629.	1.4	63
1431	Depression as a spreading adjustment disorder of monoaminergic neurons: a case for primary implication of the locus coeruleus. Brain Research Reviews, 2001, 38, 79-128.	9.1	141
1432	Effect of electroconvulsive therapy on biopterin and large neutral amino acids in severe, medication-resistant depression. Psychiatry Research, 2001, 103, 115-123.	1.7	71
1433	Hyperactive phosphoinositide signaling pathway in platelets of depressed patients: effect of desipramine treatment. Psychiatry Research, 2001, 105, 23-32.	1.7	20
1434	Cognitive and biochemical processes in depressed adult outpatients: a test of the circular process model. Journal of Behavior Therapy and Experimental Psychiatry, 2001, 32, 91-104.	0.6	6
1435	Pharmacological evidence for the role of central alpha 1B-adrenoceptors in the motor activity and spontaneous movement of mice. Neuropharmacology, 2001, 40, 254-261.	2.0	39
1436	Neuropharmacological profile of a selective sigma ligand, igmesine: a potential antidepressant. Neuropharmacology, 2001, 41, 138-149.	2.0	26
1437	CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS. Medical Clinics of North America, 2001, 85, 559-577.	1.1	30
1438	Coumarins with Monoamine Oxidase Inhibitory Activity and Antioxidative Coumarino-lignans fromHibiscussyriacus. Journal of Natural Products, 2001, 64, 1238-1240.	1.5	92
1439	Nutrients and Affective Disorders. , 2001, 5, 135-152.		1
1440	Estrogen and depressive illness in women. , 2001, , 80-95.		0
1441	Noradrenergic Pathology in Psychiatric Disorders: Postmortem Studies. CNS Spectrums, 2001, 6, 697-703.	0.7	18
1442	Biochemical, Electrophysiological and Neurohormonal Studies with B-20991, a Selective 5-HT_{1A} Receptor Agonist. Pharmacology, 2001, 62, 234-242.	0.9	4
1443	Information Processing and Psychopathology. , 2001, , 7456-7460.		0
1444	Hyperfunction of Dopaminergic and Serotonergic Neuronal Systems in Mice Lacking the NMDA Receptor Ìµ1 Subunit. Journal of Neuroscience, 2001, 21, 750-757.	1.7	167
1445	Antidepressants and the biology of depression. Nursing and Residential Care, 2001, 3, 271-275.	0.1	2
1446	Neuroanatomical studies on bipolar disorder. British Journal of Psychiatry, 2001, 178, s142-s147.	1.7	51

#	Article	IF	Citations
1447	Role of Norepinephrine in the Pathophysiology of Neuropsychiatric Disorders. CNS Spectrums, 2001, 6, 663-670.	0.7	49
1448	Association analysis of the pituitary adenyl cyclase activating peptide gene (PACAP) on chromosome 18p11 with schizophrenia and bipolar disorders. Journal of Neural Transmission, 2001, 108, 849-854.	1.4	19
1449	Second Messenger-Regulated Protein Kinases in the Brain. Journal of Neurochemistry, 2001, 74, 21-33.	2.1	112
1450	Inactivation of monoamine oxidase B by 1-phenylcyclopropylamine. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1757-1760.	1.0	13
1451	On the feasibility of designing new antidepressants. Human Psychopharmacology, 2001, 16, 53-59.	0.7	9
1452	Neurotrophins: possible role in affective disorders. Human Psychopharmacology, 2001, 16, 61-64.	0.7	11
1453	The platelet as a peripheral marker in psychiatric illness. Human Psychopharmacology, 2001, 16, 229-236.	0.7	59
1454	Expanding the horizons of depression: beyond the monoamine hypothesis. Human Psychopharmacology, 2001, 16, 203-218.	0.7	105
1455	The cognitive neuroscience paradigm: A unifying metatheoretical framework for the science and practice of clinical psychology. Journal of Clinical Psychology, 2001, 57, 1067-1088.	1.0	25
1456	Title is missing!. Neurophysiology, 2001, 33, 294-303.	0.2	3
1457	Biological Perspectives. Perspectives in Psychiatric Care, 2001, 37, 140-146.	0.9	3
1458	Extrapyramidal symptoms and antidepressant drugs: neuropharmacological aspects of a frequent interaction in the elderly. Molecular Psychiatry, 2001, 6, 134-142.	4.1	56
1459	Serine/threonine kinases as molecular targets of antidepressants: implications for pharmacological treatment and pathophysiology of affective disorders. , 2001, 89, 149-170.		28
1460	Elevated plasma nitrate levels in depressive states. Journal of Affective Disorders, 2001, 63, 221-224.	2.0	212
1461	Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors. Neuropsychopharmacology, 2001, 25, 871-880.	2.8	641
1462	Correlation between Platelet Î±₂-Adrenoreceptors and Symptom Severity in Major Depression. Neuropsychobiology, 2001, 44, 122-125.	0.9	9
1463	Predictive Value of Amino Acids in the Treatment of Major Depression with Fluvoxamine. Neuropsychobiology, 2001, 44, 134-138.	0.9	13
1464	Psychopharmacological challenge studies in psychiatric research. International Review of Psychiatry, 2001, 13, 40-46.	1.4	1

#	Article	IF	Citations
1465	Depression â€“ emerging insights from neurobiology. British Medical Bulletin, 2001, 57, 61-79.	2.7	181
1466	Psychopharmacological challenge studies in psychiatric research. International Review of Psychiatry, 2001, 13, 40-46.	1.4	2
1467	An E-box Motif Residing in the Exon/Intron 1 Junction Regulates Both Transcriptional Activation and Splicing of the Human Norepinephrine Transporter Gene. Journal of Biological Chemistry, 2001, 276, 24797-24805.	1.6	17
1468	St. John's Wort Extract Ze 117 (Hypericum perforatum) Inhibits Norepinephrine and Serotonin Uptake into Rat Brain Slices and Reduces Î²-Adrenoceptor Numbers on Cultured Rat Brain Cells. Pharmacopsychiatry, 2001, 34, 56-60.	1.7	37
1469	Antidepressants: pharmacological profile and clinical consequences. International Journal of Psychiatry in Clinical Practice, 2001, 5, 19-28.	1.2	12
1470	Cyclic AMP response element-binding protein and depression. Expert Review of Neurotherapeutics, 2002, 2, 347-354.	1.4	13
1471	Dual serotonin and noradrenaline uptake inhibitor class of antidepressants â€" Potential for greater efficacy or just hype?. , 2002, 58, 169-222.		100
1472	A Polymorphism of the Norepinephrine Transporter Gene in Bipolar Disorder and Schizophrenia: Lack of Association. Neuropsychobiology, 2002, 45, 182-185.	0.9	28
1473	From Vastation to Prozac Nation. Transcultural Psychiatry, 2002, 39, 267-294.	0.9	7
1474	Stress, Metaplasticity, and Antidepressants. Current Molecular Medicine, 2002, 2, 629-638.	0.6	107
1475	Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Molecular Psychiatry, 2002, 7, 254-275.	4.1	1,121
1476	Behavioural effects of acute phenylalanine and tyrosine depletion in healthy male volunteers. Journal of Psychopharmacology, 2002, 16, 51-55.	2.0	27
1477	Parental Depression: Animal Models of an Adverse Life Event. American Journal of Psychiatry, 2002, 159, 1265-1283.	4.0	234
1478	Probing Brain Reward System Function in Major Depressive Disorder. Archives of General Psychiatry, 2002, 59, 409.	13.8	214
1479	Modulation of brain stem monoamines and Î³-aminobutyric acid by NK1 receptors in rats. NeuroReport, 2002, 13, 1809-1812.	0.6	38
1480	Sleepâ€"wake effects of yohimbine and atropine in rats with a clomipramine-based model of depression. NeuroReport, 2002, 13, 1603-1606.	0.6	8
1481	Effects of Reboxetine on Anxiety, Agitation, and Insomnia: Results of a Pooled Evaluation of Randomized Clinical Trials. Journal of Clinical Psychopharmacology, 2002, 22, 388-392.	0.7	30
1482	The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. International Journal of Neuropsychopharmacology, 2002, 5, 375-388.	1.0	276

#	Article	IF	Citations
1483	Brain imaging: a key to understanding depression. British Journal of Hospital Medicine, 2002, 63, 332-336.	0.3	0
1484	Synthesis and Pharmacological Testing of 1,2,3,4,10,14b-Hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and Its Enantiomers in Comparison with the Two Antidepressants Mianserin and Mirtazapine. Journal of Medicinal Chemistry, 2002, 45, 3280-3285.	2.9	48
1485	The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. European Neuropsychopharmacology, 2002, 12, 461-475.	0.3	161
1486	Monoamine transporter gene structure and polymorphisms in relation to psychiatric and other complex disorders. Pharmacogenomics Journal, 2002, 2, 217-235.	0.9	138
1487	Monoamine oxidase: radiotracer development and human studies. Methods, 2002, 27, 263-277.	1.9	70
1488	Immunomodulatory effect of antidepressants. Current Opinion in Pharmacology, 2002, 2, 428-432.	1.7	27
1489	Behavioral responses to social stress in noradrenaline transporter knockout mice: Effects on social behavior and depression. Brain Research Bulletin, 2002, 58, 279-284.	1.4	68
1490	Epinephrine- and thrombin-stimulated high-affinity GTPase activity in platelet membranes from patients with psychiatric disorders. Psychiatry Research, 2002, 112, 111-119.	1.7	11
1491	Divergent endocrine abnormalities in melancholic and atypical depression: clinical and pathophysiologic implications. Endocrinology and Metabolism Clinics of North America, 2002, 31, 37-62.	1.2	97
1492	Mood Disorders: Unipolar and Bipolar. , 2002, , 277-308.		2
1493	Functional Neuroscience of Mood Disorders. , 0, , 803-814.		0
1494	Lower Sensitivity to Stress and Altered Monoaminergic Neuronal Function in Mice Lacking the NMDA Receptor Îµ4 Subunit. Journal of Neuroscience, 2002, 22, 2335-2342.	1.7	90
1495	Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test. European Journal of Pharmacology, 2002, 436, 197-205.	1.7	168
1496	Rosmarinic acid and caffeic acid produce antidepressive-like effect in the forced swimming test in mice. European Journal of Pharmacology, 2002, 449, 261-267.	1.7	167
1497	The medical benefit of 5-HT research. Pharmacology Biochemistry and Behavior, 2002, 71, 555-568.	1.3	202
1498	Effects of Acute and Chronic Reboxetine Treatment on Stress-induced Monoamine Efflux in the Rat Frontal Cortex. Neuropsychopharmacology, 2002, 27, 237-247.	2.8	87
1499	Role of Gi Proteins in the Antidepressant-like Effect of Amitriptyline and Clomipramine. Neuropsychopharmacology, 2002, 27, 554-64.	2.8	13
1500	Historical studies of premenstrual tension up to 30 years ago: Implications for future research. Current Psychiatry Reports, 2002, 4, 411-418.	2.1	5

#	Article	IF	Citations
1502	Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology, 2002, 160, 353-361.	1.5	278
1503	Extracellular 5-Hydroxytryptamine in Median Raphe Nucleus of the Conscious Rat Is Decreased by Nanomolar Concentrations of 8-Hydroxy-2-(Di-n-Propylamino)tetralin and Is Sensitive to Tetrodotoxin. Journal of Neurochemistry, 2002, 63, 2165-2171.	2.1	49
1504	Chronic Imipramine Administration Amplifies the Serotonin_{2A} Receptorâ€Induced Intracellular Ca²⁺ Mobilization in C6 Glioma Cells Through a Calmodulinâ€Dependent Pathway. Journal of Neurochemistry, 1998, 71, 1709-1718.	2.1	15
1505	Nicotinic acetylcholine receptors as targets for antidepressants. Molecular Psychiatry, 2002, 7, 525-535.	4.1	261
1506	Post-Genomic Era and Gene Discovery for Psychiatric Diseases: There Is a New Art of the Trade?: The Example of the HUMTH01 Microsatellite in the Tyrosine Hydroxylase Gene. Molecular Neurobiology, 2002, 26, 389-403.	1.9	9
1507	Central GABAergic systems and depressive illness. Neurochemical Research, 2003, 28, 965-976.	1.6	52
1508	Cytokine-purine interactions in behavioral depression in rats. Integrative Psychological and Behavioral Science, 2003, 38, 189-202.	0.3	18
1509	Differential effects of KATP channel blockers on [3H]-noradrenaline overflow after short- and long-term exposure to (+)-oxaprotiline or desipramine. Naunyn-Schmiedeberg's Archives of Pharmacology, 2003, 367, 168-175.	1.4	1
1510	Effect of maternal docosahexaenoic acid supplementation on postpartum depression and information processing. American Journal of Obstetrics and Gynecology, 2003, 188, 1348-1353.	0.7	168
1511	Motor activity and autonomic cardiac functioning in major depressive disorder. Journal of Affective Disorders, 2003, 76, 23-30.	2.0	101
1512	Recognition of childhood depression. Journal of Affective Disorders, 2003, 77, 1-9.	2.0	6
1513	The neurobiology of bipolar disorder. American Journal of Medical Genetics Part A, 2003, 123C, 76-84.	2.4	51
1514	Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying combined 5-HT uptake inhibiting and Î±2-adrenoceptor antagonistic activities: a novel series of potential antidepressants. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2719-2725.	1.0	24
1515	Erotomania induced by venlafaxine: a case study. Acta Psychiatrica Scandinavica, 2003, 107, 314-317.	2.2	24
1517	Thyroid indices and treatment outcome in bulimia nervosa. Acta Psychiatrica Scandinavica, 2003, 108, 190-195.	2.2	14
1518	The Complex Epilepsy Patient: Intricacies of Assessment and Treatment. Epilepsia, 2003, 44, 3-8.	2.6	17
1519	The Myth of Reserpine-Induced Depression: Role in the Historical Development of the Monoamine Hypothesis. Journal of the History of the Neurosciences, 2003, 12, 207-220.	0.1	96
1520	The efficacy of reboxetine in preventing and reverting a condition of escape deficit in rats. Biological Psychiatry, 2003, 53, 890-898.	0.7	10

#	Article	IF	Citations
1521	Elevated agonist binding to Î±2-adrenoceptors in the locus coeruleus in major depression. Biological Psychiatry, 2003, 53, 315-323.	0.7	123
1522	Antidepressant Activity of Quercetin, a Bioflavonoid, in Streptozotocin-Induced Diabetic Mice. Journal of Medicinal Food, 2003, 6, 391-395.	0.8	85
1523	Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biological Psychiatry, 2003, 54, 388-398.	0.7	421
1524	Monoamine Oxidase and Cigarette Smoking. NeuroToxicology, 2003, 24, 75-82.	1.4	218
1525	Trace amine receptors as targets for novel therapeutics: legend, myth and fact. Current Opinion in Pharmacology, 2003, 3, 90-97.	1.7	149
1526	Neuroendocrine immune interactions in health and disease. International Immunopharmacology, 2003, 3, 1235-1246.	1.7	47
1527	The Neurobiology of Depression: Perspectives from Animal and Human Sleep Studies. Neuroscientist, 2003, 9, 82-98.	2.6	47
1528	Essential considerations when choosing a modern antidepressant. International Journal of Psychiatry in Clinical Practice, 2003, 7, 3-8.	1.2	5
1529	"Serotonin depression"--a biochemical subgroup within the affective disorders?. Science, 2003, 191, 478-480.	6.0	608
1531	Dose-Related Effects of Chronic Antidepressants on Neuroprotective Proteins BDNF, Bcl-2 and Cu/Zn-SOD in Rat Hippocampus. Neuropsychopharmacology, 2003, 28, 53-62.	2.8	160
1532	Tryptophan Depletion Alters the Decision-Making of Healthy Volunteers through Altered Processing of Reward Cues. Neuropsychopharmacology, 2003, 28, 153-162.	2.8	239
1533	Clinical and Neurobiological Effects of Tianeptine and Paroxetine in Major Depression. Journal of Clinical Psychopharmacology, 2003, 23, 155-168.	0.7	141
1534	Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. International Clinical Psychopharmacology, 2003, 18, 9-14.	0.9	86
1535	Noradrenaline in mood and anxiety disorders: basic and clinical studies. International Clinical Psychopharmacology, 2003, 18, 191-202.	0.9	85
1536	Role of the cytokine network in major psychoses. Advances in Molecular and Cell Biology, 2003, 31, 999-1031.	0.1	9
1537	The Biological, Social, and Psychological Relationship Between Depression and Chronic Pain. Cranio - Journal of Craniomandibular Practice, 2003, 21, 286-294.	0.6	32
1538	StÃ¶rungen der Neurotransmission als Grundlage psychiatrischer Erkrankungen. , 2003, , 123-140.		2
1539	Depressive Episode und rezidivierende depressive StÃ¶rung. , 2003, , 1159-1210.		4

#	Article	IF	Citations
1540	Depression: A Neuropsychiatric Perspective. , 0, , 197-229.		6
1541	Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. International Clinical Psychopharmacology, 2003, 18, 9-14.	0.9	21
1542	Noradrenaline in mood and anxiety disorders: basic and clinical studies. International Clinical Psychopharmacology, 2003, 18, 191-202.	0.9	44
1543	Biological Psychiatry Sketchedâ€"Past, Present, and Future. , 0, , 3-32.		3
1544	A Regulated Interaction of Syntaxin 1A with the Antidepressant-Sensitive Norepinephrine Transporter Establishes Catecholamine Clearance Capacity. Journal of Neuroscience, 2003, 23, 1697-1709.	1.7	150
1545	A Mutation in the Human Norepinephrine Transporter Gene (SLC6A2) Associated with Orthostatic Intolerance Disrupts Surface Expression of Mutant and Wild-Type Transporters. Journal of Neuroscience, 2003, 23, 4470-4478.	1.7	124
1547	Personality, Serotonin, and Noradrenaline. , 2004, , 379-408.		56
1548	Monoamines and depression. , 2004, , 91-143.		1
1552	Trastornos del Ã¡nimo, psicofÃ¡rmacos y tiroides. Revista Medica De Chile, 2004, 132, 1413.	0.1	8
1553	Personality and Hormones. , 2004, , 353-377.		60
1554	DepressÃ£o em crianÃ§as e adolescentes com epilepsia. Revista De Psiquiatria Clinica, 2004, 31, 290-299.	0.6	3
1555	Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression. Neuropsychopharmacology, 2004, 29, 385-392.	2.8	268
1557	Brain-Derived Tumor Necrosis Factor-Î± and Its Involvement in Noradrenergic Neuron Functioning Involved in the Mechanism of Action of an Antidepressant. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 1216-1225.	1.3	54
1558	Lack of Plasma Norepinephrine Cyclicity, Increased Estradiol during the Follicular Phase, and of Progesterone and Gonadotrophins at Ovulation in Women with Premenstrual Syndrome. Neuropsychobiology, 2004, 50, 10-15.	0.9	24
1559	Invited review: the evolution of antidepressant mechanisms. Fundamental and Clinical Pharmacology, 2004, 18, 1-21.	1.0	158
1560	Contribution of the stress-induced degeneration of the locus coeruleus noradrenergic neurons to the pathophysiology of depression: a study on an animal model. Acta Neuropsychiatrica, 2004, 16, 190-199.	1.0	6
1561	24-h Monitoring of plasma norepinephrine, MHPG, cortisol, growth hormone and prolactin in depression. Journal of Psychiatric Research, 2004, 38, 503-511.	1.5	89
1562	Do epilepsy and psychiatric disorders share common pathogenic mechanisms? A look at depression and epilepsy. Clinical Neuroscience Research, 2004, 4, 31-37.	0.8	10

#	Article	IF	Citations
1563	Amitriptyline administration transforms tumor necrosis factor-alpha regulation of norepinephrine release in the brain. Brain Research, 2004, 1023, 112-120.	1.1	14
1564	The effects of tyrosine depletion in normal healthy volunteers: implications for unipolar depression. Psychopharmacology, 2004, 171, 286-297.	1.5	102
1565	Sex differences in the pituitary-adrenal response following acute antidepressant treatment in sheep. Psychopharmacology, 2004, 171, 450-457.	1.5	13
1567	Evidence for a role of the arachidonic acid cascade in affective disorders: a review. Bipolar Disorders, 2004, 6, 95-105.	1.1	50
1568	Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. International Journal of Neuropsychopharmacology, 2004, 7, 193-218.	1.0	213
1569	Imbalance of Glial-Neuronal Interaction in Synapses: A Possible Mechanism of the Pathophysiology of Bipolar Disorder. Neuroscientist, 2004, 10, 199-206.	2.6	18
1570	Mechanisms of depression: the role of neurogenesis. Drug Discovery Today Disease Mechanisms, 2004, 1, 407-411.	0.8	42
1571	Future Antidepressants. CNS Drugs, 2004, 18, 705-732.	2.7	47
1572	Serotonin and brain development. International Review of Neurobiology, 2004, 59, 111-174.	0.9	283
1574	Antidepressants: Past, Present and Future. Handbook of Experimental Pharmacology, 2004, , .	0.9	21
1575	Dopamine overflow is increased in olfactory bulbectomized rats: an in vivo microdialysis study. Physiology and Behavior, 2004, 81, 111-119.	1.0	55
1576	Central monoamines and their role in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 435-451.	2.5	407
1577	Clinical response to antidepressant treatment and 3-methoxy-4-hydroxyphenylglycol levels: mini review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 611-616.	2.5	34
1578	Noradrenaline storage function of species-specific protein bodies, markers of monoamine neurons in human locus coeruleus demonstrated by dopamine-Î²-hydroxylase immunogold localization. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 829-847.	2.5	4
1579	Chronic treatment with desipramine and fluoxetine modulate BDNF, CaMKKÎ± and CaMKKÎ² mRNA levels in the hippocampus of transgenic mice expressing antisense RNA against the glucocorticoid receptor. Neuropharmacology, 2004, 47, 1062-1069.	2.0	50
1580	Mice with reduced brain-derived neurotrophic factor expression show decreased choline acetyltransferase activity, but regular brain monoamine levels and unaltered emotional behavior. Molecular Brain Research, 2004, 121, 28-36.	2.5	154
1581	Differential effects of milnacipran, fluvoxamine and paroxetine for inhibited and agitated depression. European Psychiatry, 2004, 19, 450-451.	0.1	2
1582	Neural predictive error signal correlates with depressive illness severity in a game paradigm. NeuroImage, 2004, 23, 269-280.	2.1	41

#	Article	IF	Citations
1583	Selective effects of simultaneous monoamine depletion on mood and emotional responsiveness. International Journal of Neuropsychopharmacology, 2004, 7, 9-17.	1.0	13
1584	The Role of Monoamine Oxidase Inhibitors in Current Psychiatric Practice. Journal of Psychiatric Practice, 2004, 10, 239-248.	0.3	118
1585	Pharmacologic Differences Among the SSRIs: Focus on Monoamine Transporters and the HPA Axis. CNS Spectrums, 2004, 9, 23-31.	0.7	85
1586	Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?. Behavioural Pharmacology, 2005, 16, 333-352.	0.8	169
1589	Neurobiological Background for Performing Surgical Intervention in the Inferior Thalamic Peduncle for Treatment of Major Depression Disorders. Neurosurgery, 2005, 57, 439-448.	0.6	75
1592	Is mood chemistry?. Nature Reviews Neuroscience, 2005, 6, 241-246.	4.9	508
1593	The Discovery of Fluoxetine Hydrochloride (Prozac). Nature Reviews Drug Discovery, 2005, 4, 764-774.	21.5	326
1594	Genetic tests of biologic systems in affective disorders. Molecular Psychiatry, 2005, 10, 719-740.	4.1	31
1595	Open-Field Behavioural Alterations in Liver-Impaired and Sham-Operated Rats after Acute Exposure to the Antidepressant Venlafaxine. Basic and Clinical Pharmacology and Toxicology, 2005, 97, 155-161.	1.2	9
1596	Structural and functional models of depression: from sub-types to substrates. Acta Psychiatrica Scandinavica, 2005, 111, 94-105.	2.2	105
1597	Submissive behavior in mice as a test for antidepressant drug activity. Pharmacology Biochemistry and Behavior, 2005, 82, 306-313.	1.3	40
1598	Distribution of L1cam mRNA in the adult mouse brain: In situ hybridization and Northern blot analyses. Journal of Comparative Neurology, 2005, 482, 386-404.	0.9	17
1599	New drug targets for depression and anxiety: Is the peptides era arriving?. Drug Development Research, 2005, 65, 93-96.	1.4	2
1600	Mood disorders and their treatment: alterations in the regulation of receptor-G protein coupling. Drug Development Research, 2005, 65, 147-155.	1.4	2
1601	Small molecule melanin-concentrating hormone receptor 1 (MCH1R) antagonists as anxiolytic and antidepressive agents. Drug Development Research, 2005, 65, 291-300.	1.4	8
1602	Preclinical approaches to examine novel concepts of the pathophysiology of depressive disorders: lessons learned from tree shrews. Drug Development Research, 2005, 65, 309-317.	1.4	4
1603	Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology, 2005, 177, 245-255.	1.5	788
1604	Translational Neuroimaging: Positron Emission Tomography Studies of Monoamine Oxidase. Molecular Imaging and Biology, 2005, 7, 377-387.	1.3	71

#	Article	IF	Citations
1607	A disfunÃ§Ã£o do lobo frontal em crianÃ§as e adolescentes com epilepsia de lobo temporal e sua possÃvel correlaÃ§Ã£o com a ocorrÃªncia de transtornos psiquiÃ¡tricos. Journal of Epilepsy and Clinical Neurophysiology, 2005, 11, 131-136.	0.1	1
1608	Brain-Derived Neurotrophic Factor and Antidepressant Activity. Current Pharmaceutical Design, 2005, 11, 1495-1510.	0.9	147
1609	The Dual Transporter Inhibitor Duloxetine: A Review of its Preclinical Pharmacology, Pharmacokinetic Profile, and Clinical Results in Depression. Current Pharmaceutical Design, 2005, 11, 1475-1493.	0.9	145
1610	Clinical Characteristics as Predictors of Response to Fluvoxamine, Paroxetine and Milnacipran in Patients with Depression. Current Psychiatry Reviews, 2005, 1, 319-324.	0.9	2
1611	Association of BDNF Serum Concentrations with Central Serotonergic Activity: Evidence from Auditory Signal Processing. Neuropsychopharmacology, 2005, 30, 1148-1153.	2.8	54
1612	Treatment Enhances Ultradian Rhythms of CSF Monoamine Metabolites in Patients with Major Depressive Episodes. Neuropsychopharmacology, 2005, 30, 2082-2091.	2.8	14
1613	Possible structural abnormality of the brainstem in unipolar depressive illness: a transcranial ultrasound and diffusion tensor magnetic resonance imaging study. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1510-1515.	0.9	31
1614	The role for vitamin B-6 as treatment for depression: a systematic review. Family Practice, 2005, 22, 532-537.	0.8	85
1615	Nutrients, Stress, and Medical Disorders. , 2005, , .		5
1616	Continuity and Discontinuity in the Historical Development of Modern Psychopharmacology. Journal of the History of the Neurosciences, 2005, 14, 199-209.	0.1	14
1617	Depressive Illness and Emotional Learning. Current Medical Imaging, 2005, 1, 157-176.	0.4	2
1618	Effects of Intraperitoneal Administration of IFN-Î± for One, Four, and Fourteen Days on Amino Acid Levels in Various Rat Brain Regions. Journal of Interferon and Cytokine Research, 2005, 25, 187-191.	0.5	5
1619	Efficacy and Tolerability of Reboxetine in Depressive Patients Treated in Routine Clinical Practice. CNS Drugs, 2005, 19, 43-54.	2.7	12
1620	Fluoxetine-induced up-regulation of 14-3-3zeta and tryptophan hydroxylase levels in RBL-2H3 cells. Neuroscience Letters, 2005, 374, 53-57.	1.0	45
1622	Cytokines and major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 201-217.	2.5	1,010
1623	Antidepressant action: to the nucleus and beyond. Trends in Pharmacological Sciences, 2005, 26, 631-638.	4.0	178
1624	An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-Î± production culminating in increases in noradrenergic neurotransmission. Neuroscience, 2005, 133, 519-531.	1.1	53
1625	The many faces of fatigue in major depressive disorder. International Journal of Neuropsychopharmacology, 2005, 8, 93-105.	1.0	232

#	Article	IF	Citations
1626	Glycogen Synthase Kinase-3: a Putative Molecular Target for Lithium Mimetic Drugs. Neuropsychopharmacology, 2005, 30, 1223-1237.	2.8	339
1628	Melatonin in mood disorders. World Journal of Biological Psychiatry, 2006, 7, 138-151.	1.3	228
1629	Antidepressant-like effect of harmane and other Î²-carbolines in the mouse forced swim test. European Neuropsychopharmacology, 2006, 16, 324-328.	0.3	133
1630	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) Analogues:â€‰ A Promising Class of Monoamine Uptake Inhibitors. Journal of Medicinal Chemistry, 2006, 49, 1420-1432.	2.9	349
1631	The Role of CREB in Depression and Antidepressant Treatment. Biological Psychiatry, 2006, 59, 1144-1150.	0.7	321
1632	Relevancia histÃ³rica de la teorÃa neuronal un siglo despuÃ©s del Nobel de Cajal: implicaciones psiquiÃ¡tricas y psicofarmacolÃ³gicas. Psiquiatria Biologica, 2006, 13, 167-182.	0.0	4
1633	Links Between Depression and Substance Abuse in Adolescents. American Journal of Preventive Medicine, 2006, 31, 161-174.	1.6	87
1634	The involvement of G proteins and regulators of receptorâ€“G protein coupling in the pathophysiology, diagnosis and treatment of mood disorders. Clinica Chimica Acta, 2006, 366, 37-47.	0.5	35
1635	The possible role of tissue-type plasminogen activator and the plasminogen system in the pathogenesis of major depression. Medical Hypotheses, 2006, 66, 319-322.	0.8	30
1636	Phosducin-like protein levels in leukocytes of patients with major depression and in rat cortex: The effect of chronic treatment with antidepressants. Psychiatry Research, 2006, 141, 287-294.	1.7	6
1637	Major depression and the synthetic enhancer substances, (â^')-deprenyl and R-(â^')-1-(benzofuran-2-yl)-2-propylaminopentane. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 5-14.	2.5	12
1638	A history of the Collegium Internationale Neuro-Psychopharmacologicum (1957â€“2004). Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 599-616.	2.5	11
1639	Experimental Protocols for the Study of Stress in Animals and Humans. , 2006, , 21-35.		1
1640	BEHAVIORAL DETERMINANTS OF DRUG ACTION: THE CONTRIBUTIONS OF PETER B. DEWS. Journal of the Experimental Analysis of Behavior, 2006, 86, 359-370.	0.8	14
1641	Efficacy and Tolerability of Reboxetine Compared with Citalopram. Journal of Clinical Psychopharmacology, 2006, 26, 121-127.	0.7	41
1643	Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system. International Clinical Psychopharmacology, 2006, 21, S17-S20.	0.9	46
1644	Panic comorbidity with bipolar disorder: what is the manic?panic connection?. Bipolar Disorders, 2006, 8, 648-664.	1.1	36
1645	Chronic intraperitoneal injection of interferon-Î± reduces serotonin levels in various regions of rat brain, but does not change levels of serotonin transporter mRNA, nitrite or nitrate. Psychiatry and Clinical Neurosciences, 2006, 60, 499-506.	1.0	23

#	Article	IF	Citations
1646	The Promises and Pitfalls of Reboxetine. CNS Neuroscience & Therapeutics, 2003, 9, 327-342.	4.0	32
1647	Neurotransmitter transporters and their impact on the development of psychopharmacology. British Journal of Pharmacology, 2006, 147, S82-S88.	2.7	196
1648	Trace amineâ€associated receptors and their ligands. British Journal of Pharmacology, 2006, 149, 967-978.	2.7	271
1649	Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology, 2006, 186, 362-372.	1.5	216
1650	Serotonergic modulation of the limbic system. Neuroscience and Biobehavioral Reviews, 2006, 30, 203-214.	2.9	257
1651	Repeated treatment with antidepressants enhances dopamine D1 receptor gene expression in the rat brain. European Journal of Pharmacology, 2006, 532, 208-213.	1.7	17
1652	Animal models of depression in drug discovery: A historical perspective. Pharmacology Biochemistry and Behavior, 2006, 84, 436-452.	1.3	175
1653	Chronic mild stress inhibits BDNF protein expression and CREB activation in the dentate gyrus but not in the hippocampus proper. Pharmacology Biochemistry and Behavior, 2006, 85, 842-849.	1.3	246
1654	The role of GABAB receptors in depression and antidepressant-related behavioural responses. Drug Development Research, 2006, 67, 477-494.	1.4	13
1655	The Biochemistry of the Functional Psychoses. Advances in Enzymology and Related Areas of Molecular Biology, 2006, 29, 479-553.	1.3	10
1656	Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications. Expert Opinion on Therapeutic Targets, 2006, 10, 377-392.	1.5	34
1657	Effects of a Î±2C-Adrenoreceptor Gene Polymorphism on Neural Responses to Facial Expressions in Depression. Neuropsychopharmacology, 2006, 31, 1750-1756.	2.8	80
1658	Serotonin Reuptake Inhibitors: The Corner Stone in Treatment of Depression for Half a Century â€“ A Medicinal Chemistry Survey. Current Topics in Medicinal Chemistry, 2006, 6, 1801-1823.	1.0	62
1659	Science, Gender, and the Emergence of Depression in American Psychiatry, 1952â€“1980. Journal of the History of Medicine and Allied Sciences, 2006, 61, 187-216.	0.1	26
1660	A 60-Year-Old Woman Who Has Felt Sad for Much of Her Life. JAMA - Journal of the American Medical Association, 2006, 295, 318.	3.8	4
1661	Heterotrimeric G Proteins: Insights into the Neurobiology of Mood Disorders. Current Neuropharmacology, 2006, 4, 127-138.	1.4	28
1662	Three-dimensional models of neurotransmitter transporters and their interactions with cocaine andS-citalopram. World Journal of Biological Psychiatry, 2006, 7, 99-109.	1.3	10
1663	Vmat2Heterozygous Mutant Mice Display a Depressive-Like Phenotype. Journal of Neuroscience, 2007, 27, 10520-10529.	1.7	135

#	Article	IF	Citations
1664	Abnormal Neurotransmitter Release Underlying Behavioral and Cognitive Disorders: Toward Concepts of Dynamic and Function-Specific Dysregulation. Neuropsychopharmacology, 2007, 32, 1452-1461.	2.8	68
1665	Translational Research in Late-Life Mood Disorders: Implications for Future Intervention and Prevention Research. Neuropsychopharmacology, 2007, 32, 1857-1875.	2.8	43
1666	A possible role for the endocannabinoid system in the neurobiology of depression. Clinical Practice and Epidemiology in Mental Health, 2007, 3, 25.	0.6	43
1668	Innovations in CNS drug discovery: differentiating strategies to treat depression. Expert Opinion on Drug Discovery, 2007, 2, 1369-1377.	2.5	1
1669	Regulators of G-protein-coupled receptorâ€“G-protein coupling: antidepressants mechanism of action. Expert Review of Neurotherapeutics, 2007, 7, 75-84.	1.4	23
1670	The Evolving Neurobiology of Depression: From Synapses to Neurons, Circuits and Loops. Australian and New Zealand Journal of Psychiatry, 2007, 41, 561-562.	1.3	3
1671	Anxiety and Comorbid Measures Associated With PLXNA2. Archives of General Psychiatry, 2007, 64, 318.	13.8	52
1673	The "chemical imbalance" explanation for depression: Origins, lay endorsement, and clinical implications.. Professional Psychology: Research and Practice, 2007, 38, 411-420.	0.6	54
1674	Half a Century of Antidepressant Drugs. Journal of Clinical Psychopharmacology, 2007, 27, 555-559.	0.7	68
1675	A Clinical View of BDNF-TrkB Signaling in the Treatment of Major Depression. Current Signal Transduction Therapy, 2007, 2, 186-189.	0.3	1
1676	Atypical antipsychotics in bipolar depression: Neurobiological basis and clinical implications. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 275-282.	2.5	44
1677	Involvement of dopamine (DA)/serotonin (5-HT)/sigma (Ïƒ) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist. Brain Research Bulletin, 2007, 74, 58-65.	1.4	45
1678	Major depressive disorder viewed as a dysfunction in astroglial bioenergetics. Medical Hypotheses, 2007, 68, 370-377.	0.8	27
1679	The Role of Dopamine in the Pathophysiology of Depression. Archives of General Psychiatry, 2007, 64, 327.	13.8	991
1680	Role of Î±2 Receptors in Quercetin-Induced Behavioral Despair in Mice. Journal of Medicinal Food, 2007, 10, 165-168.	0.8	20
1681	The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. Journal of Psychopharmacology, 2007, 21, 461-471.	2.0	311
1682	Dentate gyrus neurogenesis and depression. Progress in Brain Research, 2007, 163, 697-822.	0.9	88
1684	Dopamine D2-Like Receptors and the Antidepressant Response. Biological Psychiatry, 2007, 61, 145-153.	0.7	146

#	Article	IF	Citations
1685	Genetic Dissection of the Tail Suspension Test: A Mouse Model of Stress Vulnerability and Antidepressant Response. Biological Psychiatry, 2007, 62, 81-91.	0.7	19
1686	High-Efficacy 5-HT_{1A} Agonists for Antidepressant Treatment:â€‰ A Renewed Opportunity. Journal of Medicinal Chemistry, 2007, 50, 5024-5033.	2.9	60
1687	Neuroimmune Correlates of Sleep in Depression: Role of Cytokines. , 2007, , 295-319.		1
1688	Norepinephrine in mood disorders. , 0, , 363-384.		1
1689	The clinical role of norepinephrine antidepressants in depression and anxiety disorders. , 2007, , 535-556.		1
1690	Antidepressant-like effects of the ethanolic extract of Xiaobuxin-Tang, a traditional Chinese herbal prescription in animal models of depression. Chinese Medical Journal, 2007, 120, 1792-1796.	0.9	17
1691	Proteomic analysis of rat cortical neurons after fluoxetine treatment. Brain Research, 2007, 1135, 41-51.	1.1	33
1692	Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. European Journal of Pharmacology, 2007, 568, 177-185.	1.7	116
1693	Behavioral effects of the Î²3 adrenoceptor agonist SR58611A: Is it the putative prototype of a new class of antidepressant/anxiolytic drugs?. European Journal of Pharmacology, 2007, 573, 139-147.	1.7	51
1694	Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. , 2007, 115, 116-147.		208
1697	Enantioseparation of the antidepressant reboxetine. Journal of Pharmaceutical and Biomedical Analysis, 2008, 48, 991-996.	1.4	4
1698	Galanin â€“ 25 years with a multitalented neuropeptide. Cellular and Molecular Life Sciences, 2008, 65, 1791-1795.	2.4	28
1699	Galanin â€“ 25 years with a multitalented neuropeptide. Cellular and Molecular Life Sciences, 2008, 65, 1854-1863.	2.4	83
1700	Striatal dopamine D2 receptors in medication-naive patients with major depressive disorder as assessed with [11C]raclopride PET. Psychopharmacology, 2008, 197, 581-590.	1.5	61
1701	Basal and stress-induced modulation of activity-regulated cytoskeletal associated protein (Arc) in the rat brain following duloxetine treatment. Psychopharmacology, 2008, 201, 285-292.	1.5	28
1703	Neither single-marker nor haplotype analyses support an association between monoamine oxidase A gene and bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 350-356.	1.8	7
1704	Antidepressant drugs modulate growth factors in cultured cells. BMC Pharmacology, 2008, 8, 6.	0.4	22
1705	Enhanced Response of Growth Hormone to Growth Hormone-Releasing Hormone and a Decreased Content of Hypothalamic Somatostatin in a Stress-Induced Rat Model of Depression. Journal of Neuroendocrinology, 2008, 10, 259-265.	1.2	3

#	Article	IF	Citations
1706	Depressive illness: biological mechanisms of cardiac risk. Stress and Health, 2008, 24, 213-222.	1.4	7
1708	Neurotransmission and bipolar disorder: A systematic familyâ€based association study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 1270-1277.	1.1	26
1709	A final common pathway for depression? Progress toward a general conceptual framework. Neuroscience and Biobehavioral Reviews, 2008, 32, 508-524.	2.9	75
1711	Neurostimulatory therapeutics in management of treatmentâ€resistant depression with focus on deep brain stimulation. Mount Sinai Journal of Medicine, 2008, 75, 263-275.	1.9	13
1713	Gaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5â€HT in the UK. British Journal of Pharmacology, 2008, 154, 1583-1599.	2.7	19
1714	Norepinephrine and serotonin imbalance in the locus coeruleus in bipolar disorder. Bipolar Disorders, 2008, 10, 349-359.	1.1	58
1715	Sequential improvement of anxiety, depression and anhedonia with sertraline treatment in patients with major depression. Journal of Clinical Pharmacy and Therapeutics, 2000, 25, 363-371.	0.7	2
1716	Enhanced norepinephrine output during long-term desipramine treatment: A possible role for the extraneuronal monoamine transporter (SLC22A3). Journal of Psychiatric Research, 2008, 42, 605-611.	1.5	20
1717	Differential Susceptibility to Extinction-Induced Despair and Age-Dependent Alterations in the Hypothalamic-Pituitary-Adrenal Axis and Neurochemical Parameters. Neuropsychobiology, 2008, 58, 138-153.	0.9	14
1718	Association analysis of monoamine oxidase A gene and bipolar affective disorder in Han Chinese. Behavioral and Brain Functions, 2008, 4, 21.	1.4	11
1719	Biochemical genetics of neurotransmitter enzymes and receptors: Relationships to schizophrenia and other major psychiatric disorders. Clinical Genetics, 1981, 19, 358-372.	1.0	19
1720	Clinical Neuroanatomy: A Neurobehavioral Approach. , 2008, , .		0
1722	Theory of active antidepressants: A nonsynaptic approach to the treatment of depression. Neurochemistry International, 2008, 52, 34-39.	1.9	51
1723	Folic acid administration produces an antidepressant-like effect in mice: Evidence for the involvement of the serotonergic and noradrenergic systems. Neuropharmacology, 2008, 54, 464-473.	2.0	118
1724	Desipramine potentiation of the acute depressant effects of ethanol: Modulation by Î±2-adrenoreceptors and stress. Neuropharmacology, 2008, 55, 803-811.	2.0	19
1725	Stress at work alters serum brain-derived neurotrophic factor (BDNF) levels and plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in healthy volunteers: BDNF and MHPG as possible biological markers of mental stress?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 679-685.	2.5	79
1726	Potential antidepressant properties of cysteamine on hippocampal BDNF levels and behavioral despair in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1590-1594.	2.5	21
1727	Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. European Psychiatry, 2008, 23, 396-402.	0.1	95

#	Article	IF	Citations
1728	Serotoninâ€“dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders. Progress in Brain Research, 2008, 172, 213-230.	0.9	39
1729	Towards the Mental Health Ontology. , 2008, , .		19
1730	El sistema noradrenÃ©rgico en la neurobiologÃa de la depresiÃ³n. Psiquiatria Biologica, 2008, 15, 162-174.	0.0	0
1731	Agomelatina: un nuevo enfoque farmacolÃ³gico en el tratamiento de la depresiÃ³n con traducciÃ³n clÃnica. Psiquiatria Biologica, 2008, 15, 125-139.	0.0	11
1732	Elevated Brain Serotonin Turnover in Patients With Depression. Archives of General Psychiatry, 2008, 65, 38.	13.8	185
1733	Perspective: Does COMT val158met Affect Behavioral Phenotypes: Yes, No, Maybe?. Neuropsychopharmacology, 2008, 33, 3027-3029.	2.8	25
1734	Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635. International Journal of Neuropsychopharmacology, 2008, 11, 465-76.	1.0	150
1735	Molecular Genetics of Brain Noradrenergic Neurotransmission. , 2008, , 129-147.		0
1736	Enhanced Adult Neurogenesis and Angiogenesis and Altered Affective Behaviors in Mice Overexpressing Vascular Endothelial Growth Factor 120. Journal of Neuroscience, 2008, 28, 14522-14536.	1.7	71
1737	Improving the Prediction of Treatment Response in Depression: Integration of Clinical, Cognitive, Psychophysiological, Neuroimaging, and Genetic Measures. CNS Spectrums, 2008, 13, 1066-1086.	0.7	150
1738	Tianeptine: An Antidepressant with Memory-Protective Properties. Current Neuropharmacology, 2008, 6, 311-321.	1.4	31
1739	Affective disorders. , 0, , 250-283.		3
1740	The Effect of Sympathetic Antagonists on the Antidepressant Action of Alprazolam. Libyan Journal of Medicine, 2008, 3, 78-83.	0.8	4
1741	Long-Chain Polyunsaturated Fatty Acids Modulate Interleukin-1Î²â€“Induced Changes in Behavior, Monoaminergic Neurotransmitters, and Brain Inflammation in Rats ,. Journal of Nutrition, 2008, 138, 954-963.	1.3	90
1742	Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues. Neuropsychiatric Disease and Treatment, 2009, 5, 369.	1.0	14
1743	Malfunction in GABA and Glutamate as Pathways to Depression: A Review of the Evidence. Clinical Medicine Therapeutics, 2009, 1, CMT.S3481.	0.1	2
1744	Neurobiology of depression, fibromyalgia and neuropathic pain. Frontiers in Bioscience - Landmark, 2009, 14, 5291.	3.0	279
1745	The Need to Operationally Define â€œDiseaseâ€• in Psychiatry and Psychology. Ethical Human Psychology and Psychiatry, 2009, 11, 120-141.	0.5	2

#	Article	IF	Citations
1746	Drug Evaluation and the Permissive Principle. Social Studies of Science, 2009, 39, 569-598.	1.5	37
1747	Antidepressants, β-Arrestins and GRKs: From Regulation of Signal Desensitization to Intracellular Multifunctional Adaptor Functions. Current Pharmaceutical Design, 2009, 15, 1699-1708.	0.9	21
1748	Are Psychostimulants a Treatment Option in Mania?. Pharmacopsychiatry, 2009, 42, 169-174.	1.7	53
1749	Unfaithful neurotransmitter transporters: Focus on serotonin uptake and implications for antidepressant efficacy. , 2009, 121, 89-99.		202
1750	Through the looking glass: Examining neuroanatomical evidence for cellular alterations in major depression. Journal of Psychiatric Research, 2009, 43, 947-961.	1.5	129
1751	Risk of postpartum depression in association with serum leptin and interleukin-6 levels at delivery: A nested caseâ€“control study within the UPPSAT cohort. Psychoneuroendocrinology, 2009, 34, 1329-1337.	1.3	57
1752	1 INTRODUCTION: PSYCHOSOCIAL STIMULI, PSYCHOPHYSIOLOGICAL REACTIONS, AND DISEASE. Acta Medica Scandinavica, 1972, 191, 11-27.	0.0	6
1753	THE BEHAVIORAL EFFECTS OF FOOD CONSTITUENTS: STRATEGIES USED IN STUDIES OF AMINO ACIDS, PROTEIN, CARBOHYDRATE AND CAFFEINE. Nutrition Reviews, 1986, 44, 61-70.	2.6	70
1754	Interaction Studies between Three Antidepressant Drugs (Zimelidine, Imipramine and Chlorimipramine) and Noradrenaline in Healthy Volunteers and some Pharmacokinetics of the Drugs Studied. Acta Pharmacologica Et Toxicologica, 1979, 45, 198-205.	0.0	9
1755	Acute Effects of Atypical Antidepressants on Various Receptors in the Rat Brain. Acta Pharmacologica Et Toxicologica, 1984, 54, 379-384.	0.0	47
1756	A COMPARISON OF LITHIUM EFFECTS ON HUMAN BRAIN AND RAT BRAIN NORADRENALINEâ€SENSITIVE ADENYLATE CYCLASE. Acta Pharmacologica Et Toxicologica, 1985, 56, 15-20.	0.0	6
1757	EFFECTS OF LITHIUM AND ANTIDEPRESSANTS ON ELECTROPHYSIOLOGICAL AND BIOCHEMICAL PROCESSES IN THE CNS.. Acta Pharmacologica Et Toxicologica, 1985, 56, 43-54.	0.0	5
1758	Chronic Treatment with Antidepressant Drugs and the Analgesia Induced by 5â€Methoxyâ€N,Nâ€dimethyltryptamine: Attenuation by Desipramine. Acta Pharmacologica Et Toxicologica, 1986, 59, 103-112.	0.0	20
1759	Association of major depression with rare functional variants in norepinephrine transporter and serotonin_{1Ã} receptor genes. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 1013-1016.	1.1	42
1760	Running exerciseâ€induced upâ€regulation of hippocampal brainâ€derived neurotrophic factor is CREBâ€dependent. Hippocampus, 2009, 19, 962-972.	0.9	105
1761	Is norepinephrine an etiological factor in some types of cancer?. International Journal of Cancer, 2009, 124, 257-263.	2.3	65
1762	Structure and localisation of drug binding sites on neurotransmitter transporters. Journal of Molecular Modeling, 2009, 15, 1155-1164.	0.8	29
1763	5HTTLPR predicts left fusiform gyrus activation to positive emotional stimuli. Magnetic Resonance Imaging, 2009, 27, 441-448.	1.0	15

#	Article	IF	Citations
1764	The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. European Journal of Clinical Pharmacology, 2009, 65, 571-577.	0.8	125
1765	Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. Molecular Psychiatry, 2009, 14, 359-375.	4.1	354
1766	Key neurochemical markers for the prevention of suicide. TrAC - Trends in Analytical Chemistry, 2009, 28, 1037-1047.	5.8	5
1767	Prevalence of antidepressants and biosimilars in elite sport. Drug Testing and Analysis, 2009, 1, 286-291.	1.6	14
1769	Depression: An Evolutionarily Conserved Mechanism to Terminate Separation Distress? A Review of Aminergic, Peptidergic, and Neural Network Perspectives. Neuropsychoanalysis, 2009, 11, 7-51.	0.1	162
1770	Cardiovascular Abnormalities in Patients with Major Depressive Disorder. CNS Drugs, 2009, 23, 583-602.	2.7	92
1771	The involvement of serotonergic system in the antidepressant effect of zinc in the forced swim test. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 323-329.	2.5	117
1772	Ascorbic acid administration produces an antidepressant-like effect: Evidence for the involvement of monoaminergic neurotransmission. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 530-540.	2.5	121
1773	Inhibitory effect of antidepressants on the NMDA-evoked [3H]noradrenaline release from rat hippocampal slices. Neurochemistry International, 2009, 55, 383-388.	1.9	15
1774	Association of monoamine oxidase A (MAOA) polymorphisms and clinical subgroups of major depressive disorders in the Han Chinese population. World Journal of Biological Psychiatry, 2009, 10, 544-551.	1.3	20
1775	Serotonin Modulation of Cerebral Glucose Metabolism in Depressed Older Adults. Biological Psychiatry, 2009, 66, 259-266.	0.7	46
1776	Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models. Neuropsychopharmacology, 2009, 34, 74-89.	2.8	301
1777	Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. Chemical Communications, 2009, , 3677.	2.2	95
1778	Is elevated noradrenaline an aetiological factor in a number of diseases?. Autonomic and Autacoid Pharmacology, 2009, 29, 143-156.	0.5	24
1779	Zinc-induced adaptive changes in NMDA/glutamatergic and serotonergic receptors. Pharmacological Reports, 2009, 61, 1184-1191.	1.5	49
1780	Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders. Current Pharmaceutical Design, 2009, 15, 1595-1611.	0.9	107
1781	Depression has a Strong Relationship to Alterations in the Immune, Endocrine and Neural System. Current Psychiatry Reviews, 2009, 5, 287-297.	0.9	16
1782	Opiates as Antidepressants. Current Pharmaceutical Design, 2009, 15, 1612-1622.	0.9	109

#	Article	IF	Citations
1783	Monoaminergic Neurotransmission: The History of the Discovery of Antidepressants from 1950s Until Today. Current Pharmaceutical Design, 2009, 15, 1563-1586.	0.9	331
1784	In a mouse model relevant for post-traumatic stress disorder, selective brain steroidogenic stimulants (SBSS) improve behavioral deficits by normalizing allopregnanolone biosynthesis. Behavioural Pharmacology, 2010, 21, 438-450.	0.8	66
1785	Antidepressant effects of estrogens: a basic approximation. Behavioural Pharmacology, 2010, 21, 451-464.	0.8	47
1790	3-[(aryl)(4-fluorobenzyloxy)methyl]piperidine derivatives: high-affinity ligands for the serotonin transporter. Journal of Pharmacy and Pharmacology, 2010, 59, 1439-1445.	1.2	8
1791	Anterior cingulate pyramidal neurons display altered dendritic branching in depressed suicides. Journal of Psychiatric Research, 2010, 44, 286-293.	1.5	49
1792	Involvement of serotonin receptor subtypes in the antidepressant-like effect of trim in the rat forced swimming test. Pharmacology Biochemistry and Behavior, 2010, 95, 308-314.	1.3	34
1793	Sigma receptors: Potential targets for a new class of antidepressant drug. , 2010, 127, 271-282.		109
1794	Voxel-based analyses of gray/white matter volume and diffusion tensor data in major depression. Psychiatry Research - Neuroimaging, 2010, 181, 64-70.	0.9	175
1795	The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats. European Journal of Pharmacology, 2010, 633, 55-61.	1.7	23
1796	Antidepressant-like effect of scopoletin, a coumarin isolated from Polygala sabulosa (Polygalaceae) in mice: Evidence for the involvement of monoaminergic systems. European Journal of Pharmacology, 2010, 643, 232-238.	1.7	123
1797	Emerging structureâ€"function relationships defining monoamine NSS transporter substrate and ligand affinity. Biochemical Pharmacology, 2010, 79, 1083-1091.	2.0	29
1798	Modification of depression by COMT val158met polymorphism in children exposed to early severe psychosocial deprivation. Child Abuse and Neglect, 2010, 34, 387-395.	1.3	45
1799	Rethinking depression and the actions of antidepressants: Uncovering the links between the neural and behavioral elements. Journal of Affective Disorders, 2010, 120, 16-23.	2.0	34
1800	Rs 6313 polymorphism in 5â€hydroxytryptamine receptor 2A gene association with polysymptomatic primary nocturnal enuresis. Journal of Clinical Laboratory Analysis, 2010, 24, 371-375.	0.9	15
1801	Prenatal alcohol exposure: Fetal programming and later life vulnerability to stress, depression and anxiety disorders. Neuroscience and Biobehavioral Reviews, 2010, 34, 791-807.	2.9	290
1802	Synaptic imbalances in endogenous psychoses. BioSystems, 2010, 100, 113-121.	0.9	16
1803	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 1273-1279.	1.4	83
1804	The emerging modern face of mood disorders: a didactic editorial with a detailed presentation of data and definitions. Annals of General Psychiatry, 2010, 9, 14.	1.2	19

#	Article	IF	Citations
1805	Reduced signal transduction by 5â€HT₄ receptors after longâ€term venlafaxine treatment in rats. British Journal of Pharmacology, 2010, 161, 695-706.	2.7	24
1806	Fluoxetine prevents stimulationâ€dependent fatigue of synaptic vesicle exocytosis in hippocampal neurons. Journal of Neurochemistry, 2010, 114, 697-705.	2.1	19
1807	An update on the role of glutamate in the pathophysiology of depression. Acta Psychiatrica Scandinavica, 2010, 122, 192-210.	2.2	82
1808	Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Molecular Psychiatry, 2010, 15, 501-511.	4.1	384
1809	Renalase, a novel soluble FAD-dependent protein, is synthesized in the brain and peripheral nerves. Molecular Psychiatry, 2010, 15, 234-236.	4.1	69
1810	How an Age of Anxiety Became an Age of Depression. Milbank Quarterly, 2010, 88, 112-138.	2.1	60
1814	Renal Organic Cation and Anion Transport: From Physiology to Genes. , 2010, , 23-53.		5
1815	Protective effect of gan mai da zao decoction in unpredictable chronic mild stress-induced behavioral and biochemical alterations. Pharmaceutical Biology, 2010, 48, 1328-1336.	1.3	27
1816	Is Elevated Norepinephrine an Etiological Factor in Some Cases of Alzheimers Disease?. Current Alzheimer Research, 2010, 7, 506-516.	0.7	28
1818	The Role of the Aminergic Systems in the Pathophysiology of Bipolar Disorder. Current Topics in Behavioral Neurosciences, 2010, 5, 107-126.	0.8	5
1819	Caffeine-induced Augmentation of Antidepressant Therapy. Journal of Experimental and Clinical Medicine, 2010, 2, 282-286.	0.2	6
1820	Depressant-like effects of parthenolide in a rodent behavioural antidepressant test battery. Journal of Pharmacy and Pharmacology, 2010, 60, 1643-1650.	1.2	26
1821	Joining the dots: neurobiological links in a functional analysis of depression. Behavioral and Brain Functions, 2010, 6, 73.	1.4	12
1823	Depression as an evolutionary adaptation: Anatomical organisation around the third ventricle. Medical Hypotheses, 2010, 74, 735-740.	0.8	14
1824	Major depression as a potential trigger for Tako Tsubo cardiomyopathy. International Journal of Cardiology, 2010, 140, e40-e42.	0.8	13
1825	Depression, heart rate related variables and cardiovascular disease. International Journal of Psychophysiology, 2010, 78, 80-88.	0.5	108
1826	Increased blood phenylalanine to tyrosine ratio in HIV-1 infection and correction following effective antiretroviral therapy. Brain, Behavior, and Immunity, 2010, 24, 403-408.	2.0	79
1827	Depression and the role of genes involved in dopamine metabolism and signalling. Progress in Neurobiology, 2010, 92, 112-133.	2.8	83

#	Article	IF	Citations
1828	Antidepressant-like action of the ethanolic extract from Tabebuia avellanedae in mice: Evidence for the involvement of the monoaminergic system. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 335-343.	2.5	63
1829	Effect of triiodothyronine on 5-HT1A and 5-HT1B receptor expression in rat forebrain and on latency to feed in the novelty suppressed feeding test. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 632-638.	2.5	6
1830	From synapse to nucleus: Novel targets for treating depression. Neuropharmacology, 2010, 58, 683-693.	2.0	94
1831	Antidepressant-like pharmacological profile of 3-(4-fluorophenylselenyl)-2,5-diphenylselenophene: Involvement of serotonergic system. Neuropharmacology, 2010, 59, 172-179.	2.0	32
1832	Is elevated norepinephrine an etiological factor in some cases of epilepsy?. Seizure: the Journal of the British Epilepsy Association, 2010, 19, 311-318.	0.9	40
1833	Relevance of Norepinephrineâ€“Dopamine Interactions in the Treatment of Major Depressive Disorder. CNS Neuroscience and Therapeutics, 2010, 16, e1-17.	1.9	119
1834	Bringing Clinicians to Bear in the Hypothesis Generation Process. Academic Psychiatry, 2010, 34, 241-242.	0.4	2
1835	Serotonergic and Noradrenergic Modulation of Emotion Processing by Single Dose Antidepressants. Neuropsychopharmacology, 2010, 35, 521-533.	2.8	59
1837	Evidence of involvement of the human Par-4 (PAWR) gene in major depressive disorder. World Journal of Biological Psychiatry, 2011, 12, 288-295.	1.3	3
1838	Why Does Depression Hurt? Ancestral Primary-Process Separation-Distress (PANIC/GRIEF) and Diminished Brain Reward (SEEKING) Processes in the Genesis of Depressive Affect. Psychiatry (New) Tj ETQq1 1 0.784314 rgBT /Overl	8.3	156
1839	Antidepressants in counselling psychology: Relevance, effectiveness and implications for practice. Counselling Psychology Quarterly, 2011, 24, 139-156.	1.5	0
1840	The tale of Rauwolfia Serpentina and the contributions of Asian Psychiatry. Asian Journal of Psychiatry, 2011, 4, 214-215.	0.9	2
1841	The role of the central noradrenergic system in behavioral inhibition. Brain Research Reviews, 2011, 67, 193-208.	9.1	36
1842	Antidepressants elevate GDNF expression and release from C6 glioma cells in a Î²-arrestin1-dependent, CREB interactive pathway. International Journal of Neuropsychopharmacology, 2011, 14, 1289-1300.	1.0	41
1843	The Human Condition. , 2011, , .		16
1844	Noradrenaline release in rodent tissues is inhibited by interleukin-1Î² but is not affected by urotensin II, MCH, NPW and NPFF. Pharmacological Reports, 2011, 63, 102-111.	1.5	9
1845	Functional Neuroimaging in Geriatric Depression. Psychiatric Clinics of North America, 2011, 34, 403-422.	0.7	17
1846	The antidepressant action of imipramine and venlafaxine involves suppression of nitric oxide synthesis. Behavioural Brain Research, 2011, 218, 57-63.	1.2	56

#	Article	IF	Citations
1847	Regulation of dorsal raphe nucleus function by serotonin autoreceptors: A behavioral perspective. Journal of Chemical Neuroanatomy, 2011, 41, 234-246.	1.0	73
1848	Role of 5-HT1A and 5-HT1B receptors in the antidepressant-like effect of piperine in the forced swim test. Neuroscience Letters, 2011, 504, 181-184.	1.0	19
1849	Stuck in a rut: rethinking depression and its treatment. Trends in Neurosciences, 2011, 34, 1-9.	4.2	319
1850	Beyond the serotonin hypothesis: Mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 730-743.	2.5	258
1851	Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1575-1585.	2.5	91
1852	Development of new radiopharmaceuticals for imaging monoamine oxidase B. Nuclear Medicine and Biology, 2011, 38, 933-943.	0.3	40
1853	Relationships between stress, social adaptation, personality traits, brain-derived neurotrophic factor and 3-methoxy-4-hydroxyphenylglycol plasma concentrations in employees at a publishing company in Japan. Psychiatry Research, 2011, 186, 326-332.	1.7	29
1854	Downregulation and Upregulation of Glial Connexins May Cause Synaptic Imbalances Responsible for the Pathophysiology of Bipolar Disorder. CNS Neuroscience and Therapeutics, 2011, 17, 281-293.	1.9	18
1855	The Noradrenergic Action in Antidepressant Treatments: Pharmacological and Clinical Aspects. CNS Neuroscience and Therapeutics, 2011, 17, 723-732.	1.9	74
1856	Biological Alterations in Depression. , 0, , .		3
1857	A New Class of Antidepressant Drugs in the Treatment of Psychiatric Disorders: The Triple Reuptake Inhibitors. , 0, , .		0
1858	Cognitive and Psychiatric Aspects of Parkinsonâ€™s Disease. , 2011, , .		0
1859	Prioritization and Evaluation of Depression Candidate Genes by Combining Multidimensional Data Resources. PLoS ONE, 2011, 6, e18696.	1.1	27
1860	Modification of cortical neuron responses to acetylcholine by viloxazine. Journal of Pharmacy and Pharmacology, 2011, 31, 87-90.	1.2	6
1861	The inhibition of human platelet 5-hydroxytryptamine uptake by tricyclic antidepressive drugs. The relation between structure and potency. Journal of Pharmacy and Pharmacology, 2011, 21, 751-760.	1.2	117
1862	Comparative Studies of the Effects of RS-8359 and Safrazine on Monoamine Oxidase In-vitro and In-vivo in Mouse Brain. Journal of Pharmacy and Pharmacology, 2011, 41, 32-36.	1.2	29
1863	Neurobiology of depression: findings, controversies and perspectives. Neuropsychiatry, 2011, 1, 199-202.	0.4	1
1864	The Role of Serotonin in Depression and Clotting in the Coronary Artery Disease Population. Journal of Cardiovascular Nursing, 2011, 26, 423-429.	0.6	18

#	Article	IF	Citations
1865	New Strategies in the Development of Antidepressants: Towards the Modulation of Neuroplasticity Pathways. Current Pharmaceutical Design, 2011, 17, 521-533.	0.9	46
1866	Pharmacological Properties of 403U76, a New Chemical Class of 5-Hydroxytryptamine- and Noradrenaline-reuptake Inhibitor. Journal of Pharmacy and Pharmacology, 2011, 47, 775-781.	1.2	28
1867	Pharmacogenetics of Antidepressants. Frontiers in Pharmacology, 2011, 2, 6.	1.6	72
1868	The psychological neuroscience of depression: Implications for understanding effects of deep brain stimulation. Scandinavian Journal of Psychology, 2011, 52, 411-419.	0.8	7
1869	Sex Differences in Adolescent Depression: Do Sex Hormones Determine Vulnerability?. Journal of Neuroendocrinology, 2011, 23, 383-392.	1.2	108
1870	The GABAergic deficit hypothesis of major depressive disorder. Molecular Psychiatry, 2011, 16, 383-406.	4.1	687
1871	Affective neuroscientific and neuropsychoanalytic approaches to two intractable psychiatric problems: Why depression feels so bad and what addicts really want. Neuroscience and Biobehavioral Reviews, 2011, 35, 2000-2008.	2.9	90
1872	The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: A microdialyis study in olfactory bulbectomized rats. Pharmacology Biochemistry and Behavior, 2011, 97, 444-452.	1.3	22
1873	Antidepressant activity of methyl jasmonate, a plant stress hormone in mice. Pharmacology Biochemistry and Behavior, 2011, 98, 8-11.	1.3	22
1874	Regulation of monoamine transporters: Role of transporter phosphorylation. , 2011, 129, 220-238.		120
1875	Depression and antidepressants: Insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters. , 2011, 129, 352-368.		169
1876	The functional Val158Met polymorphism in catechol-O-methyltransferase (COMT) is associated with depression and motivation in men from a Swedish population-based study. Journal of Affective Disorders, 2011, 129, 158-166.	2.0	65
1877	Electroconvulsive therapy has acute immunological and neuroendocrine effects in patients with major depressive disorder. Journal of Affective Disorders, 2011, 131, 388-392.	2.0	66
1878	Barriers to achieving treatment goals: A focus on sleep disturbance and sexual dysfunction. Journal of Affective Disorders, 2011, 132, S14-S20.	2.0	19
1879	New views on antidepressant action. Current Opinion in Neurobiology, 2011, 21, 858-865.	2.0	27
1880	Antidepressant-like effect of m-trifluoromethyl-diphenyl diselenide in the mouse forced swimming test involves opioid and serotonergic systems. European Journal of Pharmacology, 2011, 658, 145-149.	1.7	48
1881	Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited. Expert Opinion on Investigational Drugs, 2011, 20, 1107-1130.	1.9	84
1882	Molecular imaging in patients with mood disorders: a review of PET findings. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1367-1380.	3.3	20

#	Article	IF	Citations
1883	Chronic escitalopram treatment restores spatial learning, monoamine levels, and hippocampal long-term potentiation in an animal model of depression. Psychopharmacology, 2011, 214, 477-494.	1.5	54
1884	Synthesis and antidepressant-like activity evaluation of sulphonamides and sulphonyl-hydrazones. Bioorganic and Medicinal Chemistry, 2011, 19, 4295-4306.	1.4	73
1885	Altering BDNF expression by genetics and/or environment: Impact for emotional and depression-like behaviour in laboratory mice. Neuroscience and Biobehavioral Reviews, 2011, 35, 599-611.	2.9	99
1886	Interaction of early environment, gender and genes of monoamine neurotransmission in the aetiology of depression in a large population-based Finnish birth cohort. BMJ Open, 2011, 1, e000087-e000087.	0.8	27
1887	Elevated Plasma Ceramides in Depression. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 215-218.	0.9	74
1888	Increase in Cortical Pyramidal Cell Excitability Accompanies Depression-Like Behavior in Mice: A Transcranial Magnetic Stimulation Study. Journal of Neuroscience, 2011, 31, 16464-16472.	1.7	78
1890	Molecular determinants for selective recognition of antidepressants in the human serotonin and norepinephrine transporters. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12137-12142.	3.3	69
1891	Effects of chronic antidepressant drug administration and electroconvulsive shock on activity of dopaminergic neurons in the ventral tegmentum. International Journal of Neuropsychopharmacology, 2011, 14, 201-210.	1.0	26
1892	Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?. Expert Opinion on Pharmacotherapy, 2011, 12, 2817-2831.	0.9	17
1893	Selectively Bred Rodents as Models of Depression and Anxiety. Current Topics in Behavioral Neurosciences, 2011, 12, 139-187.	0.8	40
1894	Application of Complementary and Alternative Medicine on Neurodegenerative Disorders: Current Status and Future Prospects. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-2.	0.5	15
1895	A Standardized Chinese Herbal Decoction, Kai-Xin-San, Restores Decreased Levels of Neurotransmitters and Neurotrophic Factors in the Brain of Chronic Stress-Induced Depressive Rats. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-13.	0.5	40
1896	Mechanistic Study on the Antidepressant-Like Effect of Danggui-Shaoyao-San, a Chinese Herbal Formula. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-7.	0.5	27
1897	Molecular and Cellular Mechanisms of Antidepressant Action. Current Topics in Behavioral Neurosciences, 2012, 14, 309-325.	0.8	19
1898	Neurobiology of Depression and Novel Antidepressant Drug Targets. Current Pharmaceutical Design, 2012, 18, 5791-5801.	0.9	20
1899	History and Therapeutic Use of MAO-A Inhibitors: A Historical Perspective of MAO-A Inhibitors As Antidepressant Drug. Current Topics in Medicinal Chemistry, 2012, 12, 2275-2282.	1.0	30
1900	Possible prenatal impact of sertraline on human placental glutathione S-transferase-Ï€. Human and Experimental Toxicology, 2012, 31, 457-464.	1.1	5
1901	Agomelatine: a review for general practitioners. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2012, 54, 181-187.	0.2	3

#	Article	IF	Citations
1903	Direct Alteration of a Specific Inhibitory Circuit of the Hippocampus by Antidepressants. Journal of Neuroscience, 2012, 32, 16616-16628.	1.7	47
1906	Recent Developments in the Regulation of Monoamine Oxidase Form and Function: Is the Current Model Restricting Our Understanding of the Breadth of Contribution of Monoamine Oxidase to Brain [dys]Function?. Current Topics in Medicinal Chemistry, 2012, 12, 2163-2176.	1.0	35
1908	Noradrenergic Dysfunction in Depression and Suicide. Frontiers in Neuroscience, 2012, , 29-64.	0.0	19
1910	Antidepressant effects of standardized extract of Centella asiatica L in olfactory bulbectomy model. Biomedicine and Aging Pathology, 2012, 2, 48-53.	0.8	17
1911	Brain-derived neurotrophic factor gene polymorphisms, neurotransmitter levels, and depressive symptoms in an elderly population. Age, 2012, 34, 1529-1541.	3.0	21
1912	Synergistic antidepressant-like action of gaboxadol and escitalopram. European Neuropsychopharmacology, 2012, 22, 751-760.	0.3	11
1913	Î±2 adrenergic receptor dysregulation in depressive disorders: Implications for the neurobiology of depression and antidepressant therapy. Neuroscience and Biobehavioral Reviews, 2012, 36, 2214-2225.	2.9	94
1914	Taurine and glutathione levels in plasma before and after ECT treatment. Psychiatry Research, 2012, 198, 53-57.	1.7	9
1915	Clinical characteristics associated with different strengths of loudness dependence of auditory evoked potentials (LDAEP) in major depressive disorder. Psychiatry Research, 2012, 200, 374-381.	1.7	28
1916	Pathophysiology of Mood Disorders in Temporal Lobe Epilepsy. Revista Brasileira De Psiquiatria, 2012, 34, 233-259.	0.9	36
1917	Fructus Aurantii induced antidepressant effect via its monoaminergic mechanism and prokinetic action in rat. Phytomedicine, 2012, 19, 1101-1107.	2.3	29
1919	Design of novel quinazolinone derivatives as inhibitors for 5HT₇receptor. Journal of Receptor and Signal Transduction Research, 2012, 32, 3-16.	1.3	1
1920	Effect of dialkyl- [2-(1-oxa-3,4,9-triaza-fluoren-2-yl-methoxy)ethyl] amines on biogenic amines: new potential antidepressants. Canadian Journal of Physiology and Pharmacology, 2012, 90, 1585-1590.	0.7	0
1921	Cognitive Mechanisms of Treatment in Depression. Neuropsychopharmacology, 2012, 37, 117-136.	2.8	440
1922	An Evolutionary Framework to Understand Foraging, Wanting, and Desire: The Neuropsychology of the SEEKING System. Neuropsychoanalysis, 2012, 14, 5-39.	0.1	109
1923	The neurobiology of depressionâ€"revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367, 2378-2381.	1.8	155
1924	Genetic Mouse Models of Depression. Current Topics in Behavioral Neurosciences, 2012, 14, 55-78.	0.8	25
1925	Towards a glutamate hypothesis of depression. Neuropharmacology, 2012, 62, 63-77.	2.0	831

#	Article	IF	Citations
1926	Effects of a putative antidepressant with a rapid onset of action in defeated mice with different coping strategies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 38, 317-327.	2.5	18
1927	Antidepressant-like effect of the ethanolic extract from Suanzaorenhehuan Formula in mice models of depression. Journal of Ethnopharmacology, 2012, 141, 257-264.	2.0	55
1928	Key players in major and bipolar depressionâ€"A retrospective analysis of in vivo imaging studies. Behavioural Brain Research, 2012, 232, 358-390.	1.2	35
1929	The antidepressant-like action of a simple selenium-containing molecule, methyl phenyl selenide, in mice. European Journal of Pharmacology, 2012, 690, 119-123.	1.7	23
1930	Targeting the Glutamatergic System to Treat Major Depressive Disorder. Drugs, 2012, 72, 1313-1333.	4.9	181
1931	Depression: A neuropsychoanalytic perspective. International Forum of Psychoanalysis, 2012, 21, 207-213.	0.4	43
1932	CHAPTER 7. The Neurobiology of Depression and Anxiety: How Do We Change from Models of Drug Efficacy to Understanding Mood and Anxiety Disorders?. RSC Drug Discovery Series, 2012, , 159-183.	0.2	2
1933	Involvement of monoaminergic systems in the antidepressant-like effect of Eugenia brasiliensis Lam. (Myrtaceae) in the tail suspension test in mice. Journal of Ethnopharmacology, 2012, 143, 720-731.	2.0	34
1934	Modulatory effects of acupuncture on murine depression-like behavior following chronic systemic inflammation. Brain Research, 2012, 1472, 149-160.	1.1	22
1935	The genetics of selective serotonin reuptake inhibitors. , 2012, 136, 375-400.		38
1936	Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response. Pharmacogenomics Journal, 2012, 12, 78-85.	0.9	27
1937	Monoamine Theories of Depression: Historical Impact on Biomedical Research. Journal of the History of the Neurosciences, 2012, 21, 366-392.	0.1	81
1938	Pharmacogenetics of antidepressants and mood stabilizers. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 106, 715-744.	1.0	9
1939	Preclinical discovery of duloxetine for the treatment of depression. Expert Opinion on Drug Discovery, 2012, 7, 745-755.	2.5	9
1940	Antidepressants and Major Depressive Disorder. , 2012, , .		0
1941	Antioxidants as Antidepressants. CNS Drugs, 2012, 26, 477-490.	2.7	144
1943	The Origins of Human Modernity. Humanities, 2012, 1, 1-53.	0.1	12
1944	Evidence for Transcriptional Factor Dysregulation in the Dorsal Raphe Nucleus of Patients with Major Depressive Disorder. Frontiers in Neuroscience, 2012, 6, 135.	1.4	35

#	Article	IF	Citations
1945	New Approaches for the Therapy of Treatment Refractory Depression. , 2012, , .		0
1947	Neurotransmission in Mood Disorders. , 2012, , .		1
1948	Immune activation and neuropsychiatric symptoms in human immunodeficiency virus type 1 infection. Neurobehavioral HIV Medicine, 2012, , 1.	2.0	1
1949	The genetics of major depression. , 0, , 212-229.		0
1950	Monoamine Oxidase-A Physically Interacts with Presenilin-1(M146V) in the Mouse Cortex. Journal of Alzheimer's Disease, 2012, 28, 403-422.	1.2	18
1951	Memantine: A New Mood Stabilizer for Treatment-Resistant Bipolar Disorders. , 2012, , .		2
1952	Pharmacology and neuroimaging of antidepressant action. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 106, 643-655.	1.0	0
1953	The 5-HT deficiency theory of depression: perspectives from a naturalistic 5-HT deficiency model, the tryptophan hydroxylase 2 ^{Arg} 439 ^{His} knockin mouse. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367, 2444-2459.	1.8	144
1954	Reuptake Inhibitors of Dopamine, Noradrenaline, and Serotonin. Handbook of Experimental Pharmacology, 2012, , 339-347.	0.9	18
1955	Ferulic acid exerts antidepressant-like effect in the tail suspension test in mice: Evidence for the involvement of the serotonergic system. European Journal of Pharmacology, 2012, 679, 68-74.	1.7	77
1956	MicroRNAs and depression. Neurobiology of Disease, 2012, 46, 272-278.	2.1	95
1957	Depression and type 2 diabetes: Inflammatory mechanisms of a psychoneuroendocrine co-morbidity. Neuroscience and Biobehavioral Reviews, 2012, 36, 658-676.	2.9	204
1958	Tobacco addiction and the dysregulation of brain stress systems. Neuroscience and Biobehavioral Reviews, 2012, 36, 1418-1441.	2.9	137
1959	Influence of chronic administration of antidepressant drugs on mRNA for galanin, galanin receptors, and tyrosine hydroxylase in catecholaminergic and serotonergic cell-body regions in rat brain. Neuropeptides, 2012, 46, 81-91.	0.9	27
1960	The PSD-95/nNOS complex: New drugs for depression?. , 2012, 133, 218-229.		68
1961	Ion channels and schizophrenia: a gene set-based analytic approach to GWAS data for biological hypothesis testing. Human Genetics, 2012, 131, 373-391.	1.8	33
1962	New paradigms for treatmentâ€resistant depression. Annals of the New York Academy of Sciences, 2013, 1292, 21-31.	1.8	89
1963	Behavioral Neurobiology of Depression and Its Treatment. Current Topics in Behavioral Neurosciences, 2013, , .	0.8	4

#	Article	IF	Citations
1964	mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants. Neuropharmacology, 2013, 66, 40-52.	2.0	105
1965	Multiple pharmacological actions of Yiqi Huatan Decoction (ç›Šæ°”åŒ–ç—°æ–¹) in a model of depression in rats. Chinese Journal of Integrative Medicine, 2013, 19, 200-205.	0.7	3
1966	Black bile: Are elevated monoamines an etiological factor in some cases of major depression?. Medical Hypotheses, 2013, 80, 823-826.	0.8	12
1967	A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: Do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression?. Neuropharmacology, 2013, 67, 304-317.	2.0	139
1968	Effect of the COMT val158met polymorphism on white matter connectivity in patients with major depressive disorder. Neuroscience Letters, 2013, 545, 35-39.	1.0	68
1969	Social vs. environmental stress models of depression from a behavioural and neurochemical approach. European Neuropsychopharmacology, 2013, 23, 697-708.	0.3	94
1970	Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a Pilot and Replication Study. Molecular Psychiatry, 2013, 18, 332-339.	4.1	165
1971	Potential Mechanisms of Action of Lithium in Bipolar Disorder. CNS Drugs, 2013, 27, 135-153.	2.7	337
1972	Neuronal Network Plasticity and Recovery From Depression. JAMA Psychiatry, 2013, 70, 983.	6.0	142
1973	Endocannabinoid system and mood disorders: Priming a target for new therapies. , 2013, 138, 18-37.		187
1974	Branched-chain amino acids alter neurobehavioral function in rats. American Journal of Physiology - Endocrinology and Metabolism, 2013, 304, E405-E413.	1.8	45
1975	Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB1 receptor antagonists. Journal of Neural Transmission, 2013, 120, 177-186.	1.4	29
1976	The Chlorpromazine Enigma. Journal of the History of the Neurosciences, 2013, 22, 14-29.	0.1	35
1977	Evidence that the anxiolytic-like effects of the beta3 receptor agonist Amibegron involve serotoninergic receptor activity. Pharmacology Biochemistry and Behavior, 2013, 110, 27-32.	1.3	12
1978	Acute neural effects of selective serotonin reuptake inhibitors versus noradrenaline reuptake inhibitors on emotion processing: Implications for differential treatment efficacy. Neuroscience and Biobehavioral Reviews, 2013, 37, 1786-1800.	2.9	57
1979	Neuroimaging Approaches to the Understanding of Depression and the Identification of Novel Antidepressants. , 2013, , 343-411.		3
1980	Antidepressants act directly on astrocytes: Evidences and functional consequences. European Neuropsychopharmacology, 2013, 23, 171-185.	0.3	111
1981	Novel systemically active galanin receptor 2 ligands in depressionâ€like behavior. Journal of Neurochemistry, 2013, 127, 114-123.	2.1	35

#	Article	IF	Citations
1982	Region-specific regulation of 5-HT1B receptors in the rat brain by chronic venlafaxine treatment. Psychopharmacology, 2013, 229, 177-185.	1.5	5
1983	Antidepressant Effect of Aminophylline After Ethanol Exposure. Scientia Pharmaceutica, 2013, 81, 211-222.	0.7	2
1984	The biomedical model of mental disorder: A critical analysis of its validity, utility, and effects on psychotherapy research. Clinical Psychology Review, 2013, 33, 846-861.	6.0	377
1985	Evidence of the involvement of the monoaminergic systems in the antidepressant-like effect of Aloysia gratissima. Journal of Ethnopharmacology, 2013, 148, 914-920.	2.0	18
1986	The discovery of 071031B, a novel serotonin and noradrenaline reuptake inhibitor. Neuroscience Letters, 2013, 544, 68-73.	1.0	17
1987	Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies. Cellular Physiology and Biochemistry, 2013, 31, 761-777.	1.1	5,968
1988	Cytokines as biomarkers in depressive disorder: Current standing and prospects. International Review of Psychiatry, 2013, 25, 592-603.	1.4	124
1989	Role of Hypothalamic-pituitary-adrenal-axis in Affective Disorders: Anti-depressant and Anxiolytic Activity of Partial 5-HT1A Agonist in Adrenalectomised Rats. Indian Journal of Psychological Medicine, 2013, 35, 290-298.	0.6	8
1990	Imbalance between Th17 and Treg Cells May Play an Important Role in the Development of Chronic Unpredictable Mild Stress-Induced Depression in Mice. NeuroImmunoModulation, 2013, 20, 39-50.	0.9	78
1991	The fiery landscape of depression: A review of the inflammatory hypothesis. Pakistan Journal of Medical Sciences, 2013, 29, 877-84.	0.3	10
1992	Amitriptyline may have a supportive role in cancer treatment by inhibiting glutathione S-transferase pi (GST-Ì€) and alpha (GST-Î±). Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 131-136.	2.5	19
1993	Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET. Molecular Psychiatry, 2013, 18, 93-100.	4.1	98
1994	Cognitive abnormalities and hippocampal alterations in monoamine oxidase A and B knockout mice. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12816-12821.	3.3	44
1995	Psychiatry and Fads: Why is This Field Different from All other Fields?. Canadian Journal of Psychiatry, 2013, 58, 555-559.	0.9	8
1996	Quest for Biomarkers of Treatment-Resistant Depression: Shifting the Paradigm Toward Risk. Frontiers in Psychiatry, 2013, 4, 57.	1.3	18
1997	Mitochondrial dysfunction, oxidative stress, and major depressive disorder. Neuropsychiatric Disease and Treatment, 2013, 9, 567.	1.0	104
1998	Mouse models of stress-induced depression-like behavior: stress vulnerability and antidepressant response as traits. , 0, , 179-194.		0
1999	Bipolar Spectrum: A Review of the Concept and a Vision for the Future. Psychiatry Investigation, 2013, 10, 218.	0.7	39

#	Article	IF	Citations
2000	A Pill for the Ill? Patientsâ€™ Reports of Their Experience of the Medical Encounter in the Treatment of Depression. PLoS ONE, 2013, 8, e66338.	1.1	4
2001	Influence of COMT val158met Genotype on the Depressed Brain during Emotional Processing and Working Memory. PLoS ONE, 2013, 8, e73290.	1.1	59
2002	Neural Plasticity and Proliferation in the Generation of Antidepressant Effects: Hippocampal Implication. Neural Plasticity, 2013, 2013, 1-21.	1.0	73
2003	Mitochondrial Functions in Mood Disorders. , 2013, , .		2
2004	Biological Markers and Genetic Factors of Major Depressive Disorder. , 0, , .		0
2006	During the Long Way to Mars: Effects of 520 Days of Confinement (Mars500) on the Assessment of Affective Stimuli and Stage Alteration in Mood and Plasma Hormone Levels. PLoS ONE, 2014, 9, e87087.	1.1	46
2007	Loss of Ahi1 Impairs Neurotransmitter Release and Causes Depressive Behaviors in Mice. PLoS ONE, 2014, 9, e93640.	1.1	23
2008	IFN-ÃŽÂ³ differentially modulates memory-related processes under basal and chronic stressor conditions. Frontiers in Cellular Neuroscience, 2014, 8, 391.	1.8	46
2009	Cerebellar dysregulation and heterogeneity of mood disorders. Neuropsychiatric Disease and Treatment, 2014, 10, 1381.	1.0	5
2010	Antidepressant, anxiolytic, and anticataleptic effects of aqueous leaf extract of Antiaris toxicaria Lesch. (Moraceae) in mice: possible mechanisms of actions. Journal of Basic and Clinical Physiology and Pharmacology, 2014, 25, 429-438.	0.7	2
2011	Changes of Dopamine Transporter Availability in Depressed Patients with and without Anhedonia: A ¹²³I-N-ω-Fluoropropyl-Carbomethoxy-3Î²- (4-Iodophenyl)tropane SPECT Study. Neuropsychobiology, 2014, 70, 235-243.	0.9	18
2013	Positron Emission Tomography Molecular Imaging in Late-Life Depression. Journal of Geriatric Psychiatry and Neurology, 2014, 27, 13-23.	1.2	10
2014	Imaging the pathophysiology of major depressive disorder - from localist models to circuit-based analysis. Biology of Mood & Anxiety Disorders, 2014, 4, 5.	4.7	59
2015	The relationship between the monoaminergic and hormonal systems and endogenous intoxication in mixed anxiety-depressive disorder. Neurochemical Journal, 2014, 8, 311-318.	0.2	0
2016	Stimulants for Treating Bipolar Disorder. Harvard Review of Psychiatry, 2014, 22, 358-362.	0.9	4
2017	The Plasma Concentration of Copper and Prevalence of Depression Were Positively Correlated in Shift Nurses. Biological Research for Nursing, 2014, 16, 175-181.	1.0	10
2018	Low baseline salivary 3-methoxy-4-hydroxyphenylglycol (MHPG) in drug-naÃ¯ve patients with short-illness-duration first episode major depressive disorder. Journal of Affective Disorders, 2014, 161, 4-7.	2.0	3
2019	The effects of acute pharmacological stimulation of the 5-HT, NA and DA systems on the cognitive judgement bias of rats in the ambiguous-cue interpretation paradigm. European Neuropsychopharmacology, 2014, 24, 1103-1111.	0.3	53

#	Article	IF	Citations
2020	Impact of COMT genotype on serotonin-1A receptor binding investigated with PET. Brain Structure and Function, 2014, 219, 2017-2028.	1.2	13
2021	The Antidepressant Fluoxetine Mobilizes Vesicles to the Recycling Pool of Rat Hippocampal Synapses During High Activity. Molecular Neurobiology, 2014, 49, 916-930.	1.9	12
2023	Piperine Reverses Chronic Unpredictable Mild Stress-Induced Behavioral and Biochemical Alterations in Rats. Cellular and Molecular Neurobiology, 2014, 34, 403-408.	1.7	31
2024	Is elevated norepinephrine an etiological factor in some cases of Parkinsonâ€™s disease?. Medical Hypotheses, 2014, 82, 462-469.	0.8	10
2025	Affective Neuroscience Strategies for Understanding and Treating Depression. Clinical Psychological Science, 2014, 2, 472-494.	2.4	68
2026	The bipolar spectrum: Conceptions and misconceptions. Australian and New Zealand Journal of Psychiatry, 2014, 48, 314-324.	1.3	59
2027	Different biogenetic causal explanations and attitudes towards persons with major depression, schizophrenia and alcohol dependence: Is the concept of a chemical imbalance beneficial?. Journal of Affective Disorders, 2014, 168, 224-228.	2.0	53
2028	Mice Genetically Depleted of Brain Serotonin Do Not Display a Depression-like Behavioral Phenotype. ACS Chemical Neuroscience, 2014, 5, 908-919.	1.7	49
2029	Antidepressants that inhibit both serotonin and norepinephrine reuptake impair long-term potentiation in hippocampus. Psychopharmacology, 2014, 231, 4429-4441.	1.5	14
2030	Bias and discriminability during emotional signal detection in melancholic depression. BMC Psychiatry, 2014, 14, 122.	1.1	5
2031	Antagonistic interactions between dexamethasone and fluoxetine modulate morphodynamics and expression of cytokines in astrocytes. Neuroscience, 2014, 280, 318-327.	1.1	10
2032	Stabilizing autism: A Fleckian account of the rise of a neurodevelopmental spectrum disorder. Studies in History and Philosophy of Science Part C:Studies in History and Philosophy of Biological and Biomedical Sciences, 2014, 46, 65-78.	0.8	8
2033	Is elevated norepinephrine an etiological factor in some cases of schizophrenia?. Psychiatry Research, 2014, 215, 497-504.	1.7	32
2034	Antidepressant effects of insulin in streptozotocin induced diabetic mice: Modulation of brain serotonin system. Physiology and Behavior, 2014, 129, 73-78.	1.0	65
2035	Imaging studies on dopamine transporter and depression: A review of literature and suggestions for future research. Journal of Psychiatric Research, 2014, 51, 7-18.	1.5	64
2036	Fluoxetine: a case history of its discovery and preclinical development. Expert Opinion on Drug Discovery, 2014, 9, 567-578.	2.5	116
2037	The Korean medication algorithm for depressive disorder: Second revision. Journal of Affective Disorders, 2014, 167, 312-321.	2.0	21
2038	Serotonergic and noradrenergic systems are implicated in the antidepressant-like effect of ursolic acid in mice. Pharmacology Biochemistry and Behavior, 2014, 124, 108-116.	1.3	43

#	Article	IF	Citations
2039	Guanidine-based Î±2-adrenoceptor ligands: Towards selective antagonist activity. European Journal of Medicinal Chemistry, 2014, 82, 242-254.	2.6	9
2040	Modulation of microglial function by the antidepressant drug venlafaxine 28 November 2014. Interdisciplinary Toxicology, 2014, 7, 201-207.	1.0	21
2041	Properties and use of SSRIs for depressive disorders. The Prescriber, 2014, 25, 24-26.	0.1	1
2042	The COMT gene variant is associated with depression's decreased positive affect symptoms in Chinese adults. PsyCh Journal, 2014, 3, 264-272.	0.5	3
2043	Î±₂-adrenoceptor binding in Flinders-sensitive line compared with Flinders-resistant line and Sprague-Dawley rats. Acta Neuropsychiatrica, 2015, 27, 345-352.	1.0	12
2044	Alterations in Gene Expression in Depression. Advances in Protein Chemistry and Structural Biology, 2015, 101, 97-124.	1.0	3
2050	Supplement of 5-hydroxytryptophan before induction suppresses inflammation and collagen-induced arthritis. Arthritis Research and Therapy, 2015, 17, 364.	1.6	21
2051	Long-term consequences of chronic fluoxetine exposure on the expression of myelination-related genes in the rat hippocampus. Translational Psychiatry, 2015, 5, e642-e642.	2.4	24
2052	Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression. Journal of Clinical Psychopharmacology, 2015, 35, 454-459.	0.7	9
2053	From Physiome to Pathome: A Systems Biology Model of Major Depressive Disorder and the Psycho-Immune-Neuroendocrine Network. Current Psychiatry Reviews, 2015, 11, 32-62.	0.9	20
2054	Ethics of Psychopharmacology. , 2015, , .		0
2055	Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. Therapeutics and Clinical Risk Management, 2015, 11, 1193.	0.9	19
2056	Metabonomic Evaluation of Chronic Unpredictable Mild Stress-Induced Changes in Rats by Intervention of Fluoxetine by HILIC-UHPLC/MS. PLoS ONE, 2015, 10, e0129146.	1.1	18
2057	Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochemical Pharmacology, 2015, 95, 81-97.	2.0	195
2058	Long-term imipramine treatment increases N-methyl-d-aspartate receptor activity and expression via epigenetic mechanisms. European Journal of Pharmacology, 2015, 752, 69-77.	1.7	24
2059	Biomarker approaches in major depressive disorder evaluated in the context of current hypotheses. Biomarkers in Medicine, 2015, 9, 277-297.	0.6	59
2060	Biogenic Amines and the Amino Acids GABA and Glutamate: Relationships with Pain and Depression. Modern Problems of Pharmacopsychiatry, 2015, 30, 67-79.	2.5	39
2061	Diagnosis as a Detriment: A Cognitive Approach to Understanding the Depressive Experience. Ethical Human Psychology and Psychiatry, 2015, 17, 125-134.	0.5	1

#	Article	IF	Citations
2062	The Bipolar Spectrum: Conceptions and Misconceptions. Focus (American Psychiatric Publishing), 2015, 13, 75-84.	0.4	1
2063	Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 125-130.	0.7	25
2064	Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders. European Neuropsychopharmacology, 2015, 25, 599-656.	0.3	113
2065	Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response. Neuroscience and Biobehavioral Reviews, 2015, 51, 164-188.	2.9	214
2066	GABAergic Control of Depression-Related Brain States. Advances in Pharmacology, 2015, 73, 97-144.	1.2	107
2067	Decreased inÂvivo Î±2 adrenoceptor binding in the Flinders Sensitive Line rat model of depression. Neuropharmacology, 2015, 91, 97-102.	2.0	22
2068	Disturbance of hippocampal H₂S generation contributes to CUMS-induced depression-like behavior: involvement in endoplasmic reticulum stress of hippocampus. Acta Biochimica Et Biophysica Sinica, 2015, 47, 285-291.	0.9	29
2069	Antidepressant-like effects of the cannabinoid receptor ligands in the forced swimming test in mice: Mechanism of action and possible interactions with cholinergic system. Behavioural Brain Research, 2015, 284, 24-36.	1.2	55
2070	Adenosine signaling in reserpine-induced depression in rats. Behavioural Brain Research, 2015, 286, 184-191.	1.2	36
2071	The antidepressant-like effect of vagus nerve stimulation is mediated through the locus coeruleus. Journal of Psychiatric Research, 2015, 68, 1-7.	1.5	54
2072	The serotonin transporter in depression: Meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression. Journal of Affective Disorders, 2015, 186, 358-366.	2.0	75
2073	Role of the Endocannabinoid System in Depression: from Preclinical to Clinical Evidence. , 2015, , 97-129.		22
2074	Circuit to Construct Mapping: A Mathematical Tool for Assisting the Diagnosis and Treatment in Major Depressive Disorder. Frontiers in Psychiatry, 2015, 6, 29.	1.3	12
2075	An excitatory synapse hypothesis of depression. Trends in Neurosciences, 2015, 38, 279-294.	4.2	221
2076	Critical periods for the neurodevelopmental processes of externalizing and internalizing. Development and Psychopathology, 2015, 27, 321-346.	1.4	21
2077	Functional and Structural Remodeling of Glutamate Synapses in Prefrontal and Frontal Cortex Induced by Behavioral Stress. Frontiers in Psychiatry, 2015, 6, 60.	1.3	65
2079	Neuroticism and serotonin 5-HT1A receptors in healthy subjects. Psychiatry Research - Neuroimaging, 2015, 234, 1-6.	0.9	26
2080	Antidepressant-like effects of methanolic extract of Bacopa monniera in mice. BMC Complementary and Alternative Medicine, 2015, 15, 337.	3.7	25

#	Article	IF	Citations
2081	Effects of Antidepressants on DSP4/CPT-Induced DNA Damage Response in Neuroblastoma SH-SY5Y Cells. Neurotoxicity Research, 2015, 28, 154-170.	1.3	7
2082	A brief history of the development of antidepressant drugs: From monoamines to glutamate.. Experimental and Clinical Psychopharmacology, 2015, 23, 1-21.	1.3	344
2083	Serotonin: A never-ending story. European Journal of Pharmacology, 2015, 753, 2-18.	1.7	197
2084	Noradrenaline transmission reducing drugs may protect against a broad range of diseases.. Autonomic and Autacoid Pharmacology, 2015, 34, 15-26.	0.5	15
2085	Neurotrophic factor-Î±1 prevents stress-induced depression through enhancement of neurogenesis and is activated by rosiglitazone. Molecular Psychiatry, 2015, 20, 744-754.	4.1	56
2086	Antidepressant-like activity of a new piperazine derivative of xanthone in the forced swim test in mice: The involvement of serotonergic system. Pharmacological Reports, 2015, 67, 160-165.	1.5	32
2087	The effect of central noradrenergic system lesion on dopamine (DA) and serotonin (5-HT) synthesis rate following administration of 5-HT3 receptor ligands in chosen parts of the rat brain. Pharmacological Reports, 2015, 67, 146-151.	1.5	9
2088	Impact of lithium alone and in combination with antidepressants on cytokine production in vitro. Journal of Neural Transmission, 2015, 122, 109-122.	1.4	32
2089	The selective noradrenergic reuptake inhibitor reboxetine restores spatial learning deficits, biochemical changes, and hippocampal synaptic plasticity in an animal model of depression. Journal of Neuroscience Research, 2015, 93, 104-120.	1.3	22
2090	Zinc deficiency in rats is associated with up-regulation of hippocampal NMDA receptor. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 56, 254-263.	2.5	43
2091	8. Antipsychotics. , 2016, , 183-198.		0
2093	The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatric Disease and Treatment, 2016, 12, 541.	1.0	56
2094	The Network Model of Depression as a Basis for New Therapeutic Strategies for Treating Major Depressive Disorder in Parkinsonâ€™s Disease. Frontiers in Human Neuroscience, 2016, 10, 161.	1.0	12
2095	Circuits Regulating Pleasure and Happinessâ€"Mechanisms of Depression. Frontiers in Human Neuroscience, 2016, 10, 571.	1.0	55
2096	Molecular Neurobiology and Promising New Treatment in Depression. International Journal of Molecular Sciences, 2016, 17, 381.	1.8	52
2097	Biphasic Effects of Î±-Asarone on Immobility in the Tail Suspension Test: Evidence for the Involvement of the Noradrenergic and Serotonergic Systems in Its Antidepressant-Like Activity. Frontiers in Pharmacology, 2016, 7, 72.	1.6	17
2099	Using tests and models to assess antidepressant-like activity in rodents. Current Issues in Pharmacy and Medical Sciences, 2016, 29, 61-65.	0.1	4
2100	Depression: Loss of Reinforcers or Loss of Reinforcer Effectiveness? â€“ Republished Article. Behavior Therapy, 2016, 47, 595-599.	1.3	13

#	Article	IF	Citations
2102	The dysregulated brain: consequences of spatial and temporal brain complexity for bipolar disorder pathophysiology and diagnosis. Bipolar Disorders, 2016, 18, 696-701.	1.1	6
2103	Neuroscience and the future for mental health?. Epidemiology and Psychiatric Sciences, 2016, 25, 95-100.	1.8	30
2104	The ubiquitination of serotonin transporter in lymphoblasts derived from fluvoxamine-resistant depression patients. Neuroscience Letters, 2016, 617, 22-26.	1.0	12
2105	Effects of DNA methylation inhibitors and conventional antidepressants on mice behaviour and brain DNA methylation levels. Acta Neuropsychiatrica, 2016, 28, 11-22.	1.0	39
2106	TDO as a therapeutic target in brain diseases. Metabolic Brain Disease, 2016, 31, 737-747.	1.4	32
2108	DNA Damage in Major Psychiatric Diseases. Neurotoxicity Research, 2016, 30, 251-267.	1.3	49
2109	Diagnosis and causal explanation in psychiatry. Studies in History and Philosophy of Science Part C:Studies in History and Philosophy of Biological and Biomedical Sciences, 2016, 60, 15-24.	0.8	21
2110	Relationships between serum BDNF and the antidepressant effect of acute exercise in depressed women. Psychoneuroendocrinology, 2016, 74, 286-294.	1.3	26
2111	The Psycho-Neurology of Cross-Species Affective/Social Neuroscience: Understanding Animal Affective States as a Guide to Development of Novel Psychiatric Treatments. Current Topics in Behavioral Neurosciences, 2016, 30, 109-125.	0.8	15
2112	Major depressive disorder. Nature Reviews Disease Primers, 2016, 2, 16065.	18.1	1,171
2113	History of the Discovery of Antidepressant Drugs. , 2016, , 365-383.		3
2114	Depression-like behavior in rat: Involvement of galanin receptor subtype 1 in the ventral periaqueductal gray. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4726-35.	3.3	35
2115	Chronic Kappa opioid receptor activation modulates NR2B: Implication in treatment resistant depression. Scientific Reports, 2016, 6, 33401.	1.6	18
2116	Reducing central serotonin in adulthood promotes hippocampal neurogenesis. Scientific Reports, 2016, 6, 20338.	1.6	41
2117	Loss of NMDA receptors in dopamine neurons leads to the development of affective disorder-like symptoms in mice. Scientific Reports, 2016, 6, 37171.	1.6	20
2118	Depression, Chemical Imbalances, and Feminism. Journal of Feminist Family Therapy, 2016, 28, 159-173.	0.2	10
2119	An assessment of the catecholamine hypothesis of bipolar disorder. , 0, , 21-42.		1
2121	Traditional and Novel Possible Targets for Antidepressant Drugs. , 2016, , 43-73.		1

#	Article	IF	Citations
2122	The importance of n-6/n-3 fatty acids ratio in the major depressive disorder. Medicina (Lithuania), 2016, 52, 139-147.	0.8	95
2123	Of rodents and humans: A comparative review of the neurobehavioral effects of early life SSRI exposure in preclinical and clinical research. International Journal of Developmental Neuroscience, 2016, 51, 50-72.	0.7	90
2124	The influence of dizocilpine on the reserpine-induced behavioral and neurobiological changes in rats. Neuroscience Letters, 2016, 614, 89-94.	1.0	13
2125	The 5-HT1A receptor in Major Depressive Disorder. European Neuropsychopharmacology, 2016, 26, 397-410.	0.3	138
2126	Novel approaches for the management of depressive disorders. European Journal of Pharmacology, 2016, 771, 236-240.	1.7	35
2127	Palliative medicine specialistsâ€™ causal explanations for depression in the palliative care setting: a qualitative in-depth interview study. BMJ Supportive and Palliative Care, 2016, 6, 178-185.	0.8	3
2128	Neurobiological effects of exercise on major depressive disorder: A systematic review. Neuroscience and Biobehavioral Reviews, 2016, 61, 1-11.	2.9	189
2129	The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature. L'Encephale, 2016, 42, 156-164.	0.3	44
2130	Drugs related to monoamine oxidase activity. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 69, 112-124.	2.5	60
2131	Fluoxetine-induced toxicity results in human placental glutathione S-transferase-‹b›Ï€‹/b›(GST-‹b›Ï€‹/b›) dysfunction. Drug and Chemical Toxicology, 2016, 39, 439-444.	1.2	8
2132	Role of TrkB in the anxiolytic-like and antidepressant-like effects of vagal nerve stimulation: Comparison with desipramine. Neuroscience, 2016, 322, 273-286.	1.1	24
2133	5HT3 receptors: Target for new antidepressant drugs. Neuroscience and Biobehavioral Reviews, 2016, 64, 311-325.	2.9	31
2134	The central nervous norepinephrine network links a diminished sense of emotional well-being to an increased body weight. International Journal of Obesity, 2016, 40, 779-787.	1.6	16
2135	Simultaneous determination of 8 neurotransmitters and their metabolite levels in rat brain using liquid chromatography in tandem with mass spectrometry: Application to the murine Nrf2 model of depression. Clinica Chimica Acta, 2016, 453, 174-181.	0.5	55
2136	Circulating tumour necrosis factor is highly correlated with brainstem serotonin transporter availability in humans. Brain, Behavior, and Immunity, 2016, 51, 29-38.	2.0	42
2137	Microglial dysfunction connects depression and Alzheimerâ€™s disease. Brain, Behavior, and Immunity, 2016, 55, 151-165.	2.0	100
2138	Assessing the connection between organophosphate pesticide poisoning and mental health: A comparison of neuropsychological symptoms from clinical observations, animal models and epidemiological studies. Cortex, 2016, 74, 405-416.	1.1	38
2139	The role of serotonergic, adrenergic and dopaminergic receptors in antidepressant-like effect. Pharmacological Reports, 2016, 68, 263-274.	1.5	63

#	Article	IF	Citations
2140	Effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor, on monoamine system in mice and rats. Journal of Pharmacological Sciences, 2016, 130, 1-7.	1.1	13
2141	Meditate don't medicate: How medical imaging evidence supports the role of meditation in the treatment of depression. Radiography, 2016, 22, e54-e58.	1.1	4
2142	Animal models of major depression and their clinical implications. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 293-310.	2.5	276
2143	Towards a theory of mood function. Philosophical Psychology, 2016, 29, 179-197.	0.5	9
2144	Low-Level Laser Irradiation Improves Depression-Like Behaviors in Mice. Molecular Neurobiology, 2017, 54, 4551-4559.	1.9	61
2145	Regulation of G-protein coupled receptor signalling underpinning neurobiology of mood disorders and depression. Molecular and Cellular Endocrinology, 2017, 449, 82-89.	1.6	18
2146	Antidepressant-like deliverables from the sea: evidence on the efficacy of three different brown seaweeds via involvement of monoaminergic system. Bioscience, Biotechnology and Biochemistry, 2017, 81, 1369-1378.	0.6	10
2147	Aligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery. Neuroscience and Biobehavioral Reviews, 2017, 76, 4-21.	2.9	41
2148	New directions for the treatment of depression: Targeting the photic regulation of arousal and mood (PRAM) pathway. Depression and Anxiety, 2017, 34, 588-595.	2.0	22
2149	Vagal Nerve Stimulation for Treatment-Resistant Depression. Neurotherapeutics, 2017, 14, 716-727.	2.1	136
2150	Ziziphi spinosae lily powder suspension in the treatment of depression-like behaviors in rats. BMC Complementary and Alternative Medicine, 2017, 17, 238.	3.7	30
2151	Estrogen receptor Î² deficiency impairs BDNFâ€“5-HT 2A signaling in the hippocampus of female brain: A possible mechanism for menopausal depression. Psychoneuroendocrinology, 2017, 82, 107-116.	1.3	67
2152	Optogenetics and the Dissection of Neural Circuits Underlying Depression and Substance-use Disorders. , 0, , 257-275.		0
2153	HCN Channel Targets for Novel Antidepressant Treatment. Neurotherapeutics, 2017, 14, 698-715.	2.1	41
2154	Elucidating the aberrant brain regions in bipolar disorder using T1-weighted/T2-weighted magnetic resonance ratio images. Psychiatry Research - Neuroimaging, 2017, 263, 76-84.	0.9	18
2155	Serotonin Dysfunction, Aggressive Behavior, and Mental Illness: Exploring the Link Using a Dimensional Approach. ACS Chemical Neuroscience, 2017, 8, 961-972.	1.7	59
2156	The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Molecular Psychiatry, 2017, 22, 666-679.	4.1	347
2157	Anti-inflammatory and protective effects of MT-031, a novel multitarget MAO-A and AChE/BuChE inhibitor in scopolamine mouse model and inflammatory cells. Neuropharmacology, 2017, 113, 445-456.	2.0	26

#	Article	IF	Citations
2158	Treatment Associated Changes of Functional Connectivity of Midbrain/Brainstem Nuclei in Major Depressive Disorder. Scientific Reports, 2017, 7, 8675.	1.6	61
2159	Leonurine Exerts Antidepressant-Like Effects in the Chronic Mild Stress-Induced Depression Model in Mice by Inhibiting Neuroinflammation. International Journal of Neuropsychopharmacology, 2017, 20, 886-895.	1.0	50
2160	Drug repurposing may generate novel approaches to treating depression. Journal of Pharmacy and Pharmacology, 2017, 69, 1428-1436.	1.2	25
2161	Multitarget botanical pharmacotherapy in major depression. International Clinical Psychopharmacology, 2017, 32, 299-308.	0.9	8
2162	Methylene blue and its analogues as antidepressant compounds. Metabolic Brain Disease, 2017, 32, 1357-1382.	1.4	35
2163	Fatigue and stress reactivity are differently related to cigarette craving and hormone responses to neurotransmitter related drugs in nicotine deprived smokers. Personality and Individual Differences, 2017, 118, 77-83.	1.6	3
2165	Neuropathology of suicide: recent findings and future directions. Molecular Psychiatry, 2017, 22, 1395-1412.	4.1	111
2166	Neurobiology of Chronic Stress-Related Psychiatric Disorders: Evidence from Molecular Imaging Studies. Chronic Stress, 2017, 1, 247054701771091.	1.7	63
2167	Biological hypotheses and biomarkers of bipolar disorder. Psychiatry and Clinical Neurosciences, 2017, 71, 77-103.	1.0	164
2168	Can a systems approach produce a better understanding of mood disorders?. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 3335-3344.	1.1	0
2169	The role of phospholipid as a solubility- and permeability-enhancing excipient for the improved delivery of the bioactive phytoconstituents of Bacopa monnieri. European Journal of Pharmaceutical Sciences, 2017, 108, 23-35.	1.9	26
2170	Cellular and molecular mechanisms triggered by Deep Brain Stimulation in depression: A preclinical and clinical approach. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 73, 1-10.	2.5	29
2171	4. Ein RÃ¼ckblick: Kreative Personen als Urheber bedeutender medizinischer Innovationen. , 2017, , 81-190.		0
2172	Computational Model of Antidepressant Response Heterogeneity as Multi-pathway Neuroadaptation. Frontiers in Pharmacology, 2017, 8, 925.	1.6	10
2173	The Relationships among Tryptophan, Kynurenine, Indoleamine 2,3-Dioxygenase, Depression, and Neuropsychological Performance. Frontiers in Psychology, 2017, 8, 1561.	1.1	58
2174	Serum 25-Hydroxyvitamin D Concentrations and Indicators of Mental Health: An Analysis of the Canadian Health Measures Survey. Nutrients, 2017, 9, 1116.	1.7	19
2175	Psychiatric Disorders. , 2017, , 515-532.		0
2176	From Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder. Frontiers in Cellular Neuroscience, 2017, 11, 305.	1.8	154

#	Article	IF	Citations
2177	Zinc in the Monoaminergic Theory of Depression: Its Relationship to Neural Plasticity. Neural Plasticity, 2017, 2017, 1-18.	1.0	58
2178	Social inequality, scientific inequality, and the future of mental illness. Philosophy, Ethics, and Humanities in Medicine, 2017, 12, 10.	0.7	13
2179	Animal models for bipolar disorder: from bedside to the cage. International Journal of Bipolar Disorders, 2017, 5, 35.	0.8	55
2180	Animal models of maternal depression for monitoring neurodevelopmental changes occurring in dams and offspring. Interdisciplinary Toxicology, 2017, 10, 35-39.	1.0	4
2181	Aldosterone Action on Brain and Behavior. , 2017, , 159-179.		4
2182	Mental Disorders are Not Real: Using Skepticism and Critical Thinking to Challenge Key Myths in the Science of Mental Health. Journal of Mental Disorders and Treatment, 2017, 03, .	0.1	0
2183	Mad Data: Between Symptom and Experience. American Quarterly, 2017, 69, 327-331.	0.1	1
2185	Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease. Trends in Neurosciences, 2018, 41, 211-223.	4.2	212
2186	Does ceasing exercise induce depressive symptoms? A systematic review of experimental trials including immunological and neurogenic markers. Journal of Affective Disorders, 2018, 234, 180-192.	2.0	23
2188	Exploring the sortilin related receptor, SorLA, in depression. Journal of Affective Disorders, 2018, 232, 260-267.	2.0	2
2189	Evaluation of Neurotransmitter Alterations in Four Distinct Brain Regions After Rapid Eye Movement Sleep Deprivation (REMSD) Induced Mania-Like Behaviour in Swiss Albino Mice. Neurochemical Research, 2018, 43, 1171-1181.	1.6	15
2190	Natural Polyphenols and Terpenoids for Depression Treatment: Current Status. Studies in Natural Products Chemistry, 2018, 55, 181-221.	0.8	11
2191	Simultaneous Multiple MS Binding Assays for the Dopamine, Norepinephrine, and Serotonin Transporters. ChemMedChem, 2018, 13, 453-463.	1.6	9
2192	Neuropharmacological characterization of frutalin in mice: Evidence of an antidepressant-like effect mediated by the NMDA receptor/NO/cGMP pathway. International Journal of Biological Macromolecules, 2018, 112, 548-554.	3.6	18
2193	A brief history of antidepressant drug development: from tricyclics to beyond ketamine. Acta Neuropsychiatrica, 2018, 30, 307-322.	1.0	68
2194	Evaluation of antidepressant activity of methanolic extract of Saraca asoca bark in a chronic unpredictable mild stress model. NeuroReport, 2018, 29, 134-140.	0.6	14
2195	Understanding the pathophysiology of depression: From monoamines to the neurogenesis hypothesis model - are we there yet?. Behavioural Brain Research, 2018, 341, 79-90.	1.2	219
2196	Antidepressant Therapy for Depression: An Update. , 2018, , 241-255.		0

#	Article	IF	Citations
2197	Does the 5-HT_{1A} rs6295 polymorphism influence the safety and efficacy of citalopram therapy in the oldest old?. Therapeutic Advances in Drug Safety, 2018, 9, 355-366.	1.0	6
2198	Translational Shifts in Preclinical Models of Depression: Implications for Biomarkers for Improved Treatments. Current Topics in Behavioral Neurosciences, 2018, 40, 169-193.	0.8	8
2199	Applications for Î±-lactalbumin in human nutrition. Nutrition Reviews, 2018, 76, 444-460.	2.6	186
2200	Society and â€˜good womanâ€™: A critical review of gender difference in depression. International Journal of Social Psychiatry, 2018, 64, 396-405.	1.6	42
2201	Antidepressant effects of magnolol in a mouse model of depression induced by chronic corticosterone injection. Steroids, 2018, 135, 73-78.	0.8	53
2202	Antidepressants Rescue Stress-Induced Disruption of Synaptic Plasticity via Serotonin Transporterâ€“Independent Inhibition of L-Type Calcium Channels. Biological Psychiatry, 2018, 84, 55-64.	0.7	33
2203	Assessment of leukocyte activity in mice devoid of the glucocorticoid receptor in the noradrenergic system (GR DBHCre). Immunobiology, 2018, 223, 227-238.	0.8	2
2204	Impact, Diagnosis, Phenomenology, and Biology. Handbook of Experimental Pharmacology, 2018, 250, 3-33.	0.9	0
2205	Interpersonal Maneuvers of Manic Patients. Focus (American Psychiatric Publishing), 2018, 16, 466-471.	0.4	0
2206	Neuropeptide and Small Transmitter Coexistence: Fundamental Studies and Relevance to Mental Illness. Frontiers in Neural Circuits, 2018, 12, 106.	1.4	87
2207	Introductory Chapter: â€œFeel Goodâ€•Chemical Dopamine - Role in Health and Disease. , 2018, , .		0
2208	Of Minds and Brains and Cocreation: Psychopharmaceuticals and Modern Technological Imaginaries. Christian Bioethics, 2018, 24, 224-245.	0.1	2
2210	The engagement of brain cytochrome P450 in the metabolism of endogenous neuroactive substrates: a possible role in mental disorders. Drug Metabolism Reviews, 2018, 50, 415-429.	1.5	35
2211	Psychopharmacology: From serendipitous discoveries to rationale design, but what next?. Brain and Neuroscience Advances, 2018, 2, 239821281881262.	1.8	12
2212	Let The Drugs Lead The Way! On the Unfolding of a Research Program in Psychiatry. Philosophy, Psychiatry and Psychology, 2018, 25, 289-302.	0.2	3
2213	Explaining Biological Depression Theories. Philosophy, Psychiatry and Psychology, 2018, 25, 309-310.	0.2	1
2214	Nicotinamideâ€™s Ups and Downs: Consequences for Fertility, Development, Longevity and Diseases of Poverty and Affluence. International Journal of Tryptophan Research, 2018, 11, 117864691880228.	1.0	2
2215	Depression. Lancet, The, 2018, 392, 2299-2312.	6.3	2,026

#	Article	IF	Citations
2216	Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. Journal of Neural Transmission, 2018, 125, 1719-1733.	1.4	92
2217	Cerebrospinal fluid monoamine metabolite concentrations in depressive disorder: A meta-analysis of historic evidence. Journal of Psychiatric Research, 2018, 105, 137-146.	1.5	37
2218	Clinical implications and electrochemical biosensing of monoamine neurotransmitters in body fluids, in vitro, in vivo, and ex vivo models. Biosensors and Bioelectronics, 2018, 121, 137-152.	5.3	69
2219	Leaves of Spondias mombin L. a traditional anxiolytic and antidepressant: Pharmacological evaluation on zebrafish (Danio rerio). Journal of Ethnopharmacology, 2018, 224, 563-578.	2.0	37
2220	Association of the loudness dependence of auditory evoked potentials with clinical changes to repetitive transcranial magnetic stimulation in patients with depression. Journal of Affective Disorders, 2018, 238, 451-457.	2.0	30
2221	Mice exposed to bisphenol A exhibit depressive-like behavior with neurotransmitter and neuroactive steroid dysfunction. Hormones and Behavior, 2018, 102, 93-104.	1.0	46
2222	Neuroendocrine Abnormalities in Major Depression: An Insight Into Glucocorticoids, Cytokines, and the Kynurenine Pathway. , 2018, , 45-60.		8
2223	Phytochemistry and pharmacology of anti-depressant medicinal plants: A review. Biomedicine and Pharmacotherapy, 2018, 104, 343-365.	2.5	69
2224	Of Drugs and Droogs: Cultural Dynamics, Psychopharmacology, and Neuroscience in Anthony Burgessâ€™s A Clockwork Orange. Literature and Medicine, 2018, 36, 101-123.	0.3	7
2225	Differentially expressed genes related to major depressive disorder and antidepressant response: genome-wide gene expression analysis. Experimental and Molecular Medicine, 2018, 50, 1-11.	3.2	33
2226	Antidepressant-Like Effects of Gyejibokryeong-hwan in a Mouse Model of Reserpine-Induced Depression. BioMed Research International, 2018, 2018, 1-12.	0.9	29
2227	Effects of Monoamines and Antidepressants on Astrocyte Physiology: Implications for Monoamine Hypothesis of Depression. Journal of Experimental Neuroscience, 2018, 12, 117906951878914.	2.3	44
2228	Assessment of Translocator Protein Density, as Marker of Neuroinflammation, in Major Depressive Disorder: A Pilot, Multicenter, Comparative, Controlled, Brain PET Study (INFLADEP Study). Frontiers in Psychiatry, 2018, 9, 326.	1.3	14
2229	Lateral Habenula Gone Awry in Depression: Bridging Cellular Adaptations With Therapeutics. Frontiers in Neuroscience, 2018, 12, 485.	1.4	24
2230	Mitochondria and Mood: Mitochondrial Dysfunction as a Key Player in the Manifestation of Depression. Frontiers in Neuroscience, 2018, 12, 386.	1.4	211
2231	Profiling and Co-expression Network Analysis of Learned Helplessness Regulated mRNAs and lncRNAs in the Mouse Hippocampus. Frontiers in Molecular Neuroscience, 2017, 10, 454.	1.4	18
2232	Regulation of monoamine transporters and receptors by lipid microdomains: implications for depression. Neuropsychopharmacology, 2018, 43, 2165-2179.	2.8	29
2233	The brain-adipocyte-gut network: Linking obesity and depression subtypes. Cognitive, Affective and Behavioral Neuroscience, 2018, 18, 1121-1144.	1.0	35

#	Article	IF	Citations
2234	Mechanisms. , 2018, , 153-176.		0
2235	Sub-chronic treatment with cannabidiol but not with URB597 induced a mild antidepressant-like effect in diabetic rats. Neuroscience Letters, 2018, 682, 62-68.	1.0	23
2236	Pathologic role of nitrergic neurotransmission in mood disorders. Progress in Neurobiology, 2019, 173, 54-87.	2.8	24
2237	Butanol Fraction of Olax Subscorpioidea Produces Antidepressant Effect: Evidence for the Involvement of Monoaminergic Neurotransmission. Drug Research, 2019, 69, 53-60.	0.7	11
2238	Investigation of Antidepressant, Anxiolytic and Sedative Activities of the Aqueous Leaf Extract of Musa sapientum Linn. (Banana; Musaceae). Drug Research, 2019, 69, 136-143.	0.7	4
2239	The intentionality and intelligibility of moods. European Journal of Philosophy, 2019, 27, 118-135.	0.2	12
2240	Cerebral Glucose Metabolism in Patients with Chronic Mental and Cognitive Sequelae after a Single Blunt Mild Traumatic Brain Injury without Visible Brain Lesions. Journal of Neurotrauma, 2019, 36, 641-649.	1.7	26
2241	Depression and schizophrenia viewed from the perspective of amino acidergic neurotransmission: Antipodes of psychiatric disorders. , 2019, 193, 75-82.		11
2242	Dexmedetomidine Alleviates Postpartum Depressive Symptoms following Cesarean Section in Chinese Women: A Randomized Placeboâ€Controlled Study. Pharmacotherapy, 2019, 39, 994-1004.	1.2	24
2243	Effects of regulating gut microbiota on the serotonin metabolism in the chronic unpredictable mild stress rat model. Neurogastroenterology and Motility, 2019, 31, e13677.	1.6	86
2244	120th Anniversary of the Kraepelinian Dichotomy of Psychiatric Disorders. Current Psychiatry Reports, 2019, 21, 65.	2.1	15
2245	Tianeptine, an atypical pharmacological approach to depression. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2019, 12, 170-186.	0.2	9
2246	Comorbid brain disorders associated with diabetes: therapeutic potentials of prebiotics, probiotics and herbal drugs. Translational Medicine Communications, 2019, 4, .	0.5	12
2247	Biological Psychiatry and Psychopharmacology. , 2019, , 397-458.		0
2248	Novel Targets for Fast Antidepressant Responses: Possible Role of Endogenous Neuromodulators. Chronic Stress, 2019, 3, 247054701985808.	1.7	18
2249	Bipolar Disorder: Its Etiology and How to Model in Rodents. Methods in Molecular Biology, 2019, 2011, 61-77.	0.4	24
2250	Monoaminergic system and depression. Cell and Tissue Research, 2019, 377, 107-113.	1.5	101
2251	Fluoxetine induces glucose uptake and modifies glucose transporter palmitoylation in human peripheral blood mononuclear cells. Expert Opinion on Therapeutic Targets, 2019, 23, 883-891.	1.5	15

#	Article	IF	Citations
2252	Neuropsychiatric aspects of Parkinson disease psychopharmacology: Insights from circuit dynamics. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 165, 83-121.	1.0	12
2253	Mental energy: plausible neurological mechanisms and emerging research on the effects of natural dietary compounds. Nutritional Neuroscience, 2021, 24, 850-864.	1.5	5
2254	Computational Analysis of Therapeutic Neuroadaptation to Chronic Antidepressant in a Model of the Monoaminergic Neurotransmitter and Stress Hormone Systems. Frontiers in Pharmacology, 2019, 10, 1215.	1.6	2
2255	Adrenergic Receptors as Pharmacological Targets for Neuroinflammation and Neurodegeneration in Parkinsonâ€™s Disease. , 2019, , .		2
2256	Structure and Gating Dynamics of Na+/Clâ€“ Coupled Neurotransmitter Transporters. Frontiers in Molecular Biosciences, 2019, 6, 80.	1.6	32
2257	A novel electrochemical epinine sensor using amplified CuO nanoparticles and an-hexyl-3-methylimidazolium hexafluorophosphate electrode. New Journal of Chemistry, 2019, 43, 2362-2367.	1.4	246
2258	Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study. Trials, 2019, 20, 34.	0.7	6
2259	Frâ€HMGB1 and dsâ€HMGB1 activate the kynurenine pathway via different mechanisms in association with depressiveâ€like behavior. Molecular Medicine Reports, 2019, 20, 359-367.	1.1	11
2260	P2X7 Receptor Signaling in Stress and Depression. International Journal of Molecular Sciences, 2019, 20, 2778.	1.8	84
2261	Nitric oxide: Antidepressant mechanisms and inflammation. Advances in Pharmacology, 2019, 86, 121-152.	1.2	29
2262	Rubiscolin-6, a Î´-Opioid Peptide from Spinach RuBisCO, Exerts Antidepressant-Like Effect in Restraint-Stressed Mice. Journal of Nutritional Science and Vitaminology, 2019, 65, 202-204.	0.2	13
2263	The Role of Chemokines in the Pathophysiology of Major Depressive Disorder. International Journal of Molecular Sciences, 2019, 20, 2283.	1.8	94
2264	Curcumin in Depressive Disorders. , 2019, , 459-477.		0
2265	An East Meets West Approach to the Understanding of Emotion Dysregulation in Depression: From Perspective to Scientific Evidence. Frontiers in Psychology, 2019, 10, 574.	1.1	17
2266	Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms. Journal of Chemical Neuroanatomy, 2019, 98, 104-116.	1.0	57
2267	Direct effect of common mental disorders on xerostomia in adults estimated by marginal structural models: A populationâ€based study. Community Dentistry and Oral Epidemiology, 2019, 47, 267-273.	0.9	2
2268	Cortical and striatal serotonin transporter binding in a genetic rat model of depression and in response to electroconvulsive stimuli. European Neuropsychopharmacology, 2019, 29, 493-500.	0.3	3
2269	Ceasing exercise induces depression-like, anxiety-like, and impaired cognitive-like behaviours and altered hippocampal gene expression. Brain Research Bulletin, 2019, 148, 118-130.	1.4	19

#	Article	IF	Citations
2270	Influence of carbon nanostructure and oxygen moieties on dopamine adsorption and charge transfer kinetics at glassy carbon surfaces. Electrochimica Acta, 2019, 304, 221-230.	2.6	21
2271	Impacts of Psychological Stress on Osteoporosis: Clinical Implications and Treatment Interactions. Frontiers in Psychiatry, 2019, 10, 200.	1.3	60
2272	Child and Adolescent Depression: A Review of Theories, Evaluation Instruments, Prevention Programs, and Treatments. Frontiers in Psychology, 2019, 10, 543.	1.1	132
2273	Overcoming Resistance to Selective Serotonin Reuptake Inhibitors: Targeting Serotonin, Serotonin-1A Receptors and Adult Neuroplasticity. Frontiers in Neuroscience, 2019, 13, 404.	1.4	29
2274	Catecholamines: Knowledge and understanding in the 1960s, now, and in the future. Brain and Neuroscience Advances, 2019, 3, 239821281881068.	1.8	12
2275	Patient Assessment in Clinical Pharmacy. , 2019, , .		6
2278	Reviews on Biomarker Studies in Psychiatric and Neurodegenerative Disorders. Advances in Experimental Medicine and Biology, 2019, , .	0.8	6
2279	The Role of Biomarkers in Psychiatry. Advances in Experimental Medicine and Biology, 2019, 1118, 135-162.	0.8	29
2280	The Monoamine Hypothesis of Depression Revisited: Could It Mechanistically Novel Antidepressant Strategies?. , 2019, , 63-73.		12
2281	History of Psychopharmacology. Annual Review of Clinical Psychology, 2019, 15, 25-50.	6.3	51
2282	Proteomic Markers for Depression. Advances in Experimental Medicine and Biology, 2019, 1118, 191-206.	0.8	11
2283	Dopamine in psychiatry: a historical perspective. Journal of Neural Transmission, 2019, 126, 473-479.	1.4	9
2284	Resistant Depression. , 0, , .		0
2286	Reactive Depression: Lost in Translation!. Journal of Nervous and Mental Disease, 2019, 207, 755-759.	0.5	3
2287	Genetic variants in major depressive disorder: From pathophysiology to therapy. , 2019, 194, 22-43.		57
2288	The possible beneficial effects of creatine for the management of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 89, 193-206.	2.5	28
2289	Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments. International Journal of Neuropsychopharmacology, 2019, 22, 119-135.	1.0	116
2290	Is Autophagy Involved in the Diverse Effects of Antidepressants?. Cells, 2019, 8, 44.	1.8	29

#	Article	IF	Citations
2291	A gender-specific COMT haplotype contributes to risk modulation rather than disease severity of major depressive disorder in a Chinese population. Journal of Affective Disorders, 2019, 246, 376-386.	2.0	6
2292	Tianeptina, un abordaje farmacolÃ³gico atÃpico de la depresiÃ³n. Revista De PsiquiatrÃa Y Salud Mental, 2019, 12, 170-186.	1.0	18
2293	Mir363-3p attenuates post-stroke depressive-like behaviors in middle-aged female rats. Brain, Behavior, and Immunity, 2019, 78, 31-40.	2.0	25
2294	The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography. Brain Stimulation, 2019, 12, 714-723.	0.7	24
2295	Supplementation of dietary non-digestible oligosaccharides from birth onwards improve social and reduce anxiety-like behaviour in male BALB/c mice. Nutritional Neuroscience, 2020, 23, 896-910.	1.5	27
2296	Computational modeling of the monoaminergic neurotransmitter and male neuroendocrine systems in an analysis of therapeutic neuroadaptation to chronic antidepressant. European Neuropsychopharmacology, 2020, 31, 86-99.	0.3	0
2297	Elevated expression of unfolded protein response genes in the prefrontal cortex of depressed subjects: Effect of suicide. Journal of Affective Disorders, 2020, 262, 229-236.	2.0	19
2298	The Neurobiology of Mixed States. Psychiatric Clinics of North America, 2020, 43, 139-151.	0.7	9
2299	Stress hypothesis overload: 131 hypotheses exploring the role of stress in tradeoffs, transitions, and health. General and Comparative Endocrinology, 2020, 288, 113355.	0.8	51
2300	Î²-Catenin Role in the Vulnerability/Resilience to Stress-Related Disorders Is Associated to Changes in the Serotonergic System. Molecular Neurobiology, 2020, 57, 1704-1715.	1.9	4
2301	Opioid receptor modulation of neural circuits in depression: What can be learned from preclinical data?. Neuroscience and Biobehavioral Reviews, 2020, 108, 658-678.	2.9	25
2302	An investigation into serotonergic and environmental interventions against depression in a simulated delayed reward paradigm. Adaptive Behavior, 2020, 28, 241-260.	1.1	1
2303	Therapeutic Potential of Hericium erinaceus for Depressive Disorder. International Journal of Molecular Sciences, 2020, 21, 163.	1.8	69
2304	A Proposed Role for Pro-Inflammatory Cytokines in Damaging Behavior in Pigs. Frontiers in Veterinary Science, 2020, 7, 646.	0.9	24
2305	Molecular mechanisms of psychiatric diseases. Neurobiology of Disease, 2020, 146, 105136.	2.1	21
2306	Glucocorticoids in the Physiological and Transcriptional Regulation of 5-HT1A Receptor and the Pathogenesis of Depression. Neuroscientist, 2022, 28, 59-68.	2.6	11
2307	Fifty Years of Research on Schizophrenia: The Ascendance of the Glutamatergic Synapse. American Journal of Psychiatry, 2020, 177, 1119-1128.	4.0	34
2308	The genetic architecture of human brainstem structures and their involvement in common brain disorders. Nature Communications, 2020, 11, 4016.	5.8	26

#	Article	IF	Citations
2309	Antidepressant and Anti-Neuroinflammatory Effects of Bangpungtongsung-San. Frontiers in Pharmacology, 2020, 11, 958.	1.6	23
2310	Hopelessness, Dissociative Symptoms, and Suicide Risk in Major Depressive Disorder: Clinical and Biological Correlates. Brain Sciences, 2020, 10, 519.	1.1	26
2311	Noradrenergic Source of Dopamine Assessed by Microdialysis in the Medial Prefrontal Cortex. Frontiers in Pharmacology, 2020, 11, 588160.	1.6	17
2312	Dualism and the â€˜difficult patientâ€™: why integrating neuroscience matters. BJ Psych Advances, 2020, 26, 327-330.	0.5	4
2313	Effects of EGCG on depression-related behavior and serotonin concentration in a rat model of chronic unpredictable mild stress. Food and Function, 2020, 11, 8780-8787.	2.1	22
2314	Nicotine Rescues Depressive-like Behaviors via Î±7-type Nicotinic Acetylcholine Receptor Activation in CaMKIV Null Mice. Molecular Neurobiology, 2020, 57, 4929-4940.	1.9	11
2315	Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets. Expert Opinion on Therapeutic Targets, 2020, 24, 1187-1209.	1.5	11
2316	Toward Circuit Mechanisms of Pathophysiology in Depression. American Journal of Psychiatry, 2020, 177, 381-390.	4.0	77
2317	Low dopamine transporter binding in the nucleus accumbens in geriatric patients with severe depression. Psychiatry and Clinical Neurosciences, 2020, 74, 424-430.	1.0	18
2318	A Brief History of Psychopharmacology. , 2020, , 1-34.		0
2319	Erxian decoction, a famous Chinese medicine formula, antagonizes corticosterone-induced injury in PC12 cells, and improves depression-like behaviours in mice. Pharmaceutical Biology, 2020, 58, 498-509.	1.3	14
2320	GSK3Î²: A Master Player in Depressive Disorder Pathogenesis and Treatment Responsiveness. Cells, 2020, 9, 727.	1.8	42
2321	Global cortical hypoexcitability of the dominant hemisphere in major depressive disorder: A transcranial magnetic stimulation study. Neurophysiologie Clinique, 2020, 50, 175-183.	1.0	11
2322	The role of vitamin C in stress-related disorders. Journal of Nutritional Biochemistry, 2020, 85, 108459.	1.9	60
2323	Citalopram-induced pathways regulation and tentative treatment-outcome-predicting biomarkers in lymphoblastoid cell lines from depression patients. Translational Psychiatry, 2020, 10, 210.	2.4	7
2324	Cortisol and Major Depressive Disorderâ€"Translating Findings From Humans to Animal Models and Back. Frontiers in Psychiatry, 2019, 10, 974.	1.3	123
2325	Topologically Guided Prioritization of Candidate Gene Transcripts Coexpressed with the 5-HT1A Receptor by Combining In Vivo PET and Allen Human Brain Atlas Data. Cerebral Cortex, 2020, 30, 3771-3780.	1.6	10
2326	Antidepressants in inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 184-192.	8.2	47

#	Article	IF	Citations
2327	Molecular docking utilising the OliveNetâ„¢ library reveals novel phenolic compounds which may potentially target key proteins associated with major depressive disorder. Computational Biology and Chemistry, 2020, 86, 107234.	1.1	2
2328	Deep Brain Stimulation of the Medial Forebrain Bundle in a Rodent Model of Depression: Exploring Dopaminergic Mechanisms with Raclopride and Micro-PET. Stereotactic and Functional Neurosurgery, 2020, 98, 8-20.	0.8	15
2329	A hypothesis of monoamine (5-HT) â€“ Glutamate/GABA long neural circuit: Aiming for fast-onset antidepressant discovery. , 2020, 208, 107494.		80
2330	Low-Dose Ketamine Improves LPS-Induced Depression-like Behavior in Rats by Activating Cholinergic Anti-inflammatory Pathways. ACS Chemical Neuroscience, 2020, 11, 752-762.	1.7	26
2331	Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications. Journal of Neurology, 2020, 267, 2042-2053.	1.8	20
2332	Serious infection may systemically increase noradrenergic signaling and produce psychological effects. Medical Hypotheses, 2020, 139, 109692.	0.8	12
2333	Circuits and functions of the lateral habenula in health and in disease. Nature Reviews Neuroscience, 2020, 21, 277-295.	4.9	269
2334	Stress-Induced Morphological, Cellular and Molecular Changes in the Brainâ€”Lessons Learned from the Chronic Mild Stress Model of Depression. Cells, 2020, 9, 1026.	1.8	34
2335	On the diagnostic and neurobiological origins of bipolar disorder. Translational Psychiatry, 2020, 10, 118.	2.4	7
2336	Ventricular volume, white matter alterations and outcome of major depression and their relationship to endocrine parameters â€“ A pilot study. World Journal of Biological Psychiatry, 2021, 22, 104-118.	1.3	9
2337	In vitro characterization of the serotonin biosynthesis pathway by CEST MRI. Magnetic Resonance in Medicine, 2020, 84, 2389-2399.	1.9	4
2338	New agents and perspectives in the pharmacological treatment of major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 106, 110157.	2.5	13
2339	Benefits of animal models to understand the pathophysiology of depressive disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 106, 110049.	2.5	14
2340	Neuromodulation in Psychiatric disorders: Experimental and Clinical evidence for reward and motivation network Deep Brain Stimulation: Focus on the medial forebrain bundle. European Journal of Neuroscience, 2021, 53, 89-113.	1.2	23
2341	Microglia in depression: current perspectives. Science China Life Sciences, 2021, 64, 911-925.	2.3	131
2342	Genetically encoded sensors enable micro- and nano-scopic decoding of transmission in healthy and diseased brains. Molecular Psychiatry, 2021, 26, 443-455.	4.1	9
2343	Acute Citalopram administration modulates anxiety in response to the context associated with a robotic stimulus in zebrafish. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 108, 110172.	2.5	9
2344	Early Life Adversity as a Moderator of Symptom Change following Selective Serotonin Reuptake Inhibitors and Cognitive Behavioral Therapy. Cognitive Therapy and Research, 2021, 45, 343-354.	1.2	2

#	Article	IF	Citations
2346	Brain Imaging and the Mechanisms of Antidepressant Action. , 2021, , 248-260.		0
2347	Brain Imaging of Reward Dysfunction in Unipolar and Bipolar Disorders. , 2021, , 39-48.		0
2348	Molecular Imaging of Dopamine and Antipsychotics in Bipolar Disorder. , 2021, , 236-247.		0
2349	The neural substrates of different depression symptoms: Animal and human studies. , 2021, , 59-79.		1
2350	Amine Precursors in Depressive Disorders and the Blood-Brain Barrier. , 2021, , 1-40.		1
2351	Treatment resistant depression. , 2021, , 33-84.		0
2352	Magnetoencephalography Studies in Mood Disorders. , 2021, , 192-205.		0
2354	Functional Near-Infrared Spectroscopy Studies in Mood Disorders. , 2021, , 166-174.		0
2356	Neuroimaging Studies of Effects of Psychotherapy in Depression. , 2021, , 261-272.		0
2357	Elevated Brain Fatty Acid Amide Hydrolase Induces Depressive-Like Phenotypes in Rodent Models: A Review. International Journal of Molecular Sciences, 2021, 22, 1047.	1.8	13
2358	Indian Rauwolfia research led to the evolution of neuropsychopharmacology & the 2000 Nobel Prize (Part II). Indian Journal of Medical Research, 2021, .	0.4	1
2359	Using iPSC Models to Understand the Role of Estrogen in Neuronâ€“Glia Interactions in Schizophrenia and Bipolar Disorder. Cells, 2021, 10, 209.	1.8	7
2360	Neuroimaging Brain Inflammation in Mood Disorders. , 2021, , 121-134.		0
2361	An Overview of Machine Learning Applications in Mood Disorders. , 2021, , 206-218.		0
2362	Role of central serotonin and noradrenaline interactions in the antidepressantsâ€™ action: Electrophysiological and neurochemical evidence. Progress in Brain Research, 2021, 259, 7-81.	0.9	5
2363	Atomoxetine (Strattera)-Induced Pathologic Laughing in a Patient With Pontine Hemorrhage: A Case Report. Clinical Neuropharmacology, 2021, 44, 77-79.	0.2	0
2364	â€œNovel Psychopharmacology for Depressive Disordersâ€• Advances in Experimental Medicine and Biology, 2021, 1305, 449-461.	0.8	12
2365	Recommended resources on the neuroscience of depression: Genetics, cell biology, neurology, behavior, and diet. , 2021, , 531-537.		2

#	Article	IF	Citations
2366	Between Temperament and Psychopathology: Examples from Neuropharmacological Challenge Tests in Healthy Humans. Neuropsychobiology, 2021, 80, 84-100.	0.9	4
2367	Electrophysiological Biomarkers for Mood Disorders. , 2021, , 175-191.		1
2368	Integrating Endocannabinoid Signalling In Depression. Journal of Molecular Neuroscience, 2021, 71, 2022-2034.	1.1	12
2369	SSRIs and Non-SSRIs (through 1999): Case Histories of Significant Medical Advances. SSRN Electronic Journal, 0, , .	0.4	0
2370	Antidepressant Drugs. , 2021, , .		0
2371	Memantine in neurological disorders â€“ schizophrenia and depression. Journal of Molecular Medicine, 2021, 99, 327-334.	1.7	27
2372	Neuroanatomical Findings in Bipolar Disorder. , 2021, , 16-27.		0
2373	Imaging Glutamatergic and GABAergic Abnormalities in Mood Disorders. , 2021, , 105-120.		0
2374	Magnetic Resonance Spectroscopy Investigations of Bioenergy and Mitochondrial Function in Mood Disorders. , 2021, , 83-104.		0
2375	Brain Imaging Methods in Mood Disorders. , 2021, , 1-6.		0
2376	Effects of Lithium on Brain Structure in Bipolar Disorder. , 2021, , 219-235.		1
2377	Update on GPCR-based targets for the development of novel antidepressants. Molecular Psychiatry, 2021, , .	4.1	21
2378	Cannabidiol antidepressant-like effect in the lipopolysaccharide model in mice: Modulation of inflammatory pathways. Biochemical Pharmacology, 2021, 185, 114433.	2.0	31
2379	Modeling heritability of temperamental differences, stress reactivity, and risk for anxiety and depression: Relevance to research domain criteria (RDoC). European Journal of Neuroscience, 2022, 55, 2076-2107.	1.2	5
2380	Role of the Intestinal Microbiome, Intestinal Barrier and Psychobiotics in Depression. Nutrients, 2021, 13, 927.	1.7	55
2381	Role of 5-Hydroxytryptamine and Intestinal Flora on Depressive-Like Behavior Induced by Lead Exposure in Rats. BioMed Research International, 2021, 2021, 1-14.	0.9	6
2382	Reduced Plasma Dopamine-Î²-Hydroxylase Activity Is Associated With the Severity of Bipolar Disorder: A Pilot Study. Frontiers in Psychiatry, 2021, 12, 566091.	1.3	5
2383	Heterogeneity of the mechanisms of action of antidepressants. V M Bekhterev Review of Psychiatry and Medical Psychology, 2021, , 11-17.	0.1	0

#	Article	IF	Citations
2385	Measuring maniaâ€like elevated mood through amphetamineâ€induced 50â€kHz ultrasonic vocalizations in rats. British Journal of Pharmacology, 2022, 179, 4201-4219.	2.7	19
2386	Ketamine and the Future of Rapid-Acting Antidepressants. Annual Review of Clinical Psychology, 2021, 17, 207-231.	6.3	40
2387	Re-assessing the catecholamine hypothesis of depression: the case of melancholic depression. Molecular Psychiatry, 2021, 26, 6121-6124.	4.1	6
2388	DNA methylation in stress and depression: from biomarker to therapeutics. Acta Neuropsychiatrica, 2021, 33, 217-241.	1.0	11
2389	The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics. Revista Brasileira De Psiquiatria, 2022, 44, 81-93.	0.9	2
2390	Antidepressant-like effect of Campomanesia xanthocarpa seeds in mice: Involvement of the monoaminergic system. Journal of Traditional and Complementary Medicine, 2021, , .	1.5	2
2391	Molecular imaging of the serotonin transporter availability and occupancy by antidepressant treatment in late-life depression. Neuropharmacology, 2021, 194, 108447.	2.0	10
2392	Integrating the monoamine and cytokine hypotheses of depression: Is histamine the missing link?. European Journal of Neuroscience, 2022, 55, 2895-2911.	1.2	11
2393	Potential Role of Adult Hippocampal Neurogenesis in Traumatic Brain Injury. Current Medicinal Chemistry, 2022, 29, 3392-3419.	1.2	5
2394	Selective Serotonin Reuptake Inhibitors and Clozapine: Clinically Relevant Interactions and Considerations. Neurology International, 2021, 13, 445-463.	1.3	12
2395	Are Noradrenergic Transmission Reducing Drugs Antidepressants?. Frontiers in Behavioral Neuroscience, 2021, 15, 673634.	1.0	1
2396	Neuroimaging Biomarkers in Pediatric Mood Disorders. , 2021, , 28-38.		0
2397	Neuroanatomical Findings in Unipolar Depression and the Role of the Hippocampus. , 2021, , 7-15.		0
2398	Functional Connectome in Bipolar Disorder. , 2021, , 59-82.		0
2399	Resting-State Functional Connectivity in Unipolar Depression. , 2021, , 49-58.		0
2400	Imaging Genetic and Epigenetic Markers in Mood Disorders. , 2021, , 135-150.		0
2401	fMRI Neurofeedback as Treatment for Depression. , 2021, , 151-165.		0
2402	Psychopharmacologic Agents in Child Psychiatry. Archives of General Psychiatry, 1966, 14, 472.	13.8	13

#	Article	IF	Citations
2403	Depression and MHPG Excretion. Archives of General Psychiatry, 1972, 26, 246.	13.8	145
2404	Afternoon Continuous Plasma Levels of 3-Methoxy-4-hydroxyphenylglycol and Age. Archives of General Psychiatry, 1987, 44, 804.	13.8	20
2405	No Abnormality in the Gene for the G Protein Stimulatory Î± Subunit in Patients With Bipolar Disorder. Archives of General Psychiatry, 1997, 54, 44.	13.8	52
2406	The differential diagnosis of depression. Relevance of positron emission tomography studies of cerebral glucose metabolism to the bipolar-unipolar dichotomy. JAMA - Journal of the American Medical Association, 1987, 258, 1368-1374.	3.8	68
2409	Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depression and Anxiety, 2000, 12, 2-19.	2.0	510
2410	The Emotion of Pain and its Chemistry. Novartis Foundation Symposium, 1979, , 305-313.	1.2	2
2411	The role of monoamines and acetylcholine-containing neurons in the regulation of the sleep-waking cycle. , 1972, 64, 166-307.		443
2412	Biological Psychiatry in the Nineteenth and Twentieth Centuries. , 2008, , 381-418.		8
2413	Neuroendocrine Markers of CNS Drug Effects. , 1981, , 3-19.		1
2414	Relationships between receptor affinities of different antidepressants and their clinical profiles. , 1983, , 251-267.		4
2415	Antidepressants and â^•adrenoceptors. , 1983, , 268-287.		5
2416	Trans-synaptic mechanisms in the action of imipramine. , 1983, , 19-31.		3
2417	Defective Second-messenger Function in the Etiology of Endogenous Depression: Novel Therapeutic Approaches. , 1988, , 277-293.		5
2418	5-HT and Depression: the Present Position. , 1988, , 120-136.		12
2419	Regulation of 5-hydroxytryptamine (5HT) uptake: endocoid modulators and the action of imipramine. , 1984, , 109-116.		3
2420	Peripheral Biological Markers for Mood Disorders. , 2009, , 121-149.		2
2421	The Effect of Sex Steroids on Brain Mechanisms Relating to Mood and Sexuality. CPOBGYN Clinical Perspectives in Obstetrics and Gynecology, 1994, , 327-333.	0.1	3
2422	Cognitive Behavior Modification: The Clinical Application of Cognitive Strategies. Springer Series in Cognitive Development, 1983, , 221-266.	2.8	5

#	Article	IF	Citations
2423	Secondary Amenorrhea and the Menopause. , 1987, , 369-386.		2
2424	Psychological Effects of Cholinomimetic Agents. , 1979, , 3-14.		36
2425	Affective Changes with Deanol. , 1979, , 33-44.		1
2426	MHPG, Amitriptyline and Depression: A Collaborative Study. , 1977, , 215-224.		5
2427	Stress, Brain Adenosine Signaling, and Fatigue-Related Behavioral Processes. , 2013, , 535-558.		5
2428	Pathophysiology of Mood Disorders and Mechanisms of Action of Antidepressants and Mood Stabilizers. , 2013, , 103-134.		2
2429	Alcohol- and Aldehyde-Dehydrogenase: Modulation By Biogenic Amine Metabolites, Neuropeptides and Psychoactive Agents. Advances in Experimental Medicine and Biology, 1993, 328, 591-603.	0.8	1
2431	The Role of Noradrenaline in Depression and its Therapy. , 1997, , 193-196.		1
2432	The Affective Disorders. , 1984, , 349-381.		6
2433	The Biochemistry of Affective Disorders. , 1972, , 371-416.		5
2434	Brain Reinforcement Centers and Psychoactive Drugs. , 1978, , 25-76.		8
2436	Atypical Cycloid Psychoses. , 1982, , 259-291.		3
2439	Brain Centers of Reinforcement and the Effects of Alcohol. , 1972, , 85-106.		7
2440	Norepinephrine in Cerebrospinal Fluid. , 1980, , 141-152.		14
2441	Cerebrospinal Fluid Studies of Neurotransmitter Function in Manic and Depressive Illness. , 1980, , 685-717.		53
2442	Brain-Endocrine Interaction: Are Some Effects of ACTH and Adrenocortical Hormones on Neuroendocrine Regulation and Behaviour Mediated Via Central Catecholamine Neurons?. , 1973, , 409-425.		6
2443	Lithium and Depression. , 1973, , 253-267.		21
2444	Neurochemical Changes Elicited by Stress. , 1978, , 119-172.		75

#	Article	IF	Citations
2445	The Biology of Affective Illness: Amine Neurotransmitters and Drug Response. , 1978, , 41-73.		7
2446	Norepinephrine Metabolism in Depressive Disorders: Implications for a Biochemical Classification of Depressions. , 1978, , 75-101.		5
2447	Biology of the Striatum. , 1973, , 333-350.		22
2448	Catecholamines and Affective Illness: Studies with L-DOPA and Alpha-Methyl-Para-Tyrosine. Advances in Behavioral Biology, 1971, , 135-161.	0.2	8
2449	Effects of Tricyclic Antidepressants on Norepinephrine Metabolism: Basic and Clinical Studies. Advances in Behavioral Biology, 1971, , 215-236.	0.2	14
2450	The Catecholamines: Possible Role in Affect, Mood, and Emotional Behavior in Man and Animals. , 1975, , 73-117.		12
2451	Catecholamines and Depression: A Further Specification of the Catecholamine Hypothesis of the Affective Disorders. , 1975, , 119-133.		36
2452	The Limbic-Hypothalamic-Pituitary-Adrenal System and Human Behavior. , 1978, , 109-145.		13
2453	Approaches to Brain Amines in Psychiatric Patients: A Reevaluation of Cerebrospinal Fluid Studies. , 1978, , 147-185.		28
2454	Amine Hypotheses of Affective Disorders. , 1978, , 187-297.		60
2455	Impulse Problems and Drug Addiction: Cause and Effect Relationships. , 1979, , 97-112.		6
2456	Recognition Sites for Antidepressant Drugs. , 1984, , 307-330.		3
2457	Presentation of Depression in an Emergency Setting. , 1984, , 219-232.		1
2458	Agonist-Stimulation of Cerebral Phosphoinositide Turnover Following Long-Term Treatment with Antidepresants. Advances in Experimental Medicine and Biology, 1987, 221, 531-547.	0.8	9
2459	The Use of Antidepressant Drugs in the Elderly Patient. Advances in Behavioral Biology, 1973, , 225-237.	0.2	4
2460	Affective Changes Associated with L-DOPA Therapy. Advances in Behavioral Biology, 1973, , 97-104.	0.2	1
2462	Nutrition and Childhood Neuropsychological Disorders. Critical Issues in Neuropsychology, 1988, , 291-335.	0.4	1
2463	The Utilization of Pupillometry in the Differential Diagnosis and Treatment of Psychotic and Behavioral Disorders. , 1974, , 75-134.		2

#	Article	IF	Citations
2464	Use of Phosphatidylcholine in Brain Diseases: An Overview. Advances in Behavioral Biology, 1987, , 121-136.	0.2	7
2465	Quantitative Cytoarchitectonic Findings in Postmortem Brain Tissue from Mood Disorder Patients. Neurobiological Foundation of Aberrant Behaviors, 2002, , 291-324.	0.2	1
2466	The Biology of Late-Life Depression. , 1993, , 59-73.		1
2467	Depression in Infants. Issues in Clinical Child Psychology, 1994, , 401-426.	0.2	4
2468	Effects of Lithium on Brain Metabolism. , 1986, , 55-97.		2
2469	Hormone Imbalance in Depressive States. , 1969, , 525-553.		1
2470	Monoaminergic Innervation of Cingulate Cortex. , 1993, , 285-310.		25
2471	Neuropeptide Y in Relation to Behavior and Psychiatric Disorders. , 1993, , 511-554.		8
2472	A Role for CREB in Antidepressant Action. , 1997, , 173-194.		6
2473	Antidepressant Properties of Specific Serotoninâ€"Noradrenaline Reuptake Inhibitors. , 1997, , 35-52.		6
2474	Major Depressive Disorder. , 2008, , 73-83.		3
2475	Biological Theories of Depression and Implications for Current and New Treatments. , 2011, , 1-32.		2
2476	Neuroplasticity â€" A New Approach to the Pathophysiology of Depression. , 2011, , 1-12.		4
2477	A Computational Hypothesis on How Serotonin Regulates Catecholamines in the Pathogenesis of Depressive Apathy. Springer Series in Cognitive and Neural Systems, 2019, , 127-134.	0.1	2
2478	Galanin, Galanin Receptor Subtypes and Depression-Like Behaviour. Exs, 2010, 102, 163-181.	1.4	51
2479	Depressive Disorders: Prevalence, Costs, and Theories. , 2016, , 1-41.		3
2480	Political Pills: Psychopharmaceuticals and Neoliberalism as Mutually Supporting. , 2017, , 189-225.		11
2481	Psychoneuroendocrinological and Cognitive Interactions in the Interface Between Chronic Stress and Depression. , 2017, , 161-172.		4

#	Article	IF	Citations
2482	New Hypotheses to Guide Future Antidepressant Drug Development. Handbook of Experimental Pharmacology, 2004, , 519-563.	0.9	2
2483	Biological Markers of Depression. Handbook of Experimental Pharmacology, 2004, , 117-148.	0.9	3
2485	Monoamine Oxidase: Radiotracer Development and Human Studies. , 2003, , 457-476.		3
2486	Antidepressant and Antimanic Drugs. Handbook of Experimental Pharmacology, 1995, , 465-490.	0.9	4
2487	Monoamine Oxidase Inhibitors as Antidepressants. Handbook of Experimental Pharmacology, 1980, , 369-397.	0.9	10
2488	Biochemical Effects of Antidepressants in Animals. Handbook of Experimental Pharmacology, 1980, , 471-490.	0.9	14
2489	Drug-Induced Alterations in Animal Behavior as a Tool for the Evaluation of Antidepressants: Correlation with Biochemical Effects. Handbook of Experimental Pharmacology, 1980, , 505-526.	0.9	3
2490	The Role of Cyclic Nucleotides in the Nervous System. Handbook of Experimental Pharmacology, 1982, , 389-463.	0.9	20
2491	Cerebrospinal Fluid Amine Metabolite Studies in Depression: Research Update. , 1985, , 129-143.		3
2492	Psychopharmakotherapie affektiver Psychosen. , 1987, , 273-325.	0.0	8
2493	Catecholamines and Mood: Neuroendocrine Aspects. Current Topics in Neuroendocrinology, 1988, , 141-182.	0.9	20
2494	Cholinergic Mechanisms in Mood: Neuroendocrine Aspects. Current Topics in Neuroendocrinology, 1988, , 211-229.	0.9	6
2495	Unsolved Problems in the Pharmacotherapy of Depression. , 1988, 5, 159-165.		3
2496	Neural Substrates of Thought and Affective Disorders. , 1989, , 225-234.		2
2497	Psychologische Aspekte der HyperprolaktinÃmie. , 1988, , 134-168.		3
2498	Psychotherapie bei HyperprolaktinÃmie?. , 1988, , 210-216.		2
2499	The Role of Dopamine in the Control of Neurobiological Functions. Basic and Clinical Aspects of Neuroscience, 1989, , 1-17.	0.2	9
2500	Theoretical and Practical Implications of a Controlled Trial of an Î±2-Adrenoceptor Antagonist in the Treatment of Depression. , 1989, 7, 105-108.		1

#	Article	IF	Citations
2501	GABA Receptors Inside and Outside the Brain. , 1992, , 215-232.		1
2502	Clinical Manifestations as a Determinant of Dementia. Monographien Aus Dem Gesamtgebiete Der Psychiatrie, 1978, , 17-38.	0.1	1
2503	Wirkung von Lithium auf die BewegungsaktivitÃt von Versuchstieren. , 1986, , 51-59.		6
2504	Depression in Late Life: An Update. , 1990, 9, 197-215.		17
2505	Depressive StÃ¶rungen. , 2017, , 1711-1817.		1
2506	â€œIn vitroâ€•effect of some 5-hydroxy-indolalkylamine derivatives on monoamine uptake system. Journal of Neural Transmission Supplementum, 1998, 52, 343-349.	0.5	4
2507	Antidepressiva: Grundlagen und Therapie. , 1983, , 57-159.		7
2508	The Functional Approach of Biological Research in Psychiatry. Acta Neurochirurgica Supplementum, 1991, 52, 149-153.	0.5	2
2509	Neurobiology of Monoaminergic Neurotransmission and Antidepressants. , 2014, , 321-341.		3
2510	Psychological changes following hormonal therapy. , 1976, , 127-133.		2
2511	Pilot Trial of Mianserin Hydrochloride for Childhood Hyperactivity. , 1984, , 197-210.		6
2512	Comprehensive Thyroid Evaluation in Psychiatric Patients. , 1984, , 29-45.		6
2513	The Influence of Estrogens on the Psyche in Climacteric and Post-menopausal Women. , 1976, , 84-93.		16
2514	The effect of rubidium and lithium on adenylate cyclase and neurotransmitter receptors. , 1984, , 59-75.		6
2515	Biological Research on Depression in Childhood. , 1983, , 229-248.		3
2516	INTRODUCTION: PSYCHOSOCIAL STIMULI, PSYCHOPHYSIOLOGICAL REACTIONS, AND DISEASE. , 1972, , 11-27.		11
2517	THE IDENTIFICATION OF DEPRESSED PATIENTS WHO HAVE A DISORDER OF NE METABOLISM AND/OR DISPOSITION. , 1973, , 1091-1096.		41
2518	CHANGES IN HUMAN SERUM DOPAMINES-Î²-HYDROXYLASE ACTIVITY IN VARIOUS PHYSIOLOGICAL AND PATHOLOGICAL STATES. , 1973, , 1109-1114.		6

#	Article	IF	Citations
2519	AFFECTIVE DISORDERS: THE CATECHOLAMINE HYPOTHESIS REVISITED. , 1973, , 1157-1164.		13
2520	CATECHOLAMINE METABOLISM AND AFFECTIVE DISORDERS: STUDIES OF MHPG EXCRETION. , 1973, , 1165-1171.		12
2521	BRAIN BIOGENIC AMINES IN MENTAL DYSFUNCTIONS ATTRIBUTABLE TO THYROID HORMONE ABNORMALITIES. , 1980, , 143-184.		1
2522	Suicide and Depression in the United States. , 1983, , 11-22.		2
2523	Suicide and Serotonin. , 1983, , 367-404.		4
2524	BIOCHEMICAL DISCRIMINATION OF SUBGROUPS OF DEPRESSIVE DISORDERS BASED ON DIFFERENCES IN CATECHOLAMINE METABOLISM. , 1982, , 23-33.		6
2525	CHOLINERGIC REM SLEEP INDUCTIONâ€"A TRAIT MARKER OF AFFECTIVE ILLNESS?. , 1982, , 397-404.		3
2526	Non-synaptic Interneuronal Communication: Physiological and Pharmacological Implication. , 1983, , 83-111.		4
2527	CLINICAL PHARMACOLOGY OF ANXIOLYTICS AND ANTIDEPRESSANTS: A PSYCHOPHARMACOLOGICAL PERSPECTIVE. , 1991, , 1-28.		13
2528	The Pharmacodynamics and Toxicology of Steroids and Related Compounds. Advances in Lipid Research, 1977, 15, 61-157.	1.8	11
2529	Sympathomimetic Amines. , 1971, , 269-344.		11
2530	Biological Factors in the Affective Disorders and Schizophrenia. , 1974, , 9-37.		7
2531	PERIPHERAL MARKERS IN AFFECTIVE DISORDERS. , 1991, , 95-144.		6
2532	NEUROENDOCRINE CHALLENGE TESTS IN AFFECTIVE DISORDERS: IMPLICATIONS FOR FUTURE PATHOPHYSIOLOGICAL INVESTIGATIONS. , 1991, , 145-190.		2
2533	Effects of Pharmacological Agents on MHPG. , 1983, , 45-67.		18
2534	Preliminary Characterization of Plasma MHPG in Man. , 1983, , 107-128.		10
2535	Relationship between Psychiatric Diagnostic Groups of Depressive Disorders and MHPG. , 1983, , 129-144.		5
2536	Catecholaminergic Neurons. , 1990, , 1023-1049.		29

#	Article	IF	Citations
2537	MONOAMINES AND DEPRESSION: THE PRESENT STATE OF THE ART. , 1986, , 335-361.		4
2538	GEROVITAL H3, MONOAMINE OXIDASES, AND BRAIN MONOAMINES. , 1974, , 157-165.		4
2539	Monoamine oxidase inhibitors and amine precursors. , 1982, , 249-279.		6
2540	Affective Disorders. , 1976, , 136-236.		2
2541	Norepinephrine in the Affective Disorders: Receptor Assessment Strategies. , 1985, , 235-268.		4
2542	Parkinsonism and Depression: Dopaminergic Mediation of Neuropathologic Processes in Human Beings. , 1985, , 269-282.		2
2544	Modes of action of antidepressants. , 1977, , 137-155.		3
2545	Catecholamines in depression. , 1977, , 283-301.		12
2546	BIOCHEMICAL DISCRIMINATION OF SUBTYPES OF DEPRESSIVE DISORDERS. , 1979, , 1860-1862.		29
2547	TRACE AMINES IN DEPRESSION: TYRAMINE AND OCTOPAMINE DEFICIT. , 1979, , 1872-1874.		1
2548	Antidepressant-like effect of hydroalcoholic extract from barks of Rapanea ferruginea: Role of monoaminergic system and effect of its isolated compounds myrsinoic acid A and B. Behavioural Brain Research, 2020, 389, 112601.	1.2	2
2549	Adult Hippocampal Neurogenesis in Major Depressive Disorder and Alzheimerâ€™s Disease. Trends in Molecular Medicine, 2020, 26, 803-818.	3.5	98
2550	Phosphorylation of human recombinant tyrosine hydroxylase isoforms 1 and 2: an additional phosphorylated residue in isoform 2, generated through alternative splicing.. Journal of Biological Chemistry, 1991, 266, 17124-17130.	1.6	78
2551	Thyroid Function in Affective Disorders and Alcoholism. Endocrinology and Metabolism Clinics of North America, 1988, 17, 55-82.	1.2	25
2552	A multifactorial approach to depression : the inadequacy of pharmacologic inference and psychosocial hypotheses. Psychiatrie Et Psychobiologie, 1986, 1, 49-61.	0.1	1
2553	Ã‰volution des idÃ©es sur le mÃ©canisme d'action des antidÃ©presseurs : le concept d'hÃ©tÃ©ro-rÃ©gulation des rÃ©cepteurs. Psychiatrie Et Psychobiologie, 1986, 1, 62-74.	0.1	3
2555	Learned helplessness in the perspective of the depressive disorders: conceptual and definitional issues. Journal of Abnormal Psychology, 1978, 87, 3-20.	2.0	119
2556	Influence of aerobic exercise on depression. Journal of Personality and Social Psychology, 1984, 46, 1142-7.	2.6	107

#	Article	IF	Citations
2558	Personality science: Three approaches and their applications to the causes and treatment of depression.. , 2011, , .		4
2559	Sequential improvement of anxiety, depression and anhedonia with sertraline treatment in patients with major depression. Journal of Clinical Pharmacy and Therapeutics, 2000, 25, 363-371.	0.7	34
2560	11. The effects of positive affect and arousal on working memory and executive attention. Advances in Consciousness Research, 2002, , 245-287.	0.2	94
2561	Pharmacology of Antidepressants. Journal of Clinical Psychopharmacology, 1997, 17, 2S-18S.	0.7	208
2562	The Three Faces of the Antidepressants:. Journal of Nervous and Mental Disease, 1999, 187, 174-180.	0.5	28
2563	Commentary and Update on the Contribution of the GABA Hypothesis to Understanding the Mechanism of Action of Electroconvulsive Therapy. Journal of ECT, 2021, 37, 4-9.	0.3	10
2564	A Possible Cardiovascular Effect of Lithium. American Journal of Psychiatry, 1979, 136, 577-579.	4.0	7
2565	Elevated Plasma Ceramides in Depression. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 215-218.	0.9	40
2566	Tachykinins and Tachykinin Receptor Antagonists in Depression: Therapeutic Implications. , 2011, , 350-357.		7
2567	Depression and epilepsy. Neurology, 2002, 58, S27-39.	1.5	286
2568	A hormetic approach to understanding antidepressant effectiveness and the development of antidepressant tolerance â€“ A conceptual view. Psychiatria Polska, 2020, 54, 1067-1090.	0.2	6
2569	Î²-Arrestin signaling complex as a target for antidepressants and as a depression marker. Drug News and Perspectives, 2009, 22, 467.	1.9	23
2570	Do Antidepressants Cure or Create Abnormal Brain States?. PLoS Medicine, 2006, 3, e240.	3.9	74
2571	A Fine-Mapping Study of 7 Top Scoring Genes from a GWAS for Major Depressive Disorder. PLoS ONE, 2012, 7, e37384.	1.1	29
2572	Gene Organization and Polymorphisms of Monoamine Transporters: Relationship to Psychiatric and Other Complex Diseases. , 0, , 111-169.		11
2573	Cortical-Limbic-Striatal Dysfunction in Depression: Converging Findings in Basal Ganglia Diseases and Primary Affective Disorders. , 0, , 321-338.		3
2574	Antidepressants: Mechanism of Action, Toxicity and Possible Amelioration. Journal of Applied Biotechnology & Bioengineering, 2017, 3, .	0.0	13
2575	Depressive disorders: Defi nitions, contexts, differential diagnosis, neural correlates and clinical strategies. Archives of Depression and Anxiety, 2019, 5, 009-033.	0.8	52

#	Article	IF	Citations
2576	The Chemical Imbalance Hypothesis: An Evaluation of the Evidence. Ethical Human Psychology and Psychiatry, 2015, 17, 60-75.	0.5	7
2577	Signaling Pathways Involved in Antidepressant-Induced Cell Proliferation and Synaptic Plasticity. Current Pharmaceutical Design, 2014, 20, 3776-3794.	0.9	28
2578	Vitamin D and N-Acetyl Cysteine Supplementation in Treatment-Resistant Depressive Disorder Patients: A General Review. Current Pharmaceutical Design, 2020, 26, 2442-2459.	0.9	7
2579	Serotonin – Kynurenine Hypothesis of Depression: Historical Overview and Recent Developments. Current Drug Targets, 2013, 14, 514-521.	1.0	135
2580	Altered Glial Plasticity in Animal Models for Mood Disorders. Current Drug Targets, 2013, 14, 1249-1261.	1.0	21
2581	Monoamino Oxidase A: An Interesting Pharmacological Target for the Development of Multi-Target QSAR. Mini-Reviews in Medicinal Chemistry, 2012, 12, 947-958.	1.1	21
2582	A Potential Contribution of Chemokine Network Dysfunction to the Depressive Disorders. Current Neuropharmacology, 2016, 14, 705-720.	1.4	33
2583	Simultaneous Determination of Epinephrine and Tyrosine Using a Glassy Carbon Electrode Amplified with ZnO-Pt/CNTs Nanocomposite. Current Analytical Chemistry, 2019, 15, 166-171.	0.6	21
2585	Pathophysiology of Depression and Novel Sources of Phytochemicals for its Treatment â€“ A Systematic Review. Acta Medica Bulgarica, 2020, 47, 69-74.	0.0	3
2586	A unifying framework for depression: Bridging the major biological and psychosocial theories through stress. Clinical and Investigative Medicine, 2013, 36, 170.	0.3	36
2587	Effects of Uric Acid on the Alterations of White Matter Connectivity in Patients with Major Depression. Psychiatry Investigation, 2018, 15, 593-601.	0.7	5
2588	Abnormalities in Catecholamines and the Pathophysiology of Bipolar Disorder. Medical Psychiatry, 2007, , 33-66.	0.2	2
2589	Bipolar disorder. Dialogues in Clinical Neuroscience, 1999, 1, 41-51.	1.8	10
2590	Pathophysiology of depression and mechanisms of treatment. Dialogues in Clinical Neuroscience, 2002, 4, 7-20.	1.8	159
2591	The clinical pharmacology of depressive states. Dialogues in Clinical Neuroscience, 2002, 4, 47-56.	1.8	10
2592	Future prospects in depression research. Dialogues in Clinical Neuroscience, 2006, 8, 175-189.	1.8	21
2593	Mood disorder and epilepsy: a neurobiologic perspective of their relationship. Dialogues in Clinical Neuroscience, 2008, 10, 39-45.	1.8	82
2594	Applications of magnetic resonance imaging for treatment-resistant late-life depression. Dialogues in Clinical Neuroscience, 2015, 17, 151-169.	1.8	15

#	Article	IF	Citations
2595	The effects of drugs on human models of emotional processing: an account of antidepressant drug treatment. Dialogues in Clinical Neuroscience, 2015, 17, 477-487.	1.8	52
2596	Emotional dysfunction in Parkinson's disease. Behavioural Neurology, 2011, 24, 201-17.	1.1	46
2597	Study on Antidepressant-Like Effects of Radon Inhalation on Forced Swim Induced Depression in Mice. Radioisotopes, 2016, 65, 493-506.	0.1	4
2598	Polyamines: The possible missing link between mental disorders and epilepsy (Review). International Journal of Molecular Medicine, 2020, 45, 3-9.	1.8	17
2599	A PSYCHOBIOLOGICAL APPROACH TO AFFECTIVE ILLNESS. Psychiatric Annals, 1973, 3, 19-53.	0.1	78
2600	THE USE OF DRUGS IN DEPRESSION: ITS THEORETICAL AND PRACTICAL BASIS. Psychiatric Annals, 1973, 3, 56-75.	0.1	26
2601	Psychiatric Aspects of Oral Contraceptive Use. Psychiatric Annals, 1976, 6, 81-99.	0.1	5
2602	Depression at the Biochemical Level. Psychiatric Annals, 1980, 10, .	0.1	1
2603	The Role of Serotonin in Depression. Psychiatric Annals, 1989, 19, 348-353.	0.1	13
2604	The Role of Norepinephrine in Depression. Psychiatric Annals, 1989, 19, 354-359.	0.1	4
2605	A Neurochemical Perspective on Monoamine Oxidase Inhibitors. Psychiatric Annals, 2001, 31, 354-360.	0.1	1
2606	Monoamine Oxidase Inhibitors Revisited. Psychiatric Annals, 2001, 31, 361-370.	0.1	11
2607	A Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Selegiline Transdermal System Without Dietary Restrictions in Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2003, 64, 208-214.	1.1	121
2608	Anti depressant activity of Mamsyadi Kwatha: An Ayurvedic compound formulation. AYU: an International Quarterly Journal of Research in Ayurveda, 2013, 34, 113.	0.3	9
2609	Evaluation of anti-depressant and anxiolytic activity of Rasayana Ghana Tablet (A compound Ayurvedic) Tj ETQq0 0 0 rgBT /Overlock 10 T 375.	0.3	23
2610	Molecular mechanism of noradrenaline during the stress-induced major depressive disorder. Neural Regeneration Research, 2018, 13, 1159.	1.6	55
2611	Antidepressant-like effect of a standardized hydroethanolic extract of Asparagus adscendens in mice. Indian Journal of Pharmacology, 2019, 51, 98.	0.4	9
2612	Neurochemicals, Behaviours and Psychiatric Perspectives of Neurological Diseases. Neuropsychiatry, 2018, 08, .	0.4	16

#	Article	IF	Citations
2613	The Effect of Sympathetic Antagonists on the Antidepressant Action of Alprazolam. Libyan Journal of Medicine, 2008, 3, 78-83.	0.8	3
2614	Circadian Rhythm Hypotheses of Mixed Features, Antidepressant Treatment Resistance, and Manic Switching in Bipolar Disorder. Psychiatry Investigation, 2013, 10, 225.	0.7	39
2615	Neurobiology of Depression. Taehan Uihak Hyophoe Chi the Journal of the Korean Medical Association, 2003, 46, 783.	0.1	2
2616	Memantine: New prospective in bipolar disorder treatment. World Journal of Psychiatry, 2014, 4, 80.	1.3	25
2617	Clinical, Research and Treatment Approaches to Affective Disorders. , 2012, , .		2
2618	Mathematical Models: Interactions Between Serotonin and Dopamine in Parkinsonâ€™s Disease. , 0, , .		3
2620	Therapeutic Modalities for Treatment Resistant Depression: Focus on Vagal Nerve Stimulation and Ketamine. Clinical Psychopharmacology and Neuroscience, 2014, 12, 83-93.	0.9	29
2621	Serotonergic and noradrenergic function in depression: clinical correlates. Dialogues in Clinical Neuroscience, 2000, 2, 299-308.	1.8	6
2623	Familial Orthostatic Tachycardia due to Norepinephrine Transporter (SLC6A2) Deficiency. Advances in Behavioral Biology, 2002, , 499-504.	0.2	0
2625	Noradrenalin-selektive Antdeessva(NRI). , 2002, , 365-402.		0
2626	Non-Monoaminergig Transmitters, Glia Cell Markers, Cell Adhesion Molecules and Synaptic Proteins in Postmortem Brain Tissue. Neurobiological Foundation of Aberrant Behaviors, 2002, , 387-394.	0.2	0
2627	Neurobiologische Grundlagen. , 2002, , 1-77.		0
2628	Nicht-selektive Monoamin- RÃ¼ckaufnahme-Inhibitoren (NSMRI). , 2002, , 103-221.		0
2629	Positron Emission Tomography and Single Photon Emission Computed Tomography Imaging of Antidepressant Treatment Effects in Major Depression. , 2002, , 308-345.		0
2631	Catecholamines and Behavior. , 2003, , 524-527.		0
2632	3 Cases of Epilepsy with Major Depression Receiving Hospital Treatment. Journal of the Japan Epilepsy Society, 2004, 22, 186-194.	0.1	0
2633	Bipolar Mood Disorders. Handbook of Experimental Pharmacology, 2004, , 421-446.	0.9	0
2634	Pathology of Affect: Nuerobiological Aspects. , 2004, , 191-198.		0

#	Article	IF	Citations
2635	Biological Theories of Depression and Implications for Current and New Treatments. , 2004, , 1-32.		2
2636	Looking Beyond the Monoamine Hypothesis. European Neurological Review, 2006, , 1.	0.5	2
2637	Î²â€Adrenoceptor Function in Human Adult Skin Fibroblasts: A Study of Manicâ€Depressive Illness. Novartis Foundation Symposium, 1986, 123, 30-41.	1.2	3
2638	Depressive StÃ¶rungen. , 2008, , 1401-1472.		0
2639	StÃ¶rungen der Neurotransmission und Signaltransduktion als Grundlage psychischer Erkrankungen. , 2008, , 157-183.		0
2641	Melatonin and Affective Disorders. Novartis Foundation Symposium, 1985, 117, 253-265.	1.2	10
2642	Agomelatina: un fÃ¡rmaco nuevo con acciÃ³n antidepresiva que afecta a los sistemas melatonÃ©rgico y serotonÃ©rgico. European Psychiatry (Ed EspaÃ±ola), 2008, 15, 375-381.	0.0	0
2643	Psychiatric Disorders. , 2009, , 461-475.		0
2644	Neurobiology and the genetics of suicide. , 2009, , 166-182.		1
2645	An Agent-Based Data Mining System for Ontology Evolution. Lecture Notes in Computer Science, 2009, , 836-847.	1.0	3
2646	Introducing Nanoneuroscience as a Distinct Discipline. Biological and Medical Physics Series, 2009, , 1-34.	0.3	0
2647	Depression: Phenomenology, Epidemiology, and Pathophysiology. Medical Psychiatry, 2009, , 1-21.	0.2	4
2648	Regulation of G Protein Receptor Coupling, Mood Disorders and Mechanism of Action of Antidepressants. , 2010, , 63-81.		1
2650	Genes and Mental Illness. , 2010, , 3-10.		0
2651	Aminergic Hypotheses for Depression. , 2010, , 70-73.		0
2652	StÃ¶rungen der Neurotransmission und Signaltransduktion als Grundlage psychischer Erkrankungen. , 2011, , 217-250.		0
2653	Depressive StÃ¶rungen. , 2011, , 1575-1664.		0
2654	Advanced Human Cognition: A Faustian Deal. , 2011, , 171-200.		0

#	Article	IF	Citations
2655	Anti-anxiety and anti-depressant activities of Sarasvata choorna in experimental animals. AYU: an International Quarterly Journal of Research in Ayurveda, 2011, 32, 590.	0.3	6
2656	Depression: An Evolutionary Adaptation Organised Around the Third Ventricle. The Frontiers Collection, 2012, , 23-32.	0.1	0
2657	Symptoms of Parkinson's Disease. , 2011, , .		0
2658	Neurophysiological and Neuropsychological Models of Depression. , 2011, , 60-89.		0
2659	Development of Brain Monoaminergic Systems. , 2011, , 130-151.		0
2660	Beta-Arrestins in Depression: A Molecular Switch from Signal Desensitization to Alternative Intracellular Adaptor Functions. , 2011, , 404-423.		1
2661	Genetic Regulation of Emotion Brain Circuitries. , 2011, , 108-129.		0
2662	Noradrenergic System in Depression. , 2011, , 204-217.		1
2663	Affektive Erkrankungen. , 2012, , 315-324.		0
2666	Antidepressant Pharmacotherapy â€“ Do the Benefits Outweigh the Risks?. , 0, , .		0
2667	Die moderne Psychopharmakologie aus wissenschafts historischer Sicht. , 2012, , 23-36.		0
2670	Antidepressants and Morphological Plasticity of Monoamine Neurons. , 0, , .		0
2674	Gender Disparity of Depression: The Role of Endocannabinoids and Noradrenergic Function. , 2013, , 157-172.		0
2677	The Effects of OnDam-tang-Kami-bang (ODK) in Antioxidant and Serotonin Metabolism Testing on P815 Cell. Journal of Oriental Neuropsychiatry, 2013, 24, 189-200.	0.1	3
2678	Psychiatric Disturbances of Attention. , 2014, , 525-581.		0
2680	Importance of G Protein-Coupled Receptor Genetics in Clinical Medicine. Methods in Pharmacology and Toxicology, 2014, , 289-298.	0.1	1
2684	Bipolar Disorders. , 2014, , 223-251.		0
2685	Imaging of the Antidepressant Drug Response Using SPECT and PET. , 2014, , 325-345.		0

#	Article	IF	Citations
2687	Biochemical Basis of Mental Disease. , 1967, , 249-282.		0
2688	Somatic Findings of Melancholia with special reference to the endocrine system. Okayama Igakkai Zasshi, 1968, 80, 867-873.	0.0	0
2689	Interactions between Adrenocortical Steroid Hormones, Electrolytes, and the Catecholamines. Advances in Behavioral Biology, 1971, , 177-195.	0.2	1
2690	Antidepressants and Related Drugs. , 1971, , 357-386.		3
2691	Pharmacologyâ€"The Biology of Lithium. , 1973, , 167-188.		4
2692	HYPOTHALAMIC RELEASING HORMONES AND CATECHOLAMINES: A NEW INTERFACE. , 1973, , 1149-1155.		1
2693	Serum dopamine-β-hydroxylase activity in manic depressive psychosis. Okayama Igakkai Zasshi, 1976, 88, 571-591.	0.0	0
2694	The Measurement of Biogenic Amine Turnover Using Oxygen-18. , 1977, , 95-104.		0
2696	A Comparison of the Effect of Lithium Aid Haloperidol on Human Peripheral Î²-Adrenergic Adenylate Cyclase. , 1977, , 27-39.		0
2697	The Search for Genetic Polymorphisms of Human Biogenic-Amine Related Enzymes. , 1977, , 241-260.		2
2698	Cyclic AMP in severe depression. , 1977, , 343-364.		0
2699	Treatment of Senile Dementia. Monographien Aus Dem Gesamtgebiete Der Psychiatrie, 1978, , 56-63.	0.1	0
2700	NOREPINEPHRINE AND SEROTONIN METABOLISM IN THE RAT BRAIN: EFFECTS OF CHRONIC PHENELZINE ADMINISTRATION. , 1978, , 629-640.		3
2701	PRECLINICAL PSYCHOPHARMACOLOGY AND THERAPEUTICS: A PHARMACOLOGIST'S POINT OF VIEW. , 1978, , 165-169.		0
2702	A PHARMACOTHERAPEUTIC APPROACH TO RESEARCH INTO DEPRESSIVE ILLNESS. , 1978, , 647-653.		0
2703	Relevance of Research in Parkinsonâ€™s Disease to Psychiatry. , 1978, , 94-105.		1
2704	Drug Treatment of Depression. , 1978, , 333-360.		0
2705	Lithium und Endokrinium. Ergebnisse Der Inneren Medizin Und Kinderheilkunde, 1978, , 29-83.	0.2	1

#	Article	IF	Citations
2706	StÃ¶rungen der Neurotransmission assoziiert mit neurologischen und psychiatrischen Syndromen. , 1978, , 145-155.		0
2707	EXPLORATION OF AFFECTIVE ILLNESS. , 1978, , 761-772.		0
2709	CENTRAL BETA-ADRENERGIC RECEPTOR SUBSENSITIVITY DEVELOPS AFTER REPEATED ADMINISTRATION OF ANTIDEPRESSANT DRUGS. , 1979, , 743-745.		1
2711	Noradrenergic Function in Affective Illness. , 1979, , 127-137.		5
2712	Biogenic Amine Metabolites in Cerebrospinal Fluid of Patients with Affective Disorders. , 1979, , 163-171.		1
2713	Convulsive Therapy. , 1980, , 315-349.	0.0	1
2714	Hormonal Influences on Î±-Adrenoreceptors: Preliminary Results. , 1980, , 55-61.		1
2715	Stoffwechselpathologie der Zyklothymie und Schizophrenie. , 1980, , 65-113.	0.0	1
2716	Biochemical Assessment of Antidepressive Drugs. , 1981, , 67-78.		0
2717	Alteration in Brain Receptors in Affective Disorders. , 1981, , 297-314.		0
2718	Changes in Central 5-Hydroxytryptamine Turnover Induced by Acute and Chronic Inhibition of the Re-Uptake Process. , 1981, , 149-154.		3
2719	NORADRENALINE, DOPAMINE AND MOOD. , 1981, , 17-29.		0
2720	Alteration in Brain Receptors in Affective Disorders. , 1981, , 297-314.		1
2721	The effect of electroconvulsive therapy on plasma cyclic-AMP, non-esterified fatty acid, tryptophan and tyrosine in depression.. Keio Journal of Medicine, 1981, 30, 193-204.	0.5	2
2722	Hormonal Markers in Schizophrenia and Depression. , 1981, , 339-362.		0
2723	Hormonal Markers in Schizophrenia and Depression. , 1981, , 339-362.		0
2724	HIGH RISK STUDIES IN AFFECTIVE DISORDERS. , 1982, , 3-11.		3
2725	Endorphin Dysfunction in Panic Anxiety and Primary Affective Illness. , 1982, , 355-374.		0

#	Article	IF	Citations
2726	CNS Amine Metabolites. , 1984, , 49-108.		2
2727	The Role of Endorphins in Neurobiology, Behavior, and Psychiatric Disorders. , 1984, , 349-383.		4
2728	Psychoendocrinology of Depression. , 1984, , 343-356.		1
2729	Biological Tests in the Diagnosis and Treatment of Affective Disorders. , 1984, , 383-398.		0
2730	Opposite effects of lithium and rubidium on neurohormone-stimulated cyclic AMP accumulation in rat brain. , 1984, , 37-57.		6
2731	Neuromuscular Psychophysiology of Depression. , 1984, , 131-137.		0
2732	Mood Disorders: Historical Perspective and Current Models of Explanation. , 1984, , 21-42.		0
2733	Clinical Pharmacokinetics of Antidepressants. , 1984, , 119-137.		0
2734	Molekulare Wirkungsmechanismen von Antidepressiva. , 1985, , 1-16.		2
2736	Effects of Desipramine on Melatonin and Cortisol in Normal and Depressed Subjects. , 1985, , 253-261.		0
2737	The Serotonin-Noradrenaline Link-Hypothesis of Affective Disorders. , 1985, , 411-416.		1
2738	Amphetamine Induced Arousal in Human Subjects as a Model for Mania. , 1985, , 435-441.		0
2739	The Psychopharmacology of Mania: Towards a Unifying Hypothesis. , 1985, , 423-429.		0
2740	Norepinephrine in the Affective Disorders: Classic Biochemical Approaches. , 1985, , 213-233.		2
2741	Pharmakoendokrinologie und Depressionsforschung. , 1986, , 72-76.		0
2742	Ã‰valuation de la rÃ©activitÃ© des rÃ©cepteurs bÃªta-adrÃ©nergiques cardiaques chez des sujets dÃ©primÃ©s. Psychiatrie Et Psychobiologie, 1986, 1, 156-161.	0.1	0
2743	PRESYNAPTIC ALPHA-2 ADRENOCEPTORS. , 1986, , 23-28.		0
2744	New Approaches to the Pharmacological Treatment of Anxiety and Depression. , 1986, , 215-228.		0

#	Article	IF	Citations
2745	Neuropsychological Aspects of Cerebrovascular Disease and its Treatment. , 1986, , 55-94.		2
2746	Calcium Antagonistic Properties of Antimanic Compounds. , 1986, , 300-309.		1
2747	Biological Studies of the Nosology of the Major Psychoses: A Status Report on the Schizoaffective Disorders. , 1986, , 232-259.		0
2748	Der Beitrag der Biochemie zur Psychiatrischen Forschung und Therapie. , 1986, , 55-65.		0
2749	Biochemische und pharmakologische Grundlagen der Psychopharmakatherapie der Depression im Alter. , 1986, , 79-88.		0
2750	Lithium Pharmacology and Physiology. , 1987, , 233-273.		1
2751	Tricyclic Antidepressants: Animal Pharmacology (Biochemical and Metabolic Aspects). , 1987, , 157-197.		3
2752	Affective Disorders. , 1987, , 61-91.		1
2753	Tricyclic and Monoamine Oxidase Inhibitor Antidepressants: Structure-Activity Relationships. , 1987, , 83-155.		3
2754	Stress, Psychosomatics, and Stress Coping from a Clinical-Psychological Point of View. , 1987, , 126-161.		0
2755	Paraganglionic Cell Response to Chronic Imipramine: A Structural Model. , 1987, , 266-268.		0
2756	Funktionelles Ungleichgewicht im zentralen Nervensystem als Grundlage affektiver Erkrankungen. , 1988, , 54-59.		1
2757	Sleep Polygraphic Recordings as a Probe for Central Dopamine Deficiency: Polygraphic and Clinical Criteria of Dopamine-dependent Depressions. , 1988, , 228-234.		1
2758	Animal Models for Affective Disorders. , 1988, , 43-95.		0
2759	Urin-MHPG-Ausscheidung bei manischen Psychosen. , 1988, , 228-229.		0
2760	Biological Aspects of Course and Outcome in Depressive Illness: Needed Areas of Research. , 1988, , 92-110.		0
2761	Stress, Neurochemie und Depression. PSZ-Drucke, 1988, , 93-114.	0.1	0
2762	Noradrenergic and Serotonergic Dysfunction in the Affective Disorders. , 1989, , 45-48.		1

#	Article	IF	Citations
2763	Neuere biologische Untersuchungsverfahren und ihre Bedeutung fÃ¼r die Psychiatrie. , 1989, , 251-281.		2
2764	Neurobiological Models. , 1989, , 143-177.		0
2765	Peripheral Blood Cell Biological Markers in Depression. , 1989, , 203-208.		0
2767	Circadian and Ultradian Rhythms of 3-Methoxy-4-Hydroxyphenylglycol in Subtypes of Depressive Illness. , 1989, , 231-235.		1
2768	Influence of Psychotropic Drugs on Pituitary Hormone Secretion with Special Reference to Norepinephrine Reuptake Inhibition. , 1990, , 311-326.		0
2769	Corticotropin Releasing Factor, the Amygdaloid Complex, and Depression: A Hypothetical Interrelationship. , 1990, , 508-519.		0
2770	Familial Parkinsonâ€™s Disease and Familial Manic-Depressive Illness. Advances in Behavioral Biology, 1990, , 201-204.	0.2	1
2772	Imipramine. , 1990, , 133-141.		1
2773	Pharmakologische Grundlage der â€šTherapieresistenzâ€˜ bei der Behandlung mit Antidepressiva. , 1990, , 71-83.		1
2774	Clinical Investigations with Phosphodiesterase Inhibitors. , 1990, , 336-346.		0
2775	The mechanism of action of antidepressants revised. , 1990, 32, 29-37.		4
2776	Balance and Imbalance of Transsynaptic Neurotransmission as Conditions for Normal and Pathological Behaviour: Examples Only. , 1990, , 421-426.		0
2777	Historische Betrachtung des Serotonins bei AngstzustÃnden und Depression. , 1991, , 3-14.		0
2779	Zum gegenwÃrtigen Stand der biologischen Depressionsforschung. , 1991, , 159-179.		0
2780	Katecholamin-Hypothese. , 1991, , 21-27.		0
2781	The Switch Process and the Effect of Lithium. , 1991, , 327-342.		0
2782	Pharmakotherapie der Bulimia nervosa. , 1991, , 151-172.		1
2783	Serotoninwiederaufnahmehemmer und Depression. , 1991, , 233-253.		0

#	Article	IF	Citations
2784	Biochemical and Pharmacological Approaches in the Study of Sympathetic Nerves. , 1992, , 191-208.		0
2785	Biochemical and Pharmacological Approaches in the Study of Sympathetic Nerves. , 1992, , 191-208.		0
2786	Advances in Biological Psychiatry. , 1992, , 145-162.		1
2787	The mellow horn of the pensive soul. , 1992, , 1-34.		0
2788	Trizyklische Antidepressiva. , 1993, , 11-103.		1
2789	Antidepressiva mit neuartigen Wirkmechanismen. , 1993, , 399-432.		0
2790	Wirkungsmechanismus von Antidepressiva? Die Suche nach dem Licht im Dunkeln. , 1993, , 15-25.		0
2791	Neurobiologische Grundlagen psychiatrischer Erkrankungen. , 1993, , 35-54.		0
2792	Biological Model. , 1994, , 111-139.		0
2793	Synergistic sedative effect of selective MAO-A, but not MAO-B, inhibitors and melatonin in frogs. , 1994, 41, 141-144.		1
2794	Neurobiologische Grundlagen psychiatrischer Erkrankungen. , 1996, , 37-59.		0
2795	Neuere Ergebnisse molekulargenetischer Untersuchungen bei psychotischen Erkrankungen. , 1996, , 67-75.		0
2796	Affective Disorders. , 1996, , 35-83.		0
2797	Neurobiochemie suizidalen Verhaltens. , 1996, , 47-72.		2
2799	Effects of Antidepressants on Transmembrane Signaling. , 1998, , 1-6.		0
2800	Participation of Cytoskeletal Elements in Neuronal Signal Transduction: New Insight into the Molecular Basis of Antidepressant Action. , 1998, , 121-132.		0
2801	Protein Phosphorylation System in the Mechanism of Action of Antidepressants. , 1998, , 69-84.		0
2802	Lithium in biology. Perspectives on Bioinorganic Chemistry, 1999, , 1-50.	0.4	0

#	Article	IF	Citations
2803	Neurobiologische Grundlagen psychiatrischer Erkrankungen. , 1999, , 43-66.		0
2804	This issue: Monoamine Oxidase Inhibitors: Part 1. Psychiatric Annals, 2014, 44, 492-493.	0.1	0
2805	Aetiopathogenesis of Bipolar Disorder. , 2015, , 389-419.		0
2806	This issue: Monoamine Oxidase Inhibitors: Part 2. Psychiatric Annals, 2014, 44, 552-554.	0.1	0
2810	Acquainted With the Night Again and Again: Key Factors Associated With Relapse in Major Depressive Disorder. Journal of Clinical Psychiatry, 2015, 76, e1315-e1317.	1.1	0
2811	Depressive StÃ¶rungen. , 2016, , 1-107.		0
2813	StÃ¶rungen der Neurobiochemie und Signaltransduktion als Grundlage psychischer Erkrankungen. , 2016, , 1-35.		0
2814	Drugs for Treatment of Neurological and Psychological Conditions. , 2016, , 587-621.		0
2815	Deep Brain Stimulation: A Promising Therapeutic Approach to the Treatment of Severe Depressed Patients â€" Current Evidence and Intrinsic Mechanisms. , 2017, , 251-264.		0
2816	Mathematical Models of Neuromodulation and Implications for Neurology and Psychiatry. Springer Series in Bio-/neuroinformatics, 2017, , 191-225.	0.1	1
2817	StÃ¶rungen der Neurobiochemie und Signaltransduktion als Grundlage psychischer Erkrankungen. , 2017, , 245-278.		0
2818	A Matter of Chemistry. , 2017, , 117-140.		0
2819	Neurobiology of psychiatric disorders. , 2017, , .		0
2820	BIOMARKERS OF DEPRESSION: NEW CHALLENGES. Acta Medica Medianae, 2017, 56, 44-49.	0.0	0
2821	Antidepresan Ä°laÃ§larÄ±n Ã–ÄŸrenme ve Bellek MekanizmasÄ±na Etkileri. Arsiv Kaynak Tarama Dergisi, 2017, 26, 178-178.	0.1	1
2823	What Is the Real Response of Ventral Tegmental Area Dopaminergic Neurons to Bupropion? Excitation of Inhibition.. Basic and Clinical Neuroscience, 2019, 10, 281-304.	0.3	1
2824	In vitro cytogenotoxic evaluation of sertraline. Interdisciplinary Toxicology, 2018, 11, 181-188.	1.0	8
2825	The Role of Neurotransmitters in Personality. , 2019, , 1-3.		0

#	Article	IF	Citations
2829	Counselors' Neuroscience Conceptualizations of Depression. Journal of Mental Health Counseling, 2019, 41, 260-279.	0.6	1
2831	Comparison of Morning and Evening/Night Dosing on the Efficacy of Escitalopram in Major Depressive Disorder at Naturalistic Setting. Chronobiology in Medicine, 2019, 1, 152-156.	0.2	0
2832	Phytochemicals as Antidepressants. , 2020, , 115-131.		2
2833	Perinatal Psychiatry: Ready for Prime Time?. Agents and Actions Supplements, 2020, , 1-9.	0.2	0
2834	Emerging intervention of antidepressant with DMARD in non-cancerous nociceptive persistent pain associated depression in FCA induced rheumatoid arthritic rats. Brazilian Journal of Pharmaceutical Sciences, 0, 56, .	1.2	0
2835	Antidepressant-like effects of aqueous leaf extract of Macaranga barteri Mull. and Arg (Euphorbiaceae) in rats. Journal of Applied Pharmaceutical Science, 0, , .	0.7	0
2836	PSÄ°KOSOSYAL STRESÄ°N (ZÄ°HÄ°NSEL STRESÄ°N) KEMÄ°K SAÄžLIÄžINA ETKÄ°LERÄ°. Geriatrik Bilimler Dergisi, 0, , .	1.0	0
2837	Manipulation of vocal communication and anxiety through pharmacologic modulation of norepinephrine in the Pink1-/- rat model of Parkinson disease. Behavioural Brain Research, 2022, 418, 113642.	1.2	13
2840	Progress in pharmacotherapy of depression: research implications. , 1983, , 253-265.		0
2841	Bupropion: an empirical pharmacological approach to drug development. , 1983, , 195-224.		0
2842	A double-blind comparative trial of oxaprotiline with amitriptyline and placebo in outpatients with moderate depression: relationship of urinary MHPG levels. , 1983, , 319-330.		0
2843	Urinary MHPG and Treatment Response: A Review. , 1983, , 167-192.		3
2844	GABA receptor agonists: pharmacological spectrum and clinical actions. , 1983, , 386-394.		0
2845	Effects of antidepressant treatments on â€˜whole bodyâ€™ norepinephrine turnover. , 1983, , 327-338.		0
2846	Bipolar Disorders. , 2021, , 261-296.		0
2847	Affective Disorders. , 2021, , .		0
2848	Developmental Programming During Psychological Stress in Pregnancy: A Neurobiological Perspective. Agents and Actions Supplements, 2020, , 11-32.	0.2	0
2849	Role of Neurotransmitters in Personality, The. , 2020, , 4497-4499.		0

#	Article	IF	Citations
2850	Unipolar depression. , 2020, , 613-631.		0
2851	Influence of Gut Microbiota on Mental Health via Neurotransmitters: A Review. Journal of Artificial Intelligence for Medical Sciences, 2020, 1, 1-14.	1.3	10
2852	Psychopharmacology: A Brief Overview of Its History. , 2020, , 1-41.		0
2853	Mechanisms of Psychiatric Comorbidities in Epilepsy. Current Topics in Behavioral Neurosciences, 2020, , 107-144.	0.8	2
2856	Possible involvement of NO-sGC-cGMP signaling in the antidepressant like effect of pyridoxine in mice. Metabolic Brain Disease, 2021, , 1.	1.4	0
2860	Neurochemical Transmission. , 0, , 545-641.		0
2861	Was erklÃrbar ist: Ã„tiologie und Entwicklungs psychopathologie. , 2008, , 33-72.		0
2862	Die moderne Psychopharmakologie aus wissenschaftshistorischer Sicht. , 2008, , 11-25.		0
2863	Affektive StÃ¶rungen. , 2008, , 873-909.		0
2864	Decoding the Genetics and Underlying Mechanisms of Mood Disorders Sevilla D. Detera-Wadleigh and Takeo Yoshikawa. Nucleic Acids and Molecular Biology, 2009, , 1-50.	0.2	0
2865	The catecholamine hypothesis. , 2020, , 111-134.		0
2866	Brain Bio-Amines and Schizophrenia: A Summary of Research Findings and Implications for Nursing. Journal of Psychosocial Nursing and Mental Health Services, 1979, 17, 28-34.	0.3	0
2867	DEPRESSIVE ILLNESS: ITS SOCIOPSYCHIATRIC IMPLICATIONS. Psychiatric Annals, 1974, 4, 54-68.	0.1	1
2868	Electroconvulsive Therapy: Old Question, New Answers. Psychiatric Annals, 1978, 8, 47-65.	0.1	0
2869	Regulation of serotonin type 2 (5-HT2) and beta-adrenergic receptors in rat cerebral cortex following novel and classical antidepressant treatment. Journal of Psychiatry and Neuroscience, 1991, 16, 209-14.	1.4	10
2870	Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide. Journal of Psychiatry and Neuroscience, 1993, 18, 214-25.	1.4	30
2871	Recent advances in antidepressant drug treatment. Western Journal of Medicine, 1979, 131, 104-13.	0.3	2
2872	Neurochemical and psychoanalytical approaches to mania. Journal of the Royal Society of Medicine, 1977, 70, 20-5.	0.1	1

#	Article	IF	Citations
2873	Tricyclic antidepressants and monoamines: the relationship between uptake blockade and potentiation of neuronal responses. British Journal of Pharmacology, 1975, 53, 459P.	2.7	3
2874	Lack of association between the norepinephrine transporter gene and major depression in a Han Chinese population. Journal of Psychiatry and Neuroscience, 2007, 32, 121-8.	1.4	31
2875	Amitriptyline and excessive appetite. Cmaj, 1967, 97, 1361.	0.1	0
2876	Manic reaction associated with procarbazine hydrochloride therapy of Hodgkin's disease. Cmaj, 1967, 97, 1350-3.	0.1	4
2877	Dopamine and disease. Cmaj, 1970, 103, 824-32.	0.1	9
2879	The effect of amitriptyline on presynaptic receptors in the dog saphenous vein [proceedings]. British Journal of Pharmacology, 1979, 67, 422P-423P.	2.7	1
2880	The effects of mianserine, amitriptyline, ciclazindol and viloxazine on presynaptic alpha-receptors in isolated rat atria [proceedings]. British Journal of Pharmacology, 1980, 68, 184P-185P.	2.7	2
2882	Postpartum mental syndromes. Canadian Family Physician, 1980, 26, 1546-50.	0.1	1
2884	Norepinephrine and serotonin metabolism and clinical response to combined imipramine and amitriptyline therapy in depression. Indian Journal of Psychiatry, 1991, 33, 193-9.	0.4	3
2886	Evaluation of the anti-depressant activity of Myristica fragrans (Nutmeg) in male rats. Avicenna Journal of Phytomedicine, 2012, 2, 72-8.	0.1	10
2887	Effects of Yulangsan polysaccharide on monoamine neurotransmitters, adenylate cyclase activity and brain-derived neurotrophic factor expression in a mouse model of depression induced by unpredictable chronic mild stress. Neural Regeneration Research, 2012, 7, 191-6.	1.6	5
2888	Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia. Innovations in Clinical Neuroscience, 2015, 12, 26S-40S.	0.1	15
2889	Roland Kuhn-100th Birthday of an Innovator of Clinical Psychopharmacology. Psychopharmacology Bulletin, 2012, 45, 48-50.	0.0	7
2890	Effects of C-Terminal Domain of the Heavy Chain of Tetanus Toxin on Gut Microbiota in a Rat Model of Depression. Clinical Pharmacology and Translational Medicine, 2019, 3, 152-159.	0.3	2
2891	From the Second Half of the Twentieth Century to the Early Twenty-First: The Psychopharmacologic Era. , 2022, , 237-326.		0
2892	GABA System in Depression: Impact on Pathophysiology and Psychopharmacology. Current Medicinal Chemistry, 2022, 29, 5710-5730.	1.2	14
2893	Astroglial Serotonin Receptors as the Central Target of Classic Antidepressants. Advances in Neurobiology, 2021, 26, 317-347.	1.3	7
2895	Alteration of the Î±5 GABA receptor and 5HTT lead to cognitive deficits associated with major depressive-like behaviors in a 14-day combined stress rat model. International Journal of Neuroscience, 2023, 133, 959-976.	0.8	1

#	Article	IF	Citations
2896	Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history. Journal of the Neurological Sciences, 2022, 434, 120096.	0.3	10
2897	Nitrous Oxide: an emerging novel treatment for treatment-resistant depression. Journal of the Neurological Sciences, 2022, 434, 120092.	0.3	3
2899	Development of Mixed Anxiety/Depression-Like State as a Consequence of Chronic Anxiety: Review of Experimental Data. Current Topics in Behavioral Neurosciences, 2021, , .	0.8	3
2900	Perspective Chapter: Depression as a Disorder of Monoamine Axon Degeneration May Hold an Answer to Two Antidepressant Questions - Delayed Clinical Efficacy and Treatment-Resistant Depression. , 0, , .		0
2901	Psychiatric Manifestations in Patients with Biopterin Defects. Neuropediatrics, 2022, 53, 176-181.	0.3	1
2902	Differences in Cerebral Distribution between Imipramine and Paroxetine via Membrane Transporters at the Rat Blood-Brain Barrier. Pharmaceutical Research, 2022, 39, 223-237.	1.7	2
2905	Colorimetric Nanozyme Sensor Array for the Pattern Recognition of Monoamine Neurotransmitters Using Dendritic Mesoporous Silica Embedded with Metal Nanoparticles. SSRN Electronic Journal, 0, , .	0.4	0
2906	Neuroinflammation and Mitochondrial Dysfunction Link Social Stress to Depression. Current Topics in Behavioral Neurosciences, 2022, , 59-93.	0.8	18
2907	Genetic animal models for psychiatric disorders. , 2022, , 241-267.		0
2908	Depression management and pharmacoepigenetics. , 2022, , 67-84.		0
2909	Deep Brain Stimulation Neuromodulation for the Treatment of Mood Disorders: Obsessive Compulsive Disorder and Treatment Resistant Depression. Frontiers in Psychiatry, 2021, 12, 764776.	1.3	2
2910	NÃ¶robilim Ve Psikiyatri HemÅŸireliÄŸinde KullanÄ±mÄ±: Hayal Ya Da GerÃ§ek?. Sakarya Medical Journal, 0, , .	0.1	0
2911	Neuroanatomical, Biochemical, and Functional Modifications in Brain Induced by Treatment with Antidepressants. Molecular Neurobiology, 2022, 59, 3564-3584.	1.9	10
2912	Reinforcement Learning in Patients With Mood and Anxiety Disorders vs Control Individuals. JAMA Psychiatry, 2022, 79, 313.	6.0	50
2913	Structureâ€“activity relationship of three new piperazine derivates with anxiolytic-like and antidepressant-like effects. Canadian Journal of Physiology and Pharmacology, 2022, 100, 521-533.	0.7	3
2914	Coexpression of gene transcripts with monoamine oxidase a quantified by human in vivo positron emission tomography. Cerebral Cortex, 2022, 32, 3516-3524.	1.6	5
2915	Efficacy of Sertraline Combined with Cognitive Behavioral Therapy for Adolescent Depression: A Systematic Review and Meta-Analysis. Computational and Mathematical Methods in Medicine, 2021, 2021, 1-10.	0.7	8
2916	Estrogen, the Peripheral Immune System and Major Depression â€“ A Reproductive Lifespan Perspective. Frontiers in Behavioral Neuroscience, 2022, 16, 850623.	1.0	7

#	Article	IF	Citations
2917	Genetics of monoamine metabolizing enzymes: psychopharmacogenetics. , 0, , 265-287.		0
2918	Major Depression, Bipolar Syndromes, and Schizophrenia. , 2008, , 495-510.		0
2932	Biological Treatments of Mood Disorders. , 0, , 143-166.		0
2934	Introductory and Basic Aspects. , 0, , 2-50.		0
2935	Clinics. , 0, , 51-110.		0
2937	The Inhibition of Glutathione S-Transferases and Butyrylcholinesterase by Antidepressants: A Mini-Review on Enzyme-Drug Interaction. Current Enzyme Inhibition, 2022, 18, .	0.3	0
2938	Evaluation of anxiolytic and antidepressant effect of Saraswata Churna in the pilocarpine induced rat model of epilepsy. International Journal of Health Sciences, 0, , 8148-8157.	0.0	0
2940	Singleâ€Molecule Sensing of Acidic Catecholamine Metabolites Using a Programmable Nanopore. Chemistry - A European Journal, 2022, 28, .	1.7	1
2941	Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review. Frontiers in Psychiatry, 2022, 13, .	1.3	12
2942	Natural Products for the Treatment of Post-stroke Depression. Frontiers in Pharmacology, 2022, 13, .	1.6	8
2943	Measurement of Noradrenaline and Serotonin Metabolites With Internal Jugular Vein Sampling: An Indicator of Brain Monoamine Turnover in Depressive Illness and Panic Disorder. Frontiers in Psychiatry, 2022, 13, .	1.3	2
2947	Alterations of monoamine neurotransmitters, HPA-axis hormones, and inflammation cytokines in reserpine-induced hyperalgesia and depression comorbidity rat model. BMC Psychiatry, 2022, 22, .	1.1	13
2948	Antidepressant Effects of South African Plants: An Appraisal of Ethnobotanical Surveys, Ethnopharmacological and Phytochemical Studies. Frontiers in Pharmacology, 0, 13, .	1.6	6
2949	Colorimetric nanozyme sensor array for the pattern recognition of monoamine neurotransmitters using dendritic mesoporous silica embedded with metal nanoparticles. Sensors and Actuators B: Chemical, 2022, 369, 132287.	4.0	8
2950	Pathophysiology of Depression: Stingless Bee Honey Promising as an Antidepressant. Molecules, 2022, 27, 5091.	1.7	4
2951	Dopamine Receptors: Is It Possible to Become a Therapeutic Target for Depression?. Frontiers in Pharmacology, 0, 13, .	1.6	10
2952	An Integrated Nursing Model of Depressive Behavior in Adults. Nursing Clinics of North America, 1991, 26, 573-584.	0.7	5
2953	The discovery of tricyclic antidepressants and their mode of action. , 2023, , 159-171.		0

#	Article	IF	Citations
2954	Commentary on The discovery of tricyclic antidepressants and their mode of action by F. Sulser and R. Mishra. , 2023, , 153-159.		1
2955	Commentary on Monoamine oxidase and its inhibitors in relation to antidepressive activity by E. Albert Zeller. , 2023, , 137-143.		0
2956	Brain matrix metalloproteinase-9 activity is altered in the corticosterone mouse model of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2023, 120, 110624.	2.5	3
2957	Brain targeting drug delivery systems for the management of brain disorders. , 2022, , 289-345.		0
2958	Hippocampal neuroplasticity, major depression and, not to forget: ECT. Molecular Psychiatry, 0, , .	4.1	4
2959	Depression in multiple system atrophy: Views on pathological, clinical and imaging aspects. Frontiers in Psychiatry, 0, 13, .	1.3	3
2960	Relationship between nuclei-specific amygdala connectivity and mental health dimensions in humans. Nature Human Behaviour, 2022, 6, 1705-1722.	6.2	19
2961	Development of Reward Circuitry During Adolescence: Depression, Social Context, and Considerations for Future Research on Disparities in Sexual and Gender Minority Youth. Annual Review of Developmental Psychology, 2022, 4, 231-252.	1.4	1
2962	Epitaxial Self-Assembly of Interfaces of 2D Metalâ€“Organic Frameworks for Electroanalytical Detection of Neurotransmitters. ACS Nano, 2022, 16, 13869-13883.	7.3	12
2963	Recent advances in dopamine D₂ receptor ligands in the treatment of neuropsychiatric disorders. Medicinal Research Reviews, 2023, 43, 55-211.	5.0	8
2964	Neurophysiological mechanisms of implicit and explicit memory in the process of consciousness. Journal of Neurophysiology, 2022, 128, 872-891.	0.9	3
2965	Fast antidepressant action of ketamine in mouse models requires normal VGLUT1 levels from prefrontal cortex neurons. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, , 110640.	2.5	1
2967	The Role of Vesicle Release and Synaptic Transmission in Depression. Neuroscience, 2022, 505, 171-185.	1.1	2
2968	All the brain's a stage for serotonin: the forgotten story of serotonin diffusion across cell membranes. Proceedings of the Royal Society B: Biological Sciences, 2022, 289, .	1.2	5
2969	Delineation of biomarkers and molecular pathways of residual effects of fluoxetine treatment in juvenile rhesus monkeys by proteomic profiling. Zoological Research, 2023, 44, 30-42.	0.9	1
2970	Amine Precursors in Depressive Disorders and the Blood-Brain Barrier. , 2022, , 525-564.		0
2971	Psychopharmacology: A Brief Overview of Its History. , 2022, , 621-660.		0
2972	Potential of Capric Acid in Neurological Disorders: An Overview. Neurochemical Research, 2023, 48, 697-712.	1.6	4

#	Article	IF	Citations
2973	Mental health progress requires causal diagnostic nosology and scalable causal discovery. Frontiers in Psychiatry, 0, 13, .	1.3	2
2974	Neuroinflammation and neuroprogression in depression: Effects of alternative drug treatments. Brain, Behavior, & Immunity - Health, 2022, 26, 100554.	1.3	8
2975	Polymorphisms in the adrenergic neurotransmission pathway impact antidepressant response in depressed patients. , 2022, , 101016.		3
2976	Acute Stress Induces Different Changes on the Expression of BDNF and trkB in the Mesocorticolimbic System of Two Lines of Rats Differing in Their Response to Stressors. International Journal of Molecular Sciences, 2022, 23, 14995.	1.8	3
2977	Regulatory effects and potential therapeutic implications of alarin in depression, and arguments on its receptor. Frontiers in Psychiatry, 0, 13, .	1.3	0
2978	Melancholia as psychalgia: the integration of psychophysiological theory and psychopathologic observation in the mid-19th century. Molecular Psychiatry, 2023, 28, 230-235.	4.1	1
2979	Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms. Psychopharmacology, 2023, 240, 27-40.	1.5	5
2980	Anxiety, Depression, and Delirium in Terminally Ill Cancer Patient. , 0, , .		1
2981	Anti-Inflammatory Treatment Efficacy in Major Depressive Disorder: A Systematic Review of Meta-Analyses. Neuropsychiatric Disease and Treatment, 0, Volume 19, 1-25.	1.0	11
2982	Active vs passive novelty-related strategies: Sex differences in exploratory behaviour and monoaminergic systems. Behavioural Brain Research, 2023, 441, 114297.	1.2	2
2983	Nosologies/Diagnostic Systems. , 2023, , 1-48.		0
2984	Adaptogenic property of Asparagus racemosus: Future trends and prospects. Heliyon, 2023, 9, e14932.	1.4	3
2987	ANTIDEPRESSANT-LIKE ACTIVITY OF METHANOLIC EXTRACT OF WITHANIA QARAITICA IN MICE. International Journal of Pharmacy and Pharmaceutical Sciences, 0, , 25-30.	0.3	0
2988	Resilience to depression: Implication for psychological vaccination. Frontiers in Psychiatry, 0, 14, .	1.3	4
2989	Psychosocial Sciences: Theories and Applications. , 2023, , 147-184.		0
2990	Depressive Disorders. , 2023, , 531-567.		0
2991	Application of Antipsychotic Drugs in Mood Disorders. Brain Sciences, 2023, 13, 414.	1.1	9
2992	TRKB interaction with PSD95 is associated with latency of fluoxetine and 2R,6Râ€hydroxynorketamine. European Journal of Neuroscience, 2023, 57, 1215-1224.	1.2	0

#	Article	IF	Citations
2993	Inhibition of Microglial GSK3Î² Activity Is Common to Different Kinds of Antidepressants: A Proposal for an In Vitro Screen to Detect Novel Antidepressant Principles. Biomedicines, 2023, 11, 806.	1.4	7
2994	Neurobiological effects of gallic acid: current perspectives. Chinese Medicine, 2023, 18, .	1.6	29
2995	The History of Drug Development in Psychiatry: A Lesson in Serendipity. Advances in Neurobiology, 2023, , 19-35.	1.3	0
2996	Endocannabinergic modulation of central serotonergic activity in healthy human volunteers. Annals of General Psychiatry, 2023, 22, .	1.2	1
2997	Efficacy and Safety of Clonidine in the Treatment of Acute Mania in Bipolar Disorder: A Systematic Review. Brain Sciences, 2023, 13, 547.	1.1	1
2998	Review of Î²â€carboline and its derivatives as selective MAOâ€A inhibitors. Archiv Der Pharmazie, 2023, 356, .	2.1	4
2999	Impact of St. Johnâ€™s wort extract Ze 117 on stress induced changes in the lipidome of PBMC. Molecular Medicine, 2023, 29, .	1.9	0
3000	The Serotonergic System and Bone Metabolism During Pregnancy and Lactation and the Implications of SSRI Use on the Maternal-Offspring Dyad. Journal of Mammary Gland Biology and Neoplasia, 2023, 28, .	1.0	2
3010	Medication for Depression: Monoamine Enhancers and Esketamine (Antidepressants). , 2023, , 1-53.		0
3012	Neuroscience-Based Nomenclature (NbN): New Pharmacological Driven Classification of Psychotropics. , 2023, , 1-12.		0
3015	Neurobiological Foundations of Mood Disorders. , 2023, , 1-33.		0
3018	Adrenoceptors: A Focus on Psychiatric Disorders and Their Treatments. Handbook of Experimental Pharmacology, 2023, , .	0.9	0
3022	Commentary: Recent disputes on the role of serotonin in depression. Psychological Medicine, 0, , 1-3.	2.7	0
3031	The possible place for psychedelics in pharmacotherapy of mental disorders. Pharmacological Reports, 2023, 75, 1313-1325.	1.5	2
3033	Microbiota-Gut-Brain Axis and Antidepressant Treatment. Current Topics in Behavioral Neurosciences, 2023, , .	0.8	0
3035	PET Biomarkers in Psychiatry. , 2023, , 81-104.		0
3043	Serotonin: The Link between Gut Microbiome and Brain. , 0, , .		0